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ABSTRACT 
Anthropogenic activities have drastically altered chemical exposure, with traces of 
synthetic chemicals detected ubiquitously in the environment. Many of these chemicals 
are thought to perturb endocrine function, leading to declines in reproductive health and 
fertility, and increases in the incidence of cancer, metabolic disorders and diabetes.  
There are over 90 million unique chemicals registered under the Chemical Abstracts 
Service (CAS), of which only 308,000 were subject to inventory and/or regulation, in 
September 2013. However, as a specific aim of the EU REACH regulations, the UK is 
obliged to reduce the chemical safety initiatives reliance on in vivo apical endpoints, 
promoting the development and validation of alternative mechanistic methods. The 
human health cost of endocrine disrupting chemical (EDC) exposure in the EU, has 
been estimated at €31 billion per annum. In light of the EU incentives, this study aims 
to evaluate current in silico and in vitro tools for EDC screening and hazard 
characterisation; testing the hypothesis that in silico virtual screening accurately predicts 
in vitro mechanistic assays. Nuclear receptor binding interactions are the current focus 
of in silico and in vitro tools to predict EDC mechanisms. To the author’s knowledge, 
no single study has quantitatively assessed the relationship between in silico nuclear 
receptor binding and in vitro mechanistic assays, in a comprehensive manner.  
Tripos ® SYBYL software was used to develop 3D-molecular models of nuclear 
receptor binding domains. The ligand binding pockets of estrogen (ERα and ERβ), 
androgen (AR), progesterone (PR) and peroxisome proliferator activated (PPARγ) 
receptors were successfully modelled from X-ray crystal structures. A database of 
putative-EDC ligands (n= 378), were computationally ‘docked’ to the pseudo-molecular 
targets, as a virtual screen for nuclear receptor activity. Relative to in vitro assays, the in 
silico screen demonstrated a sensitivity of 94.5%. The SYBYL Surflex-Dock method 
surpassed the OECD Toolbox ER-Profiler, DfW and binary classification models, in 
correctly identifying endocrine active substances (EAS). Aiming to evaluate the current 
in vitro tools for endocrine MoA, standardised ERα transactivation (HeLa9903), stably 
transfected AR transactivation (HeLa4-11) assays in addition to novel transiently 
transfected reporter gene assays, predicted the mechanism and potency of test 
substances prioritised from the in silico results (n = 10 potential-EDCs and 10 hormone 
controls). In conclusion, in silico SYBYL molecular modelling and Surflex-Dock 
virtual screening sensitively predicted the binding of ERα/β, AR, PR and PPARγ 
potential EDCs, and was identified as a potentially useful regulatory tool, to support 
EAS hazard identification.  
Keywords: Endocrine Disrupt*, Test Methods, Prioritisation, Regulation, SYBYL 
Surflex-Dock
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1 INTRODUCTION 
1.1 The Scientific Context 
The use and manufacture of chemicals is fundamental to the western mode of living and 
economy, subsequently synthetic chemicals are ubiquitous to the modern environment 
(OECD Observer, 2010a). Annually, the chemical industry turnover is €1.8 trillion; 
accounting for 7% of global trade (OECD Observer, 2010b). In October 2014, over 90 
million unique organic and inorganic chemicals were CAS registered, of which only 
311,000 were subject to inventory or regulation (CHEMLIST®)
1
. However, chemicals 
are not restricted by national borders and the reporting of bioaccumulation of lipophilic 
synthetic chemicals in the polar regions, due to aerial and aquatic migratory movements, 
emphasises the potential global environmental threat of the chemical industry (Czub et 
al. 2008).  
Traces of synthetic chemicals are found ubiquitously in the environment. An estimated 
50,000 chemicals are thought to prevail in UK surface waters (Matthiessen and 
Johnson, 2007), contaminating wildlife habitats and potable water sources. The ubiquity 
of human exposure to chemicals, via food, water, consumer products and household 
agents, has led to growing concern regarding the potential health threats. Biomonitoring 
studies have added to concerns by demonstrating the absorbance and accumulation of 
anthropogenic chemicals in human tissues. The High Production Volume (HPV) 
plasticiser Bisphenol A (BPA), has been detected in human autopsy adipose (3.78 ng/g), 
liver (1.48 ng/g) and brain (0.91 ng/g) tissues by gas chromatography mass 
spectrometry (GC/MS) (Geens et al., 2012). In addition, polybrominated biphenyl ether 
(PBDE) flame retardants have been detected in the hair of newborns (0.048-1.01 pg/mg) 
and children (0.208-2.695 ng/mg) by GC/MS (Aleska et al., 2013).  
Worldwide production of the organochlorine pesticide, Dichlorodiphenyltrichloroethane 
(DDT), exceeded 40,000 tonnes per annum for thirty years (1950-1980) (Geisz et al., 
2008). Despite the worldwide ban of DDT for agricultural purposes (1972-2004
2), it’s 
metabolite, Dichlorodiphenyldichloroethylene (4,4’-DDE), can still be detected in 
human serum and adipose tissues (Ozen et al., 2012), highlighting the long-term 
consequences of lacklustre chemical regulation. Furthermore, significant differences in 
the concentration of environmental pollutants (Cd, Ni, PCB-153 and 4,4’-DDE) 
detected in blood suggest regional differences in exposure and pollutant body burden 
                                                 
1
 http://www.cas.org/content/regulated-chemicals  
2
 Restricted worldwide under the Stockholm Convention 
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(Foster et al., 2012). These regional differences have been supported by Braun et al.’s 
(2012) study, which demonstrated regional differences in urinary BPA concentration, 
with urban and rural Egyptian locations having levels of 1.0 and 0.6 ng/ml, respectively. 
Age matched American girls participating in the NHANES (US National Health and 
nutrition Examination Survey) typically presented higher BPA concentrations 
2.60ng/ml.    
The sewage sludge contaminants Nonylphenol (50-1070 μg NP kg-1), Di-(2-ethylhexyl) 
phthalate (30-4920 μg DEHP kg-1), Polychlorinated biphenyl (0.007–89.19 μg ƩPCB 
kg
-1
), PBDE (0.07-24.91 μg ƩPBDE kg-1) and Benzo(a)anthracene (<1.0-235 μg BaP 
kg
-1
) have been detected in livestock tissue (Rhind et al., 2011). Bellingham et al. 
(2012) reported a significant (p<0.001) association between spermatogenic 
abnormalities and pastoral sewage sludge exposure
3
 in sheep; in utero and postnatal 
exposure reduced germ cell numbers per testis, impairing sperm production. 
Subsequently, the wider consequences of exposure to anthropogenic chemicals for the 
environment have become of paramount concern, and adverse effects observed in 
exposed wildlife have added weight to human health concerns.  
1.1.1 A Human Health Concern? 
In 1992, Carlsen et al. suggested a global 0.8% annual decline in sperm count (1938-
1990), reporting a reduction from 113 x 10
6
/ml to 66 x 10
6
/ml over 50 years. Sperm 
concentrations below 48 x 10
6
/ml may hinder the potential fertility of males (Guzick et 
al., 2001), although lower thresholds have also been proposed (40 x 10
6
/ml by Bonde et 
al., 1998; 20 x 10
6
/ml by Paasch et al., 2008). Founding biological plausibility in the 
testicular dysgenesis syndrome (Skakkebaek, 2001), a number of epidemiology studies 
have drawn associations between declines in male reproductive health and exposure to 
anthropogenic chemicals (see Bergman et al., 2012).  
Andersen et al., (2012) demonstrated a link between maternal occupational pesticide 
exposure and impaired reproductive function; a significant association between in utero 
pesticide exposure and male offspring reproductive tract abnormalities (cryptorchidism 
and hypospadias) (p=0.047). Abnormalities observed in the male offspring cohort 
persisted into adolescence (6-11 years of age), and re-examination by Wohlfarh-Veje et 
al. (2012a) showed significantly reduced testicular volume (p=0.05), 24% smaller testes 
and 9.4% shorter penile length. Furthermore, a relationship between cryptorchidism 
incidence and PDBE exposure has been reported (Krysiak-Baltyn et al., 2012) and 
increased DEHP concentrations have been associated with male infertility and altered 
sex steroid hormone circulation (Mendiola et al., 2012).  
                                                 
3
 Application of 2.25 tonnes dry matter per hectar twice per year to pastoral land 
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In 2010, 48.5 million couples sought in vitro fertilisation (IVF) treatment (ART, 2011) 
and 2% of UK births were due to IVF (HFEA, 2011). Ehrlich et al. (2012) identified a 
statistically significant positive dose-response relationship between urinary BPA 
concentration and IVF implantation failure (p=0.06). Epidemiology and toxicology 
studies have identified a plethora of chemicals that may interfere with reproductive 
health. 4,4’-DDE has been associated with increased incidence of spontaneous abortion, 
foetal loss and preterm birth (Longnecker et al., 2005; Weselak et al., 2008). 
Furthermore, perturbation of the sex ratio was observed in Seveso (Italy), subsequent to 
the accidental release of dioxins in 1976. A significant skew in the sex ratio (48 females 
to 26 males) was reported, which Mocarelli et al. (1996) attributed to maternal and 
paternal dioxin exposure. Thus, chemical exposure may have long-term effects on 
reproductive health and population fecundity. 
Testicular Germ Cell Tumour (TGCT) incidence is increasing in Caucasian populations, 
rendering it the most commonly diagnosed malignant neoplasm in men aged 15-35 
years of age (Chia et al., 2010). Multifactorial in aetiology, the development of TGCT 
is linked to insufficient androgen action in utero (Rajpert-de Meyts, 2006). A number of 
epidemiological studies have reported positive associations between anthropogenic 
chemicals and TGCT (Hardell et al., 2003; Hardell et al., 2004). Chlordanes, 4,4’-DDE 
and some PCB congeners are believed to antagonise the androgen receptor, dampening 
androgen responses (Kojima et al., 2004; Vinggaard et al., 2008). 
Exogenous chemicals capable of perturbing endogenous endocrine function have been 
termed endocrine disrupting chemicals (EDCs). The endocrine system encompasses a 
number of pathways and chemical cues (hormones) that control developmental events 
such as proliferation, growth, differentiation (histogenesis and organogenesis) and 
regulatory processes including metabolism, homeostasis, respiration, excretion, 
movement, reproduction and sensory perception. Subsequently, any substance capable 
of interfering with the synthesis, secretion, transport, binding, action or elimination of 
endogenous hormones, may be an endocrine disruptor. Human health end-points 
associated with endocrine disruption include, reproductive and developmental toxicity; 
teratogenicity; carcinogenicity; neurotoxicity; and, metabolic syndrome (Holt and 
Hanley, 2006).  
1.1.2 Mechanism of Action 
The mechanistic pathways underlying EDC activities encompass a plethora of 
biological receptors, such as: (1) nuclear hormone receptors; (2) non-nuclear steroid 
hormone receptors; (3) non-steroid receptors; and, (4) orphan receptors, such as the Aryl 
Hydrocarbon Receptor (AhR) (Filby et al., 2006). Hormones and their respective 
agonists (chemicals that mimic the action of endogenous hormones causing a cellular 
response) and antagonists (chemicals that can bind, block or dampen agonist mediated 
responses) interact with these receptors to initialise (or block) signal transduction, gene 
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transcription and mRNA translation, which ultimately leads to a cellular response. It is 
the ratio and interplay of all of these pathways that leads to a ‘normal’ homeostatic 
balance (Diamanti-Kandarakis et al., 2009).  
Binding interactions of EDCs can be important in elucidating the biological 
mechanisms by which toxicological endpoints are elicited. For example, an estrogenic 
phenotype may be the result of agonistic activity at the estrogen receptor (ER) or by 
competitively binding to the androgen receptor (AR), thereby blocking the action of 
endogenous androgens, creating an estrogenic environment (Sohoni and Sumpter, 
1998). Furthermore, a substance may mediate phenotypic effects by multiple pathways; 
Prochloraz and Linuron lead to an antiandrogenic phenotype, by both antagonising the 
androgen receptor and by inhibiting the biosynthesis of testosterone (Hotchkiss et al., 
2008).   
 
Figure 1.1 Ligand-Dependent Transactivation of Nuclear Receptors 
Hormones and their respective agonists (chemicals that mimic the action of endogenous hormones 
causing a cellular response) and antagonists (chemicals that can bind, block or dampen agonist mediated 
responses) interact with nuclear receptors (ligand-dependent transcription factors) to initialise (or block) 
signal transduction, gene transcription and mRNA translation, which lead to cellular response 
The endocrine system is highly conserved throughout vertebrates, which mirrors and 
justifies the inter-species extrapolations fundamental to conventional toxicology. 
However, extrapolating in vivo endpoints in one species to another is not without its 
caveats. Differences in the ontogeny of reproductive functions and structures; in the 
metabolism of xenobiotics and endogenous sex steroids; and, in variable body burdens, 
can lead to significant interspecies differences. Assessment of the efficacy of the OECD 
two-year carcinogenicity test guideline, suggested less than 70% concordance between 
rats and mice (Omenn, 2001). Considering phylogenetic distances, human to rodent 
tumour induction concordance may be even lower. Consequently, lifetime rodent 
bioassays, commonly utilised in chronic toxicity testing, may not always correctly 
predict the risk to humans and other species (Selkirk et al., 2005).  
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Potential inter- and intra-species variance in biological machinery complicates 
regulatory risk assessment (Hartig et al., 2007; 2008). Species differences in nuclear 
receptor structure, functionality and xenobiotic binding affinity have been reported. 
Variations in toxic effect as a consequence of genetic polymorphisms and endocrine 
receptor isoforms have also been observed. Västermark et al. (2011) identified an 
association between polymorphic variation in the human androgen receptor gene and 
Testicular Germ Cell Cancer (TGCC) (Odds Ratio 2.07; CI 95% 1.03 – 4.15). The 
authors suggest that minor differences in ligand binding domain may confer elevated 
susceptibility to the effect of endocrine disruptors, leading to androgen insensitivity. 
Comparative analysis of the agonistic activity of pesticides in human and mouse 
pregnane X receptors (PXR)
4
 in silico, demonstrated that a wide range of pesticides 
possess PXR mediated transcriptional activity in both humans and mice. Furthermore, 
pesticide binding to the PXR receptor was shown to be species dependent (Kojima et 
al., 2011).  
Ishiniwa et al. (2010) sequenced the homology of the AhR gene in Japanese field mice 
(Apodemus speciosus) identifying 49 functional alleles expressing phenotypic variance. 
The authors suggest that the AhR polymorphisms detected may alter an individual’s 
susceptibility to disruption by agonists and antagonists of the AhR, such as the common 
chemical by-product, dioxin. Furthermore, functional variation in mouse and human 
AhR unliganded cytoplasm-nucleus shuttling and chaperone proteins, may alter ligand 
binding potential; C57BL/6 mice transfected with human AhR showed lower induction 
of cytochromes 1A1 and 1B1, than wildtype models (Bergman et al., 2011), 
highlighting the uncertainty in extrapolating toxicological findings within species to 
another. This provides further evidence to suggest that rodent species, such as rats and 
mice, may not always be good predictive models of toxic effects in humans, due to 
significant variations in the receptor binding that mediates cellular response, and 
subsequent toxicity (Kojima et al., 2011).  
Endocrine receptor polymorphisms have also been identified in ecological and wildlife 
models; Wells and Van Der Kraak (2000) demonstrated varying binding affinities of 
several EDCs to rainbow trout and goldfish androgen receptors (ARs), emphasising the 
need for multiple models in chemical risk assessment, while Wilson et al. (2007) 
identified similar species variance in the fathead minnow, rainbow trout and human 
ARs. Eco-epidemiological and toxicological studies in birds have found similar 
variances in the development of toxic endpoints within the genus and throughout the 
Aves (birds) class. Dietary exposure to DDE resulted in eggshell thinning in some avian 
species, including the peregrine falcon (Falco peregrines), sparrow hawk (Accipiter 
nisus) and golden eagle (Aguila chrysaetos). However, laboratory studies demonstrated 
that susceptibility to 2,4’-DDE toxicity, and the manifestation of endocrine endpoints, 
was dependent on the avian species considered (Vos et al., 2000).  
                                                 
4
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It is thus clear, that as a relatively new mode of toxicity, the basic biology and 
mechanisms of endocrine disruption are still to be elucidated. Furthermore, if toxicity in 
one species is not necessarily predictive of toxicity in another, the efficacy of 
extrapolations integral to toxicological study and regulatory risk assessment may be 
compromised.  
1.2 A Regulatory Conundrum  
The uncertainty in endocrine disruptor science has been exploited by the media to 
generate headlines such as “Poison” (Girling, 2004), “Ban gender bender used in baby 
bottles” (Derbyshire, 2010a) and “Babies in womb exposed to ‘Gender-bending’ 
chemicals” (Cook, 2006). Public perception of risk is influenced by the media and 
scientific uncertainty (Chryssochoidis et al., 2009). This uncertainty is mirrored and 
enhanced by the varied regulatory stances of European Union (EU) jurisdictions; BPA 
is banned in some US states and Denmark, but remains legal in other EU member states, 
such as the UK. Consequently, endocrine disruption has become a field of hot public, 
regulatory and scientific debate.   
Between 1997 and 2007 it was estimated that global spending on endocrine research 
exceeded $100 million. A figure that has undoubtedly increased in light of the European 
Commission’s (EC) strategy under the Fifth Framework Programme, funding over €60 
million on 23 projects under the auspices of CREDO (Cluster of Research into 
Endocrine Disruption in Europe) and €50 million under the Sixth Research Framework 
Programme. Thus, endocrine disruption presents a cost burden at both national and 
international levels. 
The EC has defined EDCs as “exogenous substances that alter function(s) of the 
endocrine system and consequently cause adverse health effects in an intact organism, 
or its progeny, or (sub) populations” (EC, 1998; ECETOC, 2009). However, there is 
currently no globally accepted regulatory definition of an EDC between jurisdictions, 
consequent to epistemological problems, not only in the science, but regarding the 
regulatory and economic implications of a stringent definition. Furthermore, a lack of 
coherence in acceptance criteria and terminology has curtailed the distinction between 
an endocrine active substance (EAS) and an endocrine disrupter (ED). Nuclear receptor 
binding or ‘endocrine activity’, is not necessarily indicative of endocrine disruption, 
presenting no hazard in itself, but rather the mechanism to a hazard.  
1.2.1 Chemical Safety Testing Strategies 
The focus on apical endpoints utilised by in vivo studies limits their ability to elucidate 
specific biological mechanisms. Subsequently, there is debate regarding the efficacy of 
animal models in accurately predicting possible human health and ecological impacts. 
However, irrespective of the legitimacy of extrapolating animal data to predict 
interspecies health risks, these studies remain the focus of regulatory safety assessment. 
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Understanding the uncertainty and applicability of testing methods is essential in 
effectively characterising and communicating risks. 
Contrary to a conventional toxicological study, which generally extrapolates high dose 
toxicity to low dose exposure, it is generally accepted that endocrine disruption is a 
mechanism that may result in a hazard, rather than being a hazard itself, and 
subsequently may not conform to archetype dose-response relationships; demonstrating 
low-dose toxicity or hormesis (EC, 1999). Non-monotonic relationships have been 
observed for a number of EDCs; induction of metabolising enzymes or conjugation 
substances may result in U-shaped dose responses. Effects at low and at high levels of 
exposure, and diminished or non-existent toxicity at intermediate exposure levels due to 
increased metabolic breakdown or elimination, further complicates testing strategies and 
regulatory risk assessment, which balances chemical safety with economic feasibility.  
Furthermore, due to cost and time restraints, only a limited number of chemicals are 
investigated in chronic two-year toxicity studies, such as those utilised for the 
assessment of carcinogenicity or reproductive and developmental toxicity (e.g. only if 
production exceeds 1000t/year) (Borlak, 2006). Consequently, there is uncertainty in the 
risks of chronic exposure to most chemicals.  
Low tier testing is deliberately over-responsive, detecting chemicals with the capacity to 
interact with biological receptors without necessarily inducing adverse endpoints, in 
order to minimise the risk that EDC’s will go undetected; i.e. presenting a low false 
negative and high false positive rate. It is unlikely that in vitro and in vivo assays will 
supersede in vivo tests in a weight-of-evidence (WoE) assessment, due to limited 
pharmacokinetic and pharmacodynamics parameters (e.g ADME). However, a two-year 
carcinogenicity study uses approximately 800 animals per species (N3CRs, 2014; Long, 
2007) and costs in excess of $1 million (~£601,214) (Schmidt, 2006). Thus, utilising 
endocrine-relevant in vivo test guidelines for the screening and prioritisation of 
chemicals on the market (>12,399 unique registered substances
5
 in excess of 1 
tonne/year), is not feasible. Furthermore, a positive bioassay result is not necessarily 
indicative of a positive result in an intact organism, and the European Food Safety 
Authority (EFSA) stress that all evidence should be assessed in a WoE approach 
(EFSA, 2010).   
Aiming to develop alternative non-animal approaches to toxicological study, the 2010 
European Partnership for Alternative Approaches to Animal Testing (EPAA) 
‘Harnessing the Chemistry of Life: Revolutionising Toxicology’ workshop, gathered 
international experts in chemistry, systems biology and toxicology to discuss the 
challenges and potential solutions these sciences may offer. Assurance of in silico and 
                                                 
5
 As of the 19
th
 March 2014, the European Chemical Agency (ECHA) REACH database contained 12,399 
unique substances, from 47,731 dossiers (http://echa.europa.eu/information-on-chemicals/registered-
substances [Accessed 31/03/2014 12.10am]).  
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in vitro predictions, in lieu of chronic animal studies, was highlighted as a significant 
challenge to future work (Kimber et al., 2011). Furthermore, the necessity of 
incorporating metabolism, toxicodynamics and toxicokinetics into non-animal models 
was stressed.  
An ideal screening tool should be rapid, cost effective and reflective of multiple 
mechanisms of concern (Ankley et al., 1998). Many in vitro screening programs have 
been developed to identify potential EDCs and assess both ecological and human health 
risk, by assessing competitive binding of xenobiotics to receptors (Van Der Kraak, 
2000). More recently, alternative in silico bioinformatics approaches have been 
suggested to predict mechanisms and prioritise chemicals for in vitro and in vivo 
screening (Bohl et al., 2007; Schilter et al., 2014).  
1.3 The EDC Problem  
Chemicals are detected ubiquitously in the environment, wildlife and humans. Chemical 
exposure, at environmentally relevant concentrations, has been linked to declines in 
wildlife ecology. Furthermore, the breadth of research has started to bridge the gap 
between effects observed in wildlife and human epidemiological speculation (Bergman 
et al., 2012).  
In the EU, the human health costs of EDC exposure has been estimated at €31 billion 
per annum (HEAL, 2014). In crude calculations by economists, Hunt and Ferguson, 
evaluated the monetary cost of: reproductive disorders; fertility problems; 
cryptorchidism; hypospadias; cancer of the breast; prostate and testes; behavioural 
disorders, such as autism and attention deficit hyperactivity disorder (ADHD); and, 
metabolic disorders such as obesity and diabetes (HEAL, 2014). Of the €636-637 bn/y 
cost identified, 2-5% was attributed to EDC exposure. The estimation is biased and does 
not account for potential health costs incurred by banning chemicals; via reduction in 
cleanliness, pest control and economic factors, which can also negatively impact health 
quality. Nevertheless, the calculation emphasises the potential health cost of inadequate 
chemical regulation. 
EDC’s are restricted by EU law, but without specific scientific criteria to enable 
adequate regulation, abidance to the legislation is questionable. The EC missed the 2013 
deadline for defining an EDC for regulatory purposes, undoubtedly due to the 
implications of a stringent definition. For example, the EC definition necessitates 
“adverse health effects in an intact organism…” Adopting this definition would mean 
that lower tier testing, including some in vivo bioassays, in vitro assays and in silico and 
QSAR predictions, would not be sufficient to regulate chemicals, requiring a tier 5 in 
vivo test (~2 years). This reliance on in vivo toxicology studies conflicts with national 
(UK/EU) and international (OECD) obligations to reduce scientific procedures on 
animals. The economic, ethical and time infeasibility of testing 311,000 chemicals in 
vivo, demands the development of alternative methods (in silico and in vitro) to 
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elucidate endocrine mechanisms of action. Data gaps currently add significant 
uncertainty to the applicability of mechanistic studies in regulatory risk assessment.  
1.4 Research Aims and Objectives  
To the author’s knowledge, no single study has quantitatively assessed the relationship 
between in silico nuclear receptor binding and in vitro mechanistic assays, in a 
comprehensive manner. This study aims to evaluate current in silico and in vitro tools 
for EDC screening and hazard characterisation; testing the hypothesis that in silico 
virtual screening accurately predicts in vitro mechanistic assays, which are more adept 
to elucidate endocrine mechanism of action (MoA) than traditional in vivo toxicity tests. 
Detailed review of EDC literature aims to identify caveats and considerations, 
knowledge of which may reduce the uncertainty of in silico and in vitro analyses. The 
historical context and molecular mechanisms underpinning endocrine disruptor science 
are elucidated, assessing their relevance to chemical screening and regulation.  
Nuclear receptor (NR) agonism and antagonism is a biological mechanism by which 
adverse endocrine endpoints may be incurred. Binding interactions of NRs are currently 
the focus of in vitro and in silico tools used to predict EDC mechanisms. As previously 
alluded to, it is not feasible to assess ‘all’ potential effects putatively ascribed to 
endocrine active substances. Consequently, in silico and in vitro approaches were 
prioritised based on their regulatory acceptance, biological plausibility and availability. 
The purpose of this thesis is not to provide a detailed review of all MoA and test 
guidelines associated with EDCs, but to evaluate the current state of the science 
regarding adoption of in silico and in vitro tools, to characterise EDC hazards for 
regulatory purposes. Consequently, it is anticipated that the methods adopted herein will 
reflect the current assumptions regarding EDC mechanisms. The aims and objectives of 
this study are summarised in Table 1. 
Computational chemistry can characterise the dynamics, energetics and structure of 
ligand-receptor interactions (Taft et al., 2007). Thus, computational chemistry presents 
a solid foundation for in silico toxicological study, particularly with regard to receptor-
mediated activity. It is anticipated that in silico molecular modelling of nuclear 
receptors will generate computational 3D-representations of nuclear receptor binding 
domains. Aiming to evaluate the possibility of adopting in silico molecular modelling to 
EDC hazard characterisation, modelled nuclear receptors were virtually screened 
against a chemical database of potential EDC’s. Curated on the basis of regulatory 
concern, exposure, structural variability and assumed functionality, the chemical 
database aims to include a diverse array of potential-EDCs, for virtual screening. The 
sensitivity of in silico molecular modelling for EDC hazard characterisation will be 
assessed relative to published in vitro bioassay results.  
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A number of in vitro studies have shown that EDC binding affinity is species specific 
(Lange et al., 2012; Wilson et al., 2007). Interspecies variation in NR homology and 
binding affinity has also been reported in silico (Wu et al., 2010; Kojima et al., 2011). 
Phylogenetic analysis of nuclear receptor sequence homology aims to identify species 
differences at the most basic biological level. The harvesting of nuclear receptor (ER, 
AR, etc.) sequences published on databanks
6
, using DNA base-pair homology search 
terms (BLAST), will be used to phylogenetically map evolutionary changes in receptor 
sequence, which may impede comparisons between species. However, receptor 
sequence variance is not necessarily representative of receptor function variance; many 
amino acid substitutions, deletions or insertions may not affect the binding interactions. 
Thus, the aforementioned objective of phylogenetic analysis is inadequate to determine 
functional differences in receptor binding.  
Table 1.1 Summary of Thesis Aims and Objectives 
As a whole, this study aims to evaluate the ‘state-of-EDC-science’ and currently available in silico and in 
vitro tools for EDC screening and hazard characteriation. Contributory aims are identified on the left side 
in bold, while objectives are stated on the right. 
 
NR structures from different species shall be virtually screened against the compound 
database, potentially enabling in silico predictions of interspecies differences in EDC 
binding. However, it should be noted that, the objectives, of phylogenetic modelling and 
molecular modelling, are inherently caveated by the availability of NR sequence and 
structure information, potentially limiting the evaluation.  
                                                 
6
 UniProt (http://www.uniprot.org/uniprot/) 
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Aiming to evaluate the current in vitro tools for endocrine modes-of-action, it is 
anticipated that potential-EDCs, prioritised on the basis of in silico screening results and 
in vitro assay requirements, will be tested in standardised in vitro mechanistic assays. In 
vitro transactivation assays are significantly cheaper (~£1,500–£2,000 per chemical) 
than in vivo exploration (OECD, 2012). However, the cost renders testing ‘all’ 
chemicals in vitro infeasible – cheaper, high-throughput virtual screening, as suggested 
herein, is thus required. Virtual screening has been suggested as a tier 1 regulatory test 
(OECD conceptual framework level 1), driving the development of molecular methods 
(Worth et al., 2014; Kojima et al. 2011; Cronin & Worth, 2008).  
The in vitro methods aim to provide mechanistic and potency information for EDC 
hazard characterisation. Recently adopted by the OECD, in vitro estrogen receptor 
agonism transactivation assays, in addition to more novel in vitro methods, will be used 
to assess the MoA of potential EDCs. The in silico and in vitro results will be compared 
to the literature and in vivo evidence, to characterise the hazard of potential EDCs, and 
assess more formal adoption of in silico tools. 
In summary, merging the interfaces of bioinformatics, computational chemistry, 
endocrinology, in vitro cell culture and toxicology, this study aims test the null 
hypothesis that in silico and in vitro mechanistic tools, are more adept to elucidate 
endocrine MoA, than traditional in vivo toxicity tests. The sensitivity of adopted 
methods, relative to published bioassay results and OECD validated in vitro assays, will 
determine the feasibility of incorporating the novel in silico and in vitro tools into 
regulatory screening and prioritisation. It is not expected that the methods detailed 
herein, will conclusively predict endocrine disruption, but it is anticipated that the in 
silico and in vitro screens may predict endocrine activity, to prioritise chemicals for 
more conclusive higher tier testing.  
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2 BACKGROUND INFORMATION 
2.1 The ‘Start’ of the Science 
2.1.1 Endocrinology 
‘Hormone’ is derived from the Greek word ‘hormaein’ meaning to ‘arouse’ or ‘excite’, 
and was first coined by Sir Ernest Starling in 1905. Endocrinology is the study of the 
endocrine system, its diseases, and the biosynthesis and secretion of hormones that 
modulate development (histogenesis and organogenesis), metabolism, respiration, 
excretion, movement, reproduction and sensory perception. Co-ordinating internal 
physiology, the endocrine system regulates development and homeostasis, enabling 
adaptation to a milieu of nutritional and environmental changes (Figure 2.1). The 
hormones and receptors that compile the endocrine system are ubiquitous to all 
vertebrates and some invertebrates (WHO, 2002). Hormones bind to specific receptors, 
either on the surface or within the target cells, to initiate a cascade of intracellular 
reactions, which amplifies the original stimulus and generates a cellular response 
(Brook and Marshall, 2005).  
Table 2.1 Classes of Hormone 
Based on their chemical composition, Griffin and Ojeda (1996) identified three classes of hormone: 
amines, peptides and steroid hormones.  
 
There are two superfamilies of receptors: receptors for water soluble hormones such as 
insulin, which can only enter the cell via active transport; and, nuclear intracellular 
receptors that interact with the lipophilic steroid and thyroid hormones, which enter the 
cell passively. Located in either the cytosol or the nucleus of the target cell, the 
receptors mediate responses to three classes of hormone (Table 2.1).  Hormones may be 
enzymically modified by their target cells (e.g. the deiodination of T4 to T3 by 5’-
deiodinase) in order to bind and stimulate nuclear receptors. Cellular modification 
provides an important mechanism for the local regulation of hormone action at the 
target tissue. Defects in the components of these pathways, receptors or intracellular 
mediators can lead to an array of endocrinopathies (Brook and Marshall, 2005). 
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Figure 2.1 Organs and Glands Associated with the Human Endocrine System 
Co-ordinating internal physiology, the endocrine system regulates development and homeostasis via a 
multitude of organs and glands, to enable adaptation to a milieu of nutritional and environmental changes. 
Diagram details the role of: hypothalamus; pituitary; thyroid; adrenal; pancreas; pineal; and parathyroid 
glands.  
The endocrine system is generally regulated by negative feedback; the hormone 
stimulates a pathway and inhibits production of the initiating hormone. However, under 
more unusual circumstances hormone feedback can enhance, rather than inhibit, 
secretion of the initiating hormone - termed positive feedback. For example, estrogen 
induced ovulatory surges of luteinising hormone and follicle stimulating hormone 
during childbirth (Holt and Hanley, 2006).  
Logistically, the structure of hormone-receptor complexes highlights the biological 
plausibility of endocrine perturbation; larger structurally complex hormones, such as 
insulin, may be harder for xenobiotics to mimic. Furthermore, water soluble xenobiotics 
may not be actively transported across the cell membrane, unless mistaken by channel 
ion proteins. Endocinology validates the primary focus of endocrine disruption on the 
steroid hormones (estrogens and androgens) and amines (thyroid hormones). However, 
endocrine disruptor science did not begin under the auspices and biological plausibility 
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of endocrinology, but rather through adverse effects observed in wildlife populations. 
Subsequently, the science has developed under the bias of observation, in which 
mechanisms were assumed by reported apical endpoints, in a top-down manner.  
2.1.2 The Rise of Environmentalism  
As detailed in the introduction (Section 1), anthropogenic activities have drastically 
altered the pattern of chemical exposure. Concerns over the repercussions of synthetic 
chemicals on wildlife were initially highlighted in 1962, by the publication of Rachel 
Carson’s ‘Silent Spring’. The book, depicting a barren world resultant of the intensive 
use of organochlorine pesticides, prompted the then President of the USA J. F. Kennedy 
to order an examination into the misuse of pesticides (Lear, 1998). Adding evidence to 
Carson’s concerns, in 1967 Ratcliffe reported that eggshell thickness in bird species 
indigenous to Great Britain, such as the peregrine falcon (Falco peregrines), sparrow 
hawk (Accipiter nisus) and golden eagle (Aguila Chrysaetos), had declined since 1946 - 
coinciding with the introduction of the pesticide DDT (Vos et al., 2000). Exposure to 
DDE, the degradation product of DDT, has since been demonstrated to also reduce 
eggshell thickness (Struger et al., 1985) and reduce fecundity, which nearly resulted in 
the extinction of several avian species in North America. DDT was banned in Western 
Europe and North America in the 1970s (Kime, 1998). Consequent to the ban of 
organochlorine pesticides and polychlorinated biphenyls (PCBs), notable increases in 
population number and eggshell thickness have been reported.  
Exposure to Tributyltin (TBT), the active ingredient of antifouling paints used on ship 
hulls, has been shown to cause imposex in 150 species of marine snail (Matthiessen et 
al., 1995). High prevalence of intersex, a condition in which the sexual phenotype of 
molluscs is disturbed, was also reported in the German Wadden Sea periwinkle 
(Littorina littorea) following exposure to environmentally relevant concentrations of 
TBT (10 – 15 ng L-1) (Bauer et al., 1995; Bauer et al., 1997). The effects of TBT and 
Triphenyltin (TPT), on mollusc sexual development and mollusc populations, are 
considered one of the best documented incidences of ecologically relevant endocrine 
disruption to date. Matthiessen et al. (1995) demonstrated significant recovery in 
imposex-affected populations as a result of the restriction of TBT in 1987 and 
subsequent ban in 2000, highlighting the positive impact of good environmental 
regulation on biodiversity.  
The adverse effects observed in birds and molluscs, as a result of exposure to DDT and 
TBT, respectively, have now been attributed to perturbation of the endocrine system. 
The subsequent section (2.1.3 Wildlife Effects) aims to highlight the ecological impacts 
of inadequate chemical governance; summarising the epidemiological and laboratory 
evidence for endocrine disruption in wildlife (by phylogenetic Class).   
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2.1.3 Wildlife Effects 
2.1.3.1 Invertebrates 
Comprising 95% of faunal species, with 30 phyla, invertebrates represent the most 
mechanistically diverse endocrine system (WHO, 2002; Ketata et al., 2008). However, 
vertebrate neurotransmitters, neurohormones and steroid hormones have also been 
detected in invertebrates (Lafont & Mathieu, 2007). In 1996 Bettin et al. reported that 
masculinisation of female gastropods was due to elevated Testosterone, consequent to 
inhibition of an aromatase enzyme that metabolises T to 17β-estradiol (E2). More 
recently, it has been shown that the accumulation of TBT in nerves and ganglia is 
associated with neurotoxicity which stimulates the production of Penis Morphogenic 
Factor (PMF), inducing the development of male secondary sex characteristics 
(Oberdörster and McClellan-Green, 2002). Testicular ooctyes and intersex have been 
reported in populations of lobsters (Homarus americanus) living near sewage outfalls 
(Sangalang & Jones, 1997). Sewage and industrial effluent discharged into rivers, a 
source of EDCs, has been demonstrated to affect numerous invertebrate species (Oetken 
et al., 2003; Tillmann et al., 2001).   
Terpenoid and ecdysone hormones play a vital role in the physiology, morphology and 
behaviour of invertebrates, generating a wide range of phenotypic variation. Oda et al. 
(2011) investigated antipredatory responses in cladiceran, Daphnia galeata, in response 
to Methyl fenosoatote (MF) (1.9 to 30 µg/L) and the juvenile hormone-mimicking 
pesticide, fenoxycarb (12 to 200 ng L
-1
). Animals developed a longer helmet at doses of 
1.9 µg L
-1
 and 25 ng L
-1
 fenoxycarb, in a dose dependent fashion, suggesting that MF 
affects allometrical growth, altering development of Daphnia defensive morphology. As 
helmet size and phenotypic plasticity is believed to be beneficial to organisms, 
conferring adaptation, the authors suggest shifts in the biological interaction between 
predator and prey, consequent to terpenoid hormone exposure. Perfluoroctane sulfonic 
acid exposure (2184±365 ng PFOS/g body weight) in the bumblebee, Bombus terrestris, 
reduced survival and reproductive capacity (Mommaerts et al., 2011). The authors 
report antagonism of the EcR-b.act.luc reporter construct, suggesting an endocrine 
related mechanism of action.  
2.1.3.2 Fish 
Water is a key pathway for contaminant exposure and fish play an important role in 
assessing the ecological consequences of pollution. There are approximately 28,000 
species of fish, comprising teleosts, chondrichyhyes and lampreys, which may be either 
gonochoristic or hermaphroditic (Scholz and Kluver, 2009). Sumpter (2005) showed 
that environmental estrogens exposure increased vitellogenin concentration and 
decreased reproductive potential. Increased plasma levels of the egg yolk precursor 
vitellogenin can be used as a specific biomarker of estrogen exposure in fish. Elevations 
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in vitellogenin have been observed in the wild roach (Rutilus rutilus), fathead minnow 
(Pimephales promelas), carp (Cyprinus carpio) and zebrafish (Danio rerio) among 
other fish species (Bergman et al., 2012).  
Effluents from municipal waste treatment plants frequently contain high concentrations 
of estrogenic, pharmaceutical and anti-androgenic compounds (Purdom et al., 1994). 
The concentrations of 17β-Estradiol (E2) in Sewage Treatment Work (STW) effluents 
ranges from 3.7 to 80 ng L
-1
. Induction of vitellogenin and intersex in response to 
EDC’s has been reported in a number of locations worldwide (Desforges et al., 2010). 
Lange et al. (2011) exposed R. rutilus to either 50% or 100% STW effluent from 35 
days post hatch, for up to 3.5 years post exposure. The study demonstrated a 
predominance of the female phenotype and, subsequently, declines in spawning. Cotton 
and Wedekind (2009) suggest that feminisation could potentially result in moderate 
population increase, as females are a limiting factor in breeding success, however, little 
is known about the reproductive capability of sex reversed male offspring. Alterations 
in testicular histopathology, including alterations in spermatozoa parameters, have been 
observed in stickleback (Gasterosteidae) exposed to STW effluent (Bjorkblom et al., 
2009). Furthermore, the potential loss of genetic variability in affected populations may 
have serious repercussions on biodiversity (Jobling et al., 2006).  
Johnstone et al. (1978) demonstrated dietary administration of 17β-Estradiol (E2) 
suppressed both weight and length of rainbow trout (Oncorhynchus mykiss).  Population 
survival is intrinsically linked to growth, due to larger fish being more successful at 
competing for resources. Thus, exposure to chemicals that perturb individual growth 
may affect population success (Ashfield et al., 1998; Elliott, 1990). Lavelle and 
Sorensen (2011) assessed the effects of EDC exposure on P. promelas breeding, using 
competitive spawning experiments. Males exposed to E2 (44 ng L
-1
) for three weeks 
failed to compete with unexposed fish, while male fathead minnows exposed to the 
lowest dose (4 ng L
-1
) outcompeted and sired more young than unexposed individuals 
(p<0.05), indicative of hormesis
7
. The authors conclude that estrogenic effluents may 
determine the reproductive success of male fishes. Supporting this, 5 ng EE2 L
-1
 
exposure in D. rerio led to complete sex reversal and reproductive failure, however, no 
statistically significant effects were observed at 0.5 ng EE2 L
-1
 or 5 mg EE2 L
-1 
(Gutjahr-Gobell et al., 2006).  Presenting an inverted ‘U-shaped’ dose response curve, 
Gutjahr-Gobell et al.’s study adds further weight to EDC hormesis hypotheses. 
2.1.3.3 Amphibians and Reptiles 
Tetrapod in descent, amphibians and reptiles present diverse mechanisms of 
metamorphosis and reproduction. An estimated 32% of amphibian species are 
                                                 
7
 Hormesis refers to a biphasic dose response, characterised by low dose stimulation, and high dose 
inhibition 
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threatened with extinction (GAA, 2004). Xenobiotic chemicals have been shown to alter 
amphibian vitellogenin expression, metamorphosis, osmoregulation and migrational 
behaviour (WHO, 2002; Palmer & Palmer’s, 1995). Bishop et al. (1991) identified a 
significant correlation between PCB exposure in snapping turtles (Chelydra spentinia 
sepentinia) and hatchling success and developmental abnormalities.   
Devoid of distinct sex chromosomes, some amphibians and reptiles determine gender 
by incubation temperature during organogenesis (temperature-dependant sex 
determination (TSD)) (Crain & Guillette, 1998). TSD is mediated by the up-regulation 
of SOX9 at male-producing temperatures and aromatase up-regulation at female 
producing temperatures, resulting in elevated 17β-Estradiol (E2) levels in ovo (Pieau & 
Dorizzi, 2004). Exogenous hormones have been shown to alter TSD (Crain et al., 
1997).  
As a Class of approximately 8225 species, Reptilia is undoubtedly the most under-
represented ectotherm in EDC research. However, accidental contamination of Lake 
Apopoka, Florida (1980), exposed alligators to high pesticide concentrations (Crain et 
al., 1998) which stimulated research. Elevated levels of dicofol, DDT and their 
metabolites were found in alligator eggs and surviving juveniles – in which there was a 
90% decline (Heinz et al., 1991; Guillette et al., 1996; Guillette & Gunderson, 2001). 
Increased incidence of developmental abnormalities were observed in male juvenile 
alligators; these included abnormal gonads, altered hormone concentrations and an 
average 24% reduction in penis size (Guillette et al., 1996). Male testosterone levels 
were depressed to levels comparable to females from a reference site, while females 
from the contaminated site showed nearly twice the E2 plasma concentrations 
considered as normal. Unresponsive gonadal steroidogenesis, in exposed males treated 
with exogenous luteininsing hormone, indicated permanent in ovo changes in the 
gonads. However, due to the ecoepidemiological nature of the study, causality is 
difficult to define (WHO, 2002). Similar observations in alligator gonadal morphology 
have been observed in other contaminated wetlands (Hamlin et al., 2010). However, 
contradicting previous conceptions, the potential role of nitrates was also identified 
(Edwards and Guillette, 2007). Cadenas et al. (2000) demonstrated disruption of key 
steroidogenic enzymes and P450 enzymes involved in steroidogenesis and liver 
clearance, following exposure to nitrate, which is converted to nitric oxide by vertebrate 
mitochondria in mosquitofish. This impairment in liver function has been associated 
with an increase in circulating steroid hormones (Hamlin et al., 2008).   
2.1.3.4  Birds 
The complex social behaviours, neurodevelopment and reproductive success of birds, is 
intrinsically linked to hormone levels, rendering the species susceptible to endocrine 
disruption. Contrary to mammal sexual development, the male phenotype is dominant 
(the default), while the female phenotype of birds relies on the synthesis of estrogen by 
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the ovaries during embryogenesis (Brunström et al., 2003). Testosterone exposure has 
been linked to a male-biased skew of the sex ratio in spotless starlings, Sturnus unicolor 
(Veiga et al., 2004) and homing pigeons, Columba liva (Goerlich et al., 2009). 
Furthermore, Erikstad et al. (2009) identified a female-biased skew of the sex ratio of 
lesser black-backed gull (Larus Fuscus) populations with high organochlorine burdens.  
Other adverse reproductive effects observed in birds include eggshell thinning, 
embryonic foot, bill and spine deformities, chick death and retarded growth (Bowerman 
et al., 2000; Best et al., 2010). Asymmetrical primary feathers reported in great tits 
(Parus major) exposed to metal smelter fumes, indicative of elevated stress, suggest 
that the adrenocorticoid axis may also be susceptible to endocrine disruption in birds. 
Regarding social behaviour, laboratory studies have shown in ovo DDT, 
Diethylstilbesterol (DES) and EE2 exposure leads to alterations in adult male Japanese 
quail (Coturnix japonica) sexual behaviour (Bryan et al., 1989; Van den Berg et al., 
1998). Similarly, studies on Ring Doves (Streptopelia risoria) found that mixtures of 
DDE, PCBs, Mirex and Photomirex, led to altered sex hormone production, resulting in 
females failing to respond to male courtship behaviours (McArthur et al., 1983). Prior 
to this, changes in wildlife behavioural patterns were noted in gulls native to Southern 
California, in which female-female pairing was observed (Hunt and Hunt, 1977). The 
colonies under observation were in areas contaminated with high levels of 
organochlorines, leading to the suggestion that this behaviour was attributable to 
endocrine disruption (Fry and Toone, 1981). Similarly, in North American gull 
populations skewed sex ratios and female-female pairing have been observed in regions 
contaminated with DDT (Fox, 1992). 
2.1.3.5  Mammals 
Bioaccumulation of PCBs, DDT and their persistent methylsulfone metabolites has been 
reported in Baltic Grey Seals (Halichoerus grypus) and Ringed seals (Pusa hispida) 
native to the Baltic Sea. One-fortieth of the volume of The Baltic Sea is attributable to 
run-off from adjacent countries, leaving it particularly susceptible to xenobiotic 
pollution (Thulin and Andrushaitis, 2003). This bioaccumulation has been associated 
with significant declines in seal populations, uterine stenosis
8
 and occlusions in 30% of 
adult grey seals and 70% of ringed seals that were autopsied (Bergman et al., 1994). 
The Helsinki Commission (HELCOM) 1988 Ministerial Declaration reduced the burden 
of chemicals emitted into the Baltic Sea by 20 – 50%. Baltic Seal fecundity has 
subsequently improved and population numbers increased (Bergman, 1999). The 
Semifield Reproduction laboratory studies later confirmed these ecoepidemiological 
findings – demonstrating that both reproduction and immune systems were impaired by 
PCBs in common seals (Reijinders, 1986). This immune dysfunction was associated 
                                                 
8
 which is an abnormal narrowing of a tubular organ or structure, also referred to as a stricture or 
coarctation 
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with mass mortalities as a result of morbillivirus infections (Vos et al. 2000). The 
reported association between immune dysfunction and EDCs has been strengthened by 
an epizootic
9
 in striped dolphins (Stenella coeruleoalba) consequent to xenobiotic 
exposure; Aguilar and Borrell (1994) suggested that mobilised concentrations of PCBs 
led to an increase in susceptibility to the Mediterranean morbillivirus in 1990.  
Alterations in reproductive function consequent to PCB exposure, has also been 
reported in mustelids, including the European otter (Lutra lutra) and the Mink (Mustela 
vision) (Kihlström et al., 1992; Leonards, 1997; Roos et al., 2001). Laboratory studies 
in mink demonstrated a dose-response relationship between fecundity and concentration 
of PCB consumed per day (Brunstrom et al., 2001). Exposure to EDCs has also been 
tenuously associated to high levels of cryptorchidism in the male Florida panther (Felis 
concolor coryi). Sperm abnormalities, thyroid dysfunction and sterility have also been 
reported (Facemire et al., 1995). More recently, as a model of high trophic level 
carnivore organohalogen susceptibility, Kirkegaard et al. (2011) exposed post-weanling 
female Greenland sledge dogs to 128 µg PCB/day. Relative to sister controls, lower 
thyroid hormone (T3 and T4) levels were observed in bitches at 10 months of age. 
Authors reported a significant negative correlation between thyroid gland weight and 
∑DDT and a positive association between total T3 and dieldrin - supporting the 
hypothesis that organohalochlorines (OHCs) may adversely affect thyroid function. 
Alterations in thyroid function may have significant behavioural, neurological, 
neuropsychological and thermoregulational consequences throughout all periods of 
development.  
Hejmej et al. (2011) assessed the in vivo effects of exposure to 4-t-Octylphenol (OP) 
(200 mg kg
-1
 bw) on male testes and seminal vesicle development in bank vole 
(Clethyrionomys glareolus). Histological examination identified elevated expression of 
3β-hydroxysteroid dehydrogenase and androgen receptor, in addition to increased 
testosterone levels. Interestingly, the observed endpoints were more evident in voles 
kept under long photoperiods, suggesting that the susceptibility to OP toxicity varied 
with external zietgebers such as light, highlighting hormonal interplay with circadian 
rhythms. 
2.1.4 Summary 
A plethora of developmental, reproductive and behavioural perturbations have been 
reported in wildlife exposed to anthropogenic chemical contaminants.  From the birds to 
the bees, endocrine disruption appears to be omnipresent throughout phylogenic classes. 
The similarity of the endocrine system and its components throughout phyla, in 
combination with the aforementioned disruption in wildlife, has led to mounting 
concern regarding the consequences of EDC exposure on human health (Bergman et al., 
                                                 
9
 the unprecedented increase of a disease in an animal population, equivalent to an epidemic in humans 
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2012; Colborn and Clement, 1992).  The following section ‘Evidence for Endocrine 
Disruption in Humans: A Human Health Concern?’ summarises the literature pertaining 
to human endocrinology, biological plausibility, epidemiology and endocrine disruption 
in humans.  
2.2 Evidence for Endocrine Disruption in Humans: A 
Human Health Concern? 
The average human is comprised of over 10
14
 cells of more than 200 different cell types, 
which require an effective communication system to concord function (Holt and 
Hanley, 2006). As in any complex regulatory system, functional perturbation of the 
endocrine system has consequences; for example, lack of growth hormone (GH) in 
children causes dwarfism, while excess GH hormone leads to gigantism (Brook and 
Marshall, 2005). In this section, the biological plausibility and evidence pertaining to 
human endocrine disruption is captured under three headings: reproductive health; 
hormonal cancers; and, metabolism and developmental health.  
2.2.1 Reproductive Health 
Genetic sex is determined by the paternal X or Y chromosome during fertilisation. 
However, the mechanism translating a zygotes genetic sex, into the sexually dimorphic 
male and female phenotypes (gender), is dependent on a plethora of genetic, hormonal, 
psychological and social factors. The regression of the Müllerian duct and virilisation
10
 
of the Wolfian duct are vital to male development; fetal testis secrete anti-Müllerian 
hormone (AMH), a glycoprotein synthesised by the Sertoli cells during foetal life. The 
action of AMH is ipsilateral
11
 and the Müllerian duct is only sensitive to AMH between 
the 7
th
 and 8
th
 weeks of intrauterine life. In the absence of these testicular secretions, the 
female phenotype persists into postnatal life.  
Testosterone is responsible for virilisation of the Wolffian duct. Conversion of 
Testosterone to 5α-Dihydrotestosterone necessitates virilisation of the foetal external 
genitalia and the development of the prostate, which is dependent upon the 5α-reductase 
enzyme in those foetal derivatives of the urogenital sinus. Failure of one of these 
components, such as a deficiency of 5α-reductase, may lead to abnormal sexual 
differentiation (Brook and Marshall, 2005). Hermaphriditism, the presence of both 
functional testicular and ovarian tissue, and pseudohermaphroditism, which details 
either abnormal male or female sexual development, are usually indicative of early in 
utero disruption. 
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 Virilistion is the development of male secondary sex characteristics  
11
 Located or affecting on the same side of the body 
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The maintenance of reproductive capability is reliant on the secretion of a milieu of 
hormones.  In males, the control of gametogenesis, or spermatogenesis, is dependent on 
Luteinising Hormone (LH) and Follicle-Stimulating Hormone (FSH) secretion, which is 
inhibited by the negative feedback of Testosterone and Inhibin. FSH and LH also 
mediate the production of female ova, which is regulated by negative feedback of the 
ovarian hormones (estrogen, progesterone and inhibin). Ovulation is initiated by a surge 
of luteinising hormone mid-cycle, temporarily switching to positive feedback by 
estrogenic action on the pituitary, causing follicular development, luteolysis and 
menstruation. Estrogens also maintain secondary sexual characteristics (Holt and 
Hanley, 2006). Excess gonadotrophins usually reflect a loss of negative feedback from 
the testis or ovary; for example during the female menopause, depleted ova ends 
cyclical ovarian hormone production.  Inappropriately timed GnRH secretion can cause 
central precocious puberty. Cyclical gonadotrophin secretion in women is exceptionally 
vulnerable to perturbation - exercise, excessive dieting and stress, can all be sufficient to 
temporarily silence the reproductive axis (Holt and Hanley, 2006). The hormonal 
regulation and sensitivity of the reproductive axis, scientifically justifies for a role of 
EDC’s in the aetiology of reproductive disorders.     
2.2.1.1  Male Reproductive Health 
Male infertility can be consequent to defective spermatogenesis and reduced sperm 
concentrations are believed to be the cause of infertility in 20% of males (Yong et al. 
1998). Spermatogenesis may fail due to reductions in LH and FSH secretion and high 
levels of prolactin can cause testicular involution and impotence, due to its role in 
gonadotropin release. However, male infertility is typically attributed to a primary fail 
of the testis, resultant of cryptorchidism
12
 or testicular damage. Incidence rates of 
cryptorchidism, hypospadias and reductions of sperm parameters, generally coincide, 
leading to speculation of a common aetiology. The testicular dysgenesis syndrome 
(TDS) hypothesis suggests that perturbation of androgen levels during foetal 
development of Sertoli cells (the cells supporting germ cells) and Leydig cells (the site 
of androgen biosynthesis), negatively impacts the functioning and development of male 
reproductive endpoints (Skakkebaek et al., 2001).  
Spermatozoa production is under hormonal control, potentially rendering it susceptible 
to endocrine disruption (WHO, 2002). In 1992, Carlsen et al. suggested global 0.8% 
annual declines in sperm count since 1938; reporting a reduction from 113 x 10
6
/ml to 
66 x 10
6
/ml over 50 years. Sperm concentrations below 48 x 10
6
/ml are generally 
considered to hinder the potential fertility of males (Guzick et al., 2001), although, 
lower thresholds, of 40 x 10
6
/ml (Bonde et al., 1998) and 20 x 10
6
/ml (Paasch et al., 
2008) have also been proposed. The applicability of sperm counts as a biomarker of 
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 the failure of either one or both testicles to descend, representative of the incomplete movement of 
testis from an abdominal position to the ipsilateral scrotum 
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male reproductive health is however questionable, due to natural variation and 
fluctuation in counts as a result of abstinence, ethnicity, infectious disease, season, 
clothing and drug abuse (Carlsen et al., 2005). Nonetheless sperm count can be used as 
an indicator of spermatogenesis and Sertoli cell number, size and activity.  
Cryptorchidism, affects 2-4% of boys, making it the most common congenital birth 
abnormality (Bergman et al., 2011). Kristensen et al. (2010) conducted a prospective 
birth cohort study on in utero analgesic exposure, in which 2570 male newborns were 
assessed for variances in anogenital distance and testicular position. Analgesic use was 
found to be associated with congenital cryptorchidism incidence (Odds Ratio (OR) 
=1.43; 0.73, 2.79) in a dose-dependent manner. To verify associations found in the 
epidemiological study, Kristensen et al. exposed pregnant Wistar rats to subtoxic doses 
of Paracetemol (150, 250 and 350 mg kg
-1
/day) and Acetylsalicylic acid (150, 200 and 
250 mg kg
-1
/day). Intrauterine exposure to the analgesics led to a decrease in anogenital 
distance in male offspring, leading the authors to suggest that intrauterine exposure to 
mild analgesics is a risk factor for the development of male reproductive disorders.  
In concordance with Kristensen et al.’s (2010) study, occupational epidemiology has 
identified higher frequencies of orchidopexy (the surgical treatment of cryptorchidism) 
in boys from regions of intensive farming and pesticide use (Garry et al., 1996). Montes 
et al. (2010) found that mothers who bore sons with cryptorchidism generally had 
higher 4,4’-DDT and β-Hexachlorocyclohexane (β-HCH) levels (0.464 vs. 0.269 mg kg-
1
 and 0.263 vs 0.192 mg kg
-1
, respectively). In utero exposure to anti-androgenic EDCs 
may contribute to the aetiology of cryptorchidism, corroborating the conclusions of 
Anderson et al. (2008), who noted elevated cryptorchidism, decreased penis length, 
lower testis volume and lowered serum testosterone in levels in sons born to Danish 
greenhouse workers exposed to pesticides.  
In addition to cryptorchidism, reductions in foetal androgen action have been linked to 
hypospadias, a condition in which the urethra opens on the underside of the gland penis. 
Affecting an estimated 0.2 – 4% of boys at birth, the incidence of hypospadias is 
believed to be increasing (Nassar et al., 2007), raising speculation regarding the role of 
EDC’s in disease aetiology. In utero DES/progestin exposure has been associated with 
hypospadias (Klip et al., 2002). Giordano et al. (2010) reported an association between 
elevated maternal serum Hexachlorobenzene (HCB) levels and the likelihood of bearing 
a son with hypospadias. However, a number of other risk factors for cryptorchidism and 
hypospadias have been identified; including low birth weight, premature birth, 
gestational diet and alcohol consumption (Akre et al., 2008; Berkowitz and Lapinski, 
1996; Damgaard et al., 2008; Pierik et al., 2004). 
In light of the evidence, it is not infeasible to suggest that other hormonally regulated 
male reproductive parameters may be susceptible to endocrine disruption. For example, 
it has been estimated that approximately 5 – 20% of men (2.3 million) suffer from 
moderate-to-severe erectile dysfunction (Kubin et al., 2003). Adult male exposure to 
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estrogenic compounds is believed to promote gynecomastia and interfere with the 
hypothalamus-hypophyseal-gonadal axis, resulting in a loss of libido, impotence and 
low sperm counts, in men occupationally exposed to 4,4’-DDT. This association has 
also been demonstrated in the male Wistar rat; Brien et al. (2000) reported significant 
perturbation of erectile functioning for 2 weeks following a single sub-cutaneous dose 
of 500 mg 4,4’-DDE kg-1. Fruthermore, acute exposure to the antiandrogen Flutamide 
(50 mg kg
-1
) significantly decreased apomorphine-induced erections (>50%) for 12 to 
48 hours, leading authors to suggest that exogenous hormones may play a role in 
erectile dysfunction. 
2.2.1.2 Female Reproductive Health  
Female fecundity is determined by hormonal profile, menstruation, early pregnancy 
loss, ovarian reserve and failure, and reproductive senescence or menopause. The 
female reproductive system is vulnerable to a plethora of environmental stressors 
(including smoking, alcohol and caffeine consumption), psychological stressors and 
physiological factors such as age and weight. In addition, perturbations of kisspeptins 
(KiSS), pivotal hypothalamic signals for the preovulatory surge of gonadotropins 
required for cyclicity and ovulation, have been identified as possible targets of 
endocrine toxicity (Roa et al., 2008; Castellano et al., 2006; Crain et al., 2008). 
Disruption of AhR signalling cascades, that modulate follicular steroidogenesis, have 
also been implicated in reduced fecundity (Hernandez-Ochoae et al., 2009).  
Chemicals that prevail in the environment have been implicated in adverse fertility and 
pregnancy outcomes; 4,4’-DDT has been associated with spontaneous abortion 
(Venners et al., 2005); and, 4,4’-DDE has been associated with spontaneous abortion, 
foetal loss (Longnecker et al., 2005) and preterm birth. In an assessment of colostrum
13
 
organochlorine pesticide concentrations (n=63), Cioroiu et al. (2010) identified higher 
mean 4,4’-DDE (470 ng g-1) and γ-HCH (99 ng g-1) levels in women with preterm, 
relative to full term, labour (268 ng g
-1
 and 96 ng g
-1
, respectively). Furthermore, 
household pesticide usage has been associated with a six-fold increase in spontaneous 
abortion risk (Weselak et al., 2008). Further complicating the mechanisms, Kishi et al. 
(2008) demonstrated genetic susceptibility and racial differences in fertility endpoints in 
response to polyaromatic hydrocarbon exposure, possibly as a result of endocrine of 
xenobiotic metabolism receptor polymorphisms. In addition, Wohlfahrt-Veje et al 
(2012b) identified early breast development in girls prenatally exposed to non-persistent 
pesticides. 
The biological plausibility for the role of EDCs in driving precocious puberty has been 
enhanced by identification of kisspeptin and G-protein coupled receptor GPR54 
regulation of reproduction (Navarro et al., 2004). The elucidation of peripheral 
                                                 
13
 The first postnatal mammary gland secretion.  
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regulators of KiSS-1 expression, such as the adipose hormone leptin (Roa et al., 2008), 
has uncovered the pathway for metabolic control of puberty onset and GnRH secretion, 
and a number of studies discuss the role of oxytocin neurones and prostaglandin E2 
production in puberty progression (Parent et al., 2008; Ojeda et al., 2003). Adewale et 
al. (2009) reported in utero BPA exposure (50µg kg
-1
 or 50 mg kg
-1
) accelerated 
pubertal timing and disrupted ovarian development at low and environmentally relevant 
doses, without affecting the ability of GnRH neurones to respond to steroid-positive 
feedback. An in vivo rat study reported by Navarro et al. (2009) concluded that the 
hypothalamic KiSS-1 system was altered by BPA exposure (100 or 500 µg rat
-1
), 
disrupting gonadotrophin secretion and potentially affecting onset later in life. 
Furthermore, Sprague Dawley rats exposed to BPA (500 µg/50 µL or 50 µg/50 µL) 
demonstrated dose-dependent acceleration of the onset of puberty  and altered oestrous 
cyclicity, which was corroborated by in vitro analysis of dosed animal pituitary cells, 
which showed impaired GnRH-induced LH secretion (Fernàndez et al., 2009). 
Supporting the mechanistic studies, a positive correlation (p<0.001) between increased 
plasma levels of phthalates and patients with pubertal gynecomastia (DEHP: 4.66 ± 1.58 
µg/ml; MEHP: 3.19 ± 1.41 µg/ml), relative to age matched controls (DEHP: 3.09 ± 0.90 
µg/ml; MEHP 1.37 ± 0.36 µg/ml) has been reported (Durmaz et al., 2010). 
2.2.2 Hormonal Cancers 
Consequent to increased understanding of the role of steroidal hormones in disease 
progression, human exposure to environmental EDC’s has been implicated in the 
aetiology of cancer (Davis et al., 1993). Epidemiological studies have inconsistently 
reported a 3-4 fold increase in testicular germ cell cancer (TGCC) incidence in 
Caucasians over the past 30-40 years. TGCC development has been linked to inhibition 
of androgen receptor and/or biosynthesis, and reduced testosterone production in foetal 
tissues. Subsequently, it is suggested that in utero exposure to xenobiotics and 
polymorphisms in the androgen receptor gene, may play a role in the aetiology of 
TGCC (Bergman et al., 2011). In an attempt to identify genetic polymorphisms in the 
AR that might confer elevated risk of TGCC development, Västermark et al. (2011) 
genotyped 11 halotype-tagging single nucleotide polymorphsisms (SNPs) of CAG and 
GGN repeats in AR’s. For the non-coding G variant tag SNP, rs12014709 in the 
androgen receptor, the minor genotype was found in 10% of cases and in 5.1% of 
controls, suggesting the polymorphism may confer elevated TGCC risk (odds ratio 
(OR) = 2.7; 95% CI; 1.03 – 4.15). Furthermore, short GGN (<23) was associated with 
an increased risk of metastatic disease (OR: 2.15; 95% CI: 1.04 – 4.45). In support of 
the hypothesis that AR function is linked to the aetiology of TGCC, the authors 
concluded that the AR polymorphisms identified in their study may be involved in 
gene-environment interactions, increasing the susceptibility of some individuals to the 
effects of EDCs.  
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The potential role of EDCs in breast tumour proliferation has been demonstrated in a 
number of studies. Bidgoli et al. (2010) evaluated the interaction of genes associated 
with the development of breast cancer (p53, K-Ras, ER and PR), with the AhR, which 
mediates the effects of many environmental EDCs, contributing to losses in normal 
ovarian function. Data reported increases in epithelial cell expression of AhR, resulting 
in elevated susceptibility to environmentally induced tumours. The early onset of breast 
malignancy in Iranian women has been attributed to interactions between hormonal and 
environmental factors. These findings agreed with those from an in vitro examination of 
total estrogenicity of adipose tissue extract, separated on polarity, which suggested that 
breast cancer was more frequent among women with higher levels of estrogenicity, 
measured in terms of estrogen equivalents (Fernandez et al., 2007; Ibarluzea et al., 
2004). 
In vivo toxicology models have corroborated human epidemiological evidence. 
Zearalenone (ZEA) is an estrogenic secondary metabolite produced by some Giberella 
species, and a regulated contaminant in 32% of 5018 mixed cereal samples, with 
suspected carcinogenicity (Metzler et al., 2010). Phenotypic alterations in Wistar rat 
mammary tissues following exposure to 0.2 µg kg
-1
 ZEA suggest that exposure could 
contribute to the induction of breast disorders (Belli et al., 2010). Doherty et al. (2010) 
identified a 2-3 fold increase in expression of Enhancer of Zeste Homolog 2 (EZH2), in 
the mammary gland of mice, following in utero exposure to DES or BPA at levels 
approximating human exposure. The authors suggest developmental programming of 
EZH2 as a novel epigenetic mechanism regulating the mammary gland. In Sprague 
Dawley CD rats, exposure to butyl benzyl phthalate (BBP; 120 or 500 mg kg
-1
/day) 
modified the architecture and proliferative index of the mammary gland in a dose 
dependent fashion (Moral et al., 2011). BBP exposure modified genes related to 
immune function, cell signalling, proliferation, differentiation and metabolism, 
suggesting that in utero exposure to BBP may result in delayed pubertal onset and an 
increased susceptibility to mammary carcinogenesis. 
2.2.3 Metabolism and Development 
Perturbation of neurodevelopmental processes can impact sensory, motor and cognitive 
functions, and neurobehaviour, potentially leading to mental retardation, cerebral palsy, 
psychoses, epilepsy, altered maturational milestones, cognitive defects, sensory 
dysfunction and perturbed sexual dimorphism (Tilson, 1998). Choi et al. (2004) 
suggested that 50% of EDC’s may have neurotoxic potential. Some authors have 
suggested that this toxic potential may play a role in the aetiology and prevalence of 
psychiatric illnesses such as bipolar disease, depression, personality and obsessive-
compulsive disorders and psychoses (Genius, 2008). Estimates in the US suggest 
learning difficulties may affect 10% of school children, of which 17% may be affected 
by conditions such as deafness, blindness, epilepsy, speech deficits and emotional and 
behavioural problems (Schettler, 2001). In addition, the incidence of attention deficit 
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disorder (ADD) and autism spectrum disorders (ASD), have increased in Western child 
populations (Gore and Patisaul, 2010).  
It is hypothesised that there are two specific endocrine mechanisms of developmental 
neurotoxicity; perturbation of the hypothalamus-pituitary axis, which is key to 
reproductive and sexually dimorphic behaviour, and interference with circulating 
hormones (estrogen, androgens and thyroid hormones), which modulate 
neurodevelopment (Ahmed et al., 2008). Further implicating the endocrine system in 
the aetiology of neurodevelopment, hypothyroidism – a congenital or acquired 
deficiency of thyroid hormone – has been linked with clinical and subclinical neuronal 
defects. Untreated, hypothyroidism may result in cretinism
14
, mental retardation, 
deafness, short stature and facial deformities (Roberts and Ladenson, 2004). The 
incidence of congenital hypothyroidism is believed to be increasing; in the US, a 73% 
increase in incidence was reported between 1987 and 2002. However, 40% of this is 
believed to be attributable to demographic factors, including ethnicity, sex, birth 
plurality, birth weight and maternal age (Hinton et al., 2010).   
Low molecular weight phthalate (LMWP) metabolites and BPA were detected in >90% 
urine samples of third-trimester women (n=404) in American 1998 and 2002 cohorts, 
presenting mean concentrations of 419 µg L
-1
 and 1.2 µg L
-1, 
respectively (Miodovnik et 
al., 2011). Follow-up assessment of offspring at age 7 and 9 years (n=137) using the 
Social Responsiveness Scale (SRS), identified an association between increasing log-
transformed LMWP metabolite concentration and larger social deficits, including poorer 
social cognition, social communication and social awareness.  
The metabolic toxicity of EDC’s has also been suggested to occur through the profiling 
of estrogenic interference, metabolism-related effects and stress responses using 
integrated transcriptomic and proteomic characterisation techniques (De Wit et al., 
2010). Furthermore, Lee et al. (2010) examined whether in vivo levels of several POPs 
could prospectively predict occurrence of type-2 diabetes, using a nested case-control 
study within the U.S. Coronary Artery Risk Development in Young Adults (CARDIA) 
cohort. Results suggested that environmental POP exposure may increase the risk of 
developing type-2 diabetes in a non-linear fashion, particularly in obese persons.  
2.2.4 Summary 
Endocrine disruption has been observed in wildlife populations and demonstrated in 
laboratory studies. Yet, while epidemiology studies have identified associations in 
human populations, the epistemological limitations of the studies hinder defining 
causality. Furthermore, the endocrine system presents mechanisms of potential low dose 
toxicity (hormesis), sexual dimorphism, transgenerational effects and variable 
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endpoints, depending on the timing and duration of exposure and complicating health 
impact assessments. Subsequently, assessing the impact of EDC exposure on human 
health presents significant challenges. 
Research has started to bridge the gap between wildlife observations and human 
epidemiological speculation. A decade following the reproductive abnormalities 
observed in Lake Apopka alligators, research into the effects of occupational pesticide 
exposure in pregnant green-house workers identified similar human endpoints. 
Anderson et al. (2008) reported decreases in serum testosterone and testicular volume, 
with notable reductions in penile length, in sons born to mothers exposed to pesticides. 
Similar to the alligators, a reduction in inhibin B expression from the Sertoli cells 
elevated the levels of female sex hormones. Thus, steroidogenesis is expected to be 
permanently altered by pesticide-induced effects on gonadal cells during embryonic 
development (review by Hamlin et al., 2010). Similarly, sons born to mothers with 
elevated phthalate concentrations showed reduced anogenital distances and smaller 
penis volumes (Swan et al., 2005; Marsee et al, 2006). Seifert-Klauss et al. (2006) 
postulated  that these results highlight the molecular and cellular conservation in 
endocrine function throughout the vertebrates, increasing the concern, and necessity for 
further assessment of the role environmental contaminants play in congenital disorders 
(Hamlin et al., 2010). 
However, the approach to characterising regulatory risk in ecotoxicity differs to that of 
human toxicology. Ecological risk is assessed at population level, rather than the 
individual; adverse affects observed in individual organisms are not considered, unless 
the population is significantly affected. In human assessments, any elevation in risk to a 
toxicological endpoint is considered a concern. Subsequently, the regulatory burden of 
human EDC exposure must be greater. The chemical regulation, testing and 
prioritisation strategies, in addition to the policy drivers of EDC research are detailed in 
the subsequent section. 
2.3 Chemical Regulation and Testing 
The ubiquity of anthropogenic chemicals in the environment, from food and water to 
consumer products and household agents, in addition to the potential health impacts, has 
increased public concern and led to premature legislative actions by regulatory 
jurisdictions.  
2.3.1 Legislation & Regulation 
Despite lacking regulatory criterion, endocrine disruptors are prohibited by EU law. In 
lieu of the Commission’s measure, regarding specific scientific criteria in the 
determination and classification of endocrine disruption, substances registered under the 
Plant Protection Products (PPP) legislation can only be approved provided there is 
evidence that the substance, safener or synergist does not have “an inherent capacity to 
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cause endocrine disrupting, neurotoxic or immunotoxic effects” in non-target organisms 
(Regulation (EC) No 1107/2009). The PPP legislation regulates the agrochemical 
industry, which is mainly data rich. However, consumer products are generally 
regulated under the REACH (Registration, Evaluation and Authorisation of Chemicals) 
Regulations ((EC) No 1907/2006) or Cometics Directive (Regulation (EC) No 
1223/2009). Under REACH there are currently no testing strategies or guidance on how 
to identify EDCs. However, EDCs can be authorised for use under the provisions stated 
in REACH Article 57, pertaining the authorisation of CMRs and PBTs (‘substances 
possessing carcinogenic, mutagenic or reproductive toxicity’ and ‘Persistent, 
bioaccumulative and toxic substances’ respectively). CMRs and PBTs constitute 
chemicals that are of high concern, and subsequently may be listed in Annex XIV of 
REACH, preventing their release onto the market. These endpoints of toxicity may be 
indicative of an endocrine mode of action, but at the current time there is no formal 
requirement to screen for endocrine disruption under REACH. It is therefore possible, 
that some EDCs may already be in wide use throughout society - unless compounds are 
potent carcinogens, mutagens, and/or reproductive toxins or persist and bioaccumulate 
in the environment, they will not be captured by the data requirements of REACH.  
2.3.2 A Defined Mode-of-Action? 
As previously alluded to, there are a number of epistemological problems in the 
definition of an EDC. As a recently identified mechanism of toxicity, it is generally 
recognised that endocrine disruption is a mechanism that may result in a hazard, rather 
than being a hazard in itself; US EPA “…does not consider endocrine disruption to be 
an adverse effect per se, but rather to be a mode or mechanism of action potentially 
leading to other outcomes, for example, carcinogenic, reproductive, or developmental 
effects, routinely considered in reaching regulatory decisions”. Thus, there is difficulty 
in defining endocrine specific endpoints, which has lead to multiple scientific 
definitions (Table 2.2). 
Table 2.2 Scientific Definitions of EDCs Adopted by Regulatory and Advisory 
Jurisdictions 
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The phraseology and differences between definitions highlights the discordance 
between regulatory jurisdictions, academia and industry regarding EDC criteria, in 
addition to the economic implications of a stringent definition. The inclusion of the 
word ‘adverse’ requires the observed effect to elicit changes that fall outside the normal 
range of physiological variation within a population, and was included in order to 
distinguish between endocrine active and endocrine disruptive substances. However, the 
inclusion of ‘adverse’ may simply shift the assumptions, presumptions and 
epistemological problems onto the word, retaining possible subjectivity in the relevance 
of observed endpoints. Furthermore, with regards to a regulatory definition, 
incorporating ‘intact organism’ contradicts the use of castrated animals and increasing 
desire to use ex vivo and in vitro assessments, which irrespective of intactness, may 
provide useful information pertaining to risk assessment and regulation (Bergman et al., 
2011). Nevertheless, there is an urgent need for a regulatory definition of an EDC, 
particularly in light of amendments to EU legislation; Plant Protection Products, 
Biocides and REACH Regulations (Marx-Stoelting et al., 2011). 
2.3.3 Chemical Safety Test Guidelines 
Over 100,000 chemicals are listed on the European Inventory of Existing Chemicals 
Substances (EC, 1996). International harmonisation of endocrine activity testing 
strategies is vital for hazard identification and risk assessment (EFSA, 2010; 2006). In 
an attempt to harmonise member state methodologies and safeguard the environment, 
over 150 Guidelines for the Testing of Chemicals have been developed by the OECD 
since their formation in 1981 (OECD, 2013). The OECD Test Guideline Programme 
and Council Decision on the Mutual Acceptance of Data (MAD) has saved 
governments and industry an estimated €153 million (OECD, 2010a); this has been 
achieved by avoiding the duplication of testing, reducing the number of laboratory 
animals and avoiding non-tariff trade barriers. Furthermore, due to the UN’s Strategic 
Approach to International Chemicals Management (SAICM), all instruments necessary 
for the management of chemicals are universally available at no cost to the user, 
allowing conformation and regulatory acceptance of data by non-members (OECD, 
2010b).  
As a result of the national and international chemical safety initiative a number of in 
vivo and in vitro assays have been developed (OECD, 1998; EDSTAC, 1998). The 
OECD adopted the first branch of chemical test guidelines for the elucidation of 
endocrine-mediated toxicity, relevant to both human health and biotic systems 
(wildlife), in 2009. Figure 2.2 compares hierarchies for the OECD Conceptual 
Framework, Adverse Outcome Pathways (AOP) and Test Guideline Programme 
initiatives, for chemicals interacting with the hypothalamus-pituitary-gonad (HPG) axis 
(OECD, 2012). As previously alluded to, in sections 2.1 and 2.2, observations in 
wildlife populations skewed EDC research focus on estrogenicity and androgenicity 
(HPG axis); subsequently, testing initiatives have focused on these MoAs. In 
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concordance with the study of carcinogenicity and reproductive and developmental 
toxicity, core EDC strategy entails two fundamental stages of mechanistic in vitro and 
in vivo assays (EDSTAC tier 1; OECD CF tier 1-3), and in vivo tests to establish dose-
response data (EDSTAC tier 2; OECD CF tier 4 & 5) (Lee et al., 2012). 
 
Figure 2.2 Integration of AOP Paradigm and OECD Conceptual Framework with 
Suggested Endocrine Relevant Modifications 
Presenting proposed Adverse Outcome Pathway (January, 2012) maps with the OECD Conceptual 
Framework and promising assays to detect and characterise chemical effects on novel estrogen signalling 
pathways, the figure shows the progress and direction of testing for chemicals that may perturb the 
hypothalamus-pituitary-gonad (HPG) axis.  
However, the development and adoption of OECD Test Guidelines is a costly and time 
consuming process, particularly for complex modes of toxicity such as endocrine 
disruption, as validation stages may take several years. Furthermore, a widely accepted 
consideration is that “ecological importance of an effect may differ widely between 
species”. Thus, it is stipulated that conducting tests in several species, of different taxa, 
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is required to gain some indication of natural variability (OECD, 2006). In vivo 
assessment is typically regarded as the gold standard of toxicological investigation (see 
Figure 2.2). Nevertheless, there is subjectivity in what constitutes a significant effect 
(OECD, 2006), a factor further complicated by the debate regarding endocrine active 
versus endocrine disruptive classifications. Thus, the number and scope of the current 
OECD Test Guidelines may not be sufficient to elucidate the plethora of endocrine 
endpoints, nor economically and ethically feasible to utilise in large scale chemical 
screening assessments. 
The species used in chemical safety assessments are typically based on logistics such as, 
ease of breeding; purchasing; animal husbandry; duration of life cycle; 
growth/development; and, the availability of historical toxicity data, which enables and 
reduces uncertainty in extrapolation. When determining mammalian toxicity, rodent 
models are typically utilised, at least for non-pharmaceutical products (see Figure 2.3). 
In ecological risk assessment, fish (Danio rerio, Pimephales promelas or Oncorhynchus 
mykiss), bird (Coturnix japonica) or collembolan (Folsomia fimetaria) models are 
recommended.  
 
Figure 2.3 Animals used in UK Scientific Procedures in 2010 and 2011 
In 2011, of the 3.79 million procedures conducted in animals, 399,000 were for toxicological/safety 
evaluation purposes, increasing 2% from the 2010 baseline (+7,932). The proportion of animal species 
investigated were: Bird 3%; Rat 31%; All other Rodent 2%; Mouse 42%; Rabbit 3%; Other 3% and Fish 
17% in 2010. In 2011, Bird 4%; Rat 28%; All other Rodent 2%; Mouse 42%; Rabbit 3%; Other 2% and 
Fish 19% (Home Office Statistics, 2010; 2011).  
However, the reliability of extrapolating toxicity observed in one species to another is 
limited by differences in pharmacokinetics (ADME
15
) and pharmacodynamics (e.g. 
binding affinities at receptor). The species bias of regulatory toxicology is highlighted 
by the UK Home Office statistics on animal usage (Figure 2.3). In 2010, 75% of in vivo 
toxicological procedures were conducted in rodent models; representing a very limited 
assessment of the potential inter- and intra-species variation, and subsequently a large 
amount of uncertainty. 
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Regulatory bodies currently mitigate for this uncertainty in two ways. Firstly, where 
toxicological assessment of a chemical is deemed necessary (i.e. for a high production 
volume chemical under REACH), a minimum of two species are required. Secondly, 
assessment factors (also called uncertainty or safety factors) are applied during 
extrapolation of toxicological findings to predict and ensure safe levels of exposure. 
However, the efficacy and relevance of two species in determining toxicity and the 
adequacy of safety factors, in safeguarding individual humans and multiple wildlife 
species is questionable. A greater understanding of the inter- and intra-species variation 
in endocrine function is undoubtedly vital to understanding the applicability of 
extrapolating toxicological findings from one species to another. Thus, it may be 
concluded, under the present state of knowledge, that conventional in vivo approaches to 
elucidating toxicity may not be appropriate for inferring endocrine mediated 
mechanisms.   
2.3.4 Alternative (Non-Animal) Methods  
In addition to any concerns regarding the applicability of in vivo animal studies, 
consequent to animal welfare issues, initially highlighted by Russel and Burch’s (1959) 
paper detailing the 3R’s concept (Replacement, Reduction and Refinement of animals), 
the UK is obliged by EU and OECD incentives, to reduce the number of animals used in 
chemical testing strategies. The predominance of apical endpoints, in addition to 
amended chemical safety requirements (REACH), demands the development and 
validation of alternative methods, which incorporate mechanisms of toxicity. A battery 
of toxicity tests (in vitro and in vivo) has been demonstrated to provide “scientific rigor 
and flexibility” when identifying chemical toxicity; focussing efforts to major chemicals 
of concern (ECETOC, 2009). Furthermore, the AOP framework, which aims to map 
molecular initiating events (MIE) through to adverse outcomes (AO), by elucidating the 
mechanism and mode of action (Tørsløv et al., 2011), requires mechanistic in vitro 
studies to define MIE. . 
The EC ReProTect was a project which aims to develop alternative in vitro methods to 
elucidate reproductive toxicity. In a critical assessment of the efficacy of the ReProTect 
Feasibility study, Schenk et al. (2010) comparatively analysed in vitro testing results of 
10 blinded toxicologically well-defined chemicals. The vast majority of the predictions 
made based on in vitro testing correlated with in vivo finds. Thus, combining nearest 
neighbour statistical analysis with WoE approaches may effectively guide toxicity 
testing. Systems biology is increasing the availability and applicability of in silico tools. 
For example, launched in 2011, ChemProt
16
 compiled multiple chemical-protein 
annotation resources and disease-associated protein-protein interactions (PPIs). The 
database assembled over 2-million interactions for over 700,000 distinct chemicals with 
30,578 proteins, assisting in silico assessments of environmental chemicals, natural 
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products and approved drugs (Taboureau et al., 2011). However, regardless of the 
development and scientific validation of in silico and in vitro tools, their adoption into 
regulatory toxicology remains controversial.  
2.3.4.1 Regulatory Acceptance of Alternative Methods 
In a workshop held in Kansas City, Missouri (1997), thirty international scientists 
discussed the methods for detecting estrogenic/androgenic effects in the context of 
reproductive and developmental toxicity. Delegates concluded that (Quantitative) 
Structure Activity Relationships ((Q)SAR) and in vitro test systems, although useful in 
a weight-of-evidence approach could not, at the time, replace in vivo tests as the sole 
basis for screening (Ankley et al.,1998).  
Later in 2003, an evaluation of the in vitro test methods for detecting potential 
endocrine disruptors was conducted by the Interagency Coordinating Committee on the 
Validation of Alternative Methods (ICCVAM)
17
. Collating historical data from the NTP 
Interagency Centre for Evaluation of Alternative Toxicological Methods (NICEATM), 
ER and AR binding and transcriptional activation in vitro assays were appraised based 
on their incorporation to EDSP Tier 1 screening. ICCVAM concluded that there was 
little consistency amongst in vitro protocols, with no adequately detailed or standardised 
test method protocols. Recombinant rat or human nuclear receptors were superior to 
crude cytosolic preparations in binding assays, due to standardisation and significantly 
reduced contamination risk, enabling greater reproducibility and inter/intra-laboratory 
comparison (ICCVAM, 2003). Transiently transfected transactivation systems were 
demonstrated to have a higher level of responsiveness. However, stably transfected cell 
lines were more amenable to high-throughput screening, highlighting the need for a 
comparative study to determine whether transiently or stably transfected cell lines are 
more appropriate for EDC screening.  
Progression in the reliability and relevance of some in vitro tools has led to validation 
and regulatory acceptance. Developed by the Chemicals Evaluation and Research 
Institute (CERI, Japan), the HeLa9903 Stably Transfected ERα Transcriptional 
Activation (STTA) assay was adopted by the OECD as a level 2 in vitro screen for ERα 
agonistic activity in 2009 (OECD, 2003, 2009). In addition, developed under the 
auspices of the US EPA EDSP, the BG1Luc (ERα/β) STTA for ER agonists and 
antagonists, was also included in the OECD Test Guidelines Programme as a tier 2 
mechanistic in vitro assay in 2012 (OECD, 2012).   
                                                 
17
 ICCVAM contributes to the US EPAs legal requirement to safeguard public health in the Food Quality 
Protection Act (FQPA) of 1996 (Public Law [P.L.] 104-170) and the 1996 amendments to the Safe 
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In 2012 the OECD published a Guidance Document
18
 (GD)
 
to aid EDC testing strategy, 
subsequent to generating results in assays adopted by the OECD Test Guidelines 
Programme (OECD, 2012).  Reflective of the state of the science, the GD included 
estrogenic, androgenic, thyroid hormone and steroidogenic endocrine modalities. 
However, less characterised modes of toxicity, such as corticosteroid disruption, were 
not included and may not be detected by current ED assays (Trenzado et al., 2003). The 
interpretation of in vitro and/or in vivo endocrine-relevant endpoints in a WoE 
approach, requires an evaluation into the nature, quantity and quality of existing data 
and data requirements (Borgert et al., 2011). Nevertheless, it is accepted that there is 
generally “no single ‘right’ approach” to the interpretation and progression from 
conflicting ED data (OECD, 2012). The complexity of endocrine physiology and 
variations in endocrine-mediated pathogenesis requires expertise in both endocrinology 
and toxicology to effectively assess risk.  
2.3.5 Exposure 
One further aspect that should be noted is that of mixture toxicity. Contrary to standard 
toxicological assessments, which evaluate chemical toxicity in isolation, environmental 
exposure is most likely to occur as a complex chemical mixture. Chemicals with similar 
modes of action, present in a mixture at concentrations independently below No-
Observed-Adverse-Effect-Level (NOAEL) thresholds, may collectively cause adverse 
effects, complicating regulatory efforts. Silva et al. (2002) demonstrated responses of 
up to 40% maximal estrogenic effect by combining eight xenestrogens at levels 
equivalent to 50% of their individual no-observed-effect-concentrations (NOECs) in the 
yeast estrogen screen. Moreover, Rajapakse et al. (2002) identified a dose addition 
relationship following the combined exposure of 11 estrogens. Additionally, in vivo 
studies in an extended rat developmental toxicity model demonstrated three similarly 
acting androgen receptor antagonsists (at levels below their NOEC) to cause significant 
signs of feminisation (reduced anogenital index, retained nipples) (Hass et al., 2007).  
A review by Kortenkamp (2007) concluded that dose addition is generally a predictive 
tool for assessing the combined effects of EDCs acting via the same biological 
mechanism (e.g. estrogenic, anti-androgenic, androgenic or thyroid disrupting agents). 
However, this may underestimate observed effects, as independent action may not 
always be representative of mixture effects (synergism or potentiation). In order for 
mixture toxicity to be assessed, detailed mechanistic studies of the mode of action of 
                                                 
18
 Guidance Document on Standardised Test Guidelines for Evaluating Chemicals for Endocrine 
Disruption: Throughout OECD documentation a ‘test method’ is defined as “an experimental system that 
can be used to obtain a range of information from chemical properties through the adverse effects of a 
substance”. Thus, the term ‘test method’ and ‘assay’ are synonyms within the context of ecotoxicity and 
human health studies. A ‘screen’ defines an in vitro or in vivo assay which provides mechanistic 
information, but not general information on apical endpoints.  
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individual components is required, further highlighting the inadequacy of current in vivo 
regulatory tools.  
2.3.6 Summary 
The premature ban of EDCs by EU legislation has complicated the implementation of 
regulatory criteria. Testing ‘all’ chemicals for endocrine MoA in animals is both 
ethically and monetarily infeasible, necessitating the development of in silico and in 
vitro screening and prioritisation methods. Furthermore, these mechanistic studies found 
concentration-addition calculations aiming to assess complex environmental exposure. 
The ubiquitous exposure and limitations of regulatory chemical safety testing highlight 
risks to both the environment and human health. Subsequently, despite scientific 
concerns for over 20 years, EDCs remain a policy conundrum.  
2.4 Chemical Prioritisation & Screening 
2.4.1 Prioritisation 
With the plethora of legislation, schemes and definitions, but lack of universally 
accepted criterion, there is uncertainty in terming a substance as an EDC for regulatory 
purposes. However, in 2000, the European Commission (EC) published an initial list of 
564 chemical substances with known or potential ED properties; 146 substances were 
identified as either persistent or of high production volume, of which 66 had been 
demonstrated to disrupt the endocrine system of animals in vivo and 52 showed 
potential ED properties (BKH, 2000). The Environment Agency consolidated a list of 
966 chemicals with “some degree of ED activity”, of which 539 were of anthropogenic 
origin, 225 biocides, 62 naturally occurring substances, 58 pharmaceuticals, 54 metallo-
complex substances and 28 consumer products. Nonylphenol (NP), BPA, TBT, E2 and 
EE2 were the most frequently used substances in EDC studies.  
Internationally, a prioritised list of 65 chemicals was published by the Ministry of 
Environment (MoE, Japan) for full risk assessment, including: TBT; triphenyl tin 
(TPT); 4-octylphenol (OP); NP; DBP; octachlorostyrene; benzophenone; di-cyclohexyl 
phthalate; DEHP; BBP, diethylphthalate (DEP); di-(2-ethylhexyl)adipate; BPA; 2,4-
dichlorophenol; 4-nitrotoluene; diphentyl phthalate; di-hexylphthalate; dipropyl 
phthalate; HCB; HCH; chlordane; oxychlordane; trans-nonachlor; DDT; DDE; and, 
DDD (SPEED’98; ExTEND 2005).  
However, international priority substances are not necessarily indicative of, or relevant 
to, UK exposure. In 2010, the UK Drinking Water Inspectorate (DWI) commissioned an 
analysis of peer reviewed EDC literature; 509 journal articles were reviewed, 
highlighting 325 ‘potential’ EDC’s that had been detected or modelled in groundwaters, 
surface waters, freshwaters, drinking/potable waters or sewage treatment effluent (IEH, 
2012). The authors assessed the identified chemicals based on IUPAC, EU or EUROPA 
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listing; UK pesticide registration; conjugated hormone or phytestrogen; assessment by 
clinical endocrinologist; and, OECD QSAR Toolbox ER-binder or protein binder 
classification. Environmental fate, behaviour, and water treatment modelling was 
conducted for 207 compounds.  Modelled average daily intakes of chemicals were 
compared to Tolerable Daily Intakes (TDI), in order to approximate a Margin of Safety 
(MoS) for drinking water. The IEH (2012) study balanced exposure with potential ED 
potency, logically prioritising chemicals for further UK investigation and EDC 
screening. However, the prioritisation method was not high-throughput and success was 
reliant on potentially biased and retrospective published literature. Thus, the method 
would not be appropriate for prospective chemical safety assessments.    
2.4.2 EDC Screening  
As a primary goal of the US EPA ToxCast™ Program, 309 environmental chemicals 
were asessed in high-throughput (HT) screening assays and categoried in a weight-of-
evidence Toxicological Priority Index (ToxPi) score (Reif et al., 2010). Relative 
contributions of in vitro assays, chemical descriptors and biological pathways were 
visualised, with potential to incorporate exposure constraints (Gangwal et al., 2012).  
However, even at <1% of the cost of full-scale animal testing (Dix et al., 2007), the 
ToxCast™ program is far from categorising the >300,000 chemicals on the market, and 
subsequently requires the, inherently caveated, prioritisation strategies detailed 
previously (Section 2.4.1). 
Virtual in silico screening of large chemical libraries has played a significant role in 
pharmaceutical lead identification and optimisation, adopting both ligand based (e.g. 3D 
QSAR) and structure based (e.g. automated docking) screening methods (Balaji et al., 
2013). Verdani et al. (2012) detailed an in silico technology for estimating toxic 
potential (linear function from 0.0 (none) to 1.0 (extreme)) by quantifying the 
thermodynamic binding of small molecules towards a battery of proteins (10 nuclear 
receptors, 4 cytochrome P450’s, the AhR and potassium ion channel (hERG)). The 
authors suggest that the ‘VirtualToxLab’ could be used to generate toxicity alerts, but 
that compounds with high toxic potential should be further investigated for the kinetic 
stability of protein-ligand interactions using molecular dynamics (Verdani et al., 2012). 
However, the utilisation of molecular dynamic virtual screening methods for 
toxicological prioritisation is still in its infancy. 
Conversely, the adoption of the European REACH regulations has required the 
implementation of a framework for read-across and data-gap filling, and prompted the 
development of Quantitative Structure Activity Relationship (QSAR) models (EC, 
2006), such as the OECD (Q)SAR Application Toolbox (Devillers et al., 2006; Jensen 
et al., 2008; Mombelli, 2012).  
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2.4.3 The OECD Toolbox ER Profiler 
The wealth of information pertaining to functional interactions of the estrogen receptor 
(see Chapter 1) have highlighted several structural alerts for ER binding (Tong et al., 
2004; Bignon et al., 1989), leading to the successful development of the OECD 
Toolbox ER-profiler. Ligand triphenylethylene and dielthylstilbestrol backbone (Tong 
et al., 2004; Bignon et al., 1989) and number of hydroxyl groups, have been identified 
of particular significance in predicting binding affinities, as they are indicative of the 
number of intramolecular bonds that can be formed with the ER binding pocket (Li & 
Gramatica, 2010).  
Positive associations between molecular complexity and planarity with increasing 
binding potency have also been reported; phenolic compounds presenting low affinity, 
while steroids demonstrate high affinity (Liu et al., 2006). Substitutions of aromatic 
hydroxyl groups and electronegative heteroatoms at the ortho position have been noted 
to decrease binding affinity (Bradbury et al., 2000; Mekenyan et al., 2000; Liu et al., 
2006). The OECD (Q)SAR Application Toolbox ER-profiler utilises the 
aforementioned relationships, and those stipulated in Table 2.3, to quickly categorise 
chemicals on their propensity to bind to ER (Cronin & Worth, 2008; Tong et al., 2004; 
Schmieder et al., 2003; Schultz et al., 2002). Two-dimensional structures are classified 
as binders according to cyclicity and a molecular weight of <500 Da, with either 
hydroxyls or NH2 groups. Non-binders are chemicals that do not satisfy this criteria, or 
if the OH/NH2 groups are impaired by ortho-di-substitutions (Mombelli, 2012).  
In a QSAR context, sensitivity pertains to the proportion of true positives correctly 
identified, specificity details the number of non-binders correctly identified by the tool, 
and concordance quantifies the proportion of chemicals correctily identified. The 
predictive performance of the OECD (Q)SAR Toolbox ER profiler has been evaluated 
by comparing predictions with human and rat experimental binding affinities 
(Mombelli, 2012). Regardless of strength, chemicals identified as having possible 
interactions in the QSAR Toolbox, were considered positive, while non-binders were 
negative. Mombelli (2012) reported OECD Toolbox ER-profiler sensitivity of 84.1% 
(116 true positives, 22 false negatives), 68.3% specificity (71 true negatives, 33 false 
positives) and concordance of 77.3% for human datasets. Combining the rat and human 
datasets (Mekenyan et al., 2002), on the basis of significant homology and similar 
binding behaviour (Koike et al., 1987), reduced sensitivity to 70.6%, specificity to 
73.1% and concordance to 72.1% (Mombelli, 2012).  
The predictive performance of the Stably Transfected Transcriptional Activation Assay 
(STTA test) in detecting estrogenicity, relative to the in vivo Immature Rat Uterotrophic 
Assay as a gold standard, presented sensitivity, specificity and concordance of 91%, 
88% and 90%, respectively (Takeyoshi et al., 2002).  
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Table 2.3 OECD ER Binding QSAR Constraints 
Table shows the criteria utilised by the OECD Toolbox ER-Profiler in determining a chemicals 
propensity to bind with the ER.  
 
Thus, the predictive performance of the ER-profiler is lower than that of in vitro and in 
vivo testing. Mombelli (2012) compared predictivity of the OECD ER-profiler to the   
of the Murine Local Lymph Node Assay (LLNA) and Episkin® protocols, which are 
validated skin irritation models (ECVAM, 2010; Portes et al., 2002), highlighting the 
potential use of the OECD Toolbox ER-profiler as a screening tool. However, the 
inefficacy of the ER-profiler in detecting moderate binders, including the 
environmentally relevant phthalates, PCBs and tin-containing compounds, hinders 
stringent use as a screening tool.  
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2.5 Summary & Discussion 
From the birds to the bees, a plethora of developmental, reproductive and behavioural 
perturbations have been reported in wildlife exposed to anthropogenic chemicals. The 
omnipresence of endocrine disruption throughout phylogenetic classes, in addition to 
the homology of biological machinery, has mounted concern regarding the role of EDC 
exposure in the aetiology of human disease. In the EU, health costs associated with 
EDC exposures have been estimated at €31 billion per annum (HEAL, 2014). 
The literature review aimed to provide the foundation of EDC knowledge, assessing the 
historical context, caveats, epidemiological and toxicological concerns, and current 
knowledge which contribute to the understanding of in silico and in vitro approaches, 
and the context which has driven, and will continue to drive, EDC science.  
The published EDC research has focused primarily on estrogenicity and androgenicity 
of the HPG axis, which is in part justified by the endocrinology. However, endocrine 
disruptor science did not develop under the auspices of endocrinology, but through 
wildlife observations. As a result, historically the science presented bias, by assuming 
mechanisms from apical endpoints in a top-down manner. For example, intersex in 
invertebrates was attributed to estrogenicity and/or anti-androgenicity, however later 
mechanistic studies suggested significant differences in invertebrate endocrinology, 
potentially rendering observed effects incomparable. While research has started to 
bridge the gap between wildlife observations and human epidemiology, it has also 
highlighted the complexity of EDC MoA(s). A complexity stressed further by the 
potential intraspecies variation of EDC susceptibility, due to polymorphisms in 
biological receptors mediating responses.  
The aforementioned publication bias undoubtedly constrains the development of in 
silico and in vitro methods to estrogenic and androgenic MoAs. This may be a 
significant short-falling of EDC screening, which currently neglects effects on the 
amine and peptide hormones, in addition to glucocorticoid, mineralocorticoid and 
progestagen steroid hormones. Understanding endocrine mechanisms, and their 
potential disruption by exogenous chemicals, is vital to assess the impacts on 
environment and health, due to the significant costs of inadequate chemical regulation, 
both in terms of monetary cost and, mortality and morbidity of wildlife and human 
populations. Development, adoption and validation of in silico and in vitro tools are 
necessary for effective regulation.  
The ban of EDCs by some EU legislation has complicated the implementation of 
regulatory criteria. In addition, the adoption of the REACH regulations has demanded 
the implementation of frameworks for read-across and data-gap filling, and prompted 
the development of QSAR models (EC, 2006); such as the OECD QSAR Application 
Toolbox (Devillers et al., 2006), which includes a crude estrogen receptor profiler, and 
may be used in chemical screening. However, the inability of the OECD ER profiler to 
Evaluation of in silico and in vitro screening methods for EDC hazard characterisation 
 
 
 Page 41  
  
detect moderate binders, in addition to its limited scope, suggests virtual screening tool 
developments are required. The caveats of the current prioritisation and screening 
methods, in addition to the lack of regulatory criteria, also hinder the evaluation of in 
silico and in vitro tools for EDC hazard characterisation, which will inevitably present 
the same bias.  
Having achieved the aim of elucidating the historical context and drivers of endocrine 
disruptor science, the following section summarises the molecular mechanisms 
underpinning the endocrine system. Detailing the nuclear receptor classic genomic 
pathway and contributory mechanisms, the biological mechanisms founding the 
biological plausibility of in silico molecular docking, are elucidated. Focusing on the 
data-rich ER and AR, in addition to the progesterone receptor (PR) and Peroxisome 
Proliferator Activated Receptor-γ (PPARγ), which were prioritised based on literature 
review findings (sections 2.1.1, 2.1.3 and 2.2), this studies’ objective of in silico and in 
vitro comparison with published literature, has been refined.  
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3 BIOLOGICAL MECHANISMS 
3.1 Endocrine Receptors and the Classical 
Genomic Pathway 
The Nuclear Receptors regulate the transcription of target genes, controlling a gamut of 
physiological processes, ranging from metabolism to neuronal development and sexual 
differentiation (Fang et al., 2008; Fang et al., 2001). As a result, the nuclear receptors 
are among the most successful molecular targets in drug discovery history - binding a 
plethora of pharmacophores (Li et al., 2003). In parallel, the NRs were identified as 
molecular targets for endocrine disruption (Bergman et al., 2012). The following 
section details the mechanisms of nuclear receptor function, identifying pathways 
susceptible to disruption by xenobiotics and exogenous hormones.  
3.1.1 The Nuclear Receptor Superfamily 
The nuclear receptors are structurally related ligand-dependent transcription factors, 
ubiquitous to vertebrates and invertebrates, which play a vital role in endocrine 
signalling (Baker, 2004). Forty-eight nuclear receptors, including classic receptors and 
orphan receptors, have been reported in the human genome (Jin & Li, 2010; McEwan, 
2009).  
Phylogenetic analysis of the steroid receptors suggests that the receptors arose by a 
series of gene duplications from an ancestral nuclear receptor in a primitive vertebrate, 
at least 540 million years ago, and in concordance with the steroidogenic and steroid-
inactivating enzymes, such as cytochrome P450s and hydroxysteroid dehydrogenases 
(HSDs) (Baker, 2004).  Thornton (2001) suggested that a low specificity estrogen 
receptor (ER) was the ancestral steroid receptor, a duplication of which led to the 3-
ketosteroid receptor family (Eick & Thornton, 2010). The evolution of PR, TR, 
glucocorticoid and mineralocorticoid receptors is thought to have evolved via a process 
of ‘ligand exploitation’, whereby gene duplication enabled evolution of new receptors 
that were ‘liganded’ by intermediates of the steroidogenic pathway (Thornton, 2001).  
Nuclear receptors (NR) influence the interaction of transcriptional machinery with 
target genes - conformational changes, usually stimulated by hormone ligands, enable 
recruitment of coregulatory molecules and the cell’s chromatic modifying machinery. 
Uncoordinated nuclear receptors form ‘inactive’ complexes with heat shock proteins 
(HSPs) in the cytoplasm or nucleus. Consequent to ligand binding, the alpha-helices of 
the NRs present either an agonist or antagonist conformation, depending on the ligand. 
In positively regulated genes, ligand binding causes the dissociation of HSPs and 
corepressors, hetero- or homo-dimerisation, activation, recruitment of coactivators and 
translocation to nucleus (Brzozowski et al., 1997; Shiau et al., 1998).  
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The NRs interact with DNA by binding to hormone response elements (HREs) in the 
promoter sequence of target genes, or by binding to other transcription factors 
associated with target genes. Conformational changes consequent to steroid binding and 
dimerisation, reveal two polypeptide loops stabilised by zinc ions (termed zinc fingers), 
which bind to target DNA at a specific HRE. HREs are typically repeated 
hexanucleotides, separated by a spacer of a variable number of nucleotides, arranged as 
a direct repeat; for example, the AR, PR, glucocorticoids and mineralocorticoids 
receptors tend to act via response elements comprising an inverted repeat of AGAACA, 
whist estrogen receptors tend to act on elements with an inverted repeat of AGGTCA 
(Eick & Thornton, 2010).  
 
Figure 3.1 Androgen Receptor Signalling Pathways 
The nuclear receptors utilise a complex array of feedback loops, coregulators and inter-receptor cross-
talk; the diagram presented here shows the the AR signalling pathway, identifying a number of pathways, 
that may be disrupted by exogeneous chemicals (Qiagen Androgen Signalling Pathway Navigator, 
http://www.qiagen.com).  
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Upon binding to the DNA promoter or enhancer, NR AF-1 and/or AF-2 recruit (i) 
proteins (or protein complexes) with chromatin remodelling enzymatic activity; and, (ii) 
components of the general transcriptional machinery, forming the pre-initiation complex 
(Acevedo et al., 2004; Rosenfield et al., 2006), thereby activating the transcription of 
target genes. NR coactivators with enzymatic activity include CREB-binding protein 
(CBP), p300/CBP associated factor (P/CAF) and the histone acetyltransferase Tip60, 
the kinase CDK7 and ubiquitin/SUMO-1 conjugating enzyme (McEwan, 2009). 
However, in addition to these a number of NR have been demonstrated to directly bind 
general transcription factors (TATA-binding proteins, TFIIB, TFIIF and RNA 
Polymerase 2) (Lavery et al., 2005). A visual representation of the androgen receptor 
signalling pathway is shown in Figure 3.1. Additional NR signalling complexity resides 
in the dual-activity of agonists, which can bind to receptors to produce a full agonistic 
response, or partial depending on the relative binding affinity. Partial agonists may also 
act as antagonists in the presence of a stronger agonist, by competitively binding to the 
LBD of nuclear receptors (Hotchkiss et al., 2008).  
The requirement of transcription and translation to elicit an effect means that endocrine 
biological responses are generally slow, relative to cell surface receptor signalling (Holt 
and Hanley, 2006), with a characteristic lag period between the time of exposure and the 
onset of in vivo biological response (Brook and Marshall, 2005). It has been 
demonstrated that endogenous nuclear receptor function can be perturbed by exogenous 
environmental pollutants, by interaction with the ligand binding domain. Chemicals act 
as NR ligands because their stereochemistry allows them to fit, by chance, into the NR 
ligand binding pocket. McLachlan (2001) suggested that many plant and industrial 
chemicals, including pesticides, plastic components and xenobiotic drugs may interact 
with LBDs and thereby mimic, block or otherwise disrupt the natural activity of nuclear 
receptors. Subsequently, understanding the basic biology of NR is vital to understanding 
the biological plausibility of receptor mediated endocrine toxicity.   
3.1.1.1 Nuclear Receptor Structure 
All members of the steroid hormone class of the nuclear receptor family have a similar 
modular structure comprising of 5 homologous domains, which are lettered from A to 
E, from the N terminal to the C terminal (Table 3.1). X-Ray Crystallography
19
 studies 
have identified significant structural homology between nuclear receptors, suggesting 
similar functionality of domains. Contrary to this, the A/B domain (AF-1) varies, 
demonstrating distinct structural features with flexibility that renders structural 
determination difficult. Subsequently, the molecular basis of AF-1 function is uncertain, 
although a role in ligand-independent transcription has been reported (Jin & Li, 2010). 
                                                 
19
 X-ray Crystallography can be used to determine the atomic and molecular structure of proteins by 
measuring the angles and intensities of diffracted incident X-rays. The density of electrons can then be 
used to determine the mean positions of atoms, enabling the generation of the 3D structure. 
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Table 3.1 Nuclear Receptor Domains 
The nuclear receptor family present homologous modular domains, lettered from A to E, which contain 
the activation funcitons (1 and 2), DNA binding domain, and coactivator binding sites. The role of each 
domain is detailed in the table. 
 
The NR E-domain (LBD) is typically composed of 11-13 α-helices (H) arranged into a 
three-layer antiparallel ridge; helices 3, 7 and 10 forming the external surface, while the 
structure of α-helices 4, 5, 8 and 9 create a hydrophobic cavity, termed the ligand 
binding pocket (LBP). Bound ligands energetically stabilise the protein conformation 
via contacts with H3, H5, H6, H7 and H10 (Jin & Li, 2010). The hydrophobicity of the 
LBP allows NR to interact with lipid soluble ligands, leading to promiscuity of NR and 
contributing to the biological plausibility of NR mediated endocrine disruption. 
However, there is discrepancy in the response generated in different cells consequent to 
a ligand binding, restricting a cohesive model of NR action (McDonnell et al., 2002). 
There is limited structural homology in NR LBP, the cavity ranging from 100 Å
3 (ERα) 
to 1400 Å
3
 (PPARs) (Jin & Li, 2010). The size of the LBP is indicative of the 
specificity; for example, the large binding pocket of PXR (1200 Å
3
), is able to bind both 
the antibiotic Rifampicin (MW 822.94) (Chrencik et al., 2005) and the cholesterol 
lowering drug SR12813 (MW 504.53) (Watkins et al., 2001). Studies on the PPARs 
have also identified the importance of LBP shape in NR specificity (Xu et al., 1999). 
Conformational changes in the LBP, consequent to ERα agonism, have been 
demonstrated to expose the AF-2 (Tora et al., 1989), permitting interaction with 
coactivators (Shiau et al., 1998). Conversely, in antagonism, the AF-2 is translocated 
into a different position, enabling the recruitment of corepressors, rather than 
coactivators (Shiau et al., 1998; Smith et al., 1997; Barkhem et al., 2002). 
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Subsequently, the most pronounced feature of NR LBD is their plasticity; 
accommodating a number of specific ligands in a variety of conformations (Jin & Li, 
2010).  
A hydrophobic surface enclosed by α-helices 3, 4 and 12, consequent to ligand binding, 
provide a site for coregulator binding (Jin & Li, 2010; Hur et al., 2004). X-ray 
structures of NR complexes suggest a conserved mechanism of coregulator binding; the 
position of α-helices 12 critically defining coregulator binding selectivity (Xu et al., 
2002). Coactivators typically contain multiple LXXLL
20
 motifs, which adopt a two-turn 
alpha-helix conformation, with the three leucine side chains fitting into the hydrophobic 
LBD. The coactivator-NR complex is further stabilised by ‘clamping’ to a conserved 
H12 glutamate residue and H3 lysine residue. Corepressors bind to the LBD via the 
conserved LXXXIXXXL/I motif which, unlike coactivators, adopts a three-turn alpha-
helix conformation, forcing conformational change of the AF-2 and blocking LXXLL 
activation (Jin & Li, 2010).  
Interestingly, the mechanism for hormone-dependent Androgen Receptor (AR) 
activation (AF-2) varies from other NR, as AR does not interact with LXXLL motifs, or 
the associated family of coactivators (SRC-1/p160 family) (He et al., 2002; Hsu et al., 
2003). Coactivators of the AR typically contain FXXLF motifs, which alters the 
conformation of AR side chains through an induced-fit mechanism (He et al., 2004; Lee 
et al., 2001). Understanding the variances in structure, function and coregulation of the 
NR’s under investigation (ERα, ERβ, AR, PR and PPARγ) is vital for the in silico 
analysis. The following sections summarise the literature pertaining to specific 
structural and functional features of each receptor to be investigated in this study. 
3.1.2 Estrogen Receptor 
Estrogens, such as the endogenous 17β-estradiol (E2), interact with the estrogen 
receptor (ER) to elicit the transcription of associated genes regulating human 
physiology, including development, reproduction, metabolism and homeostasis 
(Ascenzi et al., 2006). Thus, perturbation of ‘normal’ estrogenic signalling may trigger 
adverse health effects. ER interacts with a number of cell check stop points and cellular 
regulators, such as; FOXC2, MAP1, SLC30A9, UBE1C and NCOA3
21
. Mammals 
express two ER subtypes, ERα and ERβ (Ramsey et al., 2004); however, a further 
subtype (ERγ) has been detected in fish (Hawkins et al., 2000; Ma et al., 2000; Menuet 
et al., 2002; Shi et al., 1997). Located on distinct chromosomes, ERα and ERβ are the 
products of separate genes (ESR1 and ESR2, respectively), which maintain 8 exons 
separated by 7 introns (Green et al., 1986). ERα is larger than ERβ (Kumar et al., 2004) 
and Pike et al. (1999, 2000) suggested that ERα and ERβ bind E2 differently, with the 
                                                 
20
 Where L = Leucine, I = Isoleucine and X = any amino acid.  
21
 http://www.uniprot.org/uniprot/P03372 
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ligand ‘upside down’ in the latter. Interestingly, ERβ can act as a dominant inhibitor of 
ERα transcriptional activity when co-expressed (Metivier et al., 2003). Mutations of ER 
have been identified in a number of diseases, while polymorphisms in ERα have been 
associated with bone mineral density (BMD); commonly detected in post-menopausal 
women, low BMD is associated with increased osteoporosis risk (Ascenzi et al., 2006). 
ERs bind a plethora of structurally diverse chemicals (Ascenzi et al., 2006), possibly as 
a consequence of the large discrepancy in volume between the ER binding cavity 
(450Å) and E2 (245Å). Consistent with the other NRs, the LBD is folded into a three-
layered antiparallel α-helical sandwich. E2 binds diagonally across the hydrophobic 
core of the LBD, formed by αH3 (Met342 to Leu354), αH6 (Trp383 to Arg394), the 
loop and αH8 (Val418 to Leu428), αH11 (Met517 to Met528), αH12 (Leu539 to 
His547) and with S1/S2 hairpin (Leu402 to Leu410), adopting a low-energy 
conformation (Brzozowski et al., 1997). The phenolic hydroxyl of the E2 A-ring 
(Figure 3.2) forms hydrogen bonds to the ER Glu353 carboxylate and guanidinium 
group of Arg394, and a water molecule. The A-ring itself poses between the side chains 
of Ala350, Leu387 and Phe404. Located at the other end of the LBP, the E2 D-ring 
forms non-polar contacts with Ile424, Gly521 and Leu525, while the 17β-hydroxyl 
(O17) group forms a hydrogen bond with His524 (Brzozowski et al., 1997). In E2 
binding, αH12 clamps over the LBP, projecting its inner hydrophobic surface (Asp538, 
Asp545) towards E2, and projecting Glu542 away (Brzozowski et al., 1997).   
DES bound ER, closely resembles the conformation of the E2-ER complex defined by 
Brzozowski et al. (1997), Tanenbaum et al. (1998)  and Shiau et al. (1998). However, 
the DES (structure C in Figure 3.2) ethyl groups projecting from the phenolic rings, fit 
into unoccupied cavities of the ER, forming non-polar contacts with Ala350, Leu384, 
Phe404 and Leu428, possibly accounting for higher affinity (Kuiper et al., 1997; Shiau 
et al., 1998). Furthermore, the A
1
 ring of DES forms van der Waals contacts with 
Met343, Leu346 and Met421, in addition to Gly521 and Leu525, further stabilising the 
complex (Shiau et al., 1998). Stabilisation is important for dimerisation and cofactor 
recruitment (Chapter 4.1).  
The ER antagonist, Raloxifene (RAL), utilises the same hydrophobic pocket of the 
LBD, mimicking the interaction of the A-ring hydroxyl, however, bonding between 
αH8 and αH11 is significantly different, with a 5.1Å displacement of the His524 
hydrogen bond to RAL’s phenolic hydroxyl (O11). The RAL side chain forms 
hydrophobic contacts with αH3, αH5/H6, αH11 and the connecting loop, which is 
stabilised by a hydrogen bond between Asp351 and the piperazine ring (N26 in Figure 
3.2). However, 11Å in length, the RAL side chain is not contained within the LBP, 
protruding from the pocket and displacing αH12 (Brzozowski et al., 1997), and 
subsequently coactivator binding.  
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Figure 3.2 Chemical Structure of Estrogen Receptor Binders (E2, DES and RAL) 
The chemical structures of the estrogen receptor agonists 17β-estradiol (A) and Diethylstilbestrol (C) and 
antagonist raloxifene (B), demonstrate the plethora of structures that interact with ER. The ethyl groups 
involved in DES non-ionic bonding are labelled in green.    
Ligand binding drives the recruitment of coregulatory molecules via the NR Box II 
peptide-LBD interface (Phillips et al., 2011); buried 1000Å into the ERα LBD and 
comprised of residues Leu345, Val355, Ile358, Ala361 and Lys362 (αH3), Phe367, 
Val368 (αH4), Leu372, Gln375, Val376, Leu379, Glu380 (αH5) and Asp538, Leu539, 
Glu542 and Met545 (αH12) (Shiau et al., 1998). However, the LBD interacts primarily 
with Ile689, and the LXXLL motif leucines (Leu690, Leu693 and Leu694); the side 
chain of Leu690 forms van der Waals contacts with the side chains of Ile358, Val376, 
Leu379, Glu380 and Met543 (Shiau et al., 1998). Subsequently, the AF-2 surface is 
believed to be formed from grove of αH3, αH4, αH5 and αH12 (Brzozowski et al., 
1997; Shiau et al., 1998). The blocking of AF-2 function (by antagonists, such as RAL, 
Figure 3.2) is a consequence of αH12 interfering with the static region of the coactivator 
recognition groove (Shiau et al., 1998).  
3.1.3 Androgen Receptor 
The androgen receptor (AR) is a ligand activated transcription factor that triggers the 
expression of genes involved in the development of the male phenotype and male 
secondary sex characteristics. Insensitivity to the action of androgens, consequent to the 
failure of androgenic compounds eliciting the AR genomic pathway, is a common cause 
of under-masculinisation in 46 XY individuals (Werner et al., 2010). Furthermore, as a 
result of location on the X chromosome (locus q11-12 in humans), males are 
hemizygous, thus mutations in the gene directly affect male sexual development. 
Carrying two copies of the X chromosome, heterozygous women are usually unaffected 
(Spencer et al., 1991). However, the formation of Barr bodies
22
, via a process of 
                                                 
22
 Named after their discoverer, Murray Barr, a Barr body is an inactive compressed X chromosome in 
female somatic cells.  
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lyonisation (X-inactivation), means that women may express two AR, complicating 
extrapolations from genotype to phenotype. 
The N-Terminal Domain (NTD) of AR contains glutamine (Glu/Q) and glycine (Gly/G) 
polymorphic repeats, termed polyQ and polyG repeats, respectively. If the polygutamate 
repeat exceeds 40 residues, the late onset neurodegenerative disorder, spinal and bulbar 
muscular atrophy (SBMA or Kennedy disease) develops (LaSpada et al., 1991). The 
length of the polyQ and polyG repeats in healthy men usually ranges from 9-36 and 10-
27 residues, respectively. The polyQ repeat induces AR transactivity (Mhatre et al., 
1993) and the polyG increases AR activity. Thus, the number of these repeats may 
predispose an individual to virilisation disorders and infertility, depending on baseline 
testosterone levels. Over 600 mutations of the AR have been identified (Gottlieb et al., 
2004); furthermore, activating mutations that lead to LBD promiscuity have been 
reported in prostate cancer tissues (Werner et al., 2010).  
The AR ligand binding domain is constructed of a hydrophobic region of 12 α-helices 
and four β-strands, which seal the binding pocket consequent to ligand activation (He et 
al., 2004), and enables AR response elements and coactivators to be recruited. 
However, adding uncertainty to the extrapolation of receptor binding studies, almost 
200 protein coregulators of the AR have been described (Heemers & Tindall, 2007).  
3.1.4 Progesterone Receptor  
Progesterone, the endogenous agonist of the progesterone receptor, is a female 
reproductive hormone, renowned for its role in uterine receptivity, implantation and 
pregnancy (Schumacher et al., 2012). However, more recently the neuroprotective 
properties of progestagens have been demonstrated in experimental models of nervous 
system injury, such as middle cerebral artery occlusion, excitotoxic neuron death and 
traumatic brain injury (Garcia-Segura et al., 2001; Stein, 2001; Wise, 2002; De Nicola 
et al., 2009), suggesting multiple functions beyond reproduction.  
The progesterone receptor (PR) encoded by the PGR gene located on chromosome 
11q22 has two main forms, A and B, the latter of which includes the transcription 
activation function TAF-3 (>165 a.a.) in a B-upstream segment (BUS) of the N-terminal 
(Kastner et al., 1990). Though the remainder of the protein sequence is similar, the two 
PR are functionally distinct, mediating different response elements and physiological 
effects. In the human PR, a number of variable sites have been identified, including four 
polymorphisms and five common haplotypes. For example, +331G/A polymorphism in 
the promotor region alters the PR transcription site, which led to increases in PR gene 
transcription in Ishikawa endometrial cancer cells in vitro (Terry et al., 2005). 
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3.1.5 Peroxisome Proliferator Activated Receptor-gamma 
The Peroxisome Proliferator Activated Receptors (PPARs) are a class of nuclear 
receptor transcription factors (Michalik et al., 2006) of genes involved in cellular 
differentiation, development, metabolism and tumourigenesis (Belfiore et al., 2009) of 
higher organisms (Berger & Moller, 2002; Feige et al., 2006). PPARs heterodimerise 
with the retinoid X receptor (RXR) and bind to specific DNA promoters, termed 
peroxisome proliferator hormone response elements (PPREs). Consistent with other 
NR, the function of PPARs is mediated by conformational changes consequent to ligand 
binding and a number of coactivator and corepressor proteins, which can activate or 
inhibit PPAR function, respectively (Yu & Reddy, 2007).  
Three subtypes of peroxisome proliferator activated receptor have been identified: 
PPARα, PPARδ and PPARγ (Berger & Moller, 2002). PPARα is expressed 
predominantly in the liver, kidney, heart, muscle and adipose tissue, while PPARδ is 
expressed in all tissues, but markedely in the lipid rich tissues of the brain, adipose 
tissues and skin. There are three alternative splice variants of the PPARγ, splice variant 
γ is expressed in all tissues, γ2 is mainly expressed in adipose tissues, while γ3 is 
expressed in macrophages, the large intestine and white adipose tissue. Each PPAR 
subtype has distinct cellular functions. Due to its agonism with TBT and TPT, leading 
to imposex in marine molluscs and adipogenesis in mammals, PPARγ will be the focus 
of this investigation.  
A number of hereditary disorders in PPARs have been identified, generally resulting in 
PPAR loss of function, which has been associated with concomitant lipodystrophy
23
, 
insulin resistance and acanthosis nigricans
24
 (Meirhaeghe & Amouyel, 2004). In 
PPARγ, a Pro12Ala gain of function mutation has been extensively studied and 
associated with decreased risk of insulin resistance. However, Pro115Gln has been 
associated with obesity; increased prevalence of PPARγ polymorphisms have been 
identified in a number of obese populations (Buzzetti et al., 2004). 
3.2 Nuclear Receptor Regulation 
3.2.1 Heat Shock Proteins (Hsp) 
Prior to ligand binding, nuclear receptors are non-covalently associated with a number 
of chaperone
25
 molecules, including heat shock proteins (Hsp), which are requisite for 
effective ligand binding (Pratt et al., 2004; Zoubeidi et al., 1007). Ligand binding 
                                                 
23
 Medical condition characterised by abnormal or degenerative adipose tissue.  
24
 Brown-black hyperpigmentation of the skin, associated with obesity or endocrinopathies such as 
hyperthyroidism, hyperthyroidism, acromegaly, Polycystic Ovaran Syndrome (PCOS) and type II 
diabetes. Pigmentation is usually found in the lateral folds of the neck, axilla, groin, forehead etc.  
25
 Chaperone proteins aid in the non-covalent folding (and unfolding) of macromolecules, preventing 
newly synthesised and assembled proteins from aggregating into non-functional structures.  
Evaluation of in silico and in vitro screening methods for EDC hazard characterisation 
 
 
 Page 52  
  
causes a conformational shift (activation) in the NR, leading to dissociation of Hsp and 
dimerisation (Tetel et al., 2009). Heat shock proteins are up-regulated in response to 
physiological stress (heat, toxins and UV) and are vital for protein folding; enhancing 
the ability of cells to cope with denatured proteins (Jäättelä, 1999). Named according to 
their weight (i.e. Hsp60 is 60 kilodaltons in size), Hsps have been implicated in an array 
of cellular processes (Smith et al., 1997). The NR typically associate with two Hsp90 
(Chambraud et al., 1990), low levels of which have been associated with dysfunctional 
nuclear receptor function in yeast mutants (Picard et al., 1990), one molecule of Hsp70 
and one molecule of either Hsp56, Hsp26 or Hsp40, to retain a non-DNA binding state 
(Morimoto et al., 1998).  
The complete binding site of Hsp to NR remains uncertain, however, Pratt et al. (1988) 
suggested that Hsp90 binds to the ligand binding domain (LBD), consequenet to the 
isolation of Hsp90-GR LBD complexes in mutant cDNA transfection studies in Cos7 
cells (Denis et al., 1988). Additionally, Chambraud et al. (1990) demonstrated an 
association between the C-terminal extremity of the DBD (residues 251-271), 
suggesting that multiple regions are involved in the formation of Hsp90 complexes. 
Typically positively charged, residues 251-271 are conserved in the NR of various 
species, adding to the plausibility of its interaction with the negatively charged ‘A-
region’ of Hsp90 (Chambraud et al., 1990).  
3.2.2 Co-Regulation 
Nuclear Receptor (NR) activity is mediated by approximately 300 NR coregulators 
(Lonard et al., 2007), including p160 factor and steroid-receptor-coactivator (SRC) 
family activators, and SMART (silencing mediator for retinoid and thyroid hormone 
receptors) and N-CoR (nuclear corepressors) repressors (Glass et al., 2000; Nettles et 
al., 2005). The functionality of nuclear receptors is largely determined by coregulators, 
which are themselves recruited on the basis of specific conformational changes in the 
LBD consequent to ligand binding (Jin & Li, 2010). Interestingly, ‘stapled’ synthetic 
peptides modulating NR behaviour, via coregulatory mechanisms have become an area 
of drug-design research (Phillips et al., 2011). The activity of NRs and their auxiliary 
coregulators is further controlled by kinases, ligases and covalent modifications 
(Goodson et al., 2009). In vitro studies suggest that coactivator recruitment is a rate 
limiting step in NR-mediated gene transcription (Rosenfield et al., 2006; Torchia et al., 
1997). Additionally, in vitro repression of NR transcriptional activity through cross-talk 
with other NR, or ‘squelching’, is reversed by the addition of coactivators (Oñate et al., 
1995). The NR auxiliary coregulators can influence target gene transcription through 
acetylation, methylation, phosphorylation, chromatin remodelling and mRNA splicing 
(Rosenfield et al., 2006; Lonard et al., 2005).  
The P160 family includes steroid receptor coactivator-1 (SRC-1/NCoA-1), which was 
one of the first ligand-dependent transcription factor coactivators reported (Oñate et al., 
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1995), SRC-2 (also referred to as GRIP1, TIF2 and NCoA-2), and SRC-3 (also termed 
AIB1, TRAM-1, p/CIP, ACTR and RAC3) (Suen et al., 1998).  The SRC coactivators 
physically associate with the LXXLL motifs (NR-box) of nuclear receptors (ER, PR and 
GR), in a ligand dependent fashion (Rosenfield et al., 2006; Oñate et al., 1995). The 
P160 family of coactivators contain two activation domains, AD1 and AD2, which 
mediate CBP association (Chen et al., 1997) and coactivator-protein interactions,  for 
example with arginine methyltransferase CARM1 (Chen et al ,1999), respectively. 
Consequent to binding, the SRC coactivators recruit other coactivators, such as CBP 
and p300/CBP-associated factors, which can remodel the chromatin via histone 
acetyltransferase activity (McKenna et al., 1998). However, estrogen receptor-
associated protein-140 (ERAP140) enhances the transcriptional activity of ERα, ERβ, 
TR, PPARγ and RARα in the absence of LXXLL motifs (Tetel et al., 2009), 
highlighting incongruity in coactivator mechanism.   
Depletion of SRC-1 in vitro has been demonstrated to hinder nuclear receptor-
dependent transcription (Torchia et al., 1997). Furthermore, decreased responsiveness to 
progesterone target tissues, partial thyroid resistance and delayed cerebellar Purkinje 
cell development, have been demonstrated in SRC-1 knockout mice in vivo (Tetel et al., 
2009). However, interestingly, SRC-2 was up-regulated in steroid-sensitive tissues, 
indicative of compensation for the loss of SRC-1 (Xu et al., 1998). SRC-2 ablation, 
knockout and microarray studies have highlighted roles in fertility, mammary gland 
development (Fernandez-Valdivia et al., 2007), cell cycle and immunity (Jeong et al., 
2007).  
Gene silencing is resultant of DNA methyltransferase (DNMT) methylation of DNA 
CpF sites (Reik et al., 2001; Klose et al., 2006), which subsequently recruit 
corepressors and histone deacetylase (HDAC) repressor complexes; e.g. Sin3, NuRD, 
CoREST and NCoR/SMRT (Tetel et al., 2009). Corepressors aid gene silencing by 
removing acetyl groups on histones, restoring a positive charge on the histone tails 
enabling tighter binding with DNA and DNA compression (Cunliffe, 2008). However, 
the mechanism of corepression in its entirety is still under elucidation.  Interestingly, 
global deletion of nuclear receptor corepressors (NCoR) is embryonic lethal (Jepsen et 
al., 2000), suggesting that loss of NCoR function cannot be compensated for by another 
coregulator (Tetel et al., 2009).  
Coactivator and corepressor messenger RNA (mRNA) is ubiquitously expressed 
(McDonnell et al., 2002). However, Misiti et al., (1998) reported significant variation in 
tissue-specific expression patterns of SRC-1, p300, SMRT and NCoR, dependent on 
hormonal regulation. For example, SRC-1 levels in the anterior pituitary (AP) were 
regulated by triiodothyronine (T3) and E2. Furthermore, coregulator expression patterns 
present sexual dimorphism; female AP samples contained an average of 40% less SRC-
1 mRNA, than male rats (Misiti et al., 1998). Variations in the relative expression of 
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coactivator and corepressors genes may add heterogeneity to hormonal responses 
(Misiti et al., 1998), and subsequently to the plethora of toxic responses.  
3.2.3 Post-Translational Modification 
Post-translational SUMOylation
26
 of the NR has been identified as a modulator of 
hormone response, in a gene and receptor specific manner (McEwan, 2009). Post-
translational SUMOylation of the AR on lysines 386 and 520 by Ubc9 and E3 ligases 
(PIASI and PIASAxa) represses AR-dependent transactivation at specific promoters. 
Conversely, SUMOylation of ERα at the hinge region lysines (K266 and K268), which 
are also subject to acetylation, enhances receptor activity (Faus et al., 2006; Popov et 
al., 2007). Subsequently, post-translational modifications provide a ‘fine-tuning’ 
mechanism of NR transactivation (McEwan, 2009).  
In addition to the NR proteins themselves, coactivators can be phosphorylated, 
methylated, ubiquitinated, SUMOylated and acetylated, altering the functionality of the 
transcriptional complex (Tetel et al., 2009). For example, ERα is phosphorylated on 
Serine-118 in response to epidermal growth factor, enhancing coactivation (McEwan, 
2009).  
3.2.4 Inter- & Intra- Receptor Cross-Talk  
There is functional cross-talk between NR (inter-receptor); for example, EDCs can 
impact ER signalling indirectly by binding to the AhR, which is activated by a wide 
variety of hydrocarbons. Cross-talk between the steroid receptors and constitutive 
androstane receptors (CAR), pregnane X receptors (PXR), peroxisome proliferator-
activated receptors (PPAR’s) and retinoid X receptors (RXR’s) may alleviate or 
aggravate responses in vivo (EFSA, 2010). The transactivation of PR is reduced by 
coexpression of ERα, possibly as a result of ‘squelching’ or shared coactivators (Oñate 
et al., 1995; Tetel et al, 2009). Inter-domain communication poses a further conundrum 
when elucidating NR modes of action (McDonnell et al., 2002). The AF-1 domain is 
required for the partial agonistic activity of tamoxifen at the LBP (AF-2), and can be 
positively affected by MAPK-directed phosphorylation (Kato et al., 1995), suggesting 
that inter-domain communications play a role in the NR response phenotype.  
Dimerisation (homo- or hetero-) of monomeric NR units is essential for transcription. 
The principle dimerisation surface of NR consists of a large contact area (1703 Å
2
 in 
ERα) on the surface of the LBD (Brzozowski et al., 1997). The dimerisation stability is 
regulated by ligand binding; agonists, antagonists and mixtures having characteristic 
effects on the rate of monomer dissociation. Dimer stability is implicated in the efficacy 
of the transcriptional complex to associate downstream factors, and thus may be 
                                                 
26
 SUMOylation is a directed enzymatic cascade involving Small Ubiquitin-like Modifier (SUMO) 
proteins 
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important in defining the in vivo potency of NR responses (Tamrazi et al., 2002); this 
demonstrates that intra-receptor communications (conformational responses) play a role 
in inter-receptor communications.  
As discussed in Section 3.2.2, understanding ‘allostery’27 is vital to understanding 
molecular signalling in cellular physiology. Bidirectional allostery has been observed 
between the DBD and LBD NR domains, termed ‘interdomain allostery’ or intra-
receptor cross-talk (Bapat et al., 2003; Kong et al., 2005). Melamed et al. (1996) 
reported variances in ER-ERE interaction consequent to LBD truncation; LBD 
truncated ER still formed dimer complexes and attached to DNA response elements, but 
less tightly. Subsequently, the conformational alterations induced by ligand binding are 
not only important for the interaction with cofactors, but also the dimerisation and DNA 
binding.  
Furthermore, in addition to receptor cross-talk, functional mutations and ligand 
dynamics, communications between coregulatory complexes highlight the complexity 
and intricacy of the ligand-dependent NR transcription (McKenna et al., 2002) that is 
pivotal to the in silico and in vitro analysis undertaken in this study.   
3.2.5 Agonism vs. Antagonism 
A number of studies have reported dual agonism/antagonism of endogenous hormones 
and xenobiotics (Jackson et al., 1997; Melamed et al., 1997; Srinivasan et al., 2013). 
For example, the endogenous hormone, estriol (E3), acts as a weak estrogen in 
ovariectomised laboratory animals at a single dose, and produces full estrogenic 
response upon chronic exposure. However, E3 has also been shown to antagonise the 
ER when co-administered with E2 (Melamed et al., 1997). Cell-free transcription assays 
highlighted the dose-dependency of antagonism, as a result of competitive binding 
kinetics (Melamed et al., 1997). The weak estrogenicity of E3 has been attributed to 
impaired association between hER and ERE, as the E3 16αhydroxyl group interferes 
with the 17α-hydrogen bond to Glutamate-419 of ERα, engendering altered LBD 
conformation (Lewis et al., 1995). Interestingly, Quartz-Crystal Microbalance 
Dissipation (QCM-D) and Surface-Plasmon Resonance (SPR) spectroscopy of ERα 
have demonstrated significant differences in viscoelastic
28
 behaviour subsequent to 4-
hydroxytamoxifen (4HT) or E2, LBD binding (Peh et al., 2007). Both ligands altered 
the biolayer water content, however, relative to E2, 4HT bound ER-ERE complexes 
were dispersed and less dense (Peh et al., 2007), consistent with the previous findings of 
                                                 
27
 Derived from allosteric, ‘allostery’ defines the alterations in enzyme shape and activity consequent to 
molecular binding of a coregulator or regulatory substance, at a site other than the LBD.  
28
 Viscoelasticity is the property used to define the interface between viscosity and elasticity; folded 
proteins, present both amorphous solid and crystal-like properties, thus viscoelasticity provides an 
Angstrom-resolution picture of protein properties (Wang & Zocchi, 2011).  
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impaired hER-ERE interaction of partial agonist complexes (Lewis et al., 1995; 
Melamed et al., 1997).  
The anti-inflammatory ERα agonist, WAY-166916, has been demonstrated to present 
dynamic binding (multiple conformations in the active site.); the bulky side group 
orientating towards H12, disrupting the activation function (AF-2), or, towards the 
hydrophobic side pocket and H8, supporting an active conformer, depending on 
orientation (Srinivasan et al., 2013). Subsequently, the same ligand can cause either 
agonistic or antagonistic responses. Adding to the complexity of this process, Brunning 
et al. (2010) also reported ‘gain of allostery’ mutations that mimic ligand-dependent 
responses with WAY-169916, with both the canonical active and inactive 
conformations of the ERα – binding the ligand in different orientations. In other words, 
nuclear receptor surface mutations can lead to stabilisation of specific protein 
conformations, which might otherwise be energetically unfavourable. Srinivasan et al. 
(2013) concluded that such ligand dynamics explain the varied pharmaceutical 
phenotypes observed in vivo, subsequent to simple-binding and in vitro reporter gene 
assay observations, further stipulating that such dynamics may be exploited to modulate 
signalling specificity. However, with regard to endocrine toxicity, if ligand dynamics 
define specific signalling and subsequently ERα phenotypes, the plethora of health 
effects associated with NR binding may be more varied than currently anticipated. 
Interestingly, the agonistic or antagonistic characteristics of a ligand are also defined by 
the concentration of coregulatory molecules; Smith et al (1997) reported activation and 
inhibition of ER consequent to 4-hydroxytamoxifen exposure, depending on coactivator 
or corepressor concentration, respectively. The bifunctionality of dynamic ligands, such 
as WAY-169916 (Brunning et al., 2010; Srinivasan et al., 2013), increases the 
complexity of ligand-dependent NR transactivation, suggesting a more complex 
Michaelis-Menten kinetics
29
, susceptible to stereoisomerism
30
 and conformation of both 
the receptor and ligand.  
3.3 Summary & Discussion  
Nuclear Receptors regulate the transcription of target genes, controlling a gamut of 
physiological processes, ranging from metabolism to neuronal development and sexual 
differentiation (Fang et al., 2008), and have subsequently been identified as molecular 
targets for endocrine disruption (Bergman et al., 2012). This chapter aimed to elucidate 
the biological mechanisms of nuclear receptor ligand-dependent transcription factors, 
and in particular the classical genomic pathway, which play vital roles in vertebrate 
                                                 
29
 In biochemistry, Michaelis-Menten Kinetics provides a descriptor of enzyme activity, relating the rate 
to substrate concentration.  
30
 Stereoisomerism reflects chemicals of the same molecular formula and functional groups, differing 
only in their three-dimensional shape, including enantiomers (varying only by reflection) and 
diastereomers (non-optically active enantiomer).  
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endocrine signalling (Baker, 2004). Concomitantly, a number of considerations for in 
silico and in vitro analyses are detailed.  
Uncoordinated (no ligand) nuclear receptors form ‘inactive’ complexes, non-covalently 
associating to chaperone molecules, such as HSP (Pratt et al., 2004). A plethora of 
structurally diverse chemicals interact with the LBD (E-domain), which stimulate 
conformational changes, enabling dissociation from HSP. The LBD consists of four 
surfaces: 1) a variable ligand binding pocket (LBP); 2) a dimerisation surface through 
which interaction with partner LBD occurs; 3) a co-regulatory binding surface; and, 4) 
the ligand dependent transcriptional activation function, AF-2. The AF-2 corresponds to 
helix 12, the position of which is dependent on ligand binding, and influences the 
recruitment of coregulators, driving either agonism or antagonism (Heldring et al., 
2007). Nuclear receptor dimer complexes bind to hormone response elements, which 
subsequently bind to the DNA promoter or enhancer, while the AF recruit chromatin 
remodelling enzymes and transcriptional machinery, forming the pre-initiation complex 
and thereby activating the transcription of target genes.   
The nuclear receptor structure and binding information (section 3.1.1), and in particular 
the detailed interactions of ER (section 3.1.2), aid the assessment of in silico NR 
molecular modelling. Less information is published regarding specific ligand 
interactions of AR, PR and PPARγ, which may hinder the assessments of their in silico 
counterparts at a molecular level. However, the polymorphisms and isoforms (detailed 
in sections 2.2 and 3.1), suggest that inter- and intra-species differences in LBD may 
play a role in EDC susceptibility.  
Additional NR signalling complexity resides in the fact that agonists may bind to 
receptors to produce a full agonistic response, or partial, depending on the relative 
binding affinity. Partial agonists may also act as antagonists in the presence of a 
stronger agonist, by competitively binding to the LBD of nuclear receptors (Hotchkiss 
et al., 2008). Functional cross-talk between NR further complicates the EDC biological 
mechanism. For example, transactivation of PR is reduced by coexpression of ERα, 
which may be due to ‘squelching’ or shared coactivators (Tetel et al., 2009). EDC 
toxicology and epidemiology studies (see section 2.1 and 2.2) have focused primarily 
on single MoAs (e.g. estrogenicity or androgenicity), thereby ignoring potential ligand 
promiscuity, or transactivation variation due to alterations in the concentration of co-
regulatory molecules. There are approximately 300 nuclear receptor coregulators 
(Lonard et al., 2007), concentrations of which vary between cells, tissues, organs and 
individuals. In vitro studies suggest that coactivator recruitment is a rate-limiting step in 
NR-mediated gene transcription, thus, the susceptibility to EDC mediated toxicity, 
consequent to molecular initiation by nuclear receptor binding, is likely to be highly 
variable.  
While toxicity studies mitigate for natural variation by using selected mutant strains, 
with fixed diet and age, extrapolating observations to other taxonomic classes may 
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present significant challenges, due to variations in supporting biological machinery. 
Furthermore, the importance of chaperones, co-regulatory molecules, transcriptional 
machinery and phosphorylation state detailed in the literature, condones the 
inconsistency of epidemiological tools, which attempt to elucidate relationships in 
highly variable cohorts (i.e. human and wildlife populations). The molecular 
‘fingerprint’ subsequent to toxicant exposure, revealed in comparative genomic analysis 
and toxicogenomics, may provide detailed MoA information and  elucidate DNA 
sequences and polymorphisms which confer elevated risk; highlighting susceptible 
individuals and demonstrating the efficacy of toxicological models (Borlak, 2006). 
Though out of the scope of this study, adoption and validation of toxicogenomic 
approaches, which combine gene expression, proteomic and metabonomic profiling 
with bioinformatics and toxicology (Borlak, 2006; Tennant, 2002), may improve the 
predictive accuracy of human risk assessment by elucidating genomic responses to 
environmental toxicants. 
Having elucidated the foundations of endocrine disruption, from the historical context 
to basic biological mechanisms, the founding theory of in silico and in vitro approaches 
has been introduced. The subsequent chapters aim to evaluate the available in silico 
(Section 4) and in vitro (Section 5) tools for EDC hazard characterisation.  
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4 ENDOCRINE ACTIVITY IN SILICO 
A plethora of virtual databases (Endocrine Disruptor Knowledge Base), QSAR (T.E.S.T.: 
The Toxicity Estimation Software Tool; OECD QSAR Toolbox), molecular modelling 
(VirtualToxNet) and decision tree (binary classification models) approaches, have been 
adopted, to computationally predict toxicity. The term ‘in silico’ refers to performance via 
computer or computer simulation; thus, endocrine disruption in silico refers to the prediction 
of endocrine disruption via computational methods. Endocrine disruption is not a toxic 
hazard per se, but a mechanism by which toxic hazards may be incurred (Section 1.1 and 
2.1). The Nuclear Receptors (ER, AR, PR and PPAR) have been identified as important 
molecular targets for endocrine disruption (Section 3.1). However it is important to note that, 
QSAR, molecular modelling and decision-trees of NR binding, do not provide sufficient 
information on in vivo cellular implications, neccessary to determine endocrine disruption, or 
toxic phenotypes (Piparo & Worth, 2010).  
The purpose of this study is not to provide a detailed review of the in silico tools available, 
but rather to explore the theory and application of molecular modelling and dynamics, to 
EDC hazard characterisation. The in silico methods developed herein may provide useful 
mechanistic information, for EDC hazard characterisation, but are not able to determine the 
toxic potencies required for risk assessment.  
4.1 The theory of in silico Nuclear Receptor Binding 
The toxicological and/or pharmacological activity of a compound is dependent on the spatial 
arrangement and electronegativity
31
 of atoms, and their subsequent interaction with 
endogenous biological systems. The interaction between a hormone and a receptor located in 
or on the target cell, forms the first step in classical genomic endocrine responses (see section 
3.1). Subsequently, characterisation of these molecular initiation events has formed an 
important area for understanding the mechanisms that govern the responses of target cells to 
hormones (Walters et al., 1998).  
Computational chemistry can characterise the dynamics, energetics and structure of these 
ligand-receptor interactions (Taft et al., 2007). Advances in computer-aided drug design 
(CADD) technologies, provide a solid foundation for in silico toxicological study. This is 
particularly true with regards to receptor-mediated toxicity, in which systems biology has 
been used to identify ligand binding domains (LBDs) and pharmacophores (the group of 
atoms in a xenobiotic substance responsible for biological action). LBD’s are encoded by 
DNA, thus based on the assumption that proteins related in sequence share similar structure 
(Dolan et al., 2008), the biological function and ‘global’ similarities of proteins can be 
                                                 
31
 Electronegativity is the tendency of an atom to attract bonding pairs of electrons, group 17 elements or 
halogens (fluorine, chlorine and bromine) are typically very electronegative, as are oxygen and nitrogen. 
Electronegativity is also indicative of polarity, due to the unbalanced distribution of electrons between 
components of a bond.  
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estimated by sequence and structural homology (Taft et al., 2007) – thereby justifying 
taxonomic ranking and phylogenetic approaches.   
Computational ligand-receptor interactions can be estimated by molecular mechanisms which 
provide static structures, or by molecular dynamics which incorporate an approximation of 
bond rotation and degrees of freedom (i.e. induced fit). There are a variety of molecular 
dynamics-based docking programs available to predict ligand-receptor interactions and 
docking. For example, QXP (quick explore) uses a superposition force field to automatically 
assign short-range attractive forces to similar atoms in different molecules in combination 
with Monte Carlo flexible docking estimations (Kövesdi et al., 1999; McMartin and 
Bohacek, 1997), while ICM (Internal Coordinate Molecular) dynamics models conformations 
based on empirical force fields with fixed degrees of freedom (Mazur et al., 2009). However, 
such timely physicochemical estimates of bond energy and orbital theory may be considered 
out of the scope of this study. Evolutionary methods for docking which incorporate genetic 
algorithms are utilised by software such as: PRO-LEADS (Murray et al., 1999); GOLD 
(Jones et al., 1997); and, AutoDock (Morris et al., 1998), which use Gaussian functions to fit 
and score the ligand into the LBD. Scoring usually represents an approximation of the 
binding free energy of the ligand-LBD complex by a sum of electrostatic and van der Waals 
interactions (Taft et al., 2007; Paulsen & Anderson, 2009). Genetic algorithm docking 
models provide a quick and easy tool to screen for ligand-receptor interactions, and may be 
more efficient in the investigation of endocrine nuclear receptor binding (Wu et al., 2010).   
A number of recent studies have utilised these computational techniques to predict endocrine 
receptor binding. In 2010, Wu et al. assessed the interspecies variation of androgen receptor 
binding in silico; the MODELLER 9V7 program was used to construct homology models of 
LBD’s collected from the Swiss-Prot Database32, and the Tripos™ SYBYL Surflex-Dock 
program (see Section 4.3.5) scored binding affinities of six model EDCs (Nonylphenol; Butyl 
benzylphthalate, BPA, 4,4’-Dichlorodiphenyldichloroethylene; 2,2’4,4’5,5’-
Hexabromodiphenyl ether, Linuron) and Testosterone. Cluster analysis demonstrated that the 
predicted binding affinities were species specific, consequent to variations in LBD hydrogen 
bonding, corroborating a number of in vivo and in vitro ecotoxicology studies, which 
compared the binding of EDCs to ARs (Wells and Van Der Kraak, 2000; Wilson et al., 
2007). In a more recent study, Kojima et al. (2011) characterised the human pregnane X 
receptor (hPXR) and mouse PXR (mPXR) agonistic activity of 200 pesticides in silico, 
demonstrating significant interspecies variation, thereby increasing the uncertainty of the 
mouse model when deciphering human risk.  
However, in order for a predictive in silico model to be a useful alternative method, 
extrapolating the results to a defined endpoint must be possible (OECD, 2009). Currently the 
reliability
33
 and relevance
34
 of in silico tools is uncertain (section 2.3.4.1), hindering 
validation attempts and regulatory acceptance (section 2.3). The OECD published validation 
                                                 
32
 Available at: http://www.uniprot.org/  
33
 The intra- and inter- laboratory reproducibility of results 
34
 Provides meaningful and useful information for a particular purpose 
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criteria for QSAR development in Guidance Document No. 69. There are a number of ER 
QSAR tools which estimate receptor binding based on the steric hindrance and presence of 
phenolic hydroxyl groups (section 2.4.3; OECD, 2012). However, QSAR studies for other 
nuclear receptors (AR, TR, PR etc.) are limited, and the OECD toolbox is not capable of 
identifying all potential EDCs, adding importance to the research conducted herein. 
Regarding the OECD principles of alternative methods, in silico prediction of nuclear 
receptors-ligand binding dynamics is concordant with the expected chemistry in vivo, i.e. the 
physical interaction of the ligand and the receptor. Consequently in silico binding has the 
potential to provide a useful alternative to in vitro binding studies, as a representation of the 
molecular initiating event in vivo. 
4.2 In silico Methodology 
The in silico research aims to elucidate the interaction between potential EDCs and nuclear 
receptors, while evaluating the potential variability of NR. Homology modelling works under 
the premise that protein sequence is indicative of protein function, thus, differences in 
sequence homology may indicate differences in protein function. Phylogeny explores the 
evolution of genetically related organisms, assuming that similar sequences derive from a 
common ancestor. Assessment of protein homology and phylogeny, therefore, provides a tool 
to visualise the fundamental inter- and intra-species differences in molecular machinery (i.e. 
NR). 
Basic Local Alignment Search Tool (BLAST) can be used to infer the functional and 
evolutionary relationship of proteins, in addition to detecting orphan receptors and gene 
families. Originally devised by Altschul et al. (1990), BLAST identifies regions of local 
similarity between nucleotide or protein sequences and calculates the statistical significance 
of matches. BLOSUM 62 (Blocks of Amino Acid Substitution Matrix) is a scoring method 
devised by Henikoff and Henikoff utilised by BLAST, which effectively aligns evolutionary 
distinct gapped sequences (Durbin et al., 1998). Results obtained using the NCBI BLAST 
tool, can subsequently be analysed in Molecular Evolutionary Genetic Analysis (MEGA); an 
integrated tool for conducting sequence alignment, estimating rates of molecular evolution, 
inferring ancestral sequences and phylogenetic trees and testing evolutionary hypotheses. 
Agglomerative/hierarchical clustering can be conducted using Unweighted Pair Group 
Method with Arithmetic mean (UPGMA) or Neighbour-joining, the latter of which assumes a 
constant rate of evolution (unsuitable for the current study). Created by Naiton & Nei, 
Neighbour-joining clusters protein sequence data; starting with an unresolved tree, with 
topology corresponding to a start network, formula iterates repeatedly over the data until all 
of the branch lengths are known.  
With regard to virtual screening, Tripos ® SYBYL software for ‘molecular modelling from 
sequence through lead optimisation’ is a commercially available bioinformatics tool for small 
molecule modelling and simulation, macromolecular modelling and simulation, lead 
identification and molecular design. SYBYL 7.3 provides “unique, competitive advantages” 
in 3D Quantitative Structure Activity Relationships (3D QSAR), cheminformatics, ligand-
based virtual screening and docking. ‘Surflex-Dock couples a unique scoring function with a 
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patented state-of-the-art search engine. The combination has been shown to yield excellent 
results in terms of docking accuracy and distinctly superior results in terms of screening 
enrichment’35.  
Surflex-Dock incorporates an empirical scoring function based on the Hammerhead docking 
system, with negative training data and a surface-based molecular similarity search engine, to 
accurately score ligand-receptor interactions. Scoring functions are derived from QSAR 
binding affinity data and negative training data to increase credibility and reduce false 
positives. Surflex-Dock can quickly score a library of ligands against a protein structure, 
predicted either in SYBYL or with experimentally defined X-ray crystal structures. 
Independent validation studies have identified Surflex, GLIDE and GOLD docking 
techniques as the most successful tools, in accurately ranking known inhibitors, in virtual 
screening experiments (Verdonk et al., 2003; Kellenberger et al., 2004; Warren et al., 2006). 
However, small variations in protein proton positions lead to large variations in SYBYL 
performance, highlighting the importance of protein preparation and local optimisation (Jain, 
2007).  
4.3 In silico Materials & Methods 
This section details the materials and methods utilised for the evaluation of in silico methods. 
The assessment of NR mechanisms in this study, were split into two core stages: (1) analysis 
of relevant NR sequence phylogeny; and (2) ligand-docking and virtual screening. Adopted 
methods for NR phylogeny modelling; chemical prioritisation for virtual screening; NR 
molecular modelling; molecular docking (virtual screening); and, methods of statistical 
analysis, are detailed in the following sub-sections.  
4.3.1 In silico Software and Programs 
 
The software, programs and databases used in the in silico method are listed in Table 4.1. As 
detailed in sections 4.1 and 4.2, a number of bioinformatics tools have been developed in 
response to high-throughput screening requirements.  However, the use, reliability and scope 
of in silico methods remain uncertain. Funded (US and EU) public biotechnology information 
hubs (UniProt, ZINC, ChemSpider, PubChem and PDB) were used in combination with 
commercial Tripos™ SYBYL molecular modelling software, to evaluate endocrine activity 
in a cost-effective manner. 
4.3.2 Nuclear Receptor Phylogeny Modelling 
Reviewed human estrogen (ER: P103372), androgen (AR: P10275), progesterone (PR: 
P06401) and Peroxisome Proliferator Activated Receptor-γ (PPARγ: P37231) protein 
sequences, downloaded from UniProt (Table 4.1), were used to initiate BLAST homology 
searches. The BLAST search parameters were set at: BLOSUM62 Matrix; No filtering; and, 
Gapped with a 250 hit cap (Wu et al., 2010). To mitigate for potential human bias, NR 
                                                 
35
 SYBYL Brochure  
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sequences from other taxonomic Classes, identified in the first search, were also used to 
initiate BLAST. Retrieved nuclear receptor sequences (Table 2 and Table 3) were renamed to 
reflect common species names and exported into active MEGA5 data files. The nuclear 
receptors retrieved for the estrogen receptor and androgen receptor are detailed (accession 
number, latin and common name) in Table 4.2 and Table 4.3 respectively. Accession 
numbers with an asterisk (*) denote sequences of functional receptor mutations linked to 
endocrine disorders.  Due to limited verified inter-species sequence publications, PR and 
PPARγ were excluded from the phylogenetic analysis.   
Table 4.1 Software and Programs for in silico Approaches 
Table shows the information hubs, databases and software used in the method adopted for in silico evaluation of 
nuclear receptor homology/phylogeny, molecular modelling and virtual screening. Excluding the commercial 
Tripos™ SYBYL® software, which requires a license, all tools are free. [All accessed 11.11.14]  
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Table 4.2 ER Sequence Accession Numbers, Latin Taxonomy and Common Name 
Table shows the retrieval information for estrogen receptor sequences, identified by BLAST homology searches, 
assessed for phylogenetic relationships (section 4.4.1). 
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Table 4.3 AR Sequence Accession Numbers, Latin Taxonomy and Common Name 
Table shows the retrieval information for androgen receptor sequences, identified by BLAST homology 
searches, assessed for phylogenetic relationships (section 4.4.1). * indicates mutated androgen receptor 
sequences.  
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Phylogenetic analyses were conducted using distance based phenetic
36
 methods, in which 
phenograms (dendograms) were calculated from sequence similarity. Sequences were aligned 
using MUSCLE software (Table 4.1) to produce a distance matrix, clustering branches by 
successively linking the taxa with minimal distances. Bootstrapped (500 replicates) 
phenograms of alignments were constructed using the Neighbour-Joining algorithm. The 
phenogram presents genetic change as horizontal lines, which represent evolutionary lineages 
and the branch lengths are proportional to amino acid substitutions per site (0.05 scale 
represents 5% difference between species). Phenogram sum branch lengths, defined as the 
phylogenetic diversity (PD) of the assembled sequence data (Faith, 1992), were stated as a 
measure of evolutionary divergence since the most recent common ancestor (Chao et al., 
2010). Phenograms were labelled and colour coded according to taxonomic clusters identified 
according to UniProt KB annotations. Species taxonomy was compared with phenogram 
topology to assess whether evolutionary distinct species present more sequence divergence, 
and potentially functional differences.  
4.3.3 Chemical Prioritisation for in silico Virtual Screening  
A database of potential EDC’s for virtual screening was assembled by the following methods. 
The EDC definition adopted for EDC classification is stated in section 4.3.3.1, while 
prioritisation methods, for construction of a chemical database, are detailed in section 4.3.3.2.  
4.3.3.1 EDC Definition 
A lack of scientific concordance regarding the significance of apical endpoints, has hindered 
the term ‘model EDC’, complicating prioritisation methods. For the purpose of this study, the 
WHO/IPCS EDC definition has been adopted (see section 2.3.2). Classified as a working 
definition by the Community Strategy for Endocrine Disruptors and acknowledged by OECD 
member states as a top-level definition, the scientific criteria are applicable to both human 
and ecological hazard and risk assessment. For chemicals with inconclusive in vivo data, but 
mechanistic in silico or in vitro evidence, the term ‘potential endocrine disruptor’ has been 
used.  
4.3.3.2 Prioritisation Method for in silico Assessment 
A basic prioritisation process was utilised to identify chemicals for in silico screening and 
subsequent in vitro assessment. The aim of prioritisation was to identify chemicals 
economically and scientifically relevant to EDC screening, while ensuring the inclusion of 
data rich chemicals with relevance to UK regulation. A chemical database (n=378) was 
curated from the prioritisation lists reported in section 2.4.1; 166 chemicals from the EC 
candidate list and 241 from the DWI report, of which 36 were EC duplicates, in addition to 9 
hormones.  
                                                 
36
 Phenetics (taximetrics) is the classification of organism based on overall similarity.  
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To enable a crude assessment of sensitivity, published bioassay data for each of the 378 
chemicals, were retrieved from PubChem (Table 4.1). Full details of the chemical database, 
summarising the published high-throughput agonism and antagonism in vitro testing results, 
are presented in 6.1Appendix A; Table_A 1. Collating information from ChemSpider, 
PubChem and ZINC
12
, Table_A 1 also summarises the classification, usage and assumed 
primary endocrine mode-of-action. For the purposes of analysis, agonists and antagonists 
were assumed positive, while compounds without positive in vitro data were treated as 
unknowns. Thus, limited in data source, due to the vast number of chemicals investigated, the 
reliability of the in silico sensitivity (%), approximated in section 4.4.3, is intrinsically linked 
to the reliability of PubChem in vitro bioassay publications. Due to the epistemological 
problems of identifying ‘negative’ activity, specificity was deemed outside the scope of this 
study.  
Three-dimensional structures of prioritised chemicals were downloaded from ZINC
12
, the 
freely available database of >35 million commercially available 3D chemical structures, in 
Mol2 format (Irwin et al., 2005). 
4.3.4 SYBYL Molecular Modelling 
In silico molecular modelling aims to generate 3D computational representations of receptor 
binding domains, which can be used to characterise the dynamics, energetics and structure of 
potential EDC ligand-receptor interactions (see sections 3.1 and 4.1).  
4.3.4.1 Nuclear Receptor Crystal Structure Selection 
It is possible to predict tertiary protein structure from sequence information. However, 
methods are caveated and the accuracy of molecular modelling is greatly enhanced by using 
X-ray and NMR protein crystallography information. 
The reliability of the in silico screen is linked to the reliability of NR modelling, thus, for the 
purpose of this study, only proteins with known crystal structures were included, as detailed 
in Table 4.4. The protein structures for NRs previously identified of interest (ER, AR, PR, 
and PPARγ) were downloaded into SYBYL 7.3 in .pdb format, and saved as mol2 files. 
4.3.4.2 Protein Preparation 
X-ray crystallography selectively favours the protein conformations most likely to crystalise 
(Srinivasan et al., 2013). Subsequently, most structural X-ray crystallography studies of NR 
are dimers with bound ligands. However, ligand binding occurs in NR LBD monomers, 
stabilised by HSP, dimerisation occurring consequently (sections 3.1 and 3.2). Subsequently, 
the cofactors and ligands bound to NR protein structures identified in Table 4.4 were 
removed to represent the biological scenario.  
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Table 4.4 Protein Database NR X-ray Crystallography Accession Information 
The receptor type, species, PDB accession number, ligand and any bound coregulators in addition to the 
publication, of all the X-ray crystal structures used in this in silico analysis are detailed.  
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Figure 4.1 SYBYL NR Protein Preparation  
This screen-shot shows the SYBYL interface and display screen. Subsequent to ligand binding NR’s dimerise. 
However, ligand binding occurs in monomers, consequently one of the monomers should be removed for 
docking studies. Removal can be achieved under the Build/Edit>>Delete>>Substructure Expression function. 
The monomer unit highlighted in green was deleted. 
Removal of NR monomers, for accurate SYBYL Surflex-Dock simulations, was achieved 
using the Build/Edit>>Delete>>Substructure Expression command (Jain, 2007). Figure 4.1 
shows the SYBYL interface, with one of NR monomers highlighted in green. NR LBD 
monomers were prepared via the interface command: Biopolymer>>Prepare 
structure>>Structure Preparation Tool, at which point unrecognised atoms were renamed
37
, 
hydrogens were added and the energy constraints of sidechain, backbone and termini 
positions were checked (highlighting energetically unfavourable regions).  
4.3.4.3 SYBYL SiteID LBP Molecular Model 
The monomeric structures of the LBDs, predicted as per 4.3.4.2, represent a number of sub-
domains (see section 3.1.1.1 and Table 3.1), many of which do not play a direct role in ligand 
binding. The PDB publishes ligand binding pocket (LBP) annotations for a number of the 
NR-superfamily; however, the detail is variable and often predicted on in silico homology 
modelling. Thus, to enable evaluation of less characterised NR, the SYBYL 7.3 (Table 4.1) 
SiteID application was used to infer the LBP  
                                                 
37
 Based on structural constraints, i.e. 4 bonds = carbon atom.  
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SiteID adopts flood-fill solvation techniques to locate potential hydrogen bonds, calculate 
solvent accessible surface area and determine hydrophobic pocket volume and depth; the 
protein is solvated with a single layer of water, thereby identifying pockets by counting the 
number of non-hydrogen atoms (75 spheres), within a specified radius (default 8Å) (Ho et al., 
1990). As standard, the ligand binding pocket identified is filled with solvent spheres, 
surrounding residues are coloured yellow and the exposed atoms are coloured red. SYBYL 
7.3 interface commands were: Biopolymer>Analyse protein>SiteID Find Pockets. The 
accuracy of the SiteID predictions were assessed relative to PDB annotations and the 
published literature summarised in section 3.1. 
4.3.5 SYBYL Surflex-Dock Virtual Screening 
Surflex-Dock enables flexible molecular docking by the incorporation of small-molecule 
force fields, which evaluate Cartesian coordinates
38
 constrained by ligand energetics (Jain, 
2007, 2003, 2000), supporting dynamic ring flexibility and optimisation of docked ligand 
poses. Surflex-Dock was used to create a novel virtual NR-binding screen, using the proteins 
detailed in section 4.3.4, to identify endocrine active substances for more conclusive in vitro 
testing, and further investigation. The Surflex-Dock virtual screening method was split into 
three main categories: database preparation; Surflex docking; and, post-processing.  
4.3.5.1 Database Preparation & Minimisation 
Energy is a function of atomic coordinates. Minimisation generates coordinates which 
correspond to a minimum energy; abiding to the chemical bonding theory that stipulates net 
inter-atomic forces should near zero (Peng et al., 1996). Jain (2007) stated that “Completely 
ignoring the strain issues of input ligands results in docking performance worse than 
random”. Thus, the minimisation of ligand databases is essential for Surflex-Dock 
performance. Table 4.5 shows the preliminary binding scores of NR receptors with randomly 
selected chemicals from prioritised database, minimised using default SYBYL Powell and 
Simplex methods, with a termination gradient of 0.05 kcal/mol and maximum iterations of 
100 (default settings).  
Repeating the simulation (R2), the standard deviations of scores generated under the same 
Surflex-Dock parameters ranged from 0.01-1.66 (-log(Kd)). Such large variance between 
binding scores leads to uncertainty and overlap of the in silico NR binding scores; thereby 
reducing significance.  
 
 
 
 
                                                 
38
 Cartesian coordinates detail the point at which perpendicular lines, measured in the same unit, meet (i.e. 
ordered pair, [0.0]).  
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Table 4.5 Surflex-Dock Score Variation using Default Minimisation for Ligand Database 
The Standard Deviation (SD) of NR-ligand scores for randomly selected chemicals in the Database, generated in 
runs of SYBYL Surflex-Dock under the same parameters, showed variation ranging from 0.01–1.66 -log(Kd), 
questioning the applicability of the default minimisation settings. R1=Replicate 1, R2=Replicate 2 
 
To reduce the output variability of results generated herein, the chemical database (n=378) 
was minimised to 10,000 iterations, 0.001 kcal/mol termination gradient and T. Giegmesiter 
Huckle Energy, using a novel minimisation script (289.new1.spl)
39
. Using this script, 
chemicals in the database were minimised closer to zero and replications of the simulation 
showed no variance in binding score (SD 0.00 -log(Kd)) (Table_A 1). All Surflex-Dock 
screens were run on three occasions (day repeats). Chemical properties, including 
molecular_weight (Da), CLogP (logarithm of the Poctanol/water partition coefficient) total_area 
(Å
2
) and molecular_volume (Å
3
), assimilated in SYBYL Molecular Spreadsheets, were 
exported.  
4.3.5.2 SYBYL Surflex-Dock Ligand-Receptor Docking (Sybyl 7.3/X) 
Surflex-Dock inputs must be protonated as expected at physiological pH, including non-polar 
hydrogens (protonation state strongly affects docking). Proteins and ligands were prepared as 
per sections 4.3.4.2 and 4.3.5.1., additional protein checks were conducted in the Surflex 
application: Surflex-Dock>Protein structure>Mol2 File>prepare.  
Surflex-Docking requires a ligand, protomol and protein. A protomol (pseudo-molecule or 
docking target) consists of molecular probes (CH4, C=O and N-H) which provide an object-
orientated framework for prototyping novel algorithms for molecular dynamics (Matthey et 
al., 2004; Balaji et al., 2013), or more simply a representation of the binding cavity to which 
putative ligands are aligned. The protomol intends to mimic the ideal interactions of the 
‘perfect ligand’ to the protein active site (Jain, 2007). 
                                                 
39
 Script created by Tripos® SYBYL for Kal Karim (kk256@le.ac.uk) Leicester University Department of 
Chemistry, College of Science and Engineering.  
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Figure 4.2 SYBYL Surflex-Dock Protomol Generation for Virtual Screening 
The NR LDB monomer is visualised in stick & line format (white = carbon; navy = nitrogen; cyan = hydrogen; 
and, red = oxygen), while the protomol generated in Surflex-dock is represented as a glomerular green mass.  
There are three methods available for protomol generation: automatic, ligand-based and 
residue based. When generating a protomol using a ligand to specify the active site, the 
voxels
40
 occupied by the ligand are explored by the protomol by default, even if they are not 
highly buried. However, as detailed in sections 3.1 and 4.3.4.1, the LBP of NR are 
notoriously large and promiscuous, consequently generating the protomol using endogenous 
hormones (e.g. E2) could bias docking scores towards ligand similarity, rather than 
propensity to bind with the receptor. Generating the protomol from LBP residues, identified 
in PDB sequence annotations, would limit the virtual screening to data-rich NR.  
NR LBD protomols were generated using Surflex’s automatic function, in which the largest 
hydrophobic pocket of the receptor is identified using the solvation method detailed 
previously (section 4.3.4.3). Default values of 0.5 for Threshold
41
 and 0 for bloat
42
 were used. 
The impact of bloat on protomol generation is shown in Figure_Apx 2. Figure 4.7 shows the 
SYBYL Surflex interface for protomol generation, highlighting the protomol in green and 
                                                 
40
 A voxel (volume pixel) is the 3D counterpart of a 2D pixel. In computer-based modelling a voxel is an array 
of elements of volume that constitute a notional three-dimensional space (i.e. representing a value on a regular 
grid in 3D space).  
41
 Threshold is a factor ranging from 0-1 determining the penetration the protomol into the protein – increasing 
the threshold, decreases the volume of the protomol. Low thresholds greatly increase the computational 
demands of protomol generation.   
42
 The bloat inflates the protomol to include nearby crevices; see Figure_Apx 2. 
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showing the spatial location of the hydrophobic pocket within the ligand binding domain. 
Generated protomols were saved as SFXC files. 
Default docking parameters were adopted for virtual screening; 0 additional starting 
conformations, 6Å expanded search, 20 conformations per fragment, up to 100 rotatable 
bonds and 10 poses per ligand. Enhancements in docking accuracy have been reported when 
incorporating ring confirmation flexibility and pre- and post- minimisation (Jain, 2007). 
Therefore, additional flags, including ring flexibility and pre- and post- dock minimisation 
were added. The Surflex-Dock details interface options are shown in Figure 4.3; the 
constraints highlighted were used to dock the NR protomols (section 4.3.5.1), for each 
protein, against the minimised ligand database (section 4.3.3 and 4.3.5.1).   
 
Figure 4.3 SYBYL Surflex-Dock Virtual Screening Parameters 
SYBYL Surflex interface shows parameters undertaken in docking studies, default parameters; 0 additional 
starting conformation, 6Å expanded search, 20 conformations per fragment, up to 100 rotatable bonds and 10 
poses per ligand. However, in addition to this flags, such as ring flexibility and pre- and post- dock minimisation 
were included.  
4.3.5.2.1 Surflex-Dock Results Processing 
Surflex-Dock employs an empirical scoring function, combining Hammerhead and Böhm 
approaches, which consider hydrophobic contact, polar interactions and entropic fixation 
costs for loss of torsional, translational and rotational degrees of freedom (Böhm, 1994; 
Eldridge et al., 1997). Contrary to other scoring functions, Surflex-Dock finds the nearest 
local optimum, rather than restricting calculations to a precise pose (Jain, 2007, 1996).  
Two scores were provided for each docked conformation: and affinity (-log(Kd)) and a crash 
score (pKd units). The crash score represents the degree of inappropriate penetration into the 
protein by the ligand, in addition to the internal steric hindrance of the ligand – in other words 
unfavourable energy states. Crash scores that are nearing zero are favourable. The Surflex-
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Dock Results Browser, Figure 4.4, shows the superimposition of the potential-EDC database 
(n=378) aligned against the ER protomol. The score presented for each ligand, in the browser 
interface, represents the highest calculated -log(Kd) value achieved from 10 poses of each 
ligand, irrespective of crash score. Scores were highlighted, saved and exported in all formats 
(mol2, SDF, HTML, MSS).  
 
Figure 4.4 SYBYL Surflex-Dock Results Browser 
Image shows the database of potential EDC ligands aligned (3 duplicates, n=378), as per the constraints 
determined by the protomol. The Surflex-Docking browser is on the left, all results were highlighted, saved and 
exported in mol2, SDF, HTML and MSS formats.  
4.3.6 Statistical Methods  
Phylogeny was identified using consensus bootstrapped Neighbour-Joining analysis. 
Bootstrapping enabled estimation of sampling distribution (Ader et al., 2008), by creating 
new alignments to replace the original dataset, thereby identifying the most probable 
topology. The number of possible topologies is proportionate to the orthologs under 
investigation; i.e. the more branches, the more scope for error. To mitigate for the large 
number of protein sequences (Table 4.2 and Table 4.3), results were bootstrapped to 500 
replicates to create a consensus phylogram, presenting the most probable topology; the more 
times a particular branch point occurred, the more valid the branching point.  
A number of epistemological problems hinder the statistical evaluation of virtual screening. 
Virtual screening is reliant on the ranking of molecular docking and scoring, however, 
validation and statistical evaluation of in silico methods are lacking (Zhao et al., 2005). The 
sensitivity, or efficacy, of identifying NR binders was evaluated by comparing the number of 
predicted positives, with true positives in vitro. However, as a MoA rather than a hazard in 
itself, endocrine activity may not be identified by in vivo animal tests, traditionally 
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considered a gold-standard. The virtual screen is not predicting endocrine toxicity, but 
interaction with nuclear receptors that form part of the biological response. Thus, in silico 
true positives must interact with NR, but may not be endocrine disruptive. Consequently, 
observed in vivo endocrine endpoints (toxicity) were not considered in the in silico sensitivity 
analyses, which were evaluated relative to published in vitro high-throughput (HTP) bioassay 
data (Table_A 1). Agonism and/or antagonism of ER(α/β), AR, PR or PPARγ pathways in 
vitro, were considered positive binders. Structurally diverse, the chemical database (n=378) 
included 118 ER, 111 AR, 6 PR and 74 PPARγ true positives in vitro (Table_A 1). Limited 
true-negative data prevented evaluation of in silico specificity.  
Regression analysis, a statistical method of inferring relationships among variables, was used 
to assess the importance of chemical MW, ClogP, total area and molecular volume, on NR 
binding. IBM SPSS and R statistics software were used to elucidate coefficients and plot 
vaues, respectively. 
4.3.7 Summary of in silico Methods 
Phenograms of ER and AR sequences (Table 4.2 and Table 4.3) identified using UniProt 
BLASTp homology searches, were conducted using the MEGA software, to present a crude 
visualisation of genotypic species variation. X-ray crystallography structures of human ERα 
(3DT3; 2Q2O; 2IOK; and, IX7R), human ERβ (IX7J), rat ERβ (IHJI), human AR (3V49), 
chimpanzee AR (IT7T), rat AR (2IHQ), mouse AR (2QPY) and human progesterone (1SQN) 
and PPAR (1PRG), were modelled in silico (Table 4.4). A prioritised chemical database of 
potential-EDC’s (n=378 section 4.3.3) were virtually screened against the in silico nuclear 
receptor LBP models, in Tripos™ SYBYL Surlfex-Dock software. Sensitivity of the in silico 
model was assessed relative to published bioassay results (6.1Appendix A). Regression 
analysis evaluated associations between in silico binding scores and chemical structural 
features (section 4.3.5.1).  
4.4 In silico Results & Discussion 
Reflective of the materials and methods (section 4.3), the in silico results arising from this 
study are detailed in order of NR phylogeny (4.4.1), molecular modelling (4.4.2) and virtual 
screening (4.4.3).  
4.4.1 Nuclear Receptor Phylogeny 
The boostrapped consensus phenogram, Figure 4.5, constructed using Neighbor-joining p-
distance amino acid substitution statistical methods, shows the evolutionary divergence of 
ERα and ERβ sequences, throughout taxonomic classes. The phenogram corroborates the 
literature on ERα and ERβ (Thornton, 2001) by suggesting gene duplication of a common 
ancestral estrogen receptor, prior to the divergence to all Chordate. The scale of 0.05 
represents 5% difference between two species; calculated as amino acid differences per site. 
The optimal tree presented (Figure 4.5) has a Ʃbranch length of 0.4565, indicative of the 
phylogenetic diversity of the receptor (Chao et al., 2010; Faith, 1992).  
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Figure 4.5 Phylogeny of the Estrogen Receptor (ERα/β)  
The bootstrap consensus (n=500) unrooted phenogram, constructed in MEGA5, using Neighbor-joining amino 
acid substitution models (p-distance), homogeneous lineage and pairwise deletion, shows the evolutionary 
relationship of estrogen receptor sequences. The phenogram identifies the gene duplication of a common 
ancestral estrogen receptor, prior to the divergence to all Chordate, corroborating the literature on ERα and ERβ 
(Thornton, 2001; Eick and Thornton, 2010).  Assuming protein sequence homology is indicative of function, 
branch lengths and topology, highlight potential inter- and intra-species differences (labelled as protein 
accession# and common name). The branch length 0.05 scale represents 5% difference in amino acid sequence 
between species. Ʃbranch length = 4.565.  
Nuclear receptor phylogeny, presented as the topology, branch length and root, suggests that 
the variance observed in protein sequence is consistent with taxonomic rank i.e. evolutionary 
distinct species present more sequence divergence. Thus, assuming protein sequence is 
indicative of function, uncertainty in extrapolating endocrine toxicological mechanisms may 
increase with evolutionary distance.  
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Figure 4.6 Phylogeny of the Androgen Receptor (AR) 
The bootstrap consensus (n=500) unrooted phenogram, constructed in MEGA5, using Neighbor-joining amino 
acid substitution models (p-distance), homogeneous lineage and pairwise deletion, shows the evolutionary 
relationship of androgen receptor sequences. The topology of the AR sequence phylogeny is consistent with 
taxonomic ranks, and divergence is clustered into clades as small as the artiodactyla order. Assuming protein 
sequence homology is indicative of function, branch lengths and topology, highlight potential inter- and intra-
species differences (labelled as protein accession# and common name). The branch length 0.05 scale represents 
5% difference in amino acid sequence between species. Ʃbranch length = 4.468.  
Conversely, the clustering of ER sequence by class increases the certainty of extrapolating 
nuclear receptor binding in one mammal to another, as sequences present significant 
homology (Figure 4.5). The topology presented in Figure 4.6 is consistent with taxonomic 
ranks; the phylogenetic divergence of AR sequence clustered into clades as small as the 
artiodactyla order. Thus, the phylogram demonstrates sequence divergence within mammals, 
which may be indicative of divergence in protein function. The AR phenogram Ʃbranch 
length was calculated to be 4.468 (Figure 4.6), which is slightly smaller than that established 
for the estrogen receptors (Figure 4.5). Interestingly, birds and reptiles, demonstrate relatively 
short branch lengths, suggesting that their AR are more homologous to the ancestral gene (i.e. 
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the root). The importance of taxonomic Class, in inferring sequence homology, was further 
corroborated by a bootstrapped consensus sub-tree of primate AR sequences (Figure_Apx 1). 
The phenogram Ʃbranch length = 0.439, suggesting conservation between primate androgen 
receptors. However, consistent with other NR topologies, sequence clustering predicted 
infraorder, such as human, simian or prosimian (Figure_Apx 1). The inclusion of mutant hAR 
sequences, splice variants and polymorphisms in Figure_Apx 1, highlight the potentially 
significant effect of small changes in sequence, on EDC susceptibility. In agreement with 
Västermark et al.’s (2011) study on genetic predictors of TGCT risk, the limited sequence 
divergence between AR phenotypes highlights the potential caveats of extrapolating 
mechanistic observations in one species, to another. 
The phenograms (Figure 4.5 and Figure 4.6) corroborate reported interspecies variation in 
nuclear receptor binding affinity. In particular, the long branch lengths connecting fish 
species highlight androgen receptor sequence divergence (Figure 4.6), reflected in trout, 
goldfish and minnow AR transactivation and binding in vitro (Lange et al., 2012; Wells & 
Van Der Kraak, 2000). The potentially significant receptor divergence between fish models 
presented, compromises the assumptions of regulatory ecotoxicology testing, which 
predominantly extrapolate findings in D. rerio, P. promelas or O. mykiss to assess 
environmental risk (Section 2.1.3 and 2.3).  
Contrary to the divergence identified, assessment of LBP cDNA sequence homology has 
identified significant homology between different metazoans (Krust et al., 1986; Koike et al., 
1987; White et al., 1987). The LBP of two metazoan ER subtypes (ERα and ERβ) are near 
identical; Leu384/Met421 in ERα corresponds to Met336/Ile373 in ERβ (Ascenzi et al., 
2006). Figure 4.5 identifies ERα and ERβ ligand binding domain sequence divergence, 
conflicting with the aforementioned literature. However, as alluded to in Section 1.4, 
phylogenetic analysis of ligand binding domain variability, may not reflect the ligand binding 
pocket; conservation of functional regions.   
The results obtained in the study reported here suggest that the uncertainty of extrapolation 
increases with species divergence. Furthermore, the phenograms produced highlight the 
potential folly of species bias in regulatory toxicology; 75% of in vivo toxicological 
procedures for human health are conducted in rats, while ecotoxicology limits itself to three 
fish (above), bird (C. japonica) and/or collemnolan (F. fimetaria) models, representing a very 
limited assessment of potential inter- and intra- species variation. Reptilia, one of the most 
under-represented ectotherms in EDC research, presents the most sequence conservation of 
the ancestral AR (Figure 4.6).  
Endocrine disruption appears omnipresent throughout phylogenetic classes, which is reflected 
by the homology of endocrine machinery. However, no invertebrate sequences were 
identified in BLAST searches (5 searches, 250 hits; section 4.3.2). The homology of the 
vertebrate nuclear receptor-superfamily, which presents >60% sequence conservation, led to 
retrieval of other members prior to retrieval of invertebrate NR-orthologs. The effets of TBT, 
on mollusc sexual development and population, are considered one of the best documented 
incidences of ecologically relevant endocrine disruption (Matthiessen et al., 1995). The 
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molluscan intersex was initially attributed to TBT estrogenicity, which spurred concerns 
regarding vertebrate exposure. However, mechanistic studies later identified significant 
differences in invertebrate endocrinology, rendering the observed effects incomparable 
(Scott, 2013). The lack of invertebrate sequence retrieval, suggests large NR sequence 
divergence, supporting reports that invertebrate and vertebrate endocrine mechanisms are 
structurally and functionally distinct. The role of terpenoid hormones in insect physiology, 
morphology and behaviour (Section 2.1.3.1) further stresses the mechanistic diversity of 
invertebrate endocrinology (WHO, 2002; Ketata et al., 2008). Thus, the relevance of the 21 
NR genes identified in Drosophilia melanogaster flies (Adams et al., 2000) and 270 in 
Caenorhabditis elegans nematode worms (Sluder et al., 1999), to the 48 NR genes identified 
in humans (Robinson-Rechavi et al., 2001), remains uncertain.  
Throughout taxonomic classes, NR present divergence in the amino acid sequences defining 
functionality (Figure 4.5, Figure 4.6 and Figure_Apx 1). However, the phylogeny does not 
consider functional conservation, highlighting the need for molecular modelling and virtual 
screening to assess structural features.  
4.4.2 SYBYL Site ID Nuclear Receptor Molecular Modelling 
The interaction between hormones and their target receptors forms the first step in classical 
genomic endocrine responses (Section 1), which found the understanding of mechanisms that 
govern cellular responses to hormones. Computational chemistry can characterise the 
dynamics, energetics and structure of these ligand-receptor interactions (Taft et al., 2007). 
Ligand binding pockets, identified and modelled in SYBYL SiteID, from X-ray 
crystallography structures, were used to generate hypothetical pseudo-docking targets 
(protomol). The protomol is fundamental to virtual screening in Surflex-Dock. To identify 
NR ligand binding pockets for protomol generation, dimers, cofactors and ligands were 
removed, and the resulting monomer was evaluated via solvation method (See 4.3.4 and 
4.3.5). In this section, the efficacy of SYBYL-SiteID solvation method (Section 4.3.4.3), is 
evaluated relative to the literature (See Section 3.1). Concordance of the in silico LBP’s to 
published structural information, supports the use of the computational molecular models to 
infer binding regions and ligand-binding relationships.  
As detailed in Sections 2 and 3, EDC research has predominantly focused on the ER and AR, 
leading to a wealth of structural information for comparison with in silico models (Sections 
3.1.2 and 3.1.3). Conversely, the neglect of other NRs, such as PR and PPARγ, hinders direct 
validation of SYBYL SiteID molecular models. Figure 4.7 shows the 3DT3 human estrogen 
receptor-α (ERα), rendered in SYBYL according to secondary structure (α-helices and β-
sheets), with the Surflex-Dock protomol superimposed. The α-helices form the three-layer 
antiparallel ridge previously detailed (Jin & Li, 2010; Brzozowski et al., 1997). The protomol 
generated for hERα (Figure 4.7:B) presents many of the structural features quantified in the 
OECD Toolbox ER-profiler (Section 2.4; Table 2.3). The ‘red’ oxygens of the protomol 
reflect the strong and moderate hydroxyl groups required for ER-binding, ‘white’ carbon 
regions form the triphenylethylene backbone, while ‘navy’ atoms identify the NH groups 
necessary for strong binding (Tong et al., 2004; Li & Gramatica, 2010). Thus, the SYBYL 
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protomol created appears to provide a 3D-molecular model of the 2D-parameters stipulated 
by the OECD Toolbox ER-profiler.   
 
 
Figure 4.7 Tripos™ SYBYL 3D-Molecular Modelling of Estrogen Receptor-α (ERα 3DT3) 
Monomer and Surflex-Dock Protomol 
A shows the rendered secondary protein structure of 3DT3 in SYBYL; α-Helices are shown as magenta coils, 
while β-sheets are as yellow arrows. The binding region (superimposed protomol) is represented as a spacefil 
model. Generated using Surflex-Dock default settings – 0.5 Threshold and 0 Bloat – the protomol is colour 
coded by atom: white = carbon; navy = nitrogen; cyan = hydrogen; and, red = oxygen. B’ shows the protomol 
separated from the protein.  
To enable closer inspection of SYBYL solvation method efficacy in predicting docking 
regions (see Sections 4.3.4.3 and 4.3.5.2), residues within 8Å of the 3DT3 ERα solvent 
spheres are highlighted in Figure 4.8, for comparison with residues identified in Section 
3.1.2. Functional groups and classification of amino acid residues are presented in 
6.1Appendix D: Figure_Apx 10. The hydrophobic core of the agonist ERα LBD 
conformation is formed by α-helices 3 (αH3: Met342-Leu354), αH6 (Trp383-Arg394), αH8 
(Val418-Leu428), αH11 (Met517-Met528), αH12 (Leu539-His547) and S1/S2 hairpin 
(Leu402-Leu410) (Brzozowski et al., 1997). Of the 24 residues highlighted in Figure 4.8, 
twelve correspond to structural features reported in the literature (Section 1): Leu349 and 
Ala350 residues of αH3; Leu384, Ille386, Leu387, Met388, Ile389, Gly390, Leu391 and 
Trp393 of αH6; and, Leu403 and Phe404 of the S1/S2 hairpin. The SYBYL molecular 
modelling identified Glu353 and Arg394 residues (Figure 4.8) which form hydrogen bonds to 
phenolic hydroxyl agonists, with carboxylate and guanidinium groups, respectively. The A-
ring of E2 has been demonstrated to pose between the Ala350, Leu387 and Phe404 residues, 
also highlighted (Brzozowski et al., 1997).  
Furthermore, in DES studies, higher affinity has been accredited to non-polar contact of 
phenolic ethyl groups with Ala350, Leu384, Phe404 and Leu428 (Shiau et al., 1998; Kuiper 
et al., 1997), all of which are highlighted in Figure 4.8. In light of the concordance, it can be 
concluded that SYBYL software accurately identified the ligand binding pocket of ERα, 
using the solvation method. 
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Figure 4.8 SYBYL SiteID Human Estrogen Receptor (3DT3) Ligand Binding Pocket 
The Human ERα (3DT3) monomer SYBYL ribbon representation, identifying α-helices and β-sheet secondary 
structure, was originally complexed to the GW368 agonist (5-(4-hydroxyphenoxy)-6-(3-hydroxyphenyl)-7-
methylnaphthalen-2-ol) for X-ray crystallography. Stick-representation of the 3DT3 molecular backbone (blue) 
highlights residues surrounding the solvent spheres yellow and exposed atoms red. Residues identified within 
8Å of the SiteID solvents spheres are labelled aqua; including: Pro224, Leu327, Arg352, Glu353, His356, 
Met337, Leu349, Ala350, Trp360, Leu384, Ile386, Leu387, Met388, Ile389, Gly390, Leu391, Trp393, Arg394, 
Leu403, Phe404, Phe445, Val446, Lys449 and Glu623.   
The SYBYL SiteID model for humanERβ and ratERβ are shown in Figure_Apx 5. Residues identified 
in the humanERβ (1L2J) ligand binding pocket: Lys401, Leu339, Glu305, Thr299, Leu298, 
Glu276 and Met295. Solvent spheres in the ratERβ LBP identified residues Ile331, Tyr352, 
Phe311, Arg301, Gly297, Met295, Val293, Met291, Leu254 and Leu253. The hERα ligand 
binding site contains 4 residues with hydrophobic side chains (Ala350, Leu384, Phe404 and 
Leu428), an arginine with a positively charged NH2 side group (Arg394) and a negatively 
charged glutamic acid residue (Glu353) (Shiau et al., 1998; Brzozowski et al., 1997). As 
shown in Figure 4.5, the ERα and ERβ paralogs arose subsequent to gene duplication, in the 
chordate common ancestor. However, the sequences have diverged, complicating direct 
comparison. Nevertheless, conservation of the ligand binding pocket may be expected as both 
receptors bind the endogenous hormone 17β-estradiol (E2). Interestingly, although the human 
and rat ERβ vary from human ERα, both of the identified LBPs (Figure_Apx 5) contain 2 
leucine residues, a positively charged arginine or lysine and residues with hydrophobic side 
chains (Met295 in humanERβ and Ile331, Phe311, Met295, Val293 and Met291 in ratERβ); 
highlighting requirements for conservation of function.  
Figure 4.9 shows the hydrophobic ligand binding pocket of the androgen receptor E-domain 
identified. Consistent with ERα, the antiparallel docking site consists of αH8, αH9, αH11 and 
αH12 (Sack et al., 2001; Brzozowski et al., 1997). Of the 21 residues highlighted in Figure 
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4.9, Gln711, Met745 and Arg752 have been shown to interact with the DHT A-ring, while 
Leu704 interacts with the DHT C-ring (Sack et al., 2001). The replacement of Thr877 with 
alanine (mutation T877A) is the most frequent mutation observed in prostate cancer patients 
in vivo and in LNCaP cells in vitro (Taplin et al., 1995; Stevens et al., 1996). Identified using 
the in silico molecular model (Figure 4.9), Thr877 plays a regulatory role in the LBP; 
substitution with alanine enables the LBP to accommodate other ligands such as progestins, 
estrogens and cortisol (Sack et al., 2001). Chimpanzee (P. troglodytes), rat (R. norvegicus) 
and mouse (M. musculus) AR LBP’s were also evaluated using SYBYL SiteID Solvation 
method (Figure_Apx 6 and Figure_Apx 7). However, as previously alluded to, validation of 
the molecular models is hindered by uncertainty of animal NR LBP interactions.  
The SYBYL SiteID model for chimpAR, ratAR and mouseAR are shown in Figure_Apx 5 and 
Figure_Apx 7. Residues identified in the chimpAR ligand binding pocket: Pro682, Gln711, 
Val715, Leu744 and Met745. Solvent spheres in the ratAR LBPs identified residues Gln711, 
Val715, Arg752, Ala748 and Met745. Residues Leu701, Leu704, Asn705, Gly708, Val715, 
Met742, Met745, Val746, Ala748, Arg752, Phe764 and Leu873 were identified in the 
mouseAR. All AR LBP contained a residue with an uncharged polar side chain (Gln/Asn) and 
at least two residues containing a hydrophobic side chain (one residue of methionine or 
alanine and a leucine), consistent with the literature (Sack et al., 2001).  
In addition, a valine residue at 715 was conserved between all investigated AR, suggesting 
that the hydrophobic-side chain amino acid is important to function. The Thr877 residue 
which determines ligand promiscuity in human AR (Sack et al., 2001; Taplin et al., 1995) 
was not detected in the chimp, rat or mouse AR LBP, which supports the intra- and iner-
species differences detailed in Sections 0 and 1 at a molecular level. Whether the slight 
differences in LBP, translate into differences in ligand binding, is evaluated in Section 4.4.3. 
 The accuracy of the SYBYL solvation method in determining the ER and AR LBP validates 
the method (Section 4.3.4) and adds weight to the residues identified for protomol generation 
in PR and PPARγ LBP molecular modelling; detailed in 6.1Appendix C: Figure_Apx 8 and 
Figure_Apx 9. Furthermore, the accuracy of the SYBYL solvation method demonstrated 
herein supports the Surflex-Dock virtual screening, which is reliant on chemical database 
minimisation and in silico modelling of the protomol and protein.  
The results demonstrate that Tripos™ SYBYL 7.3 software can ‘blindly’ predict the LBP of 
nuclear receptors, using the solvation method to identify hydrophobic cavities and interacting 
residues, in lieu of structural information and annotation, which is requisite for traditional 
QSAR approaches. Section 4.4.3 SYBYL X-Surflex-Dock in silico Virtual Screening, utilises 
the aforementioned in silico LBP’s to screen the potential-EDC chemical database (n=378). 
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Figure 4.9 SYBYL SiteID Human Androgen Receptor (3V49) Ligand Binding Pocket  
The Human AR (3V49) monomer ribbon representation in SYBYL, identifying α-helices and β-sheet secondary 
structure, was originally complexed to the PK0 selective AR modulator 4-[(4R)-4-(4-hydroxyphenyl)-3,4-
dimethyl-2,5-dioxoimidazoidin-1-yl]-2-(trifluoromethyl) benzonitrile for X-ray crystallography. Stick-
representation of the 3V49 molecular backbone (blue) highlights residues surrounding the solvent spheres 
yellow and exposed atoms red. Residues identified within 8Å of the SiteID solvents spheres are labelled aqua; 
including: Leu701, Leu704, Gln711, Met742, Leu744, Met745, Val746, Ala748, Met749, Arg752, Phe764, 
Ser778, Met780, Met787, Phe804, Lys808, Leu873, His874, Thr877, Met895 and Val903.  
4.4.3 SYBYL X-Surflex-Dock in silico Virtual Screening  
Evaluating the Cartesian coordinates constrained by ligand energetics, Tripos™ SYBYL 
software enables flexible and dynamic molecular modelling and screening in silico (Jain, 
2007). This section details the results of screening NR ligand binding pockets modelled in 
SYBYL (Section 4.3.4 and 4.4.2), against a prioritised list of potential EDC’s (n=378, 
Section 4.3.3) in Surflex-Dock. The complete in silico binding data, for hER (3DT3), hER 
(1X7J), ratER (1HJ1), hAR (3V49), chimpAR (1T7T), ratAR (21HQ), mouseAR (2QPY), hPR 
(1SQN) and hPPARγ (1PRG), is presented in 6.1Appendix E: Table_Apx 2. The scores 
represent the highest calculated -log(Kd) value achieved from 10 poses of each ligand, 
irrespective of the crash score, which denotes unfavourable penetration of the ligand.  
As detailed in the method (Section 4.3), a number of epistemological problems hinder the 
statistical evaluation of virtual screening (Zhao et al., 2005). The sensitivity of SYBYL 
Surflex-Dock in correctly identifying NR binders was evaluated by comparing the number of 
in silico predicted positives with true positives. The in silico analyses were evaluated relative 
to published in vitro high-throughput (HTP) bioassay data (Table_A 1); agonism and/or 
antagonism of ER(α/β), AR, PR or PPARγ pathways in vitro, were considered positive 
binders. Structurally diverse, the chemical database (n=378) included 118 ER, 111 AR, 6 PR 
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and 74 PPARγ true positives in vitro (309 TP total: Table_A 1); however, epistemological 
limitation in categorising a “true-negative” hindered evaluation of in silico specificity. 
PubChem Bioassay identifiers (AID#) which can be used to retrieve results are detailed in 
‘List of Prioritised Endocrine Disrupting Chemicals’ Table_A 1. 
The results were categorised as follows: true positive (TP); positive in silico (Pis); false 
negative (FN); and, negative in silico (Nis). Additionally, a category for predicted low-affinity 
binders was included to prioritise positive results: unfavourable binding in silico (FUBis); and 
false unfavourable binding (FUB). 
4.4.3.1 SYBYL Surflex-Dock Sensitivity and Specificity 
Sensitivity
43
 pertains to the proportion of correctly identified true positives, while 
specificity
46
 details the number of non-binders correctly identified by the tool. Assessing 
human predictivity relative to in vitro binding and transactivation bioassays, SYBYL Surflex-
Dock Nuclear Receptor (ER, AR, PR & PPARγ) virtual screening demonstrated a sensitivity 
of 94.5% ([309 TP/ (309 TP + 18 FN)] x100 = %). Of the 309 true positives, 291 chemicals 
were correctly identified, 18 were incorrectly scored as non-binders, and 21 were identified 
as low-affinity (6.8% of TP scored 0>2 –log(Kd)) (Table_Apx 2). 
The difficulty of ‘proving’ inactivity was highlighted during the evaluation of in vitro HTP 
bioassay data (Table_A 1); assessments were limited to active data, thereby ignoring the 
proportion of inactive and inconclusive results. For example, Endosulfan has been detected as 
positive in 3 of 16 AR in vitro bioassays (19%), consequently, Endosulfan was considered 
positive for the purpose of this study. However, the uncertainty in the published in vitro data 
increases the uncertainty of the sensitivity analysis conducted herein. Classifying chemicals 
as true negatives on comparable numbers of inactive results may be erroneous. Subsequently, 
the strength of in vitro MoA data is uncertain and prevents categorisation of chemicals as 
non-binders, thereby limiting specificity
44
 analyses. The lack of true negatives’ prevents the 
estimation of false positives, which can also be used to calculate precision
45
 and specificity
46
. 
Nevertheless, a crude maximum specificity of 80.7% was calculated, by assuming the 
absence of reported activity as inactivity ([75 TN/ (75 TN + 18 FN)] x100 = %).  
Evaluating SYBYL Surflex-Dock predictability, by receptor class, suggested hERα virtual 
screening sensitivity of 97.5% ([118 TP/ (118 TP + 3 FN)] x100 = %); correctly identifying 
115 true positives and incorrectly scoring 3 chemicals as non-binders. Ninety-four percent of 
the correctly identified TP had in silico binding scores >2 –log(Kd); 7 true positives were 
identified as low affinity in silico (unfavourable binders 0<2 –log(Kd)). Of the 378 chemicals 
screened, 360 were shown to interact with the hERα LBP in silico (TP, Pis, UFB, UFBis), 
while 18 presented repellent energy states (Nis non-binders) (Table_A 1Table_Apx 2). The 
human androgen receptor (hAR) presented sensitivity of 88.1% ([111 TP/ (111 TP + 15 FN)] 
                                                 
43
 Sensitivity (true positive rate (TPR)) = true positives / (true positives + false negatives) 
44
 Specificity (true negative rate (TNR)) = true negatives / (true negatives + false negatives) 
45
 Precision (positive predictive value (PPV)) = true positives / (true positives + false positives) 
46
 TNR = true negatives / (false positives + true negatives)  
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x100 = %); 96 of the 111 true positives were correctly identified, while 15 were incorrectly 
identified as negatives. Eighty-eight percent of the potential-EDC database was shown to 
interact with hAR in silico; of the 378 chemicals investigated only 45 demonstrated repellent 
hAR binding energetics. All hPR and hPPARγ true positives were correctly identified (6/6 and 
74/74, respectively), the hPR screen identified 351 (27 Nis) in silico binders, while the 
hPPARγ interacted with 376 (2 Nis). 
The prioritisation for database inclusion (Section 2.4 and 4.3.3) was biased towards high-
exposure biologically-active potential-EDCs, and thus not a representative sample of all 
registered chemicals. Consequently, it is not justifiable to conclude that similar proportions of 
other chemical databases would present the same skew towards binding. Evaluating the 
results via chemical class, to identify any areas of weak in silico predictivity, the following 
sections categorise in silico ligand-receptor interactions on the basis of usage – natural 
hormones, pesticides, consumer products exetera.  
4.4.3.1.1 Natural and Synthetic Hormone in silico Docking  
As the endogenous hormones by which the nuclear receptor superfamily evolved (Thornton, 
2001), high sensitivity and specificity of in silico ligand-receptor interactions would be 
expected for the natural and synthetic hormones. The SYBYL Surflex-Dock screening, 
showed a sensitivity of 94.8% ([55 TP/ (55 TP + 3 FN)] x100). However, excluding low 
affinity binders (FUB) from the positives dataset (classifying the ambiguity as a negative) 
reduced sensitivity to 90.2% ([55 TP/ (55 TP + 3 FN + 3FUB)] x100). Including presumed 
positive binders (ƩPP), on the basis of interspecies extrapolation, did not significantly affect 
sensitivity ([97 ƩPP/ (97 ƩPP + 6 ƩPN)] x100 = 94.2% sensitivity).  
Interestingly, five of the six false negative binders (FN and ƩPN) originated from the rat 
androgen receptor (21HQ) screening, highlighting either significant inter-/intra- species 
variance in rat AR, or in the reported sequence and computational modelling. The colour 
coding highlights the ligand promiscuity of endogenous hormones, corroborating the 
literature detailed in Section 1. 
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Table 4.6 In silico Nuclear Receptor Natural and Synthetic Hormone Binding Results 
Top values reflect binding score (-log(kD)) and the degree of inappropriate protein penetration (crash score) is 
shown in parentheses TP=True Positive; Pis= Positive in silico; FUB=False Unfavourable Binding; 
UBis=Unfavourable Binding in silico; Nis=Negative in silico; FN=False Negative. See section 4.3.6. and 
Appendix A for information on true positive criteria. Colour coding: TP’s are highlighted green; “assumed” 
TP’s on the basis of interspecies extrapolation are light green; False Negatives are red; in silico negatives 
“assumed” positive are in pink. Unfavourable binders are in orange.  
 
4.4.3.1.2 Plant Protection Product & Biocide in silico Docking 
The EU Plant Protection Products (PPP) and Biocide legislation regulates pesticide use and 
the agrochemical industry, and demand that a substance, safener or synergist, does not cause 
endocrine disrupting, neurotoxic or immune effects in non-target organisms. As for high 
production volume (HPV) chemicals there is a wealth of information pertaining to pesticide 
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bioactivity. As a broad chemical category including 112 unique compounds, PPP and 
Biocides in silico screening results are presented below under the umbrellas of fungicides 
(thiazole, benzimidazole, imidazole, oxazole and thiocarbamate), herbicides 
(chloroacetanillide, azole, triazine, aniline and thiazide) and insecticides (organophosphate, 
organochloride, pyrethrin and pyrethroid); however, the full dataset is available in Table_Apx 
2.  
As a whole (n=112), pesticide screening sensitivity was 96.4% ([106 TP/ (106 TP + 4 FN)] 
x100); the sensitivities of hER, hAR and hPPAR were 97.4%, 93.5% and 100%, respectively 
(Table_Apx 2). No progesterone receptor (PR) interactions had been reported
47
 for the 
pesticides investigated, preventing an estimation of sensitivity. Lacking EDC regulatory 
criteria complicates adherance to EU law (Section 2.3). Agrochemical companies typically 
only investigate endocrine mechanisms on the basis of adverse endpoints observed in vivo 
(i.e. top-down approach), consequently, many marketed chemicals may present endocrine 
activity. The SYBYL Surflex-Dock virtual screening presented here suggests many of the 
uncharacterised pesticides present the 3D-spatial arrangements of functional groups, required 
to bind at the ligand-binding pockets of hER (n=66), hAR (n=56), hPR (n=97) and hPPARγ 
(n=84). Similar to the endogenous hormones, many of the pesticides are promiscuous, 
interacting with multiple receptors of the nuclear-receptor superfamily, both in vitro and in 
silico (Table_Apx 2). 
Sub-categorising the pesticides, Table 4.7 presents the in silico SYBYL Surflex-Dock 
fungicide screening results, which accurately predicted all azole (triazole, imidazole and 
oxazole), benzimidazole and thiocarbamate fungicide ‘true’ positives; sensitivity of 100% 
([21 TP / (21 TP + 0 FN)] x100). However, the thiocarbamate fungicide, Thiram, was 
detected as a weak AR binder (FUB 1.5 –log(Kd)), reclassifying the ambiguous result as a 
false negative reduced sensitivity to 95.5% ([21 TP/ (21 TP + 1 FUB)] x100). The predicted 
binding affinities vary with species, which concords with the slight differences in protomol 
detailed in Sections 4.3.4.3 and 4.3.5.2. Prochloraz has been demonstrated to interact with 
hAR (3V49) both in silico and in vitro (Table_A 1 and Table_Apx 2). However, interactions 
with chimpAR (1T7T) and ratAR (21HQ) in silico were less favourable; 1.84 and 0.39 –
log(Kd), respectively. The crash scores, for the chimpAR (-4.2) and ratAR (-6.5) receptor-ligand 
interactions reported are more negative, suggesting inappropriate penetration into the protein 
(energetically unfavourable). Species differences in predicted ligand-NR binding were also 
identified for difenoconazole with hERβ and ratERβ; -0.49 and 6.19 –log(Kd), respectively. In 
addition, the in silico results suggest that Maneb and Carbendazim may be endocrine active, 
consistent with other thiocarbamate and benzimidazole fungicides. Though evolutionary 
distinct paralogs, ERα and ERβ LBP’s are believed to be conserved due to ligand specificity 
(see Section 3.1.1 and 3.1.2). However, marked differences in hERα, hERβ and ratERβ binding 
affinities are shown in Table 4.7 and Table 4.8. Virtual screening correctly identified all 
herbicide binders (Table 4.8); 100% sensitivity ([15 TP/ (15 TP + 0 FN)] x100). 
                                                 
47
 Only published HTP bioassay data reported on PubChem were evaluated; no academic papers were included 
as per the contraints detailed in Section 4.3.3. 
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Table 4.7 In silico Nuclear Receptor Fungicide Binding Screening Results 
Results of the in silico screening of commonly used fungicides, split into the chemical classes: triazoles; 
benzimidazoles; imidazole & oxazole; and thiocarbamates. Top values reflect binding score (-log(kD)) and the 
degree of inappropriate protein penetration (crash score) is shown in parentheses TP=True Positive; Pis= 
Positive in silico; FUB=False Unfavourable Binding; UBis=Unfavourable Binding in silico; Nis=Negative in 
silico; FN=False Negative. See section 4.3.6. and Appendix A for information on true positive criteria. Colour 
coding: TP’s are highlighted green; “assumed” TP’s on the basis of interspecies extrapolation are light green; 
False Negatives are red; in silico negatives “assumed” positive are in pink. Unfavourable binders are in orange.  
 
 
However, Bromoxynil and Alachlor, were detected as low affinity binders (0<2 –log(Kd)) for 
hERα and hAR, respectively. Bromoxynil is a nitrile herbicide which controls weeds by 
inhibiting photosynthesis, while Alachlor is a chloroacetanilide herbicide which inhibits 
geranylgeranyl pyrophosphate (GGPP) cyclisation enzymes. Reclassifying the ambiguity of 
true positive low affinity in silico binding as false negatives, reduced sensitivity to 88.2% 
([15 TP/ (15 TP + 2 FN)] x100). 
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Table 4.8 In silico Nuclear Receptor Herbicide Binding Results 
Top values reflect binding score (-log(kD)) and the degree of inappropriate protein penetration (crash score) is 
shown in parentheses TP=True Positive; Pis= Positive in silico; FUB=False Unfavourable Binding; 
UBis=Unfavourable Binding in silico; Nis=Negative in silico; FN=False Negative. See section 4.3.6. and 
Appendix A for information on true positive criteria. Colour coding: TP’s are highlighted green; “assumed” 
TP’s on the basis of interspecies extrapolation are light green; False Negatives are red; in silico negatives 
“assumed” positive are in pink. Unfavourable binders are in orange.  
 
To varying degrees all investigated herbicides presented the spatial arrangement of functional 
groups required to interact with the LBP of nuclear receptors (Table 4.8). It should be noted 
that the binding score is not necessarily predictive of in vitro agonism or antagonism, as 
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SYBYL scoring evaluates the chemistry of functional groups, not protein functionality. 
However, academic publications corroborate the endocrine activity of triazine herbicides 
detected in silico. Atrazine has been identified as an EDC in vitro (Basini et al., 2012; Kucka 
et al., 2012) and in vivo (De La Casa-Resino et al., 2012; Shelley et al., 2012), while 
simazine has been identified as an ER antagonist in Sprague-Dawley rats (Tennant et al., 
1994). 
Surflex-Dock correctly identified organophosphate insecticides with known endocrine 
activity (Table 4.9); sensitivity = 100%. However, only weak chemical interactions were 
identified for Dicofol, which structurally related to DDT, has been shown to antagonise the 
AR signalling pathway in vitro at 48.97 μM (Table_A 1). The absence of colour coding 
highlights the lack of in vitro endocrine MoA (ER, AR, PR & PPARγ) studies for 
organophosphates, nevertheless, the in silico model identified potential ED MoA for a 
number of insecticides, such as Chlorfenvinos, Fenitrothion and Parathion (Table 4.9). This 
ambiguity of Dicofol scoring was mirrored in the organochlorides which presented the lowest 
sensitivity of 72.7% (Table 4.10).  
In particular, Toxaphene scoring was ubiquitously unfavourable (-7.53 to 0.79 –log(Kd)), 
which conflicts with reports of in vitro ER signalling agonism in BG1 cells and androgen 
receptor antagonism (Table_A 1). However, as a mixture of at least 177 C10 
polychloroderivates, toxaphene highlights a limitation of the virtual screening, which utilised 
one conformation of one component the mixture, rather than deconstructing the mixture for 
individual assessment. Relative to the organophosphate insecticides, herbicides and 
fungicides, the organochlorides, notorious for their persistence and toxicity, presented very 
low affinity for the ligand binding pockets of nuclear receptors.  
Derived from Chrysanthemum cinerariifolium, pyrethrins are natural insectides, while 
pyrethroids are synthetic analogues. As reactive compounds which degrade in sunlight, the 
pyrethrins and pyrethroids do not persist in the environment and are widely used despite their 
neurotoxicity. SYBYL Surflex-Dock screening of pyrethrins and pyrethroids correctly 
identified in vitro hER, hAR and hPPARγ binders (Table 4.11).  
Interestingly, large differences in the in silico binding affinity of different species are 
reported; AR binding of fenvalerate varies from -17.0 to 3.78 –log(Kd). Interspecies variance 
in virtual screening scores suggests that molecular differences in LBP structure (Section 1 
and 4.4.2) affected protomol generation and in silico binding, increasing the uncertainty of 
extrapolating mechanistic information from one species to another. The in silico results 
(Table 4.11), suggest that human receptors may be more susceptible to perturbation of the 
classic genomic signalling pathway by pyrethrins and pyrethroids, than the chimpanzee, rat 
and mice models, typically used to infer adverse effects on human health. 
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Table 4.9 In silico Nuclear Receptor Organophosphate Insecicide Binding Results 
Top values reflect binding score (-log(kD)) and the degree of inappropriate protein penetration (crash score) is 
shown in parentheses TP=True Positive; Pis= Positive in silico; FUB=False Unfavourable Binding; 
UBis=Unfavourable Binding in silico; Nis=Negative in silico; FN=False Negative. See section 4.3.6. and 
Appendix A for information on true positive criteria. Colour coding: TP’s are highlighted green; “assumed” 
TP’s on the basis of interspecies extrapolation are light green; False Negatives are red; in silico negatives 
“assumed” positive are in pink. Unfavourable binders are in orange.  
 
The ubiquitous governance of pesticides has led to a wealth of in vivo, in vitro and in silico 
data, which enabled evaluation of the novel in silico screen. However, the majority of 
chemicals are not required to provide such extensive assurances of safety. The following sub-
sections, present the virtual screening results of industrial chemicals (REACH regulated), 
pharmaceuticals and personal-care-products.  
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Table 4.10 In silico Nuclear Receptor Organochloride Insecticide Binding Results 
Top values reflect binding score (-log(kD)) and the degree of inappropriate protein penetration (crash score) is 
shown in parentheses TP=True Positive; Pis= Positive in silico; FUB=False Unfavourable Binding; 
UBis=Unfavourable Binding in silico; Nis=Negative in silico; FN=False Negative. See section 4.3.6. and 
Appendix A for information on true positive criteria. Colour coding: TP’s are highlighted green; “assumed” 
TP’s on the basis of interspecies extrapolation are light green; False Negatives are red; in silico negatives 
“assumed” positive are in pink. Unfavourable binders are in orange.  
 
Table 4.11 In silico Nuclear Receptor Pyrethrin & Pyrethroid Insecticide Binding Results 
Top values reflect binding score (-log(kD)) and the degree of inappropriate protein penetration (crash score) is 
shown in parentheses TP=True Positive; Pis= Positive in silico; FUB=False Unfavourable Binding; 
UBis=Unfavourable Binding in silico; Nis=Negative in silico; FN=False Negative. See section 4.3.6. and 
Appendix A for information on true positive criteria. Colour coding: TP’s are highlighted green; “assumed” 
TP’s on the basis of interspecies extrapolation are light green; False Negatives are red; in silico negatives 
“assumed” positive are in pink. Unfavourable binders are in orange.  
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The large degree of inappropriate protein penetration (crash score (pKd)), of pyrethrin and 
pyrethroid insecticides, is reflective of their long functionalised backbone, which support a 
reactive cycloalkane and phenoxy groups and electronegative halogens (Cl or Br).  
4.4.3.1.3 Industrial Chemical in silico Docking 
Produced from a plethora of raw materials, ‘industrial chemicals’ or ‘commodity chemicals’ 
term the polymers, peterochemicals, inorganics and fertilisers that form the building blocks of 
manufacturing, construction, consumer goods and services. Sensitivity of SYBYL Surflex-
Dock in correctly identifying industrial chemicals known to interact with ERα, AR, PR or 
PPARγ (n=52), was 98.1% ([52 TP/ (52 TP + 1 FN)] x100) (see Table_Apx 2). A number of 
additional industrial chemicals interacted with the in silico protomols. Modelled on nuclear 
receptor LBP (45 ERα; 52 AR; 69 PR and 62 PPARγ), binding of industrial chemicals to the 
protomol pseudo-molecular target, suggests that exposure may perturb classic-genomic 
signalling (endocrine mechanisms). Table 4.12 and Table 4.13 show the virtual screening 
results for phenolic and phthalate industrial chemicals, respectively.  
Table 4.12 In silico Nuclear Receptor Phenolic Industrial Chemical Binding Results 
Top values reflect binding score (-log(kD)) and the degree of inappropriate protein penetration (crash score) is 
shown in parentheses TP=True Positive; Pis= Positive in silico; FUB=False Unfavourable Binding; 
UBis=Unfavourable Binding in silico; Nis=Negative in silico; FN=False Negative. See section 4.3.6. and 
Appendix A for information on true positive criteria. Colour coding: TP’s are highlighted green; “assumed” 
TP’s on the basis of interspecies extrapolation are light green; False Negatives are red; in silico negatives 
“assumed” positive are in pink. Unfavourable binders are in orange.  
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Table 4.13 In silico Nuclear Receptor HPV Chemical Binding Results 
Top values reflect binding score (-log(kD)) and the degree of inappropriate protein penetration (crash score) is 
shown in parentheses TP=True Positive; Pis= Positive in silico; FUB=False Unfavourable Binding; 
UBis=Unfavourable Binding in silico; Nis=Negative in silico; FN=False Negative. See section 4.3.6. and 
Appendix A for information on true positive criteria. Colour coding: TP’s are highlighted green; “assumed” 
TP’s on the basis of interspecies extrapolation are light green; False Negatives are red; in silico negatives 
“assumed” positive are in pink. Unfavourable binders are in orange.  
 
Chemicals with an unhindered hydroxyl group (-OH), in the meta- or para- position of a 
phenyl (-C6H5) or cyclopentene (-C5H4) ring, are considered ER-binders by the OECD 
QSAR Toolbox ER-profiler (Section 2.4; Table 2.3). Resonance in the aromatic ring 
(delocalisation of pi electrons) stabilises the acidity of the hydroxyl group, distinguishing 
activity from alcohols (IUPAC, 2006), and defining binding potency (Li and Gramatica, 
2010). The SYBYL in silico screening results of phenolic industrial chemicals are presented 
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in Table 4.13. As expected, all compounds were scored as potential binders; the model 
correctly identifying 10 true positives. 
The esters of phthalic acid, Phthalates, are used in the manufacturing of plastics. Bisphenols 
and phthalates are not archetypical NR-ligands, and inappropriate penetration of side-chains 
into NR proteins is reflected in the large crash scores (e.g. Diisodecylphthalate and DEHP). 
Nevertheless, the SYBYL in silico molecular model correctly identified all 14 bisphenol and 
phthalate NR binders (Table 4.13), superceeding the OECD QSAR Toolbox ER-profiler 
(Section 2.4.3).    
4.4.3.1.4 Pharmaceutical in silico Docking 
Pharmaceuticals, define pharmacologically active substances used in disease diagnosis, 
treatment and prevention. Regulated by the European Medicines Agency (EMA), Directives 
2001/83/EC and Regulation (EC) No.726/2004 stipulate the quality, manufacturing, 
pharmacovigilance and safety thresholds for pharmaceuticals, generating a plethora of 
mechanistic studies. However, these studies assess pharmacological dose-ranges, which may 
not reflect indirect environmental exposure, leading to mounting concern regarding the health 
implications of pharmaceuticals detected in potable water (IEH, 2012). The in silico 
molecular model correctly identified 56 of the 68 true positives; sensitivity = 85.0% ([68 TP/ 
(68 TP + 12 FN)] x100) (Table_Apx 2). Eleven of the twelve false negatives were incorrect 
classification of hAR (3V49) binders in silico; sensitivity of hAR model = 68.6% ([24 TP/ (24 
TP + 11 FN)] x100). This inefficiency in detecting hAR binders may reflect problems with 
the in silico molecular modelling and screening, but could also reflect the presence of 
metabolisation and/or deconjugation of pharmaceuticals in vitro and/or in vivo. Tamoxifen 
citrate and atorvastatin calcium were hAR non-binders in silico, which contradicted the in 
vitro bioassays. Assessing the information logically, the scoring error may reside in virtually 
screening the pharmaceuticals as their salts, which as mild chelating agents, prevent 
coagulation of pharmaceuticals, but may also prevent accurate binding assessments; thereby 
highlighting the limitation of evaluating chemicals in the absence of a metabolic system. Of 
the 114 pharmaceuticals investigated, 45 hERα, 52 hAR, 69 hPR and 62 hPPARγ new potential 
nuclear receptor interactions were identified in silico.   
4.4.3.1.5 Natural Compounds and Consumer Products in silico Docking 
SYBYL virtual screening correctly identified all investigated cosmetics (n=12), food 
additives (n=2) and natural compounds (n=19) that bind with nuclear receptors in vitro 
(Table_Apx 2); sensitivity = 100% ([33 TP/ 33TP] x100). Presenting a subset of the data , 
Table 4.14 shows the in silico scoring of cosmetics and personal care products. The in silico 
model correctly identified the hERα binding of parabens, but also suggested interaction with 
hAR. Used in a plethora of cosmetics and personal hygiene products, Cashmeran (6,7-
dihydro-1,1,2,3,3-pentamethyl-4(5H)-indanone) and 4,4-Dihydroxy-benzaphenone presented 
unhindered (low inappropriate protein penetration) in silico nuclear receptor activity. Natural 
extracts and consumer products present interesting regulatory considerations, as exposure 
will vary greatly on lifestyle choices (i.e. diet, bathing routine and product use). However, the 
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in silico activity suggests many natural extracts and PCP components present endocrine 
activity, which may be currently overlooked in EDC exposure and risk assessments. 
 
Table 4.14 In silico Nuclear Receptor Consumer Product Binding Results 
Top values reflect binding score (-log(kD)) and the degree of inappropriate protein penetration (crash score) is 
shown in parentheses TP=True Positive; Pis= Positive in silico; FUB=False Unfavourable Binding; 
UBis=Unfavourable Binding in silico; Nis=Negative in silico; FN=False Negative. See section 4.3.6. and 
Appendix A for information on true positive criteria. Colour coding: TP’s are highlighted green; “assumed” 
TP’s on the basis of interspecies extrapolation are light green; False Negatives are red; in silico negatives 
“assumed” positive are in pink. Unfavourable binders are in orange.  
 
4.4.4 Regression Analysis of Virtual Screening Results 
A number of structural features have been demonstrated to affect ligand binding. For 
example, the MW and partition coeffication (LogP) have been utilised as QSAR binary 
classification predictors, for ER-binding (Netzeva et al., 2006; Piparo & Worth, 2010). In 
accordance with these hypotheses, the SYBYL Surflex-Dock virtual screening results were 
analysed relative to their physicochemical properties. The physicochemical properties of the 
potential-EDC database (n=378) were calculated in SYBYL Molecular Spreadsheets, and 
exported into excel for regression analysis with IMB SPSS and R statistics software.  
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Figure 4.10 Regression Analysis of Physicochemical Properties of Chemical Database 
Plots show the regression analysis of the physicochemical properties of the prioritised chemical database 
(n=378). Indices of Molecular Weight (Da); ClogP (partition coefficient); total area (Å
2
); and, molecular volume 
(Å
3
) were included in coefficient analysis and plotting in R-statistics software. From the left-hand plot it is clear 
to see that there are positive correlations between all variables, however, the data was relatively dispersed for 
ClogP. The right hand plot shows the strong relationship between MW, total area and molecular volume, as 
expected, these variables are dependent.  
Evaluation of in silico and in vitro screening methods for EDC hazard characterisation 
 
 
 Page 98  
  
Figure 4.10 shows the relationship between the physicochemical properties of the prioritised 
chemical database (n=378). Regression of MW (Da), ClogP (calculated partition coefficient), 
total area (Å
2
), and, molecular volume (Å
3
) in R statistics software, identified positive 
correlations between all variables, suggesting non-independence and limiting the use of 
multiple regression. The ClogP coordinate data was dispersed; however, strong relationships 
between MW, total area and molecular volume were identified.   
 
Figure 4.11 Correlation Between in silico Nuclear Receptor (ERα, ERβ, AR, PR and PPARγ) 
Binding Score (-logKd) and Ligand Molecular Volume 
Plot and regression analysis in R demonstrated positive correlections between molecular volume and in silico 
SYBYL NR binding: estrogen receptor-α (era): y = 1.412 + 0.00382x [R2 = 0.284, p-value <2e-16]; estrogen 
receptor-β (erb): y = 2.72 + 0.00145x [R2 = 0.0312, p-value 0.000994]; androgen receptor (ar): y = 2.23 + 
0.00246x [R
2
 = 0.0907, p-value 1.98e-08]; progesterone receptor (pr): y = 1.892 + 0.00314x [R
2
 = 0.155, p-
value 2.15e-14]; and, peroxisome proliferator activator receptor (ppar): y = 2.078 + 0.00325x [R
2
 = 0.248, p-
value <2e-16]. Energetically unfavourable binding scores (<0–logKd) were exluded from the analyses. The 
dispersion of molecular volume coordinates, highlights the variability of the chemical database and putative 
ligands.  
The variables downloaded (MW, CLogP, area and volume) were interdependent, limiting the 
suitability of multivariate analysis (Figure 4.10). Excluding energetically unfavourable 
interactions (<0–logKd), Figure 4.11 illustrates the positive correlections between molecular 
volume and in silico SYBYL NR binding: estrogen receptor-α (era): y = 1.412 + 0.00382x 
[R
2
 = 0.284, p-value <2e-16]; estrogen receptor-β (erb): y = 2.72 + 0.00145x [R2 = 0.0312, p-
value 0.000994]; androgen receptor (ar): y = 2.23 + 0.00246x [R
2
 = 0.0907, p-value 1.98e-
08]; progesterone receptor (pr): y = 1.892 + 0.00314x [R
2
 = 0.155, p-value 2.15e-14]; and, 
peroxisome proliferator activator receptor (ppar): y = 2.078 + 0.00325x [R
2
 = 0.248, p-value 
<2e-16]. Thus, regression analysis suggests that the SYBYL Surflex-Dock NR virtual 
screening agreed with MW and LogP binding predictors.  
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4.4.5 SYBYL Surflex-Dock Virtual Screening – A ‘Good’ in silico Tool? 
The development of alternative (non-animal) methods for EDC hazard characterisation has 
become a high political priority, leading to a plethora of computational databases, QSAR, 
molecular modelling and decision tree approaches, to identify endocrine active substances 
(Piparo & Worth, 2010). Derek for Windows (DfW) detects structural alerts for 
developmental toxicity (n=3), teratogenicity (n=5), testicular toxicity (n=1) and estrogenicity 
(n=4), which indicated 72% sensitivity and 100% specificity, in a pilot validation study of 34 
chemicals (Pearl et al., 2001). In a similar vein, Toxmatch clusters chemicals on the 
assumption that structurally similar chemicals act by similar mechanisms (Enoch et al., 
2009). Quantifying interactions with in silico macromolecular targets, VirtualToxLab 
combines multidimensional QSAR with flexible docking (Verdani et al., 2012). While, a 
binary classification model of ER-binding, which utilised logP and hydrogen bond donor 
descriptors, was developed by Netzeva et al. (2006). Evaluation of the Netzeva et al. (2006) 
decision tree indicated sensitivity of 84% and specificity of 69%, relative to in vitro reporter 
gene assays (Gallegos-Saliner et al., 2006), which supplemented the development of the 
OECD QSAR Management group (OECD, 2009).  
The OECD QSAR Toolbox ER-profiler categorises two dimensional chemical structures on 
the basis of cyclicity, molecular weight (<500 Da) and hydroxyl and/or NH2 groups (Liu et 
al., 2006; Mombelli, 2012). Non-binders are chemicals which do not satisfy these criteria, or 
present steric hindrance of OH/NH2 groups by ortho-disubstitutions (see Section 2.4.3). The 
development of the ER-profiler required a wealth of structural and functional information 
(Tong et al., 2004; Bignon et al., 1989; Bradbury et al., 2000; Cronin & Worth, 2008; 
Schmieder et al., 2003). On the contrary, in agreement with VirtualToxLab flexible docking 
technologies (Verdani et al., 2012), this study generated novel three dimensional pseudo-
molecular docking targets from molecular probes (CH4, C=O and N-H), which were 
identified by rolling solvent spheres (Section 4.3.4.3) over the surface of published X-ray 
crystallography protein structures (hERα, hERβ, ratERβ, hAR, chimpAR, ratAR, mouseAR, hPR and 
hPPARγ) in Tripos™ SYBYL 7.3 software. An energetically minimised potential-EDC 3D 
database was screened against generated protomols in Surflex-Dock, which scored the in 
silico interactions according to Hammerhead and Bohn functions; accounting for 
hydrophobic contact, polar interactions and entropic fixation costs for loss of torsional and 
rotationa degrees of freedom (Bohn, 1996; Eldrige et al., 1997). Conceptually, 3D molecular 
modelling and dynamics, provide an object orientated framework for ligand-binding 
(Matthey et al., 2004; Balaji et al., 2013) which are advantageous over 2D QSAR statistical 
analyses.  
 The SYBYL Surflex-Dock virtual screening conducted in this study 
demonstrated mean sensitivity of 94.5% (291/309); representative of hERα = 
97.5% (115/118), hAR = 88.1% (96/111), hPR = 100% (6/6) and hPPARγ = 100% 
(74/74).  
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Figure 4.12 Chemical Structure of Phthalates and Polychlorinated biphenyls (PCBs) 
Esters of Phthalic acid, Phthaltes are produced by the reaction of phthalic anhydride with alcohols. The alcohol 
carbon chain length, ranging from methanol (C1) to tridecyl alcohol (C13), defines the R variable alkyl chain, 
which is used as a crude predictor of hazard; low Molecular Weight (LMW) and high MW phthalates, range 
from 194.18Da (Dimethyl phthalate) to 530.82Da (Disotridecyl phthalate). Polychlorinated biphenyls are 
synthetic compounds manufactured by reaction of biphenyl with 1 to 10 chlorine atoms. There are 209 PCB 
configurations.  
Specificity of 80.7% was calculated, however, epistemological limitations in the science and 
adopted method, hindered the definition of true negatives, which hinder the calculation 
(Section 4.4.3.1). The OECD Toolbox ER-profiler sensitivity has been reported at 84.1% 
(116/138) and 68.3% specificity (71/104) for human datasets (Mombelli, 2012). However, 
the aforementioned criterion has led to inefficiency in detecting moderate binders, such as 
phthalates and PCBs. This inefficiency can be explained by the 2D-structure of phthalates 
and PCBs (Figure 4.12). Phthalates and PCB’s do not have the NH2 or OH groups used to 
predict moderate and strong ER binding (Table 2.3), furthermore many exceed 500Da, 
leading to immediate classification as non-binders by the OECD Toolbox. 
Scoring interactions on the basis of three-dimensional hydrophobic contact, polar interaction, 
and degrees of freedom, the SYBYL Surflex-Dock method adopted in this study provides 
3D-docking flexibility, which correctly identificatied all investigated phthalate binders (Table 
4.13).  
 The SYBYL Surflex-Dock method, demonstrated higher sensitivity and 
specificity in correctly identifying endocrine active substances (EAS), than the 
OECD Toolbox ER-profiler (Mombeli, 2012), DfW (Pearl et al., 2001) and binary 
classification model (Netzeva et al., 2006).  
Superceeding currently available tools, Tripos™ SYBYL macromolecular modelling of NR 
and Surflex-Dock screening of putative ligands’, has been identified as a potentially useful 
regulatory tool to support EAS hazard identification. However, the sensitivity observed is at a 
cost of specificity. SYBYL Surflex-Dock scoring does not assess the functional importance 
of molecular probes and thus neglects the conformational changes required to define agonism 
or antagonism (Section 3.1.1.1 and 3.2.2). Predictivity was calculated relative to cell 
proliferation in dependent cell lines, reporter gene transactivation, binding assays and 
dissociation constants in vitro. Thus, sensitivity was calculated relative to endocrine activity 
(in vitro), rather than endocrine disruption (in vivo). The predictive performance of in vitro 
STTA, relative to the in vivo Immature Rat Uterotrophic Assay, presented sensitivity, 
specificity and concordance of 91%, 88% and 90%, respectively (Takeyoshi, 2006). The 
Uterotrophic Assay is OECD Conceptual Framework Level 3, i.e in vivo assay evaluating one 
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MoA (Figure 2.2), and therefore does not conclusively test for endocrine disruption. 
Highlighting the gap between in silico, in vitro and in vivo mechanistic studies, with 
conclusive in vivo chronic toxicity tests (Level 4 and 5).  Nevertheless, the predictivity of the 
SYBYL Surflex-Dock Virtual Screening surpassed that of the OECD ER-profiler, which was 
comparable in performance to validated skin irriation models (Mombeli, 2012); Murine Local 
Lymph Node Assay (LLNA); and, Episkin® protocols (ECVAM, 2010; Portes et al., 2002). 
SYBYL Surflex-Dock virtual screening has been demonstrated as a potentially useful and 
superior in silico screening tool for EDC hazard characterisation.   
4.5 In silico Summary and Conclusions 
This chapter aimed to explore the theory and application of in silico molecular modelling and 
dynamics to EDC hazard characterisation. Identified in Section 3.1, nuclear receptor 
molecular targets (ER, AR, PR and PPAR) were prioritised for investigation.  
Bootstrap-consensus phenograms, founded on Neighbour-Joining p-distance amino acid 
substitution statistical methods, successfully presented the evolutionary divergence of ERα 
(n=32) and ERβ (n=27) paralog and AR (n=58) orthologs (Thornton, 2001). Nuclear receptor 
phylogeny, presented as the topology, branch length and root, suggested sequence variance 
was consistent with taxonomic rank i.e. evolutionary distinct species present more sequence 
divergence. Thus, assuming protein sequence is indicative of function, uncertainty in 
extrapolating endocrine toxicological mechanisms may increase with evolutionary distance. 
The phenograms highlight the potential folly of species bias in regulatory toxicology; 75% of 
in vivo toxicological procedures for human health are conducted in rats (R.norvegicus), while 
ecotoxicology limits itself to three fish (D. rerio, P. promelas or O. mykiss), bird (C. 
japonica) and/or collembolan (F. fimetaria) models, representing a very limited assessment 
of potential inter- and intra- species variation. No invertebrate NR sequences were identified 
in BLAST searches, which suggests vertebrate paralogs (>60% sequence conservation) are 
more homologous, than invertebrate NR “orthologs”, corroborating suggestions that 
invertebrate endocrinology is incomparable to that of vertebrates (Scott, 2013).  
The Tripos™ SYBYL solvation method accurately predicted the LBP of hERα and hAR.; 
identifying the amino acid residues and molecular probes demonstrated to define binding 
(Brzozowski et al., 1997; Shiau et al., 1998; Sack et al., 2001). X-ray crystallography 
structures for hER (3DT3), hER (1X7J), ratER (1HJ1), hAR (3V49), chimpAR (1T7T), 
ratAR (21HQ), mouseAR (2QPY), hPR (1SQN) and hPPARγ (1PRG), were modelled. The 
SYBYL molecular modelling of chimpanzee, rat and mouse ER and AR identified 
conservation of hydrophobic (Ala, Leu and Phe) and uncharged polar (Gln/Asn) residues. In 
addition, a valine residue at 715 was conserved between all investigated AR, suggesting that 
the hydrophobic-side chain amino acid is important to function. However, the Thr877 residue 
detected in human AR, which determines ligand promiscuity (Sack et al., 2001; Taplin et al., 
1995), was not detected in the chimp, rat or mouse AR LBP, supporting phylogeny results 
and the intra- and inter-species differences detailed in Sections 2 and 3; however, 
demonstration of LBP differences in vitro and in vivo are required to clarify concerns. The 
accuracy of the solvation method in determining ER and AR LBP validates the method 
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(Section 4.3.4) for in silico predictions of less characterised NR LBP, such as PR and PPARγ; 
detailed in Appendix C: Figure_Apx 7 and Figure_Apx 8. The results suggest that Tripos™ 
SYBYL 7.3 software can ‘blindly’ predict the LBP of NR for protomol generation and virtual 
screening, in lieu of structural information and annotation, which is requisite for traditional 
QSAR approaches.  
Table 4.15 SYBYL Surflex-Dock Virtual Screening Sensitivity and Summary Data 
Table 4.15 provides a summary of the number of new potential ERα, AR PR and PPARγ binders identified in 
the SYBYL Surflex-Dock virtual screening. True positive in vitro EAS were excluded from the tally, however, 
the sensitivity in correctly identifying true positives is shown in the second column.   
 
Conceptually, 3D molecular modelling and dynamics, provide an object orientated 
framework for ligand-binding (Matthey et al., 2004; Balaji et al., 2013) which are 
advantageous over 2D QSAR statistical analyses. SYBYL Surflex-Dock virtual screening 
demonstrated mean sensitivity of 94.5%; representative of hERα = 97.5%, hAR = 88.1%, hPR 
= 100% and hPPARγ = 100%. Specificity of 80.7% was calculated, however, epistemological 
limitations in the science and adopted method, hindered the definition of true negatives, 
which then hinders the calculation (Section 4.4.3.1). Scoring interactions on the basis of 
three-dimensional hydrophobic contact, polar interaction, and degrees of freedom, the 
SYBYL Surflex-Dock method demonstrated higher sensitivity and specificity in correctly 
identifying EAS, than the OECD Toolbox ER-profiler (Mombeli, 2012), DfW (Pearl et al., 
2001) and binary classification model (Netzeva et al., 2006).  
The study reported here demonstrates important in silico developments since the initial use of 
SYBYL macromolecular modelling by Wu et al. (2010) in which interspecies variation of 
nonylphenol, BBP, BPA, 4’4-DDE, hexabromodiphenyl ether, Linuron and testosterone AR 
binding in silico were investigated. However, further investigation of interspecies ligand 
binding in vitro (Lange et al., 2012; Wilson et al., 2007; Wells & Van Der Kraak, 2000), is 
required to validate the sensitivity of molecular modelling in predicting interspecies variation.  
In conclusion, SYBYL molecular modelling and Surflex-Dock virtual screening have been 
identified as a potentially useful regulatory tool to support EAS hazard identification. 
Furthermore, a number of chemicals were shown to present endocrine activity in silico, 
justifying further investigation in vitro.   
 
4.5.1 In silico Approaches to EAS: Study Milestones 
 Phenograms identified evolutionary divergence of ER and AR amino acid sequences;  
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 A structurally diverse chemical database of 378 potential-EDCs was curated, 
including 118 ERα, 111 AR, 6 PR and 74 PPARγ EAS in vitro (n=309);  
 The ligand binding pockets of hER (3DT3), hER (1X7J), ratER (1HJ1), hAR (3V49), 
chimpAR (1T7T), ratAR (21HQ), mouseAR (2QPY), hPR (1SQN) and hPPARγ (1PRG), 
were successfully modelled in SYBYL SiteID using the solvation method;  
 Interspecies variation in virtual ER and AR ligand binding pockets were 
demonstrated;  
 In silico pseudo-molecular NR LBP targets (ERα, AR, PR and PPARγ protomols) 
were virtually screened against a compound library of 378 potential-EDCs;  
 SYBYL Surflex-Dock Nuclear Receptor (ER, AR, PR & PPARγ) virtual screening 
demonstrated a sensitivity of 94.5%; of 309 true positives, 291 chemicals were 
correctly identified, 18 were incorrectly scored as non-binders;   
 The SYBYL Surflex-Dock method superseded the OECD Toolbox ER-Profiler, DfW 
and binary classification models, in correctly identifying EAS; 
 A number of chemicals were shown to present endocrine activity in silico, 
highlighting the need for further in vitro assays and conclusive testing;  
 Regression analysis identified significant correlations between binding score, 
molecular volume, MW, molecular area and ClogP; and 
 Tripos™ SYBYL molecular modelling and Surflex-Dock virtual screening has been 
identified as a potentially useful automated tool for EDC hazard characterisation.   
4.5.2 Future Work for Development of in silico EDC Methods 
Whilst exploring the theory and application of in silico molecular modelling and dynamics to 
EDC hazard characterisation, a number of difficulties, caveats and potential developments of 
in silico methods were identified. 
The curation of a potential-EDC database from publically available information hubs 
highlighted an array of biotechnology tools. However, software and bioinformatics tools 
varied with jurisdiction, increasing disparity and disconcordance of in silico approaches. A 
harmonised data hub, pooling UK (EndiChem; RSC ChemSpider), EU (PubChem; RCSB 
PDB; VirtualToxLab; ChemProt) and US (EDKB; ZINC) sources would aid the accessibility 
and consistency of in silico approaches; under the current paradigm, the sourcing and 
significance of online data is uncertain.  
The strategy for positive NR-binding classification, for inclusion in this study, required a 
demonstration of in vitro NR activity; this comprised cell proliferation of hormone-dependent 
cell lines, reporter gene studies and radiolabelled-binding/dissociation assays (PubChem 
Bioassay databank). However, this method presented a number of caveats, including the 
potential classification of false positive binders (in vitro), on the basis of ligand-independent 
increases in transactivation or stimulation of cellular proliferation via alternative 
mechanisms. Furthermore, the significance of observations in vitro remained uncertain; for 
example, Endosulfan was classified as a positive binder of ER and AR for in silico sensitivity 
analysis on the basis of 8/16 and 3/16 positive in vitro results, respectively. This highlights 
the question, what burden of inactive in vitro data justifies classification as a non-binder? The 
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OECD stipulates that statistically significant responses in the in vitro ER STTA assay, 
repeated on 3 separate days, provide conclusive evidence that a chemical influences ER 
signalling pathways. Two day repeats provides strong evidence, while 1 day repeat suggests 
ER interaction. However, most academic research is not conducted to OECD standard, 
limiting the application of these constraints. Development of decision criteria to categorise 
academic in vitro bioassay data, would promote consistency among research groups, which 
may be evaluating in silico predictivity with inconsistent constraints. Equally, excluding the 
Uterotrophic Assay, observations of endocrine disruption in vivo are not directly comparable 
to in vitro and in silico binding predictions. Harmonised translucent bioinformatic mapping 
of in silico, in vitro and in vivo evidence is vital to understand adverse outcome pathways and 
the relevance of alternative (non-animal) lower tier testing.  
A significant limitation of in silico molecular modelling is the inability to predict cellular 
metabolism. Incorporation of metabolic simulator, such as T.I.M.E.S Tissue Metabolism 
Simulator (Mekenyan et al., 2003; Schmieder et al., 2003), may increase the sensitivity of 
nuclear receptor virtual screening  
The reliability of the in silico SYBYL screening is intrinsically linked to the reliability of NR 
modelling. For the purpose of this study, only proteins with known crystal structures were 
included, which limited the number of NR’s investigated. X-ray crystallography selectively 
favours the nuclear receptor conformations most likely to crystalise (Srinivasan et al., 2013); 
i.e. dimers with bound ligands and coregulators. X-ray crystallography of sentinel species NR 
would enable virtual screening of a larger array of species. For example, as an ecologically 
important species, a wealth of mechanistic and ecotoxicology studies have investigated 
EDC’s in fish. Interspecies variation has been reported in teleost fish ligand-dependent ER, 
AR and PXR transactivation in vitro (Lange et al., 2012; Kojima et al., 2011; Wilson et al., 
2007). X-ray crystallography of the aforementioned fish NR LBP would enable virtual 
screening, with an evaluation of sensitivity relative to in vitro reporter gene assays.  
Nuclear receptor LBP structure can be predicted from amino acid sequence in silico, in the 
absence of X-ray crystallography via structural homology modelling of protein databanks. 
However, this functionality was beyond the Tripos™ SYBYL licence available for this study. 
Accurate prediction of NR LBP, without specific X-ray crystallography studies, would enable 
3D in silico nuclear receptor screening of any NR sequence data; there are over 628 ER and 
394 AR reviewed sequences available on UniProt, including a plethora of taxonomic ranks. 
Validation of ‘blind’ molecular modelling, in addition to the ‘blind’ molecular screening 
demonstrated in this study, would enable the virtual screening of diverse nuclear receptor 
libraries with large chemical databases; automatically screening inter- and intra-species NR 
susceptibility to putative ligands.  
However, a number of advancements would need to be made, prior to achieving this, 
including the confirmation of in silico interspecies variation in vitro. Further investigation of 
interspecies ligand binding in vitro, is required to validate the sensitivity of molecular 
modelling in predicting species variation.   
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Sructural interactions of NR, identified in Section 1, highlight potential in silico 
developments. SYBYL Surflex-Dock creates a pseudo-molecular target of the molecular 
probes identified in the ligand binding pocket, thereby evaluating binding independent of the 
protein as a whole. Although ligand binding occurs in NR LBD monomers, justifying this 
method, the structural implications of monomer stabilisation by HSP association are 
uncertain. Furthermore, the conformational repercussions of predicted ligand-binding on the 
dimerisation site, DNA-binding site and cofactor regulatory site are ignored and thereby 
prevent prediction of agonism or antagonism. SYBYL Surflex-Dock pilot studies of active 
NR ligand binding domains for interaction with known cofactors conducted herein 
(Figure_Apx 3 and Figure_Apx 4), suggest that the in silico model is not appropriate to 
predict surface affinity. Development of a multi-stage NR binding model, which enabled 
prediction of the conformational repercussions of ligand-binding and cofactor binding, would 
enable predictions on agonism/antagonism. This would not be possible without collaboration 
with Tripos™ SYBYL software developers or creation of a supplementary tool.  
4.5.2.1 Summary of Future Work 
 Development of a harmonised biotechnology software hub with evaluated, translucent 
in silico, in vitro and in vivo evidence; 
 Criterion for positive/negative binding classification from pooled in vitro data; 
 Inclusion of in silico metabolic prediction software 
 Elucidation of diverse sentinel species NR X-ray crystallography structures; 
 Validation of LBP molecular modelling for inter-/intra- species variation; 
 SYBYL Surflex-Dock screening of a larger mechanistically diverse database; and, 
 Development of Surflex-Dock to incorporate multi-stage assessment. 
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5 ENDOCRINE ACTIVITY IN VITRO 
In its entirety, this study aims to evaluate the current in silico and in vitro tools for EDC 
screening and hazard characterisation. The application of in silico molecular modelling 
and virtual screening to EDC hazard characterisation was detailed in Section 1. This 
chapter aims to evaluate the currently available in vitro tools for endocrine modes-of-
action, via literature review and the testing of potential-EDCs in standardised in vitro 
mechanistic assays. The in vitro methods adopted herein provide mechanistic and 
potency information for EDC hazard characterisation.    
5.1 Introduction to in vitro Toxicology 
Cell culture, the in vitro growth of cells derived from multi-cellular organisms, enables 
investigation into cell physiology and function in a defined environment, and has been 
utilised in the study of: disease processes; receptor-ligand interactions; drug binding 
assays; mutagenicity; the production of recombinant proteins; biology; and toxicology.  
The classical genomic pathway is initiated by endogenous hormones activating the LBD 
of nuclear receptors, which causes dissociation of heat shock proteins and dimerization, 
leading to transcriptional activation and ultimately cellular response (Section 3.1).  The 
steroid hormones and NRs regulate transcription of specific genes, which regulate cell 
proliferation, foetal development and reproductive function. EDC research has focused 
primarily on estrogenicity and androgenicity of the HPG axis, consequent to 
observations in exposed wildlife. A number of in vitro tests have been developed to 
identify ER and AR agonists and antagonists, including: receptor binding; cell 
proliferation; gene expression; and inhibition/stimulation of hormone synthesis (Gray et 
al., 1998).  
Assays evaluating the direct interaction of potential-EDCs with nuclear receptors 
(binding affinity) successfully characterised ERα and ERβ using radiolabelled 
competitive binding assays (Kuiper et al., 1998). However, similar to the in silico 
assessments (Section 1), receptor binding assays do not distinguish between agonistic 
and antagonistic binding but may minimise false negatives (Vonier et al., 1996). High 
throughput techniques utilising nonradioactive fluorescence have been developed, in 
which changes in polarisation of fluorescently tagged E2 can be assessed in response to 
increasing concentrations of competitor compounds (Bolger et al., 1998). Alternatively, 
Fluorescence or Bioluminescence Resonance Energy Transfer (FRET or BRET, 
respectively) assays can measure the dimerization of nuclear receptors (Tamrazi et al., 
2002), or receptor-coregulator interactions (Liu et al., 2003), subsequent to ligand 
binding. BRET assays are characterised by an enzyme catalysed bioluminescent donor 
such as luciferase, which emits a photon of light in the presence of substrate and can be 
fused to the nuclear receptor of interest (Xu et al., 2007).  
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Cellular proliferation assays measure in vitro proliferation of hormonally dependent cell 
lines, on the premise that agonistic xenobiotics will cause cells to proliferate, while 
antagonists will inhibit the proliferation in response to endogenous hormones. The E-
screen, for example, utilises the estrogen-dependent human breast cancer cell line, 
MCF-7, to detect xenestrogens (Ankley et al., 1998). However, guidance documents 
published by the OECD (2012a) and ICCVAM (2003) did not recommend proliferation 
assays, due to the potential proliferation through cellular pathways, other than those 
involving the transcriptional activation of hormone responsive genes. Nevertheless, the 
US EDTA is leading development of a standardised test guideline for the ‘MCF-7 Cell 
Proliferation Assay for the Detection of Estrogen Receptor Agonist and Antagonist’ 
(OECD, 2013), which would be used in a battery of tier 1 tests (Figure 2.2).  
Ultimately cellular response is the result of gene transcription. Gene expression assays 
measure gene expression induced by hormone receptor activation (Zacharewski, 1997), 
via the measurement of endogenous gene products (mRNA), or the induction of 
response elements, stably or transiently, transfected with a reporter enzyme (e.g. 
luciferase or β-galactosidase). Reporter gene assays utilise in vitro eukaryotic cell lines 
which catalyse chemillumiscent, radioactive or colorimetric enzymatic reactions 
consequent to response element induction, which quantitatively represents gene 
expression. A derivative of the MCF-7 cell line, MCF-7 MVLN, has been used to detect 
estrogenic activity of single chemicals and complex mixtures in a reporter gene assay 
(Routledge & Sumpter, 1996; Zacharewski et al., 1995). Gene expression assays can 
distinguish between agonists and antagonists, as a consequence of the coregulatory 
mechanisms detailed in Section 3.2 (i.e. downsteam signalling). Nuclear receptor 
transactivation is considered one of the key mechanisms of endocrine disruption (ED). 
However, the transient transfection of plasmids is integral to novel reporter gene assays, 
which is labour intensive and introduces inter-assay variation (ICCVAM, 2003).   
However, ligand-dependent transactivation is not the only mechanism of endocrine 
disruption, which may also occur through: inter-receptor interations; hormone synthesis; 
metabolic activation and/or inactivation of hormones; distribution of hormones to target 
tissues; and, clearance of hormones from the body. The OECD H295R Steroidogenesis 
Assay utilises NCI-H295R cells, which resemble undifferentiated human foetal adrenal 
cells and express steroidogenic enzymes, to detect substances that affect the production 
of E2 and testosterone. The assay incorporates biosynthetic reactions that are stage 
specific, thus no in vivo tissue would express all the enzymes at once. Albeit not 
predictive of specific in vivo responses, validation studies demonstrated that chemicals 
were accurately flagged as reproductive toxicants or disruptive of steroidogenesis, 
(OECD, 2012a). 
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5.1.1 Testing for Estrogenicity 
Perturbation of estrogen homeostasis may trigger adverse effects on normal 
development (ontogenesis), reproductive health and the integrity of the reproductive 
system. The OECD TG455 Stably Transfected human estrogen receptor alpha (ERα) 
Transcriptional Activation Assay (ER STTA) detects chemicals that activate ERα; the 
receptor-ligand complex binds to specific DNA response elements and transactivates a 
reporter gene, such as luciferase.  
A number of studies have compared the efficacy of test methods to detect estrogenic 
chemicals. Lee et al. (2012) compared the estrogenic activity of DEHP, DBP, BBP, 
Diethyl phthalate (DEP), Tetrabromobisphenol A (TBBPA), Bisphenol A (BPA) and 
Nonylphenol (NP) in ERα STTA, ER binding (Akahori et al., 2008), E-Screen (Soto et 
al., 1995) and Yeast screening (Coldham et al., 1997) assays. In the HeLa9903 STTA, 
the estrogenic activities of BBP (PC50 4.32 x10
-6
 M), BPA (PC50 1.26 x10
-7
 M) and NP 
(PC50 2.92 x10
-6
 M), were significantly lower than 17β-Estradiol (E2 PC50 2.43 x10
-
11
M). DEHP, DBP and DEP did not show any estrogenic activity. The ERα binding 
affinities of BBP, BPA and NP were approximately 200000-fold (IC50 4.91 x 10
-4
 M), 
8000-fold (IC50 1.92 x10
-5
M) and 1400-fold (IC50 3.34 x 10
-6
M) less than E2 (IC50 2.45 
x10
-9
M), in competitive human ER binding assays. Thus, the relative potencies of 
STTA assay were comparable to ER binding, E-SCREEN, and Yeast screening assays 
(Lee et al., 2012).  
The relative potencies of potential-EDCs have been compared in luciferase reporter 
gene assays (MVLN and HGELN cell lines), competitive binding assay (hERα and 
hERβ) and proliferation of MCF-7 cells (E-Screen). The authors reported assay 
sensitivity decreased in the order of: MVLN cells ~ E-Screen> HGELN cells> binding 
ERα> binding to ERβ. Potencies obtained in cell free binding assays were 1-2 orders of 
magnitude higher than those obtained in cell culture assays. However, plotting the 
relative potencies obtained in the luciferase reporter gene assays demonstrated a slope 
of 0.957 (R=0.999). Results obtained in the E-Screen and MVLN cell line were 
significantly correlated (1.049, R=0.9891). Regardless of sensitivity, all assays ranked 
the chemical potencies in the same order (Witters et al., 2010; Gutendorf & Westendorf, 
2001).   
Numerous stably transfected human estrogen receptor alpha (ERα) transcriptional 
activation assays have been reported (Anderson et al., 2002; Escande et al., 2006; 
Takeyoshi et al., 2002; Du et al., 2010). Recently adopted by the OECD, Test Guideline 
455 identifies chemicals that induce downstream transactivation of ERα and ERα/β, in 
HeLa9903 and BG1Luc cells, respectively. Vertebrates predominantly express ERα, 
which mediates the classic estrogenic response (Anderson et al., 1972) and ERβ is 
coexpressed to a lesser extent. The BG1Luc STTA incorporates stably transfected ER in 
the human ovarian adenocarcinoma cell line (BG-1), to provide concentration-response 
data for in vitro ER agonism and/or antagonism (Rogers & Dennison, 2000; Cavailles, 
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2002). Expressing both ERα and β, the BG1Luc ER STTA surpasses the HeLa9903 ER 
STTA, which only measures interaction with ERα. Validation studies have shown the 
TG455 ER STTA to be sensitive and specific, relative to the in vivo Uterotrophic Assay;  
predictive performance of the HeLa9903 STTA in detecting estrogenicity, relative to the 
in vivo Immature Rat Uterotrophic Assay presented sensitivity, specificity and 
concordance of 91%, 88% and 90%, respectively (Takeyoshi, 2006).  
Both the ER STTA and BG1Luc ER TA quantify transactivation of responsive genes by 
measuring chemiluminescence. Luciferase activity can be quickly evaluated using a 
microplate luminometer, generating the RLU (relative luciferase units), required to 
establish a positive or negative result. However, it is important to note that some 
chemicals inhibit luciferase enzymes by protein stabilisation, which confounds 
chemiluminescence measurements (Thorne et al., 2010). Both OECD STTA assays are 
hindered by the potential for false positives, via chemicals that increase 
chemiluminescence without interacting with ERα; such as Genistein and Daidzein 
(Kuiper et al., 1998; Escande et al., 2006).  
5.1.2 Testing for Androgenicity 
There are currently no OECD Test Guidelines to assess mechanisms of androgenicity or 
AR binding. The US EPA EDSP has validated and adopted a rat AR binding assay (US 
EPA.OPPTS 890.1150) as a Tier 1 test (US EPA, 2009). Rat ventral prostate tissue 
homogenate is cultured in vitro, to assess the ability of chemicals to displace 
radiolabelled Metribolone (R1881), which is a synthetic agonist, from the androgen 
receptor. Consistent with other binding assays, the assay cannot distinguish agonists and 
antagonists. Conservation of the AR ligand binding domain reported in the literature 
(Section 3.1), justifies the extrapolation of positive results. However, the assay requires 
castration of male rats and may be considered outdated, in light of developments in 
stably transfected cell lines.  
More recently, Chatterjee et al. (2007) constructed a yeast-based beta-galactosidase 
reporter assay, by transfecting S. cerevisiae with human androgen receptor (hAR) and 
androgen-responsive elements (ARE), to assess the androgenicity of environmental pulp 
and paper mill effluents. The assay reported testosterone (EC50 16nM) and 
Dihydrotestosterone (EC50 4nM) sensitivity comparable to previously conducted in vitro 
assays (Leskinen et al., 2005; Michelini et al., 2001).  Bovee et al. (2008) developed an 
androgen bioassay with a yeast-enhanced green fluorescent protein (yEGFP) reporter. 
The assay was sensitive (EC50 50nM), reliable and reproducible. Furthermore, the 
author noted that the relative androgenic potencies were in agreement with optimised 
QSAR calculations; suggesting a lack of metabolism and crosstalk in the yeast model 
and the applicability of the QSAR model (Bovee et al., 2008).   
However, mammalian cell line-based luciferase reporter assays have been demonstrated 
to show higher sensitivity (Svovodova & Cajthaml, 2010). Kim et al. (2006) identified 
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22Rv1 prostate cells as an appropriate model for hAR-mediated reporter gene assays 
(Sun et al., 2007). Whereas Owens et al. (2006) detected the androgenic activity of 
diesel fuel and biomass combustion emissions, using MDA-kb2 cells transfected with 
androgen-responsive promoter-luciferase gene constructs.  
Consequent to the development of the MCF-7 proliferation assay (E-Screen), 
Sonnenschein and Soto (1998) developed the androgen proliferative screen assay (A-
Screen). Human prostate adenocarcinoma LNCaP-FGC cells were demonstrated to 
exhibit biphasic proliferation in response to androgens; at low androgen doses, cells 
increase their proliferation rate, while at high doses, androgens inhibited proliferation. 
The LNCaP-FGC cell proliferation assay verified DDE AR antagonism in in vivo rodent 
studies (Gray et al., 1995). However, a point mutation in the ligand binding domain of 
the LNCaP-FGC androgen receptor, associated with increased ligand promiscuity, has 
spurred the development of a stable androgen receptor transfectant of MCF-7 cells 
(MCF7-ARI), which responds to androgens by decreasing its proliferation rate (Szelei 
et al., 1997).   
In 2002, Andersen et al. used Chinese hamster ovary cells (CHO K1) to assess 
androgenicity and antiandrogenicity of 24 pesticides
48
. None of the pesticides were AR 
agonists; however, co-exposure with R1881 identified anti-androgenicity of several 
pesticides, including: Dieldrin; Endosulfran; Methiocarb; and, Fenarimol. Many of 
which have been demonstrated to agonise the estrogen receptor, highlighting ligand 
promiscuity and variable MoA, which may elicit variable in vivo endpoints (Anderson 
et al., 2002).  A cellular conformation-based screen for AR inhibitors, which exploits 
fluorescence resonance energy transfer (FRET) consequent to conformational changes 
in the androgen receptor on ligand binding, has been developed by Jones et al. (2008). 
The study demonstrated comparably sensitive to transcription-based reporter assays.  
Albeit not validated for use by regulatory authorities, a number of stably transfected AR 
transactivation assays have been developed for pharmacophore investigation i.e. drug 
identification and lead optimisation. For example, Cignal manufactures an Androgen
49
 
Receptor Reporter (luc) kit (CCS-1019L), which can be transfected into LNCaP cells to 
monitor increases and/or decreases in androgen dependent transcriptional activation.  
5.1.3 Testing for PR and PPARγ Endocrine Modes of Action 
In collaboration with estrogens, progestagens regulate proliferation and differentiation 
of reproductive tissues. However, only a limited number of studies have developed 
methods for screening agonism or antagonism of progesterone signalling, such as: 
                                                 
48
 Endosulfan, Methiocarb, Methomyl, Pirimicarb, Propamocarb, Deltamethrin, Fenpropathrin, 
Dimethoate, Chlorpyriphos, Dichlorvos, Tolchlofosmethyl, Vinclozolin, Iprodion, Fenarimol, Prochloraz, 
Fosetyl-aluminium, Chlorothalonil, Daminozid, Paclobutrazol, Chlormequatchlorid and Ethephon 
49
 http://www.sabiosciences.com/reporter_assay_product/HTML/CCS-1019L.html  
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bioassays utilising stably transfected yeasts (Li et al,. 2008; Chatterjee et al., 2008) and 
mammalian cell lines (Molina-Molina et al., 2006). S. cerevisiae yeast transfected with 
human PR, a prolactin promoter and two copies of the progesterone response element 
(PRE), to drive GFP expression in the presence of PR agonists has been developed by 
Chatterjee et al. (2008). The authors demonstrated a significant elevation in 
fluorescence in response to 0.1 nM progesterone (EC50 1nM). Human embryonic kidney 
(HEK 293) cells cotransfected with human PR and a luciferase reporter gene regulated 
by PRE, have been utilised in the development of a stably transfected hPR 
transactivation assay (Viswanath et al., 2008). A dual-luciferase reporter assay was 
utilised to monitor the PR dependent concentration of luciferase and Renilla luciferase 
control, demonstrating a comparable sensitivity to the aforementioned yeast screen 
(Svobodova & Cajthaml, 2010).  
Disruption of peroxisome proliferator activated receptors (PPARs) has largely been 
ignored by endocrine disruption testing. However, consequent to the unprecedented 
increase in obesity worldwide and the elucidation of PPAR transcriptional regulation of 
gene networks controlling intracellular lipid flux, adipocyte proliferation and 
differentiation, the potential for disruption by xenobiotics has become a high research 
priority (Grün & Blumberg, 2009). PPARγ agonists have been utilised to improve 
insulin sensitivity and glycaemic control in diabetics (Golberg, 2007). Conversely, 
persistent weight gain was observed with prolonged use (Larsen et al., 2003). PPARγ 
antagonists (SR-202, GW9662 and JTP-426267) have been demonstrated to prevent 
high-fat diet induced weight gain in rodents (Rieusset et al., 2002; Nakano et al., 2006). 
Regarding environmental and regulatory relevance, tributyl and triphenyl tin (TBT, 
TPT, respectively) have been demonstrated to agonise the PPARγ.  
5.1.4 The Caveats of in vitro Investigation 
A major limitation of in vitro test systems is the inability to replicate metabolic 
processes, integral to toxicity in vivo. However, inclusion of metabolic activation 
systems to ER and AR binding TA assays is not without caveat, and uncertainty 
regarding the differences in xenobiotic metabolism, bioavailability and toxicokinetics in 
in vivo, versus in vitro tests systems (Ankley et al., 1998), prevents incorporation into 
standardised protocols. In the 2012 guidance document, the OECD stresses the varying 
relevance and significance of in vitro metabolising systems, from one species to 
another, suggesting that the addition of a metabolising system should only be 
considered when in vivo metabolism is certain. A number of systems, such as 
‘Metapath’ are being developed, as part of the OECD Working Group on Pesticides, to 
predict xenobiotic metabolism in silico. Metapath
50
 also provides the foundation for the 
development of metabolic simulators. Conversely, in vitro tests entail the advantage of 
                                                 
50
http://yosemite.epa.gov/sab/sabproduct.nsf/373C1DB0E0591296852579F2005BECB3/$File/OPP+SAP
+document-May2011.pdf  
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investigating interactions of interest independent of the complexity inherent to an entire 
organism (e.g. ADME), which may confound the ability to detect mechanisms of action 
in vivo. However, it is important to note that chemicals which are bio-transformed to 
endocrine active metabolites may not be detected by in vitro assays, if phase I and II 
metabolism is not considered. Thus, in vitro results should not be directly extrapolated 
to the complex signalling and regulation of the intact endocrine system in vivo.  
Futher complicating in vitro investigation, sensitivity has been demonstrated to vary 
with host cell line. There is evidence to suggest STTA results vary significantly in yeast 
and mammalian cells, as a result of differences in pharmacokinetics and 
pharmacodynamics (Zacharewski, 1997).  
5.1.5 Summary 
In vitro EDC research has prioritised estrogenic and androgenic mechanisms of action, 
following apical endpoints observed in exposed wildlife. A number of in vitro tests have 
been developed to identify ER and AR agonists and antagonists, including receptor 
binding, cell proliferation, gene expression and inhibition/stimulation of hormone 
synthesis (Gray et al., 1998). The OECD Stably Transfected human ERα 
Transcriptional Activation Assay detects chemicals that activate ERα/β. Agonist bound 
receptor conformations bind to specific DNA response elements and transactivate a 
luciferase reporter gene. Validated for detecting estrogenicity, transactivation of stably 
transfected cell lines, may be considered the best current available in vitro tool to detect 
nuclear receptor interaction.  
The scope, validation and variety of in vitro assays to elucidate endocrine mechanisms, 
has reflected the state of the science. Hence, tools to decipher less conventional MoA 
are limited, while a plethora of assays evaluate ER agonism/antagonism. Time and 
monetary constraints prevent evaluation of all the aforementioned techniques in this 
study, which will focus on ER and AR STTA, for regulatory relevance and comparison 
with in silico results (Section 1).  
The remainder of this section details the in vitro evaluation of potential-EDCs, 
prioritised via in silico screening, in Stably Transfected Transcriptional Activation 
Assays (ER and AR), in addition to experimentation with transient transfection of NR, 
for novel reporter gene assays.   
5.2 In vitro Materials and Methods 
Adopted by the OECD, Test Guideline 455 defines STTA experimental method, to 
identify chemicals that induce in vitro transactivation of ERα and ERα/β elements, in 
HeLa9903 and BG1Luc cells, respectively. As a validated regulatory tool, the concepts 
and approaches detailed in TG455 were adhered to when possible. All experiments were 
conducted with aseptic technique and appropriate personal protective equipment (PPE; 
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EN374-3 standard gloves, Howie labcoat and eye protection). Contamination was 
controlled via experimentation in laminar air-flow cabinets sterilised with 70% 
Isopropanol and fortnightly laboratory cleaning of local areas with Virkon (2%) and 
Isopropanol (70%). The prioritisation and sourcing of test compounds, in vitro 
materials, including plasticware, laboratory equipment, cell culture reagents, cell lines 
and assay kits, are detailed prior to descriptions of experimental methods.  
5.2.1 In vitro Test Compounds 
5.2.1.1 Prioritisation Method for in vitro and Case Study Inclusion 
In silico screening identified a number of potential endocrine active substances (Section 
4.4.3). However, testing all potential-EDCs in vitro was outside the scope of this study, 
hence, compounds representative of chemical exposure scenarios, were prioritised for in 
vitro assessment (n=20). Assay controls, environmental contaminants and HPV 
industrial chemicals of varying regulatory data requirements (i.e. data-rich vs. data-
poor) were included: 5 endogenous hormones; 4 synthetic hormones; 5 consumer 
chemicals (preservatives, pesticides and antibiotics); 5 industrial chemicals; and, 1 UV-
filter (PCP ingredient). Concurrent assay controls serve as an indication that assays are 
operative and verify sensitivity. OECD TG455 requires demonstration of laboratory 
standards, via the testing of 14 proficiency chemicals
51
. However, the purpose of the 
study is not to inform the regulation of specific chemicals, but rather to assess the 
application of in silico and in vitro tools. Thus, strict adherance to the OECD standard 
was deemed unnecessary; 3 proficiency and 2 positive controls (PC) from TG455 were 
included. The endogenous and synthetic hormone controls tested in vitro were: 17β-
Estradiol (E2), Progesterone (PRG), Testosterone (T), Dihydrotestosterone (DHT), 
Corticosterone (C), Metribolone (R1881), Diethylstilbestrol (DES) and 17α-
Ethinylestradiol (EE2). The structure, use and affiliative nuclear receptor mechanisms, 
of the natural and synthetic hormones, are detailed in Table 5.1 and 5.2 respectively.  
In silico results (Section 4.4) highlighted the ligand promiscuity of endogenous 
hormones detailed in the literature (Section 3.2). Progesterone and the synthetic 
analogue 19-Norethindrone were included to assess promiscuity of ER/AR-regulated 
transactivation in vitro, in response to ‘non-target’ hormones (Table 5.1 & 5.2). High-
priority chemicals identified by OECD member states (Section 2.4) were prioritised on 
the basis of their environmental relevance, human exposure, structural diversity and 
breadth of toxicological data. Reflective of the regulatory scope of EDCs, preservatives, 
antibiotics, pesticides, PCP components, plasticisers and industrial chemicals were 
included.  
                                                 
51
 OECD Proficiency Chemicals: Diethylstilbestrol (DES); 17α-Estradiol; meso-Hexestol; 4-tert-
Octylphenol (4-OP); Genistein; Bisphenol A (BPA); Kaempferol; Butylbenzylphthalate (BBP); p,p’-
Methoxychlor; Ethylparaben; Atrazine (ATZ); Spironolactone; Ketoconazole; and, Reserpine.  
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Table 5.1 Natural Endogenous Hormones for in vitro Assessment 
Positive controls and endogenous hormones were identified from the literature and the OECD Test 
Guideline TG455 proficiency chemical and control lists. PubChemBioassay (Section 4.3.1; Table 4.1) 
was used as a hub for mechanistic data; AID identifiers provide a reference to the bioassay publication. 
Reported nuclear receptor interactions are summarised, highlighting potential ligand promiscuity. 
 
Anthropogenic chemicals for in vitro assessment included: 4-Benzylphenol (4-BP); 4-
Nitrophenol (4-NP); Triclosan (TCN); Methylparaben (MP); o,p-
Dichlorophenyldichloroethane (o,p-DDE); Bisphenol A (BPA); Dibutylphthalate 
(DBP); Di-(2-ethylhexyl)phthalate (DEHP); Butylbenzylphthalate (BBP); and, Octyl-4-
Methoxycinnamate (OMC).  
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Table 5.2 Synthetic Xenobiotic Hormones for in vitro Assessment 
Synthetic hormones and hormone analogues utilised in pharmacology identified in the literature review 
and OECD Test Guidelines TG455 proficiency chemical list. PubChemBioassay (Section 4.3.1; Table 
4.1) was used as a hub for mechanistic data; AID identifiers provide a reference to the bioassay 
publication. Reported nuclear receptor interactions are summarised, highlighting potential ligand 
promiscuity. 
 
As detailed previously (Section 5.1.4), the absence of metabolic systems hinders in vitro 
investigation. Yoshihara et al. (2001) demonstrated increased estrogenicity of phthalates 
treated with liver S9 fragments (human, monkey, rat and mouse), suggesting 
metabolites potentially play a significant role in the potency of chemicals. 
Subsequently, 4-Methyl-2,4-bis(4-hydroxyphenyl)pent-1-ene (MBPA), the predominant 
metabolite of BPA (Yoshihara et al., 2004), was also included in vitro. The structure, 
use and published in vitro bioassay data for environmental contaminants and HPV 
industrial chemcials, are shown in Table 5.3 and Table 5.4, respectively.   
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Table 5.3 Environmental Contaminants identified for in vitro Assessment  
Table shows the chemicals that were prioritised for in vitro mechanistic toxicity testing, including 
information on use and current assumed endocrine mechanisms. PubChemBioassay (see Section 4.3.3 & 
Table_A 1) was used as a hub for mechanistic data; AID identifiers provide a reference to the bioassay 
publication.  
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Table 5.4 HPV Industrial Chemicals for in vitro Assessment 
Table shows the High Production Volume (HPV) industrial chemicals prioritised for in vitro mechanistic 
toxicity testing. PubChemBioassay (Section 4.3.1; Table 4.1) was used as a hub for mechanistic data; 
AID identifiers provide a reference to the bioassay publication. Reported nuclear receptor interactions are 
summarised, highlighting potential ligand promiscuity. 
 
5.2.1.2 Test Compound Solutions 
Chemicals were purchased from Sigma-Aldrich Company Ltd. (Dorset) and dissolved 
in Dimethyl sulfoxide (DMSO), to make molar (0.1–1 mol/dm3 = M = mol/m3) stock 
solutions. Molarity was calculated using molecular weight (MW); 1 mole = MW (g) in 
1 L (dm
3
/m
3
). Chemical batch lot#, purity (%) and molar stock solution calculations are 
shown in Table 5.5. Presenting cytotoxicity at high doses, DMSO concentrations were 
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constrained to <0.1% (v/v), which does not interfere with assay performance (OECD, 
2012). Serial 1:10 100% DMSO dilutions of stock solutions (1mM – 0.1pM) were 
produced in 1ml aliquots (100μL TS in 900μL DMSO) and stored at -20ͦC. 
Table 5.5 Test Substance Identifiers and Stock Solution Molarity  
All in vitro test substances were purchased from Sigma-Aldrich Company Ltd., The Old Brickyard, New 
Road Gillingham, Dorset, SP8 4XT (UK). Sigma catalogue, lot and CAS numbers are shown. Purity for 
all test substances was ≥97%. Test substances were solvated in ≥99.9% dimethyl sulfoxide (DMSO) to 
make molar (0.1–1 mol/dm3 = M = mol/m3) stock solutions. Molarity was calculated using molecular 
weight (MW); 1 mole = MW (g) in 1 L (dm
3
/m
3
).  
 
5.2.2 Plasticware and Laboratory Equipment 
The sourcing of plasticware is of particular importance for EDC studies, as many 
plastics contain biphenol and phthalate plasticisers that can leech into cell culture 
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medium. All cell culture vessels (96, 24 and 12 microtitre plates), falcon tubes and 
stripipettes were purchased as sterile single use plasticware; to ensure sterility and 
quality assurance. Additionally, sterilised plasticware offers a cost effective alternative 
to recycling glassware, which would demand validation of cleaning and sterilisation 
procedures. Tissue culture flasks and microtitre plates were TC-treated to provide a 
hydrophilic surface to facilitate attachment of anchorage dependent cells. Plasticware 
consumables and suppliers are detailed in Table 5.6, while the laboratory equipment 
utilised for in vitro experimentation, is detailed in Table 5.7.  
Table 5.6 Technical Apparatus and Plasticware Suppliers 
Table details the suppliers of technical apparatus and plasticware; catalogue numbers are in square 
brackets. All assays were consistently conducted in the same brands, for consistency or error in the event 
of plasticware contamination. 
 
5.2.3 Cell Culture Materials 
The suppliers of the in vitro cell culture material are detailed in Table 5.8. Particular 
care was taken in the selection of fetal bovin serum (FBS), which is a complex mixture 
of albumins, growth factors and growth inhibitors. Susceptible to variation and 
contamination, the EU ECACC guidance on sourcing Zone 1 origin (BSE-free), sterile 
filtered and cell culture-tested FBS, was adhered to. Sigma-Aldrich charcoal-stripped 
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sterile-filtered FBS and Gibco® FBS were used for in vitro testing and cell 
maintenance, respectively. Charcoal-stripped dextran-treated FBS (DCC-FBS) is treated 
to reduce serum hormone concentratons, which may interfere with in vitro assay 
components (i.e. potentiate or synergise observed effects). Regulatory standard DCC-
FBS was used in the STTA reporter gene assays (Table 5.8).  
Table 5.7 Laboratory Equipment Required for in vitro Methods 
Table details the standard laboratory equipment adopted for use during cell maintenance, Presto® Blue 
cell viability assays, transient- and stably- transfected transactivation assays, luciferase assays and MCF-7 
proliferation assays (Appendices: 6.1G.1 MCF-7 GFP Proliferation Assay). 
 
Table 5.8  In vitro Cell Culture and Assay Material Suppliers 
Table details the sourcing and catalogue number of cell culture reagents and assay kits used in the in vitro 
cell culture, maintenance and testing.  
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5.2.4 In vitro Cell Lines and Maintenance 
Aiming to evaluate the currently available in vitro tools for endocrine MoA, an 
objective of testing potential-EDCs (n=20) in HeLa9903 and BG1Luc4E2 cells, 
validated by the OECD for dectection of estrogenicity (TG455), was defined. 
Developed by the Japanese Chemical Evaluation and Research Institute (CERI), the 
hERα-HeLa-9903 cell line is an immortalised cervical cancer cell line, stably 
transfected with hERα and a luciferase construct, bearing 5 tandem repeats of an 
estrogen response element (ERE) driven by a mouse metallothionein (MT) promoter. 
The BG-1Luc4E2 cell line, developed by Michael Denison in collaboration with the US 
NTP ICCVAM and NICEATM, is derived from human adenocarcinoma cells stably 
transfected with plasmid pGudLuc7.ERE, which endogenously express ERα and ERβ. 
Plasmid dGudLuc7.ERE contains a synthetic oligonucleotide (4x) ERE upstream of a 
mouse mammary tumor viral (MMTV) promoter and firefly luciferase gene. Both cell 
lines are appropriate for use in ER transactivation test methods, to identiy ER agonists.  
Excluding the US EPA EDSP rat AR binding assay, which is reliant on rat ventral 
prostate tissue, there are currently no regulatory Test Guidelines to assess androgenicity. 
However, mammalian cell based luciferase reporter assays have been demonstrated to 
show sensitivity (Svovodova & Cajthaml, 2010). Testing AR transactivation in vitro 
was an objective of the current study, thus, an STTA of comparable standard to TG455 
was sought. Deposited by the same research group as the HeLa9903 cell line, HeLa4-11 
cells are stably transfected with a hAR expression construct and a firefly luciferase 
reporter gene under the control of the MMTV promoter. The HeLa4-11 cell line was 
developed to detect androgenic activity and adopted to assess the androgenicity of 
potential-EDCs (n=20).  
In agreement with the literature (Lange et al., 2012; Kojima et al., 2011), HEK293 cells 
housed the evaluation of novel transiently-transfected nuclear receptor reporter gene 
assays. Human embryonic Kidney-293 (HEK293) cells are susceptible to liposomal-
transfection and an appropriate cellular host for in vitro NR reporter gene assays.  
Authenticated cryopreserved HeLa9903 [#11033105] and HeLa4-11 [#11033103] cell 
lines were purchased from Public Health England and the European Collection of Cell 
Cultures (ECACC). ECACC authenticated cryopreserved HEK293 cells [#85120602], 
were purchased from Sigma-Aldrich, the Brick Yard, Dorset (UK). Received as a live 
culture, BG1Luc4E2 cells were obtained from Michael Denison at the University of 
California
52
. 
To maintain the integrity of assay responses, TG55 advises culture in conditioned media 
for at least one passage from frozen stock in cell lines under 40 passages. Experimental 
                                                 
52
 Michael S. Denison, Ph.D. Professor, Dept. of Environmental Toxicology, 4241 Meyer Hall, One 
Shelds Ave, University of California, CA 95616, E: msdenison@ucdavis.edu (530) 754-8649.  
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assays were conducted in cells cultured for at least 3 passages from frozen stock (~1 
week). To avoid cross-contamination of cultures, cell lines were handled separately with 
allocated cell-line specific reagents, airflow cabinets were sterilised with 70% 
Isopropanol and 30-minutes ultraviolet (UV) radiation and gloves were changed, before 
handling a new cell line. Live cell culture maintenance, cryopreservation and 
resuscitation methods, are detailed in Section 5.2.4.1, Section 5.2.4.2 and Section 
5.2.4.3, respectively.  
5.2.4.1 Cell Culture Maintenance Method 
HeLa4-11, HeLa9903, BG1Luc4E2 and HEK293 cells were maintained in Eagle’s 
Minimum Essential Medium (EMEM) without phenol red (due to oestrogenicity), 
supplemented with 60 mg/L of kanamycine antibiotic and 10% Gibco® DCC-FBS 
(Table 5.8) in T25 or T75 culture flasks (Table 5.6) in a 5% CO2 incubator at 37±1ºC 
(Table 5.7). As adherent cell lines, to maintain logarithmic growth, cells were 
subcultured upon reaching 75-90% confluence (splitting 1:4, 1:5 or 1:6). Media was 
discarded into Virkon (2%) and cell monolayers were washed with Gibco® D-PBS 
(without Ca
2+
/Mg
2+
), using volumes equivalent to half the volume of culture medium 
(i.e. ~7.5–10mls). Adherent cell monolayers were detached using the protease enzyme 
trypsin; 1ml trypsin 0.5% EDTA per 25cm
2
 surface area, incubated for 2-10 minutes. 
Cells were examined under the microscope to check for detachment and floating; in 
suspension the morphology of cells change, become spherical masses. Serum-
containing medium was added to inactivate the trypsin and cell suspensions were 
centrifuged at 100xg for 5 minutes to separate and discard trypsin-contaminated media. 
Cells were resuspended in pre-warmed supplemented EMEM and seeded at 2 x 10
4
 
cells/cm
2
 density (cell counting methods are detailed in Section 5.2.5.1). 
5.2.4.2 Cryopreservation Method 
Cryopreservation provides long-term storage of cells, thereby reducing the risk of 
microbial contamination, cross-contamination, genetric drift and morphological 
changes, reducing costs and enabling experimentation at consistent passage numbers. 
The basic principle of successful cryopreservation and resuscitation is slow freeze and 
quick thaw; cooled at a rate of -1ºC to -3ºC per minute and thawed quickly by 
incubation in a 37ºC water bath for 3-5 minutes. HeLa4-11, HeLa9903, BG1Luc4E2 
and HEK293 log phase cell cultures of >90% viability (2 x 10
6
 – 4 x 106 cells/ml) were 
suspended in 90% FBS and 10% DMSO cryoprotectant, to protects cells from ice-
crystal rupture. 1ml aliquots were pipetted into cryoprotective ampoules (cryovials) and 
slowly frozen (i.e. -20ºC to -80ºC to -150ºC freezers over 3 days). 
5.2.4.3 Method of Cell Line Resuscitation from Frozen Stock 
Frozen ampoules were swabbed with 70% isopropanol, defrosted in a 37ºC water bath 
and wiped again with 70% isopropanol prior to opening.  Ampoule contents were 
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pipetted into sterile falcon tubes (15 or 50 ml) and suspended in media. Suspensions 
were centrifuged at 100xg for 5 minutes to separate and discard DMSO-contaminated 
media. Cells were resuspended in pre-warmed supplemented EMEM and seeded at 2 x 
10
4
 cells/cm
2
 density.   
5.2.5 Cell Viability and Cytoxicity Methods 
The presence of increasing levels of cytotoxicity can significantly alter or eliminate NR 
agonism sigmoidal concentration-response curves. Cells should present 80% viability; 
test substance concentrations that reduce cell number by >20%, should be regarded as 
cytotoxic and excluded from in vitro assessment. Confluency can be used as a general 
measure of cell growth, while a Hemocytometer can be used to count cells; however, 
both present subjectivity and lack precision. In this study, cell numbers were calculated 
using Invitrogen’s Countess® Cell Counter (Section 5.2.5.1) and 80% cell viability was 
assessed in Invitrogen’s PrestoBlue® assays (Section 5.2.5.2).  
5.2.5.1 Invitrogen Countess® Cell Counter 
Cells were counted using the Invitrogen Countess Slide system (Table 5.7 & Table 5.6); 
10μl of suspended cells were added to 10μl of Trypan blue in a 1.5ml sterile ampoule. 
10μl of the stained cell mixture was pipetted into a glass channel and measured using 
the Countess® Counter machine, which calculates cell number and viability on the basis 
of trypan-blue staining. Seeding density varies with cell line, however, throughout this study 
1.5 x 10
6
 cells per T75 flask (20mls of 7.5 x 10
4
 cells/ml) was kept as standard for cell 
maintenance. Cell concentrations were calculated using the following equation:  
Cell Concentration (cells/ml) x Volume (mls)   - current volume = Volume of media to add.  
        Desired Concentration (cells/ml) 
5.2.5.2 Invitrogen PrestoBlue® Cell Viability Assay 
PrestoBlue™ Cell Viability Reagent is a ready-to-use reagent for rapidly evaluating the 
viability and proliferation of a wide range of cell types. PrestoBlue™ reagent is quickly 
reduced by metabolically active cells, providing a quantitative measure of viability and 
cytotoxicity. When cells are viable, they maintain a reducing environment within their 
cytosol. PrestoBlue® reagent is a resazurin-based solution that functions as an indicator 
of cell viability, by measuring resazurin reduction, as a quantitative measure of cell 
proliferation. The cell-permeant non-fluorescent PrestoBlue® reagent is converted to 
resorufin, by the reducing environment of the viable cells. Turning red and highly 
fluorescent, the reduction of resazurin to resorufin can be detected by measuring 
fluorescence. Conversion is proportional to the number of metabolically active cells and 
thus can be measured quantitatively. PrestoBlue® cell viability reagent has been 
demonstrated to significantly outperform other resazurin-based assays, including MTT 
and CellTiter-Glo® assays (Gloeckner et al., 2001; Squatrito et al., 1995)  
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Cytotoxicity can significantly alter or eliminate NR ligand-dependent transactivation, 
thus assurances of 80% cell viability were run in conjunction with STTA assays. Cells 
were suspended in 10% DCC-FBS-EMEM at a concentration of 1 x 10
5
 cell/ml, 
dispensing  1 x 10
4
 cells/100μL volume per well, with a multichannel pipette into 
Costar™ Clear 96-well microtitre plates (Table 5.6 & Table 5.7). Testing culture 
medium was not supplemented with antibiotics (Kanamycin sulphate, G418 and/or 
Blasticidin-HCl), due to assay interference. Cells were allowed to attach, in a 5% CO2 
incubator at 37±1ºC, for 3 or 12 hours prior to chemical exposure, for HeLa4-11 and 
HeLa9903 cells, respectively. On adherence, 100 μL of 37±1ºC 10% DCC-FBS-EMEM 
testing medium was added to each well (Ʃvolume = 200μL), in addition to 0.2μL 
(200nL) of serially-diluted molar solutions of test substances in 100% DMSO (Table 
5.5). Avoiding the need for diluents, final concentrations were achieved via dilution
; 
for 
example, 0.2μL of 1x10-2 molar (10mM) stock solution was added to 200μL of culture 
medium, to produce a final concentration of 1x10
-5
 molar (10μM). The plate layouts of 
in vitro PrestoBlue® cell viability assays are detailed in 6.1Appendix G, which included 
no-cell and cell-only assay controls. Subsequent to 24-hour exposure 22μL PrestoBlue® 
reagent was added to each well and incubated at 37±1ºC for an additional 45 minutes 
(~1hour). Reduction of resazurin was measured by top-read 200ms fluorescence at 
535nm excitation and 615nm emission (12nm bandwidth), in the Varioskan plate-reader 
automatic dynamic range setting (Table 5.7).  
Results were normalised by subtracting the fluorescence of a no-cell MEM control and 
adjusted by dividing by the fluorescence of cells exposed to the DMSO vehicle control; 
to generate percentage cell viability relative to unexposed cell controls, results were 
multiplied by 100. Results were analysed using GraphPad Prism® Log(inhibition) vs. 
Response (three parameters) function, graphs show the % cell viability, measured by the 
reduction of the PrestoBlue™ resazurin-based solution by metabolically active cells, 
producing a quantifiable fluorescence. 
5.2.6 Stably-Transfected Transactivation Assay (STTA) Method 
As a performance-based test guideline (PBTG), TG455 details the methodology of in 
vitro transactivation assays and in particular, to detect ERα (HeLa9903) or ERα/β 
(BG1Luc4E2) agonists. Validation studies of STTA and BG1Luc TA demonstrated 
relevance and reliability in detecting estrogenic responses (ICCVAM, 2011; Rogers & 
Denison, 2000); ER transactivation results of 34 chemicals, in HeLa9903 and 
BG1Luc4E2 cell line methods, were in 100% agreement. Comprising several 
mechanistically and functionally similar test methods, the PBTG facilitates the 
development of new test methods in accordance with the validated principles.   Thus, all 
in vitro TA assays were conducted in concordance with the principles defined in 
TG455; however, all method variations are detailed herein.  
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In agreement with TG455, all cells for in vitro experimentation were obtained from 1-
week old cultures (Section5.2.4.1), conditioned in hormone-stripped media (Sigma 
DCC-FBS) without phenol-red for 1-2 passages, which has been shown to increase the 
sensitivity of NR reporter gene assays (ICCVAM, 2011). Cells were suspended in 10% 
DCC-FBS-EMEM at a concentration of 1 x 10
5
 cell/ml, dispensing  1 x 10
4
 cells/100μL 
volume per 96-well of Costar™ Black Clear-bottom microtitre plates (Table 5.6 & 
Table 5.7). Testing culture medium was not supplemented with antibiotics (Kanamycin 
sulphate, G418 and/or Blasticidin-HCl), due to potential assay interference. Cells were 
allowed to attach in a 5% CO2 incubator at 37±1ºC, however, evaluation under light-
microscope showed HeLa9903 and BG1Luc4E2 cells did not attach within 3 hours. 
Therefore, deviating from TG455, HeLa9903 and BG1Luc4E2 cell lines were allowed 
to attach for 12 hours prior to chemical exposure. Cell concentration and plating were 
kept constant, however the method of chemical exposure varied with ER agonism 
(Section 5.2.6.1), AR agonism (Section 5.2.6.2) or AR antagonism (Section 5.2.6.3) 
mechanisms. 
5.2.6.1 STTA Method for ER Agonism 
TG455 suggests dilution of 1.5μL of test chemical in the 100% DMSO solvent (Table 
5.5) with 500μL of DCC-FBS-EMEM media to create a diluent, 50 μL of which is 
added to each assay well (n=3) to create a final volume of 150μL per well. The volume 
cap is required for Promega Steady-Glo® Luciferase Assays, which measure the 
conversion of luciferin to oxyluciferin in the presence of media components (150μL 
media to 150μL luciferase reagent total volume 300μL). However, opting for 
standard luciferase assays (Promega E1500, Table 5.8), the cell medium is removed 
prior to cell lysis and luciferase measurement (Section 5.2.8); thus, a larger final volume 
of 200μL was adopted herein.  On cell adherence, 100 μL of 10% DCC-FBS-EMEM 
testing medium was added to each of the plated 96-wells. Within the standard error of 
the F1 0.2-2μL Finnpipette (Table 5.6), 0.2μL of serially-diluted test substances (Table 
5.5) were added to each well; achieving a final concentration 1000
th
 of the starting 
stock.  
In the presence of intraplate variation, the method was upscaled, to minimise error. In 
which case, HeLa9903 cells from a 1-week old culture suspended in 10% DCC-FBS-
EMEM at a concentration of 1x10
5
 cell/ml and plated in 1000μL (1ml) volumes  per 24-
microtitre plate well (Table 5.6). Cells were allowed to attach for 12 hours prior to 
chemical exposure. Test substances were pipetted into each well in 1μL volumes; e.g. 
1μL of 1x10-3 M 100% DMSO stock solution in 1mL cell media produces a final 
concentration of 1x10
-6
 M at 0.1% DMSO. 
The plate layouts of in vitro ER Agonism transactivation assays (HeLa9903 and 
BG1Luc4E2) are detailed in Appendix H. Evapouration of outer 96-wells was observed, 
thus all assays were conducted in wells B-G, 2-11. Each 96-plate included 1nM E2 
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positive controls (n=12) and DMSO vehicle controls (n=6), which were plated 
strategically to monitor plate reader-effects. Three replicates of 7 test substance 
concentrations (range: 1mM, 100μM, 10μM, 1μM, 100nM, 10nM, 1nM, 100pM and 
10pM (10
-3–10-11 molar)) enabled evaluation of 2 test substances per plate. All 96-wells 
presented final DMSO concentrations of 0.1%. The plate layout varied from TG455, 
which evaluated 3 test substances per plate, using outside wells and with fewer positive 
controls.  
Cells were exposed to test substances for 40 hours, rather than the 20-24 hours 
recommended by the OECD, to increase assay sensitivity; 1nM E2 failed to consistently 
drive luciferase induction after 20-24 hours, possibly as a result of slight variations in 
media components. Subsequent to 40hr exposure test media was removed from each 
microtitre plate, via pipetting and inversion. The monolayers of exposed cells were 
washed with D-PBS (~100μL/well) and lysed with 20μL/well Promega 1x Reporter 
Lysis Buffer (Table 5.8). In accordance with RLB manufacturers’ instructions a freeze-
thaw cycle (-40 ͦC for 24 hours) was adopted to ensure cell lysis. Defrosted microtitre 
plates were calibrated to room temperature on a 3D-rocking platform (Table 5.7), and 
measured in a luciferase assay (Section 5.2.8).   
5.2.6.2 STTA Method for AR Agonism 
The HeLa4-11 stably-transfected AR transactivation assays were conducted as for 
HeLa9903 and BG1Luc4E2 (Section 5.2.6.1), with slight methodological variations to 
account for differences in cell growth and mechanism. Cells were suspended in 10% 
DCC-FBS-EMEM and plated at 1 x 10
4
 cells/100μL per 96-well, of Costar™ Black 
Clear-bottom microtitre plates (Table 5.6 & Table 5.7). Cells were alowed to attach for 
3 hours prior to the addition of 100 μL of 10% DCC-FBS-EMEM and 0.2μL of test 
substances in 100% DMSO (Table 5.5) to each well and incubated at 5% CO2 at 
37±1ºC. The plate layouts of in vitro AR Agonism transactivation assays (HeLa4-11) 
are detailed in Appendix H; all assays were conducted in wells B-G numbers 2-11. Each 
96-plate included 1nM Testosterone positive controls (n=12), DMSO vehicle controls 
(n=6) and 3 replicates of 7 concentrations. Full responses were observed following 20-
24 hour chemical exposure. Media was removed post-exposure and monolayers of 
exposed cells were washed with D-PBS (~100μL/well) and lysed with 20μL/well 
Promega 1x Reporter Lysis Buffer (Table 5.8). In accordance with RLB manufacturers’ 
instructions a freeze-thaw cycle (-40 ͦC for 24 hours) was adopted to ensure cell lysis. 
Defrosted microtitre plates were calibrated to room temperature on a 3D-rocking 
platform (Table 5.7) and measured in a luciferase assay (Section 5.2.8).   
5.2.6.3 STTA Method for AR Antagonism 
To modify the STTA method to detect antagonism rather than agonism, the method 
detailed in 5.2.6.2 was modified. Cells were suspended in 10% DCC-FBS-EMEM and 
plated at 1 x 10
4
 cells/100μL per 96-well, in Costar™ Black Clear-bottom microtitre 
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plates (Table 5.6 & Table 5.7). Cells were alowed to attach for 3 hours prior to the 
addition of 100 μL of 10% DCC-FBS-EMEM supplemented with 1nM testosterone and 
0.2μL of test substance in 100% DMSO (Table 5.5) to each well. The plate layouts of in 
vitro AR Antagonism transactivation assays are detailed in Appendix H. Each 96-plate 
included 1nM Testosterone positive controls (n=6), 10μM Flutamide antagonist controls 
(n=6), DMSO vehicle controls (n=6) and 3 replicates of 7 concentrations. Assay plates 
were incubated at 5% CO2 at 37±1ºC. Full responses were observed after 20-24 hour 
chemical exposure. Media was removed, monolayers of exposed cells were washed with 
D-PBS (~100μL/well) and lysed with 20μL/well Promega 1xRLB (Table 5.8). In 
accordance with Promega’s RLB instructions, a freeze-thaw cycle (-40 ͦC for 24 hours) 
was adopted to ensure efficient cell lysis. Defrosted microtitre plates were calibrated to 
room temperature on a 3D-rocking platform (Table 5.7) and measured in a luciferase 
assay (Section 5.2.8).   
5.2.7 Transient-Transfection Transactivation Assay (TTTA) Method 
Aiming to explore the current in vitro tools for endocrine MoA, the evaluation of 
transient transfection technologies for novel reporter gene assays was an objective. 
Transfection is the transfer of nucleic acids to cells via artificial, non-viral methods. 
Including the transfer of plasmid DNA, oligonucleotides, yeast artificial chromosomes 
and RNA, transfection technologies are routinely used in the study of cellular 
metabolism, transcriptional control and protein function. Transient transfection refers to 
the temporality of nucleic acid expression; constructs have not been incorporated into 
host machinery and will not be expressed in subsequent generations. Reporter gene 
assays are typically conducted in transiently transfected cell lines, due to limited scope 
and sensitivity of stably-transfected cell lines (Lange et al. 2012; Kojima et al., 2011; 
Katsu et al., 2010, 2007). However, the validation of transient transfection methods has 
been hindered by vast variability, leading to a lack of standardisation.  
Prior to the development of polyplex transfection reagents and synthetic cationic 
liposomes, such as 1,2- dioleoyloxypropyl-3-trimethyl ammonium bromide (DOTMA) 
(Felgner et al., 1987), diethylaminoethyldextra (DEAE-dextran), calcium phosphate 
precipitation and RNA/DNA virus vectors were the only methods of mammalian cell 
nucleic acids transfer (Schenborn, 2000; Graham et al., 1973; Vaheri & Pagano, 1965). 
Demonstrated to be an effective transfection reagent (Lange et al., 2012), FuGENE® 
HD is a novel, nonliposomal formulation, designed to transfect DNA into a wide variety 
of cell lines, with high efficiency and low toxicity. FuGENE®HD does not require 
washing or culture medium changing, after introduction of the reagent/DNA complex. 
For adherent cell lines Promega FuGENE®HD instructions recommend testing 100ng 
of DNA per well in a 96-well plate format.  Increasing the amount of DNA does not 
necessarily result in higher transfection efficiencies, and a FuGENE® HD Transfection 
Reagent: DNA ratio of 3:1 or 2.5:1, are recommended.  
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In concordance with research conducted at the Japanese NINS National Institute of 
Basic Biology (NIBB) (Oka et al., 2012; Katsu et al., 2007), a novel transiently-
transfected roach (Rutilus rutilus) ERα and ARβ reporter assay was piloted herein, as 
ecological in vitro mechanistic study, relevant to UK sentinel species. Cloned R. rutilus 
ERα and ARβ DNA constructs, in pcDNA3.1 expression vectors (pcDNA3.1-
RoachERα and pcDNA3.1-RoachARβ, respectively), were received as a gift from 
Taisen Iguchi’s group at the NIBB Okazaki, Japan. FuGENE® HD transfection 
methods for roachERα and roachARβ are detailed in Sections 5.2.7.1 and 5.2.7.2, 
respectively. 
5.2.7.1 Roach ERα Transactivation Assay 
HEK293 cells from a 1 week old live culture, were seeded into 24-well plates at 5 x 10
4
 
cells per well in 900μL Dulbeco’s Modified Eagles Medium (DMEM) (Sigma D2902) 
supplemented with 10% DCC-FBS (HyClone SH30068.03). Twenty-four hours later, 
cells were transfected with the cloned R. rutilus ERα DNA construct (pcDNA3.1-
RoachERα); FuGENE® HD transfection reagent diluted in DCC-FBS DMEM (1.8μL 
FuGENE in 95.2 μL DCC-FBS DMEM) and supplemented with 1μL of pcDNA3.1-
RoachERα (0.2 μg/μL), 1μL 4xERE-tκLuc (0.4 μg/L) and 1μL pRL-TK (0.1 μg/L), was 
added to the wells of a 24-microtitre plate and incubated for 5 hours. pRL-TK contains 
the Renilla reniformis luciferase gene, with the herpes simplex virus thymidine kinase 
promoter, and was used to normalise reporter gene (firefly luciferase) results for 
transfection efficiency. Subsequent to transfection, cells were exposed to test substances 
for 48 hours; E2 (0.1pM - 100nM E2), DES (0.1pM – 100nM DES), DBP (10pM – 
1μM DBP), DEHP (0.1pM - 1 μM DEHP), BPA (0.1pM - 10 μM BPA) or 4-
benzylphenol (0.1pM - 10 μM 4-BP) in a DMSO vehicle. All chemical exposures were 
tested in triplicate. Fourty-eight hours post exposure, medium was removed from each 
well and cells were washed with Dulbeco’s Phosphate Buffered Saline (DPBS) 
(Gibco®) and 100μL of reporter lysis buffer (RLB) (1 volume of Promega 5x RLB 
diluted in 4 volumes distilled water) was added to each well shook for 15 minutes to 
enable cell lysis, cell lysates were then frozen. Roach ERα transactivation was measured 
in a dual luciferase assay (Firefly and Renilla).  
5.2.7.2 Roach ARβ Transactivation Assay 
On separate occasions, Human hepatocellular carcinoma (HepG2) cells (ATCC® HB-
8065™)  and HEK293 cells from a 1 week old live culture, were seeded into 24-well 
plates at 5 x 10
4
 cells per well in 900μL Dulbeco’s Modified Eagles Medium (DMEM) 
(Sigma D2902) with 10% DCC-FBS (HyClone SH30068.03). Twenty-four hours later, 
cells were transfected with cloned R. rutilus ARβ DNA construct (pcDNA3.1-
RoachARβ). FuGENE® HD transfection reagent diluted in DCC-FBS DMEM (1.8μL 
FuGENE in 95.2 μL DCC-FBS DMEM) was supplemented with 1μL of pcDNA3.1-
RoachARβ (0.2 μg/μL), 1μL 4xARE-tκLuc (0.4 μg/L) and 1μL pRL-TK (0.1 μg/L), 
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added to each well, swirled and incubated for 5 hours. Subsequent to transfection, cells 
were exposed to test substances (0.1pM - 1 μM molar) for 48 hours; 11-
Ketotestosterone (11-KT), 17α-Methyltestosterone (17-MT), Testosterone (T) and 
Dihydrotestosterone (DHT) in 100% DMSO vehicle were tested in triplicate. Fourty-
eight hours post exposure, media was removed and the cells were washed with D-PBS 
and lysed with 100μL Promega 1xRLB, and cell lysates were frozen. Roach ARβ 
transactivation was measured in a dual luciferase (Firefly and Renilla) assay 48 hours 
later.  
5.2.8 Luciferase Assay Method 
Firefly luciferase is a widely used reporter due to high sensitivity and low background 
chemiluminescence (Wood, 1990). Light is produced by the oxidation of luciferin via 
firefly luciferase catalysis of electron transition, to form oxyluciferin. Promega 
Luciferase Assay System (E1500) incorporates coenzyme A for improved kinetics and 
light stability (Wood, 1991). Luciferase assays are used to identify chemicals that 
activate the ER or AR, which initiates the binding to specific DNA response elements 
(i.e. ERE) and transactivates the luciferase reporter gene, resulting in increased cellular 
expression. Luciferase activity was measured by adding 100μL of lyophilised 
Luciferase Assay Reagent to each 96-well, containing 20μL of defrosted cell lysate 
equilibrated to room temperature. Plates were read immediately in the Varioskan plate 
reader with automatic dynamic range and 500ms measurement time (Table 5.7).  
5.2.9 Dual Luciferase Assay Method 
Conducted at the NIBB (Japan), Promega Dual-Luciferase ® Reporter Assay (E1960) 
reagents were prepared as per the manufacturers’ instructions; firefly luciferase assay 
reagent (LARII) was made by resuspending lyophilised Luciferase Assay Substrate in 
Luciferase Assay Buffer II, while the Renilla luciferase Stop & Glo® reagent was 
resuscitated by adding Stop and Glo® Buffer to Stop and Glo® Substrate. For the assay, 
20μL volumes of cell lysate were transferred to 96-well Costar™ Black Clear-bottom 
microtitre plates. Chemiluminescence was measured in a Promgea GloMax®- Multi 
Microplate Multimode Reader with dual injectors set to dispense 100μl of LARII and 
Stop & Glo® Reagent, measurements were read at a 2 second delay and 10 second read 
time. 
Duplicate experiments, conducted in the Cranfield laboratories were measured 
manually, in the Varioskan machine (without injectors). Firefly luciferase activity was 
measured on the addition of 100μl of LARII, to each 96-well containing 20μL cell 
lysate. Stop & Glo® Reagent (100μL) was subsequently added to each well and the 
relative light units measured, as a control for transfection efficiency.  
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5.2.10 Statistical Analysis 
The OECD suggests that in vitro transactivation results should be based 2-3 
independent runs (i.e. day repeats) of comparable and therefore reproducible results. 
Acceptability criteria for ER STTA (HeLa9903 and BG1Luc4E2) suggest mean relative 
light units (RLU) of 1nM E2 should be at least 4-fold the mean RLU of VC. For a result 
to be considered positive, the RPCmax
53
 must exceed 10% of 1nM E2 in at least 2/3 runs, 
while TG455 stipulates at least 20% of the 1nM E2 maximal response, for positive 
classification. Data outliers of the E2 reference standard were identified on the basis of 
RLU ±20% of those in the historical database. All assay plates were quality checked via 
evaluation of positive and negative control adherence to OECD principles.  
As a novel stably transfected tool, without regulatory guidance, additional statistical 
quality checks were undertaken for HeLa4-11 AR agonism and antagonism 
transactivation assays. Z’prime, or Z’factor, is a measure of statistical effect size, 
adopted in high-throughput screening to assess the significance of an assay. The 
Z’prime is defined by the means (μ) and standard deviations (σ) of positive (p) and 
negative (n) controls: 
𝑍′𝑃𝑟𝑖𝑚𝑒 = 1 − [
3(𝜎𝑝 +  𝜎𝑛)
𝜇𝑝 −  𝜇𝑛
] 
Z’prime scores of 1 are ideal, Z’ between 0.5 to 1 can be interpreted as an excellent 
assay; if σp = σn, a Z’ of 0.5 is equivalent to a 12 standard deviation separation between 
mean positive and negative controls. Z’primes between 0 and 5 can be considered 
marginal, less than zero signifies significant overlap between positive and negative 
controls, limiting the use of the assay. The small margin between maximal responses 
and vehicle controls (4-fold) in ER STTA hinders the applicability of Z’prime statistics, 
which as a stringent statistical tool requires 99% of values to occur within 3 standard 
deviations of the mean (i.e. small margin for error). In the event of large error, 
experimentation was up-scaled to 24-well plates. The data-specifics of statistical 
analyses for cell viability and transactivation assays are detailed in Section 5.2.10.1 and 
5.2.10.2, respectively.  
5.2.10.1 Cell Viability:  
The % cell viability was calculated by measuring the fluorescence of PrestoBlue™ 
resazurin-based-solution reduction by metabolically active cells. The mean fluorescent 
relative light units (RLU) of no-cell MEM control and VC-control were calculated. 
Results were normalised by subtracting the fluorescence of a no-cell MEM control and 
adjusted by dividing by the fluorescence of cells exposed to the DMSO vehicle control; 
to generate percentage cell viability relative to unexposed cell controls, results were 
                                                 
53
 The RPCmax is the maximum level of response induced by a test chemical, expressed as a percentage of 
1nM E2.  
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multiplied by 100. Graphs were drawn using GraphPad Prism® Log(inhibition) vs. 
Response (three parameters) function. 
5.2.10.2 Transactivation Assays 
The mean relative light units (RLU) of vehicle controls and positive controls were 
calculated. STTA results were normalised by subtracting vehicle control (DMSO) RLU 
and adjusted by dividing by the RLU of 1nM positive control (E2 or T maximum 
response). Thus, the final value of each well is the relative transcriptional activity for 
that well compared to the PC response. Data were presented as mean and standard error 
of the mean (SEM) of n=3 replicates of day repeat data. Data distribution was presented 
by the Standard Deviation (SD) or data range (scatter plot). Best fit values were 
calculated using GraphPad Prism® Log(agonist) vs. response – variable slope (four 
parameters) and used to calculate the LogEC50 and EC50 with 95% Confidence Intervals 
(95% CI). A dotted line at 20% normalised RLU of 1nM PC (y=0.2), highlighted the 
threshold for categorising positive, negative and/or inadequate data.   
5.3 In vitro Results and Discussion 
This section presents the results of in vitro testing of the test substances identified in 
Section 5.2.1 (Table 5.1; Table 5.2; Table 5.3; and Table 5.4), in standardised 
mechanistic assays. Stably transfected ER and AR transcriptional activation assays and 
novel transiently transfected R. rutilus (roach) ER and AR reporter gene assay results, 
are detailed herein. The in vitro methods adopted provide mechanistic and potency 
information for EDC hazard characterisation. 
5.3.1 Cell Viability and Cytotoxicity  
Cytotoxicity can significantly alter or eliminate NR agonism sigmoidal concentration-
response curves. Thus, cells should present at least 80% viability in STTA and TTTA 
methods. Test substance concentrations that reduced cell viability by >20% were 
regarded as cytotoxic. To ensure the validity of in vitro transactivation assays, 
PrestoBlue® viability assays were run in parallel. The cell viability detailed herein 
provides assurance of the STTA concentration ranges.  
Figure 5.1 shows the % cell viability of cells exposed to potential-EDC agonists, 
quantified by fluorescence emitted on reduction of PrestoBlue™ resazurin-based 
solution by metabolically active cells. Green plots show the cell viability of HeLa4-11 
cells, while red plots present HeLa9903 cell viability. The shaded region between 100-
80% cell viability shows the threshold for normal variation.  
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Figure 5.1 Assessment of Test Substance Cytotoxicity in HeLa4-11 and HeLa9903 Cells 
with PrestoBlue® Cell Viability Assay 
Drawn using GraphPad Prism® Log(inhibition) vs. Response (three parameters) line drawing function, 
graphs show the % cell viability, measured by the reduction of the PrestoBlue™ resazurin-based solution 
by metabolically active cells, producing a quantifiable fluorescence. Results were normalised by 
subtracting the fluorescence of a no-cell MEM control and adjusted by dividing by the fluorescence of 
cells exposed to the vehicle control (DMSO). To generate percentage cell viability, relative to the 
unexposed cell controls, results were then multiplied by 100. All assays were conducted in 96-well plates 
at 1x10
4
 cells per well in 200μL supplemented MEM (10% DCC-FBS, 2mM L-glutamine). Test 
substances were administed in 0.2μL measurements in 100% DMSO ~ all DMSO vehicle concentrations 
0.1%. Green plots show the cell viability of HeLa4-11 cells, while red plots present observed HeLa9903 
cell viability. The shaded region between 100-80% cell viability shows the threshold for normal variation. 
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Figure 5.2 Cytotoxicity of Coexposure to Test Substance and 1fM Testosterone in HeLa4-
11 Cells Measured with PrestoBlue® Cell Viability Assay 
Drawn using GraphPad Prism® Log(inhibition) vs. Response (three parameters) function, graphs show 
the % cell viability, measured by the reduction of the PrestoBlue™ resazurin-based solution by 
metabolically active cells, producing a quantifiable fluorescence. Results were normalised by subtracting 
the fluorescence of a no-cell MEM control and adjusted by dividing by the fluorescence of cells exposed 
to the vehicle control (DMSO). To generate percentage cell viability, relative to the unexposed cell 
controls, results were then multiplied by 100. All assays were conducted in 96-well plates at 1x10
4
 cells 
per well in 100μL supplemented MEM (10% DCC-FBS, 2mM L-glutamine). Testosterone and Test 
substances were administed 100μL 2fM diluent and 0.2μL measurements in 100% DMSO, respectively. 
All DMSO concentrations were 0.1%. The shaded region between 100-80% cell viability shows the 
threshold for normal variation. 
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Table 5.9 HeLa9903 and HeLa4-11 Cell Line Maximum Non-cytotoxic Test Substance 
Concentrations Identified in PrestoBlue® Cell Viability Assays 
Table shows the test substance (TS) concentrations shown to present at >80% viability in PrestoBlue® 
Assays. Results for single exposure in HeLa9903 and HeLa4-11 are presented in columns 2 and 3, in 
addition to coexposure of TS with 1fM of testosterone in column 4 (reflective of antagonistic assays). 
Excluding 17β-Estradiol (E2 semi-log) all exposures were in 1:10 logarithmic scales. For many TS, cell 
viability % did not reduce beyond 80% at the concentrations tested: Methylparaben, 
Butylbenzylphthalate, Diethylhexylphthalate, Dibutylphthalate, 19-Norethrindrone, Flutamide, 
Dihydrotestosterone and Octylmethoxycinnamate. HeLa9903 cell PrestoBlue® assays were tested at the 
STTA dose range, none of which presented cytotoxicity. The maximum concentrations tested by 
ECVAM, XDS and Hyoshi laboratories are presented in column 5.  
 
The maximum test substance concentrations that maintained 80% HeLa4-11 and 
HeLa9903 cell viability are detailed in Table 5.9, with reference to the maximum tested 
concentrations in STTA conducted by ECVAM, XDS and/or Hiyoshi laboratories 
(ICCVAM, 2011). Cell viability and cytotoxicity thresholds were used as a reference 
point for the transactivation assays, detailed in subsequent sections. Assuming 
concentration addition, elevated cytotoxicity in HeLa4-11 cells exposed to test 
substances in conjunction with 1fM Testosterone, was unlikely. However, to ensure the 
cell viability of AR antagonism transactivation assays, Figure 5.2 shows the 
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PrestoBlue® cell viability assays for coexposure; which are also summarised in Table 
5.9. Interestingly, coexposure of phthalates (DBP, DEHP and BBP) and 1fM 
testosterone does not induce cytotoxicity at high concentrations (1mM to 10μM), but 
increased cell viability. As detailed previously, PrestoBlue® assays measure 
fluorescence emitted consequent to the reduction of resazurin-based compounds, 
indicative of cellular metabolism. Thus, the increase in assumed % cell viability is in 
fact increased metabolism.  
Table 5.9 shows that the maximum concentrations tested by ECVAM, XDS and 
Hiyoshi laboratories, which reflected test substance solubility, rather than cell viability 
and exceeded the point of departure (POD) for cytotoxicity identified in this study. 
Results generated at cytotoxic concentrations should be evaluated with caution; due to 
possible generation of false negatives and false positives due to altered cellular 
metabolism. The POD detailed in Table 5.9, reflects the concentration ranges which do 
not affect cellular metabolism. However, the plots (Figure 5.1 and Figure 5.2) highlight 
the ‘Hill slope’ or gradient of the response, which is reflective of the rate of 
cytotoxicity; i.e. whether cell viability decreased rapidly or gradually with increasing 
concentration. BPA, 4’4-DDE and 4-Nitrophenol demonstrated POD’s for cytotoxicity 
at 1x10
-5
 Molar (Figure 5.2). However, at 1x10
-4
 M, the metabolic reduction of 
Resazurin pigments reflective of cell viability, reduced to 20%, 60% and 80%, 
respectively. The addition of 1fM testosterone did not appear to affect the cellular 
metabolism of HeLa4-11 cells (Table 5.9); agonism and antagonism cell viability (%) 
assays were in agreement. However, coexposure appeared to alleviated the cytotoxicity 
of E2, Methylparaben and 4-Benzylphenol, which all retained >80% cell viability at 
higher doses than on single exposure.  
5.3.2 HeLa9903 ERα Agonism STTA  
Adopted by the OECD, Test Guideline 455 defines STTA experimental method, to 
identify chemicals that induce in vitro transactivation of ERα and ERα/β elements, in 
HeLa9903 and BG1Luc cells, respectively.  With the aim of evaluating currently 
available in vitro tools for endocrine MoA, the objective of testing potential-EDCs 
(n=20) in HeLa9903 ERα transactivation assays was defined, the results of which are 
detailed herein.  
HeLa9903 cells from a 1-week old culture suspended in 10% DCC-FBS-EMEM at a 
concentration of 1x10
5
 cell/ml were plated in 100μL or 1000μL volumes, for 96-well 
and 24-well microtitre plates, respectively. Cells were allowed to attach for 12 hours 
prior to chemical exposure. Test substances were administered to 96-well assays in 100 
μL of 10% DCC-FBS-EMEM with 0.2μL of test substances in 100% DMSO. In 24-well 
plates, 1μL volumes of test substances (100% DMSO) were added to each well. 
HeLa9903 cells were exposed to test substances for 40-48 hours, at which point cells 
were terminated and prepared for luciferase assays (Section 5.2.6.1 and 5.2.8).  
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Figure 5.3 Estrogen Receptor-α (ERα) Transactivation in HeLa9903 Cells Exposed to 17β-
Estradiol (E2) 
Graphs show the adjusted and normalised relative light units (RLU) emitted in luciferase assays 
consequent 40-48hr 17β-Estradiol (E2) exposure. Results were normalised by subtracting vehicle control 
(DMSO) RLU and adjusted by dividing by the RLU of 1nM E2 (maximal agonistic response). Cell 
concentration was 1x10
4
/well in 96-well (200μL) and 1x105/well in 24-well (1000μL); E2 was solvated in 
100% DMSO and administered in 0.2μL and 1μL volumes, respectively. Molar concentrations were made 
by serial dilutions (log and semi-log). The top graph plots the mean and standard error of the mean (SEM) 
of the day repeat (n=4) data presented underneath as a scatter plot (showing range). Best fit values were 
calculated using GraphPad Prism® Log(agonist) vs. response – variable slope (four parameters) and were 
used to calculate the LogEC50 and EC50 with 95% Confidence Intervals (95% CI) presented in red font. 
Mean E2 agonism values: bottom -0.0555 (95% CI -0.153 to 0.0418) and top 1.083 (95% CI 1.025 to 
1.141); Hill Slope 1.077 (95% CI 0.674 to 1.481); and R square = 0.80 (n=158). The dotted line (y=0.2) 
highlights 20% 1nM E2 normalised RLU, as a threshold for categorising positive, negative and/or 
inadequate data.  
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Assays were ‘upscaled’ in the presence of intraplate variation, to minimise error. 
Throughout Section 5.3.2, data replicates are colour coded according to assay microtitre 
plate format; highlighting slight differences in method. Chemilluminscence 
measurements obtained in luciferase assays were normalised by subtracting DMSO 
vehicle control RLU and adjusted by dividing by the RLU of 1nM E2 (maximal 
agonistic response). 
Figure 5.3 shows the in vitro ERα transactivation in HeLa9903 cells exposed to semi-
log concentrations of E2 (0.1pM - 1μM). Calculated from the mean and SEM of 4 day 
repeats (n=158), the E2 LogEC50 and EC50 (95% Confidence Intervals) were, -10.20 M 
(95% CI -10.27 to -10.02) and 6.377e-11 M (95% CI 4.295e-11 to 9.476e-11), 
respectively (R
2
=0.80). The Hill slope (gradient) of the plotted data was 1.077 (95% CI 
0.7 to 1.5). The Hill slope quantifies the steepness of the curve; a standard slope has a 
Hill slope of 1.0, a steeper curve is higher (1.5), while a shallow curve has a lower value 
(0.5). Thus, the E2 dose-response observed followed a standard sigmoidal curve, 
reflective of the law of mass action (each E2 binds to a single ER).  
The US EDSP OPPTS 890.1300 and OECD TG455 define regulatory performance 
criteria for E2 agonistic responses in HeLa9903 transactivation assays. The E2 
responses demonstrated herein are in agreement with EDSP and OECD standards; 
LogEC50 between -11.3 to -10.1 M and a Hill slope value of 0.7-1.5 (ICCVAM, 2011). 
The applications of HeLa9903 cells, to academic research and publication, have been 
limited; however, the E2 reference standard results are also in agreement with Coady et 
al. (2014); whom, in collaboration with Dow Chemical Company (US), used the cell 
line to evaluate the potential endocrine activity of 2,4-Dichlorophenoxyacetic acid. 
Underneath the mean (±SEM) data (Figure 5.3), the data from intraplate replicates (n=3) 
and interplate repeats (n=4) are shown (158 data points). Colour coded according to 
microtitre plate format (i.e. 24 vs 96), the results generated from 96-well plates were 
more variable.  
Figure 5.4 presents the ERα transactivation in HeLa9903 cells consequent to 40 hour 
exposure to 17α-Ethinylestradiol (EE2) or Diethylstilbestrol (DES). The EE2 LogEC50 
and EC50 were -14.27 (95% CI -14.70 to -13.84) and 5.329e-15 (95% CI 1.776e-15 to 
1.421e-14), respectively. The sensitivity of the HeLa9903 cells in detecting EE2 
agonism, consequent to 40 hour exposure, surpassed the sensitivity of OECD STTA 
(PC50 <1.00x10
-11
) and BG1Luc ER TA assays (EC50 4.20x10
-8
 M), which demand 96-
well plates and terminate assays at 24 hours. The right side plot, shows the replicates 
(i.e. data range) of day repeats (n=6), colour coded according to plate layout. Sigmoidal 
EE2 dose-response relationships were only detectable via 24-well plate experiments, 
and the R
2
 value of 0.45, highlights the dispersion of data from the mean. The DES 
LogEC50 and EC50 were -11.83 M (95% CI -12.07 to -11.60) and 1.464e-12 M (95% CI 
8.46e-13 to 2.53e-12), respectively (R
2
 = 0.904), which supports values published by 
the OECD; STTA PC50 2.04x10
-11
 M and BG1Luc ER TA EC50 3.34x10
-11
 M. 
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Figure 5.4 Estrogen Receptor-α (ERα) Transactivation in HeLa9903 Cells Exposed to 
Synthetic Estrogens (EE2 and DES) 
Graphs show the adjusted and normalised relative light units (RLU) emitted by HeLa9903 cells in 
luciferase assays consequent 40-48hr 17α-Ethinylestradiol (EE2) or Diethylstilbestrol (DES) exposure. 
Results were normalised by subtracting vehicle control (DMSO) RLU and adjusted by dividing by the 
RLU of 1nM E2 (maximal agonistic response). Cell concentration was 1x10
4
/well in 96-well (200μL) and 
1x10
5
/well in 24-well (1000μL); test chemicals were solvated in 100% DMSO and administered in 0.2μL 
and 1μL volumes, respectively. Left graphs plots the mean and standard error of the mean (SEM) of 
repeated data, individual day repeat (n=6) results are shown as a scatter plot to the right (data range). 
GraphPad Prism® Log(agonist) vs. response (three parameters) software was used to calculate the 
LogEC50 and EC50 with 95% Confidence Intervals (95% CI), presented in blue. EE2 bottom -0.7443 (95% 
CI -1.281 to -0.2077) and top 1.030 (95% CI 0.9784 to 1.081), R square = 0.449 (n=126). DES bottom 
0.1982 (95% CI 0.1187 to 0.2778) and top 1.161 (95% CI 1.092 to 1.230), R square = 0.904 (n=42). The 
dotted line (y=0.2) highlights 20% 1nM E2 normalised RLU, as a threshold for categorising positive, 
negative and/or inadequate data.  
Highlighted by the data replicates in Figure 5.5, the ERα transactivation consequent to 
40 hour BPA exposure was highly variable. Subsequently, 96-well plate assays were 
excluded from the LogEC50 and EC50 calculations, which were -10.13 (95% CI -10.52 
to -9.74) and 7.44e-11 (95% CI 3.037e-11 to 1.824e-10), respectively. Mean values for 
BPA were calculated from 78 data points, collected over 4 day repeats (R
2
=0.589). 
Forty hour BPA exposure increased the sensitivity of STTA, relative to the STTA PC50 
2.94x10
-7
 M published by Takeyoshi (2006) and EC50 5.33x10
-7
 M reported in the 
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BG1Luc ER TA assay (ICCVAM, 2011). 4-Methyl-2,4-bis(p-hydroxyphenyl)pent-1-
ene (MBPA), is the predominant metabolite of BPA (Yoshihara et al., 2004). Yoshihara 
et al. (2001) demonstrated that many phthalate metabolites presented higher 
estrogenicity than their parent compounds. To explore the potential effects of 
metabolism on the estrogenicity and androgenicity of BPA, MBPA was evaluated in 
STTA assays. The LogEC50 and EC50 of MBPA ER transactivation, relative to 1nM E2, 
were -10.04 (95% CI -10.64 to -9.44) and 9.068e-11 (95% CI 2.29e-11 to 3.59e-10), 
respectively (R
2
=0.647). MBPA presented comparable agonistic ER transactivation 
responses to BPA.   
 
Figure 5.5 Estrogen Receptor-α (ERα) Transactivation in HeLa9903 Cells Exposed to 
Bisphenol-A or its’ Metabolite 4-Methyl-2,4-bis(p-hydroxyphenyl)pent-1-ene (MBPA) 
Graphs show the adjusted and normalised relative light units (RLU) emitted consequent to 40-48hr 
Bisphenol A (BPA) or 4-Methyl-2,4-bis(p-hydroxyphenyl)pent-1-ene exposure. Results were normalised 
by subtracting vehicle control (DMSO) RLU and adjusted by dividing by the RLU of 1nM E2 (maximal 
agonistic response). Cell concentration was 1x10
4
/well in 96-well (200μL) and 1x105/well in 24-well 
(1000μL); test chemicals were solvated in 100% DMSO and administered in 0.2μL and 1μL volumes, 
respectively. Left graphs plots the mean and standard error of the mean (SEM) of 24-well microplate 
data, individual day repeat results, for both 96-well and 24-well experiments, are shown as a scatter plot 
to the right (data range). GraphPad Prism® Log(agonist) vs. response (three parameters) software was 
used to calculate the LogEC50 and EC50 with 95% Confidence Intervals (95% CI). BPA bottom -0.1457 
(95% CI -0.3412 to 0.04970) and top 0.7288 (95% CI 0.6563 to 0.8014), R square = 0.589 (n=78). MBPA 
bottom 0.230 (95% CI 0.0910 to 0.369) and top 0.7275 (95% CI 0.644 to 0.811), R square = 0.647 
(n=28). The dotted line (y=0.2) highlights 20% 1nM E2 normalised RLU, as a threshold for categorising 
positive, negative and/or inadequate data.  
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Figure 5.6 Estrogen Receptor-α (ERα) Transactivation in HeLa9903 Cells Exposed to 
Phthalates (DBP, DEHP and BBP) 
Graphs show the adjusted and normalised relative light units (RLU) emitted consequent to 40-48hr 
exposre to either Dibutyl phthalate (DBP), Diethylhexyl phthalate (DEHP) or Butylbenzyl phthalate 
(BBP). Results were normalised by subtracting vehicle control (DMSO) RLU and adjusted by dividing by 
the RLU of 1nM E2 (maximal agonistic response). Cell concentration was 1x10
4
/well in 96-well (200μL) 
and 1x10
5
/well in 24-well (1000μL); test chemicals were solvated in 100% DMSO and administered in 
0.2μL and 1μL volumes, respectively. Lines of best fit were drawn from the mean and standard error of 
the mean (SEM). 96-well and 24-well experiment replicates are shown as a scatter plot behind (dark and 
light teal, respectively). GraphPad Prism® Log(agonist) vs. response (three parameters) was used to 
calculate the LogEC50 and EC50 with 95% Confidence Intervals (95% CI). Standard sigmoidal responses 
are shown for DBP and DEHP. DBP bottom 0.1338 (95% CI 0.05952 to 0.2081) and top 0.5424 (95% CI 
0.4347 to 0.650), R square = 0.432 (n=62). DEHP bottom 0.176 (95% CI 0.117 to 0.235) and top 1.097 
(95% CI 0.719 to 1.475), R square = 0.4998 (n=60). The dotted line (y=0.2) highlights 20% 1nM E2 
normalised RLU, as a threshold for categorising positive, negative and/or inadequate data. 
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Di-n-butyl phthalate (DBP), while negative in the in vivo Uterotrophic assay, has been 
reported positive in 6 of 11 in vitro ER STTA (PC10 4.09x10
-6
 M) and BG1Luc ER TA 
(EC50 4.09x10
-6
 M) (ICCVAM, 2011). The data collected for DBP (Figure 5.6) via the 
method detailed in this study (Section 5.2.6.1), were inadequate. The results of 7 
concentrations (100nM to 10μM) with 3 replicates, repeated on 3 days in 96 (n=1) or 24 
(n=2) well plates, were inconclusive and no conclusion on either the activity or 
inactivity could be drawn. Presented in Figure 5.6, the LogEC50 and EC50 of 
Diethylhexylphthalate (DEHP) exposure was, -4.71 M (95% CI -5.163 to -4.254) and 
1.958e-05 M (95% CI 6.873e-06 to 5.576e-05), respectively (R
2
 = 0.50). Sumitomo 
laboratories (Japan) detected DEHP ER agonism in one of three assays (PC10 -5.49 M); 
however, no ER transactivation was detected in assays conducted at Ceri, Otsuka and 
Kaneka laboratories (Takeyoshi, 2006). The results generated herein, reflective of 3 day 
repeats of 7 concenrations with three replicates (100nM to 10μM), support the findings 
of Sumitomo laboratory, by suggesting that DEHP is an in vitro ERα signalling agonist, 
albeit at a lower potency.  Butylbenzylphthalate was the most potent phthalate ER 
agonist identified in this study (Figure 5.6), the LogEC50 and EC50 were -7.11 M (95% 
CI -7.77 to -6.45) and 7.75e-08 M (95% CI 1.683e-06 to 3.569e-07), respectively. 
These results are comparable to ER STTA (PC50 4.11x10
-6
 M) and BG1Luc ER TA 
(EC50 1.98x10
-6
 M) literature values (ICCVAM, 2011). The increase in sensitivity is 
likely to be a result of increased exposure time.  
The mean data for all in vitro HeLa9903 stably transfected ER transactivation assays 
conducted herein, are summarised in Table 5.10. 4’4-DDE agonised ERα 
transactivation, presenting LogEC50 and EC50 values of -11.83 M (95% CI -12.38 to -
10.35) and 4.35e-12 M (95% CI 4.19e-13 to 4.53e-11), respectively. Transactivation 
was induced at markedly lower 4’4-DDE concentration ranges, than the EC50 3.00x10
-6
 
M reported in the literature (ICCVAM, 2011), possibly as a result of longer exposure 
times (Figure_Apx 15).  In addition, 4-Benzylphenol (4-BP) was identified as a 
potential ER agonist, LogEC50 and EC50 values were -4.87 M (95% CI -5.284 to -4.460) 
and 1.343e-05 M (95% CI 5.203-06 to 3.466e-05), respectively; 4 day repeats of 
experiments at 7 concentrations with 3 in-plate replicates (n=84). Clear negative 
responses were observed for Triclosan (2 repeats), Methylparaben (2 repeats) and 4-
Nitrophenol (3 repeats); all of which were tested at 7 concentrations (10μM - 10pM) 
with three replicates. The results of ER transactivation, consequent to 40 hour 
Octylmethoxycinnamate exposure (10μM - 10pM), were inconclusive (Figure_Apx 15).  
Supporting the in silico predictions of ligand promiscuity and OECD TG455 results, 
Testosterone (1μM-1pM) was identified as an agonist of ERα transactivation. 
Surpassing the sensitivity of the 24 hour exposure STTA (PC50 9.78x10
-6
 M) and 
BG1Luc ER TA (EC50 1.75x10
-5
), results generated herein showed transactivation with 
LogEC50 -11.16 M (95% CI -11.67 to -10.66) and EC50 6.871e-12 M (95% CI 2.16e-12 
to 2.19e-11), consequent to 40 hour testosterone exposure (2 repeats, n=29, R
2
=0.72).  
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Table 5.10 Results of HeLa9903 Stably Transfected ER Transactivation Assay to Detect 
Agonism of Estrogenic Signalling 
Table shows the mean 50% effective concentration (EC50) for test substances in the ER STTA conducted 
herein. OECD/ICCVAM ER TA values are stated in the third column.  
 
There are limited data pertaining to the agonistic response of 4-BP, 4-NP, M-BPA, 
Methylparaben, OMC and Triclosan in the HeLa9903 cell line. However, the dose-
repsonse relationships observed for 4-BP (Figure_Apx 15) and MBPA (Figure 5.5), 
support the ER activity reported in qHTS assays (Table 5.3) and Yoshihara et al.’s 
(2004) study, respectively. Conversely, the inadequate data generated in OMC assays 
(Figure_Apx 15), do not contribute to the debate regarding the estrogenicity of UV-
filters (Schlupf et al., 2001). Triclosan has been shown to antagonise the ER (Table 
5.3); however, the results of 40hr exposure in HeLa9903 cells suggest that TCN cannot 
agonise ER signalling. The chemical structure (see Table 5.3) of TCN may offer an 
explanation for antagonistic rather than agonistic responses, as ‘bulky’ chlorine 
functional groups may prevent the clamping of the ligand binding domain by α-Helices-
12, which is required for ERα agonism (See Section 3.1). Methylparaben is listed on the 
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ER binding database (NCTRER), from the negative results generated herein, binding 
may result in ER antagonistic MoA, rather than agonistic.  
The exposure time was increased, from 20-24 hours to 40 hours, consequent to 
preliminary testing for laboratory performance and optimisation of 17β-estradiol 
responses. The rate of HeLa9903 cell growth, appeared to decrease, on ‘conditioning’ in 
which the cells were starved of estrogenic hormone components (DCC-FBS, Phenol 
red-free, antibiotic-free EMEM), the increase in exposure time aimed to mitigate for the 
delayed growth, without increasing the starting cell concentration. The results generated 
herein (Table 5.10), suggest that increasing the in vitro chemical exposure time, 
increases the sensitivity of the HeLa9903 stably transfected ER transactivation assay.  
5.3.3 BG1Luc4E2 ERα/β Agonism STTA  
An objective of the in vitro screening, was to test potential-EDCs (n=20) in 
BG1Luc4E2 cells, recently validated and adopted by OECD TG455. However, 
preliminary testing demonstrated poor laboratory performance of BG1Luc ER TA; 24 
hour E2 or EE2 exposure did not induce ER transactivation. Increasing positive control 
(E2 or EE2) exposure to 40-48 hours led to an induction of ER transactivation, at 10
-8
 M 
E2 and 10
-9
 M EE2 (Figure 5.7). Figure 5.7 plots the relative light units (RLU) emitted 
in the BG1Luc4E2 ER transactivation assays in response to E2 and EE2.  The responses 
to E2 and EE2 reported herein were lower than the TG455 refererance standards; E2 
EC50 = 5.63x10
-12
 M and EE2 EC50 = 4.20x10
-8
 M (ICCVAM, 2011). Validation studies 
by ECVAM and XDS laboratories identified significant variability in BG1Luc ER TA 
response; E2 only induced transactivation in 24 of 35 assays. ICCVAM (2011) notes 
that because DMSO control RLU values are not normalised, they can vary considerably 
between test plates; ranging from 511 to 9885 RLU (mean 3749). Interestingly, the 
maximum E2 response reported herein (Figure 5.7), was comparable to that reported in 
BG1Luc validation studies (10,000 RLU); thus, the ineffectivity of the assay may be as 
a result of background luminescence.  
The BG1Luc ER TA was demonstrated to be an insensitive in vitro assay, under the 
laboratory conditions and equipment specifications (Section 5.2), available for this 
study. Further testing in the BG1Luc4E2 cell line under these conditions, was not 
expected to generate statistically significant results. OECD validation has demonstrated 
concordance between the ERα STTA and the BG1Luc ERα/β TA (OECD, 2012; 
ICCVAM, 2011). Thus, it is not injudicious to suggest that the BG1Luc ER TA results 
may have mirrored the HeLa9903 assay results detailed in Section 5.3.2. The difficulty 
in observing ER responses in vitro, in addition to the variability defined in the literature, 
suggest that utilising the endogenous ERα and ERβ to elicit transactivation of stably 
transfected response elements in the BG1Luc4E2 cell line, presents more challenges 
than the STTA, which may be considered a more sensitive assay. Conceptually, the 
variability of BG1Luc4E2 responses may reside in the feedback mechanisms of ERα 
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and ERβ responses (i.e. inter-receptor crosstalk). As detailed in Section 3.1, ERβ can act 
as a dominant inhibitor of ERα transcriptional activity, when co-expressed (Metivier et 
al., 2003). Thus, the balance of endogenous hormone receptors in BG1Luc4E2 cells 
may play a significant role in assay sensitivity.  
 
Figure 5.7 Inadequate Response of BG1Luc4E2 Estrogen Receptor (α/β) Transactivation 
Assays in 24-Well and 96-Well Formats 
Graphs show the adjusted and normalised relative light units (RLU) emitted by BG1Luc4E2 Cells 
consequent to 40-48hr exposre to positive controls (E2 and EE2). Results were normalised by subtracting 
vehicle control (DMSO) RLU. Cell concentration was 1x10
4
/well in 96-well (200μL) and 1x105/well in 
24-well (1000μL); estrogens were solvated in 100% DMSO and administered in 0.2μL and 1μL volumes, 
respectively. The dotted line (y=7460) on the top graph shows the mean RLU of the DMSO vehicle 
control, highlighting the limited responses of the BG1Luc4E2 cells observed in this study in response to 
estrogens. 
5.3.4 HeLa4-11AR Agonism STTA  
Despite being an objective of ECVAM, there are currently no regulatory test guidelines 
to assess androgenicity in vitro; excluding the rat AR binding study, which is reliant on 
rat ventral prostate tissue. Reflective of the ER STTA, mammalian cell based luciferase 
reporter assays have been demonstrated to show sensitivity in detecting androgenicity 
(Svovodova & Cajthaml, 2010). HeLa4-11 cells are stably transfected with a hAR 
expression construct and a firefly luciferase reporter gene under the control of the 
MMTV promoter. The results of stably transfected AR transactivation assays, to detect 
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AR agonism in HeLa4-11 cells, consequent to 24 hour test substance exposure (n=20), 
are detailed herein. Figure 5.8 shows the AR transactivation following Testosterone 
exposure (semi-log dilutions from 1x10
-6
 M to 1x10
-24
 M Testosterone) in 24 and 96 
well microtitre plates. Results were normalised by subtracting vehicle control (DMSO) 
RLU and adjusted by dividing by the RLU of 1nM testosterone (maximal agonistic 
response in both plate formats).  
 
Figure 5.8 Androgen Receptor Transactivation in Response to 24h Testosterone Exposure 
in HeLa4-11 Cells in 24- and 96- Microtitre Plates 
Drawn using GraphPad Prism® Log(agonist) vs. Response (three parameters), plots show the adjusted 
and normalised relative light units (RLU) emitted in luciferase assays consequent testosterone exposure in 
either 24- or 96- well plate format. Results were normalised by subtracting vehicle control (DMSO) RLU 
and adjusted by dividing by the RLU of 1nM testosterone (maximal agonistic response). Cell 
concentration was 1x10
4
/well in 96-well (200μL) and 1x105/well in 24-well (1000μL); testosterone 
solvated in 100% DMSO was administered in 0.2μL and 1μL volumes, respectively. 24-well plate data on 
the left shows the Mean and Standard error of the mean (SEM) of 2 day repeats, with the LogEC50/EC50 
and 95% Confidence Intervals (95% CI) stated in red. The bottom graph shows the mean and SEM of 96-
well day repeat data (n=4), superimposed on the individual data replicates, highlighting the distribution of 
the data over the different testing days. The dotted line (y=0.2) highlights 20% 1nM testosterone 
luciferate induction, as a threshold for categorising positive, negative and/or inadequate data. Quality 
assurance data (Z-prime) for each 96-well plate are stated in blue.  
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24-well plate Testosterone exposures presented LogEC50 and EC50 of -9.90 M (95% CI: 
-10.1 to -9.74) and 1.26e-10 M (95% CI: 8.70e-11 to 1.81e-10), respectively 
(R
2
=0.9599, n=58). The sensitivity of the HeLa4-11 24-well plate assay was 
comparable to that of the MDA-kb2 cell line, which is stably transfected with an 
androgen responsive firefly luciferase reporter gene (ARE); 28 hour 0.25 nM DHT 
exposure induced maximal AR transactivation (Orton et al., 2014). The EC50 of 
0.126nM (1.26e-10 M) identified herein, demonstrated equivalent sensitivity to the S. 
cerevisiae yeast androgen bioassay, developed by Michelini et al. (2005); EC50 of 10nM 
for testosterone, with a 0.05nM (50pM) limit of detection.  
The lower plot of Figure 5.10 presents the dose-response of Testoserone observed in 96-
well plates (i.e. increasing the throughput). All tested Testosterone concentrations 
(1x10
-6
 M to 1x10
-24
 M) induced maximal AR transactivation, consequent to 24 hour 
exposure (4/4 day repeats); See Table 5.11 for Z’Prime values. Avogadro’s constant 
(NA) 6.022x10
23
 approximates the number of constituent molecules in a mole (Mohr et 
al., 2008), thus, in light of the dilutions, the assay appears to induce maximal AR 
transactivation in response to trace concentrations of Testosterone. DMSO vehicle 
controls (n=6 per plate) did not induce AR transactivation, reducing the likelihood of 
contamination, and comparable AR transactivation sensitivity was observed on 24 hour 
exposure to R1881 and DHT (Table 5.11). The marked difference observed between 
plate formats is disconcerting; however, simple explanations may reside in cell 
concentration and cofactor expression.   
The sensitivity of AR STTA in the PALM prostatic cell line, which stably express AR 
(pSG5-puro-hAR) and ARE (pMMTV-neo-Luc), was shown to vary with cell 
concentration (Térouanne et al., 2000). PALM cells plated at a density of 8x10
4
, 2x10
4
 
and 5x10
3, led to Testosterone EC50’s of 20nM, 3nM and 0.2nM, respectively; thus 
lower cell concentrations yielded higher Testosterone sensitivity. However, the EC50 of 
the synthetic androgen, Metribolone (R1881) was independent of cell number, 
suggesting that the effect of cell concentration may not alter sensitivity ubiquitously 
(Térouanne et al., 2000). Cofactors regulate the transactivation of nuclear receptors 
(Section 3.2.2). ARA70 and ARA55 cofactors have been demonstrated to enhance AR 
transactivation, in response to residual androgen concentrations (Fujimoto et al., 1999; 
Yeh et al., 1999a). Nishimura et al. (2003) demonstrated modulation of AR 
transactivation in response to Gelsolin, the AR-associated protein involved in 
cytoskeleton reorganisation, cell morphology and motility. Furthermore, Yeh et al. 
(1999b) suggested that cross-talk between AR and HER-2/neu pathway signals, 
stimulated by growth factors may activate AR.  
The HeLa4-11 cell line may express elevated cofactor concentrations, thereby 
amplifying the response to trace testosterone concentrations. Detailed mechanistic 
information pertaining to HeLa4-11 cell modifications, were sought via the named 
distributor, Kazushi Kawaharada (DS Pharma Biomedical Co. Ltd.). However, due to 
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patenting restrictions, no additional information was provided and the mechanism 
behind HeLa4-11 AR transactivation sensitivity remains speculative. Consequently, 
despite the sensitivity of HeLa4-11 STTA in detecting AR agonists in vitro, it may be 
unwise to use the assay to predict potency.   
 
Figure 5.9 Androgen Receptor Transactivation in HeLa4-11 Cells in Response to 24h 
Estrogen Exposure (E2 and DES) 
Drawn using GraphPad Prism® Log(agonist) vs. Response (three parameters) line drawing function. 
Graphs show the adjusted and normalised relative light units (RLU) emitted during the luciferase assay, 
consequent to 17β-Estradiol (E2) or Diethylstilbestrol (DES) exposure. Results were normalised by 
subtracting vehicle control (DMSO) RLU and adjusted by dividing by the RLU of 1nM testosterone 
(maximal agonistic response). Graphs summarise day repeats replicates and presented the Mean and 
Standard Error of the mean (SEM) to calculate agonism (LogEC50/EC50) with 95% Confidence Intervals 
(95% CI). Data replicates are presented and colour coded by experiment date (day repeats). The dotted 
line (y=0.2) highlights 20% 1nM testosterone (maximal response ~ positive control) luciferate induction, 
as a threshold for categorising positive, negative and/or inadequate data. Quality assurance data (Z-prime) 
for each 96-well plate are stated in blue. 
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Figure 5.9 shows the AR transactivation in HeLa4-11 cells consequent to 24 hour E2 or 
DES exposure. The E2 LogEC50 and EC50 were -4.945 (95% CI -5.09 to -4.80) and 
1.134e-05 (95% CI: 8.124e-06 to 1.584e-05), respectively. Supporting the results 
detailed herein (15.84μM), agonistic AR transactivation in response to E2, has been 
reported at 2.23μM (Table 5.1). The comparable sensitivity of HeLa4-11 cells, in 
detecting estrogenic AR agonists supports Térouanne et al.’s (2000) theory, that 
different agonists present different mechanisms of AR transactivation.  
 
Figure 5.10 Androgen Receptor Transactivation in HeLa4-11 Cells in Response to 24h 
Progestagin Exposure (PRG and 19-ND) 
Drawn using GraphPad Prism® Log(agonist) vs. Response (three parameters) line drawing function. 
Graphs show the adjusted and normalised relative light units (RLU) emitted during luciferase assays, 
consequent to progesterone (PRG) or 19-Norethindrone (19-ND) exposure. Results were normalised by 
subtracting vehicle control (DMSO) RLU and adjusted by dividing by the RLU of 1nM testosterone 
(maximal agonistic response). The curve plots the Mean and Standard Error of the mean (SEM). Mean 
data was used to calculate agonism (LogEC50/EC50) with 95% Confidence Intervals (95% CI). Data 
replicates are shown, colour coded by experimental day, to highlight the distribution of data. The dotted 
line (y=0.2) highlights 20% positive control (1nM testosterone ~ maximal response) luciferate induction, 
as a threshold for categorising positive, negative and/or inadequate data. Quality assurance data (Z-prime) 
for each 96-well plate are stated in blue. 
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The LogEC50 and EC50 of DES AR transactivation were -11.49 M (95% CI: -11.70 to -
11.27) and 3.272e-12 M (95% CI: 2.002e-12 to 5.35e-12), respectively (Figure 5.9). 
DES has been shown to inhibit recombinant rat AR (IC50 14.13μM) and antagonise 
transactivation in the MDA cell line (27.72μM); however, the potential agonistic MoA 
of DES have been neglected (Table 5.2). The low-dose stimulation and high-dose 
inhibition, of DES induced AR transactivation observed herein, suggests a biphasic dose 
response (i.e. hormesis), which has not previously been reported. 
Figure 5.10 shows the adjusted and normalised relative light units (RLU) emitted during 
stably transfected AR transactivation assays, consequent to 24 hour progesterone (PRG) 
or 19-Norethindrone (19-ND) exposure. Similar to DES, Progesterone dose-response 
appeared to be biphasic. The PRG LogEC50 and EC50 were -11.51 M (95% CI: -11.72 to 
-11.31) and 3.08e-12 M (95% CI: 1.926e-12 to 4.944e-12). Interestingly, agonism of 
AR transactivation has been reported at 0.025 μM (Table 5.1), which bears comparison 
to a small increase in AR transactivation detected between 1x10
-8
 and 1x10
-5
 M, herein 
(Figure 5.10). The LogEC50 and EC50 for AR transactivation consequent to 19-
Norethindrone exposure were -9.12 M (95% CI: -9.29 to -8.92) and 7.841e-10 M (95% 
CI: 5.15e-10 to 1.19e-09), respectively. The synthetic progestin did not present the 
biphasic dose-response in AR transactivation observed for Progesterone.  
BPA and 4-Methyl-2,4-bis(4-hydroxyphenyl)pent-1-ene (MBPA) testing concentrations 
were 1:10 log dilutions  of 1mM to 100pM. BPA did not induce AR transactivation in 
HeLa4-11 cells; however, MBPA exposure produced a biphastic dose-response (Table 
5.11). Figure 5.11 shows the AR transactivation in HeLa4-11 cells consequent to 24 
hour MBPA or 4’4-DDE exposure. The MBPA LogEC50 and EC50 were -11.53 M (95% 
CI: -11.72 to -11.34) and 2.965e-12 M (95% CI: 1.91e-12 to 4.604-12). To the authors 
knowledge, the androgenicity of 4-Methyl-2,4-bis(4-hydroxyphenyl)pent-1-ene, has not 
previously been reported.  
4,4’-DDE has been demonstrated to inhibit the activity of R1881 in recombinant AR, 
expressed in E. coli ~ IC50 20.42μM (Table 5.3). The antagonistic properties of 4,4-
DDE in utero, have been associated with cryptorchidism incidence (Montes et al., 
2010). Figure 5.11 shows AR transactivation in response to all tested concentrations of 
4,4’-DDE (1x10-6 M to 1x10-18 M); inducing maximal agonistic response. Björk et al. 
(2011) identified alterated 4,4’-DDE agonism and antagonism of AR transactivation in 
vitro, relative to androgen receptor CAG length. AR CAG repeats have also been shown 
to affect AR function in vivo, and have been implicated in the aetiology of Testicular 
Germ Cell Cancer (Västermark et al., 2011; see Section 2.2). The AR transactivation in 
response to testosterone (Figure 5.8) and 4,4’-DDE exposure reported herein, suggest 
AR modifications in the HeLa4-11 cell line, which increase sensitivity and 
transactivational response.   
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Figure 5.11 Androgen Receptor Transactivation in HeLa4-11 Cells in Response to MBPA 
and DDE Exposure 
Excluding Mean DDE AR Agonism, in which points were connected by lines, all lines of best fit were 
drawn using GraphPad Prism® Log(agonist) vs. Response (three parameters) function. Graphs show the 
adjusted and normalised relative light units (RLU) emitted consequent to MBPA or DDE exposure. 
Results were normalised by subtracting vehicle control (DMSO) RLU and adjusted by dividing by the 
RLU of 1nM testosterone (maximal agonistic response). Graphs plot the Mean and Standard Error of the 
mean (SEM). Mean data was used to calculate agonism (LogEC50/EC50) with 95% Confidence Intervals 
(95% CI). Data replicates are colour-coded by experimental date, to show the distribution of data. The 
dotted line (y=0.2) highlights 20% positive control (1nM testosterone ~ maximal response) luciferate 
induction, as a threshold for categorising positive, negative and/or inadequate data. Quality assurance data 
(Z-prime) for each 96-well plate are stated in blue. 
The suggestion that AR responses are modified in HeLa4-11 cells is heightened by the 
in vitro AR transactivation observed consequent to Methylparaben (MeP), 
Octylmethoxycinnamate (OMC) and Triclosan (TCN) exposure (Figure 5.12). Maximal 
agonistic response was observed for all TCN and MeP concentrations, excluding 
declines in transactivation observed at cytotoxic concentrations (Figure 5.1). Triclosan 
had previously been identified as an AR antagonist (Table 5.3). OMC AR 
transactivation increased at moderately cytotoxic concentrations; exceeding the 
response of 1nM Testosterone the results hint at ligand-independent AR transactivation.  
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Figure 5.12 Androgen Receptor Transactivation in HeLa4-11 Cells in Response to 24h 
Consumer Chemical Exposure (MeP, TCN and OMC) 
Drawn using GraphPad Prism® Log(agonist) vs. Response (three parameters) function, graphs show the 
relative light units (RLU) emitted consequent to exposure to either Methylparaben (MeP), Triclosan 
(TCN) or Octylmethoxycinnamate (OMC). Results were normalised by subtracting vehicle control 
(DMSO) RLU and adjusted by dividing by the RLU of 1nM testosterone. Graphs show the Mean and 
Standard Error of the mean (SEM) best fit data used to calculate agonism (LogEC50/EC50) with 95% 
Confidence Intervals (95% CI). Replicates are colour coded according to experiment date.The dotted line 
(y=0.2) highlights 20% luciferase induction of the positive control (1nM testosterone ~ maximal 
response), as a threshold for categorising positive, negative and/or inadequate data. Quality assurance 
data (Z-prime) for each 96-well plate are stated in blue. 
Evaluation of in silico and in vitro screening methods for EDC hazard characterisation 
 
 
 Page 153  
  
Ma et al. (2003) did not detect either agonism or antagonism of AR transactivation in 
the MDA-kb2 cell line, consequent to OMC exposure. 
Table 5.11 Results of HeLa4-11 Stably Transfected AR Transactivation Assay to Detect 
Agonism of Androgenic Signalling 
Table shows the mean 50% effective concentration (EC50 (95% Confidence Interval)) for test substances 
in the AR STTA conducted herein. In the absence of regulatory criteria, Z’Prime statistical values for 96-
well plates (Mean (range)), the number of data points (N) and day repeats (DR) are detailed in columns 3 
and 4. Results highlighted in green presented ‘atypical’ dose-response relationships, presenting no AR 
activity at high concentrations, but inducing transactivation at low concentrations. The results for 
Testosterone are highlighted in red, because a dichotomy in potency was observed, dependent on culture 
condition (24 vs 96 well plates).  
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Table 5.11 summarises the results of HeLa4-11 Stably Transfected AR Transactivation 
Assays, to detect agonism of androgen receptor signalling. Exposure to 17α-
Ethinylestradiol (EE2), Bisphenol A (BPA), 4-Benzylphenol (4-BP), 4-Nitrophenol (4-
NP), Dibutylphthalate (DBP), Diethylhexylphthalate (DEHP) or Butylbenzylphthalate 
(BBP) did not induce agonistic AR responses (Table 5.11; Figure_Apx 16). The data 
presented herein strongly suggest that BPA, 4-BP, 4-NP, DBP, DEHP and BBP are not 
androgen receptor agonists in the HeLa4-11 cell line. Slight luciferase induction was 
observed at 10μM; however, this coincided with cytotoxicity (see Figure 5.1).  
Z factors were used to monitor assay sensitivity, by assessing the distance and 
distribution of 1nM Testosterone AR transactivation positive controls with background 
DMSO vehicles; inherently stringent, Z’ statistics require 99% of values to occur within 
3 standard deviations of the mean (Table 5.11; see Section 5.2.10). The mean 96-well 
plate (n=32) Z’prime value was 0.5, emphasising the statisticaly significant responses 
generated in the HeLa4-11 AR agonism transactivation assays. However, the sensitivity 
and disagreement of observed AR transactivation with literature predictions, leads the 
author to suggest that HeLa4-11 cells have been modified to increase AR 
transactivation. An array of modifications, including AR CAG repeats, cofactor 
expression and ARE modulation, may affect AR transactivation responses.   
5.3.5 HeLa4-11 AR Antagonism STTA  
As an extension to the HeLa4-11 AR transactivation assays, to detect agonists of 
androgenic signalling, the assay was mofified to detect antagonistic responses. Cells 
suspended in 10% DCC-FBS-EMEM were plated at 1 x 10
4
 cells/100μL per 96-well 
plate and allowed to attach for 3 hours, prior to the addition of 100 μL of 10% DCC-
FBS-EMEM supplemented with 1nM testosterone and 0.2μL of test substance in 100% 
DMSO. Assay plates were incubated at 5% CO2 at 37±1ºC and terminated after 20-24 
hour chemical exposure.  
Primarily used in the treatment of prostate cancer, Flutamide antagonises the AR, 
demonstrating an IC50 of 3.62x10
-6
 M when coexposed with 0.5nM DHT in MKD-kb2 
cells (Ma et al., 2003). Figure 5.13 shows the antagonism of AR transactivation in 
HeLa4-11 cells co-exposed to Flutamide (10fM-100μM) and 1fM Testosterone for 24 
hours. The LogIC50 and IC50 of Flutamide and 1fM Testosterone exposure, identified 
herein were, -4.315 M (95% CI -4.508 to -4.123) and 4.839e-05 M (95% CI 3.108e-05 
to 7.534e-05), respectively (n=99, R
2
=0.908). Flutamide was not a strong AR antagonist 
in the HeLa4-11 cell line, which may reflect the dual activity of antiandrogens detailed 
by Ma et al. (2003). Nevertheless, as a confirmed moderate antagonist, 10μM Flutamide 
+ 1fM Testosterone controls (n=3), were included in each AR antagonism 
transactivation assay; as a quality control measure all assay plates presented 10-20% 
reduction in transactivation, consequent to Flutamide exposure. 
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Figure 5.13 Antagonism of Androgen Receptor Transactivation in HeLa4-11 Cells Co-
Exposed to Flutamide and 1fM Testosterone for 24 Hours  
Drawn using GraphPad Prism® Log(inhibitor) vs. Response (three parameters). Results were normalised 
by subtracting vehicle control (DMSO) RLU and adjusted by dividing by 1fM testosterone RLU 
(maximal agonistic response). Top graph summarises day repeat data, presented as the Mean and 
Standard Error of the mean (SEM). Mean data was used to calculate inhibition (LogIC50/IC50) with 95% 
Confidence Intervals (95% CI) shown in red font. Error bars in the Day Repeat Data represent the 
standard deviation, highlighting the distribution of the data over the different testing days. Quality 
assurance data (Z-prime) for each 96-well plate repeat are stated in green. Statistics: bottom -0.3581 (95% 
CI -0.5982 to -0.1179) and top 1.01 (95% CI 0.9895 to 1.031); LogIC50 -4.315 (95% CI -4.508 to -4.123) 
and IC50 4.839e-05 (95% CI 3.108e-05 to 7.534e-05). R square = 0.908 (n=99). 
Interestingly, the endogenous and synthetic hormones inhibited 1fM Testosterone 
induced AR transactivation, with greater potency than Flutamide (Figure 5.14). The 
LogIC50 and IC50 of EE2 were, -8.389 M (95% CI: -8.76 to -8.02) and 4.081e-09 M 
(95% CI: 1.75e-09 to 9.51e-09), respectively (n=60, R
2
=0.745).  
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Figure 5.14 Antagonism of Androgen Receptor Transactivation in HeLa4-11 Cells 
Exposed to Estrogens (E2, EE2 and DES) for 24 Hours 
Drawn using GraphPad Prism® Log(inhibitor) vs. Response (three parameters) line drawing function. 
Graphs show the adjusted and normalised relative light units (RLU) emitted, consequent to coexposure of 
testosterone (1fM unless otherwise stated) and estrogens. Results were normalised by subtracting vehicle 
control (DMSO) RLU and adjusted by dividing by 1fM testosterone RLU. Mean (±SEM) data was used 
to calculate inhibition (LogIC50/IC50) with 95% Confidence Intervals (95% CI). Day repeat data plots raw 
normalised-data replicates, highlighting the distribution of the data. Z-prime’s are stated in green. E2 top 
0.7724 (95% CI 0.7465 to 0.7983) and bottom 0.5246 (95% CI 0.4927 to 0.5565). R square = 0.745 
(n=60). EE2 top 0.7409 (95% CI 0.7174 to 0.7644) and bottom 0.1814 (95% CI 0.1347 to 0.2281). R 
square = 0.910 (n=63). DES top 0.7713 (95% CI 0.7397 to 0.803) and bottom 0.09136 (95% CI -1.129 to 
1.312). R square = 0.314 (n=63).  
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Tox21 qHTS assays identified E2 AR antagonism at 0.06μM (Huang et al., 2014; see 
Table 5.1). Thus, the HeLa4-11 AR transactivation assay for antagonistic responses 
detailed herein, demonstrated higher sensitivity for E2 MoA; IC50 = 4.08nM E2 + 1fM 
Testosterone. Co-exposure of EE2 and 1fM Testosterone presented a LogIC50 -7.215 M 
(95% CI: -7.40 to -7.03) and IC50 6.091e-08 M (95% CI: 4.01e-08 to 9.25e-08); 
R
2
=0.910, n=63 (Figure 5.14).  
 
Figure 5.15 Antagonism of Androgen Receptor Transactivation in HeLa4-11 Cells 
Exposed to Progestagins for 24 Hours 
Drawn using GraphPad Prism® Log(inhibitor) vs. Response (three parameters). Graphs show the 
adjusted and normalised relative light units (RLU) emitted during the luciferase assay, consequent to 
coexposure of testosterone (1fM) and either progesterone or 19-Norethindrone. Results were normalised 
by subtracting vehicle control (DMSO) RLU and adjusted by dividing by 1fM testosterone RLU 
(maximal agonistic response). Left side graphs summarise day repeat data, presented as the Mean and 
Standard Error of the mean (SEM), which was used to calculate inhibition (LogIC50/IC50) with 95% 
Confidence Intervals (95% CI). Error shown in the Day Repeat Data (right) is equivalent to the standard 
deviation, showing the data distribution over the different testing days. Quality assurance data (Z-prime) 
for each 96-well plate are stated in green. Progesterone (PRG) top 0.8205 (95% CI 0.785 to 0.856) and 
bottom 0.315 (95% CI 0.2589 to -0.371). R square = 0.8171 (n=63). 19-Norethindrone (19-ND) top 
0.7739 (95% CI 0.7496 to 0.7981) and bottom 0.8540 (95% CI 0.7984 to 0.9097). R square = 0.146 
(n=63).  
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The antagonism of AR transactivation in response to 24 hour EE2 and 1nM 
Testosterone exposure is shown in Figure 5.14; LogIC50 and IC50 were -6.798 M (95% 
CI: -7.121 to -6.475) and 1.592e-07 M (95% CI: 7.56e-08 to 3.35e-07), respectively 
(R
2
= 0.903, n=21). The increase in Testosterone concentration decreased the sensitivity 
of the EE2 AR antagonism transactivation assay. The third graph presented in Figure 
5.14, shows the mean (±SEM) of DES + 1fM Testosterone AR transactivation 
(R
2
=0.314, n=63). Demonstrating large confidence intervals, the mean did not 
accurately reflect data replicates; DES LogIC50 -4.993 M (95% CI: -6.43 to -3.56) and 
IC50 1.016e-05 M (95% CI: 3.71e-07 to 2.78e-04). Nevertheless, the results agreed with 
the observation of DES AR antagonism at 27.72μM in the MDA cell line (Table 5.2).  
Progesterone was identified as a biphasic AR agonist in Section 5.3.4, Figure 5.15 
highlights the dual-activity of Progesterone, which demonstrated AR antagonism with a 
LogIC50 of -7.972 M (95% CI: -8.24 to -7.70) and IC50 of 1.067e-08 (95% CI 5.762e-08 
to 1.98e-08); R
2
=0.82, n=63. The synthetic progestin, 19-Norethindrone, did not 
antagonise AR transactivation in HeLa4-11 cells (Figure 5.15), contradicting the 
reported antagonism of recombinant rat AR expressed in E. coli, at 0.12μM (Table 5.2).  
Bisphenol A (IC50 1μM) has been demonstated to antagonise Metribolone (R1881) AR 
transactivation, in CHO cells transiently transfected with human AR (pSVAR0) 
(Bonefeld-Jørgensen et al., 2007). The BPA LogIC50 and IC50 antagonism of 1fM 
Testosterone AR activity, of -5.314 M (95% CI: -5.592 to -5.037) and 4.852e-06 M 
(95% CI: 2.561-06 to 9.19e-06), respectively, presented comparable potency (Figure 
5.16). The predominant metabolite of BPA, 2,4-bis(4-hydroxyphenyl)-4-methyl-1-
pentene (M-BPA) antagonised Testosterone AR transactivation at lower concentrations; 
LogIC50 -6.044 M (95% CI: -6.269 to -5.819) and IC50 9.034e-07 (95% CI: 5.38e-07 to 
1.517e-06). Yoshihara et al. (2004) reported higher estrogenicity in BPA metabolites, 
such as MBPA, the results generated herein suggest this may also apply to AR 
antagonism.   
The AR transactivation in HeLa4-11 cells consequent to 24 hour co-exposure to 1fM 
Testosterone with Dibutylphthalate (DBP), Diethylhexylphthalate (DEHP) or 
Butylbenzylphthalate (BBP), are presented in Figure 5.17. The LogIC50 and IC50 of 
DBP exposure was, -5.284 M (95% CI: -6.266 to -5.301) and 5.20e-06 M (95% CI: 
5.42e-07 to 4.99e-05), respectively (R
2
=0.58, n=42). To the author’s knowledge, DBP 
antagonism of in vitro AR transactivation has not been reported previously. DEHP 
concentrations (100pM-100μM) consistently reduced 1fM Tesosterone AR induction 
(~20%); however, a dose-response relationship was ambiguous and results were not 
statistically significant. BBP has been demonstrated to antagonise the androgenic 
response of 25pM R1881, in the AR-CALUX assay ~ IC50 13μM (Krüger et al., 2008). 
Results generated herein, identified BBP LogIC50 and IC50’s of -5.301 M (95% CI -6.20 
to -4.40) and 4.997e-06 M (95% CI: 6.32e-07 to 3.95e-05), respectively, thereby 
supporting Krüger et al.’s (2008) report.  
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Figure 5.16 Antagonism of Androgen Receptor Transactivation in HeLa4-11 Cells 
Exposed to Bisphenols (BPA and M-BPA) for 24 Hours 
Graphs, drawn with GraphPad Prism® Log(inhibitor) vs. Response (three parameters), show the adjusted 
and normalised relative light units (RLU) emitted during the luciferase assay, consequent to coexposure 
of testosterone (1fM) and either bisphenol A (BPA) or 2,4-bis(4-hydroxyphenyl)-4-methyl-1-pentene (M-
BPA). Results were normalised by subtracting vehicle control (DMSO) RLU and adjusted by dividing by 
1fM testosterone RLU (maximal agonistic response). Left side graphs summarise day repeat data, 
presented as the Mean and Standard Error of the mean (SEM), which was used to calculate inhibition 
(LogIC50/IC50) with 95% Confidence Intervals (95% CI). Error shown in the Day Repeat Data (right) is 
equivalent to the standard deviation, showing the data distribution over the different testing days. Quality 
assurance data (Z-prime) for each 96-well plate are stated in green. BPA bottom -0.2812 (95% CI -0.5712 
to 0.008806) and top 0.7641 (95% CI 0.7425 to 0.7857), R square = 0.8199 (n=63). M-BPA bottom 
0.04238 (95% CI -0.0948 to 0.1796) and top 0.8106 (95% CI 0.7835 to 0.8377), R square = 0.8247 
(n=63).  
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Figure 5.17 Antagonism of Androgen Receptor Transactivation in HeLa4-11 Cells 
Exposed to Phthalates (DBP, DEHP and BBP) for 24 Hours 
Graphs, drawn with GraphPad Prism® Log(inhibitor) vs. Response (three parameters), show the adjusted 
and normalised relative light units (RLU) emitted during the luciferase assay, consequent to coexposure 
of testosterone (1fM) and either Dibutylphthalate (DBP), Diethylhexylphthalate (DEHP) or 
Butylbenzylphthalate (BBP).  Results were normalised by subtracting vehicle control (DMSO) RLU and 
adjusted by dividing by 1fM testosterone RLU (maximal agonistic response). Left side graphs summarise 
data, presented as the Mean and Standard Error of the mean (SEM), which was used to calculate 
inhibition (LogIC50/IC50) with 95% Confidence Intervals (95% CI). Error shown in the Day Repeat Data 
(right) is equivalent to the standard deviation, showing the data distribution over the different testing 
days. Quality assurance data (Z-prime) for each 96-well plate are stated in green. DBP bottom 0.3554 
(95% CI -0.0517 to 0.763) and top 0.8331 (95% CI 0.7968 to 0.870), R square = 0.581 (n=42). DEHP R 
square = 0.541 (n=42). BBP bottom 0.3924 (95% CI 0.083 to 0.702) and top 0.797 (95% CI 0.768 to 
0.826), R square = 0.611.  
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Figure 5.18 Antagonism of Androgen Receptor Transactivation in HeLa4-11 Cells 
Exposed to Phenolic Chemicals (4-BP and 4-NP) for 24 Hours 
Graphs, drawn with GraphPad Prism® Log(inhibitor) vs. Response (three parameters), show the adjusted 
and normalised relative light units (RLU) emitted during the luciferase assay, consequent to coexposure 
of testosterone (1fM) and either 4-Benzylphenol (4-BP) or 4-Nitrophenol (4-NP). Results were 
normalised by subtracting vehicle control (DMSO) RLU and adjusted by dividing by 1fM testosterone 
RLU (maximal agonistic response). The Mean and Standard Error of the mean (SEM) was used to 
calculate inhibition (LogIC50/IC50) with 95% Confidence Intervals (95% CI). Error shown in the Day 
Repeat Data (right) is equivalent to the standard deviation, showing the data distribution over the different 
testing days. Quality assurance data (Z-prime) for each 96-well plate are stated in green.  
Figure 5.18 shows the antagonism of 1fM Testosterone AR transactivation in HeLa4-11 
cells exposed to 4-Benzylphenol or 4-Nitrophenol, for 24 hours. The antagonistic 
response of 4-Nitrophenol was ambiguous, however, 4-Benzylphenol demonstrated a 
LogIC50 and IC50 of -5.356 M (95% CI: -5.81 to -4.91) and 4.404e-06 M (95% CI: 
1.56e-06 to 1.25e-05), respectively. 4-Nitrophenol has been shown to agonise AR at 
0.001μM (see Table 5.3). However, neither agonism nor antagonism of AR 
transactivation was observed in the HeLa4-11 cell line.  
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Identified as in vitro agonists of AR transactivation in HeLa4-11 cells, in Section 5.3.4, 
Dichlorodiphenyldichloroethylene (4,4’-DDE), Octylmethoxycinnamate (OMC), 
Methylparaben (MeP) and Triclosan (TCN) did not antagonise 1fM Testosterone 
induced AR transactivation (Table 5.12; see Appendix 6.1H.3); all 96-well plates 
passed quality checks Z’ >0.65. Table 5.2 provides a summary of results generated in 
the HeLa4-11 stably transfected AR transactivation assays, conducted herein. Most 
results agreed with literature observations, presenting comparable sensitivity to the 
MDA-k2b cell line. Previously undescribed, Di-n-butylphthalate, 4-Benzylphenol and 
2,4-bis(4-hydroxyphenyl)-4-methyl-1-pentene, were identified as androgen receptor 
antagonists.  
Table 5.12 Results of HeLa4-11 Stably Transfected AR Transactivation Assay to Detect 
Antagonism of Androgenic Signalling 
In the absence of standardised in vitro assays for AR mechanisms, the table summarises the results of AR 
transactivation antagonism in the stably transfected HeLa4-11 cell line. N=number of data points, 
DR=day repeats. >80% refers to the nearest tested concentration exceeding >80% Testosterone induced 
AR transactivation.  
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5.3.6 Transient-Transfection Transactivation Assays (TTTA) 
Aiming to explore the current in vitro tools for endocrine MoA, the evaluation of 
transient transfection technologies for novel reporter gene assays was an objective. In 
line with NIBB (Japan), novel transiently-transfected roach (Rutilus rutilus) ERα and 
ARβ reporter assays were piloted herein, as ecological in vitro mechanistic studies 
relevant to UK sentinel species. The results of roachERα and roachARβ reporter assays are 
detailed in the following sections.  
5.3.6.1 Roach ERα Transactivation Assay  
The roach (R. rutilus) Estrogen Receptor α (ERα) construct  was successfully 
transfected into the HEK293 cell line, using Fugene HD® transfection reagent 
(Promega), as demonstrated by the firefly luciferase activity induced by 100 pM of the 
natural and synthetic hormones, E2 and DES (Figure 5.19). Transfection efficiency was 
controlled using Renilla luciferase activity. Interestingly, E2 appeared slightly more 
potent than DES, differing from mammalian ER receptors, but in line with the proposed 
evolution of ERα with the E2 ligand (Thornton, 2001). The anthropogenic chemicals 
Bisphenol A (>10μM BPA) and 4-Benzylphenol (>10μM 4-BP) induced Roach ERα 
activity, suggesting a biological mechanism for effects observed in fish in vivo. The 
50% effective concentration (EC50 and LogEC50) of the test substances in the Roach 
ERα Transactivation Assay were: 4.438e-11 E2 (-10.35 log EC50); 5.353e-11 DES (-
10.27 log EC50); ~1.329e-6 4-BP (-5.877 logEC50); and, 5.797e-7 BPA (-6.237 
LogEC50).  
 
Figure 5.19 Roach Estrogen Receptor alpha (ERα) Transactivation Assay 
The Graph shows the fold induction consequent to E2, DES, BPA, DBP, 4-BP and DEHP exposure. Non-
linear dose response curves were as variable slope log(agonist) vs. responses (four parameters). Error bars 
show the Standard Error of the Mean (SEM). As one might expect, the natural and synthetic hormones, 
E2 and DES, induced activity at the lowest concentrations. Furthermore, <10μM Bisphenol A (BPA) and 
<10μM 4-Benzylphenol (4-BP) induced Roach ERα activity. Results analysed in GraphPadPrism®.  
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EC50 values were calculated in GraphpadPrism®. It should be noted that Hill slope 
values ranged between 1.68 and 4.528, indicative of the steep slopes presented in Figure 
5.19. The close proximity of the point of departure to maximal response hinders the 
accuracy of the EC50’s calculated, however, may be considered typical for hormone 
responses.    
5.3.6.2 Roach ARβ Transactivation Assay 
The roach (Rutilus rutilus) Androgen Receptor β (ARβ) was successfully transfected 
into the HepG2 cell line, using Fugene HD® transfection reagent (promega), as 
demonstrated by the firefly luciferase activity induced by 100 pM of the anabolic 
steroid 17α-Methyltestosterone (17-MT) Figure 5.20. Transfection efficiency was 
controlled using Renilla luciferase activity. None of the other androgenic compounds 
tested induced activity at the concentrations tested (100nM - 0.1pM). 17-MT has been 
used in aquaculture to induce sex reversal, skewing the sex ratio towards males, which 
grow faster and are typically more ornate (Pandian et al. 1995). Considered to be more 
potent than testosterone in fish, the observed activity of 17-MT in this assay is not 
surprising; 17-MT has been tested in vivo in more than 25 species belonging to 
Salmonidae, Cichlidae, Cyprinidaw, Anbantidae, Poecilidae and Cyprinodontidae 
(Pandian et al., 1995). 
 
Figure 5.20 Roach Androgen Receptor Beta (ARβ) Transactivation Assay 
The non-linear relationship was plotted as a log(agonist) vs. response variable slope (four parameters). 
Error bars show the Standard Error of the Mean (SEM).  The Graph shows the luciferase fold induction 
consequent to exposure to 100nM – 0.1 pM exposure of testosterone, 17α-Methyltestosterone, 11-
ketotestosterone or dihydrotestosterone. Results presented using GraphPadPrism®. 
However, it is interesting to note that in human medicine 17-MT is used as a US FDA 
approved orally active synthetic androgen during menopause, and is considered to have 
relatively weak affinity to the human androgen receptor (Barrett-Connor et al., 1999). 
Furthermore, androgen receptor-independent effects in rats have led to confusion 
regarding the chemicals clinical mode of action (Mor et al., 2001). Collectively, the 
studies may suggest species variance in the binding affinity between androgenic 
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compounds and AR. The lack of activity observed for the other compounds, including 
the endogenous fish androgen, 11-Ketotestosterone (11-KT), may be as a result of 
inadequate Roach ARβ transfection, or because higher doses (> 100nM) of the 
compounds are required to induce translational activity in the mammalian assay system. 
5.4 In vitro Summary and Conclusions 
The scope, validation and variety of in vitro assays to elucidate endocrine mechanisms, 
has reflected the state of the science. Consequently, tools to decipher less conventional 
MoA are limited, while a plethora of assays evaluate ER agonism/antagonism. 
Validated by the OECD, HeLa9903 and BG1Luc4E2 cell lines were utilised in the ERα 
and ERα/β transactivation assays conducted herein. The concepts and approaches 
detailed in OECD TG455 were adhered to where possible. However, the exposure and 
attachment times were increased, subsequent to preliminary testing for laboratory 
performance and optimisation of E2 exposure in the HeLa9903 cell line.  
 The in vitro ER transactivation in HeLa9903 cells exposed to semi-log 
concentrations of E2 (1uM-0.1pM) demonstrated STTA proficiency defined 
by the US EDSP OPPTS 890 1300 and OECD TG455. 
The response of HeLa9903 ER transactivation in response to semi-log concentrations of 
E2, presented a LogEC50 of -10.2 M with a Hill slope value of 1.07 herein, adhered to 
the proficiency standards of: LogEC50 between -11.3-10.1 M and a Hill slope value of 
0.7-1.5 (ICCVAM, 2011). The increase in exposure time led to increased sensitivity in 
detecting EE2 (EC50 5.33x10
-15
 M vs <1x10
-11
 M), DES (EC50 1.46x10
-12
 vs 2.4x10
-11
 
M), BPA (EC50 7.44x10
-11
 vs 5.33x10
-7
), BBP (EC50 7.75x10
-8
 vs 4.11x10
-6
), DDE 
(EC50 4.35x10
-12
 vs 3x10
-6
 in the BG1Luc ER TA) and Testosterone (EC50 6.87x10
-12
 vs 
9.78x10
-6
). There is limited data pertaining to the agonistic response of 4-BP, 4-NP, M-
BPA, Methylparaben, OMC and Triclosan in the HeLa9903 cell line. However, the 
dose-response relationships observed for 4-BP (Figure_Apx 15) and MBPA (Figure 5.5) 
support the ER activity reported in the literature (Table 5.3; Yoshihara et al., 2004).  
 The results generated herein, suggest that increasing the in vitro chemical 
exposure time, increases the sensitivity of HeLa9903 stably transfected ER 
transactivation assay. 
The BG1Luc ER TA was demonstrated to be an insensitive in vitro assay, under the 
laboratory conditions and equipment specifications available herein (Section 5.2); 24 
hour E2 or EE2 exposure did not induce any ER transactivation, increasing exposure 
(48 hours) led to an induction of ER transactivation, at 10
-8
 M E2 and 10
-9
 M EE2 
(Figure 5.7). Thus, the transactivation responses reported herein were lower than the 
TG455 reference standards; E2 EC50 5.63x10
-12
 M and EE2 EC50 4.20x10
-8
 M 
(ICCVAM, 2011).  
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Validation studies by contract laboratories identified significant variability in BG1Luc 
ER TA response; E2 induced transactivation in 24 of 35 assays. ICCVAM (2011) notes 
that DMSO vehicle controls vary considerably between test plates; ranging from 511 to 
9885 RLU (mean 3749). Interestingly, the maximum E2 response reported herein was 
comparable to that reported in BG1Luc validation studies (10,000 RLU); thus, the 
shortfall of the assay may be due to background luminescence.  
Received in a mutual transfer agreement, the BG1Luc3E2 cells utilised herein were not 
authenticated, and estrogen insensitivity may have been a result of morphological 
changes, inconsistency in media supplementation and/or FBS batch. However, collating 
the validation studies, literature (Section 3) and in vitro assay results, the author 
suggests that the ubiquitous variability in BG1Luc4E2 ER TA responses may reside in 
ER feedback mechanisms; Metivier et al. (2003) demonstrated dominant inhibition of 
ERα transactivation by ERβ. Endogenously expressing both ERs, signal transduction in 
the BG1Luc ERα/β transactivation assay reflects in vivo co-expression. However, ERα 
and ERβ cross-talk may increase the variability of transactivation; highlighting the 
intricate balance between resembling in vivo cellular environments and standardisation 
of in vitro assays.  
 
Figure 5.21 Agonistic ER Transactivtion Concentration-Response in the HeLa9903 Stably 
Transfected Cell Line and Hek293 Cells Transiently Transfected with Rutilus rutilus 
(common roach) ERα 
Graphs show the adjusted and normalised relative light units (RLU) emitted by HeLa9903 cells and 
HEK293 cells in luciferase assays, consequent 40-48hr exposure to DES, E2, DEHP, BPA, 4-BP or DBP. 
Results were normalised by subtracting vehicle control (DMSO) RLU and adjusted by dividing by the 
RLU of 1nM E2 (maximal agonistic response). The dotted line (y=0.2) highlights 20% 1nM E2 
normalised RLU, as a threshold for categorising positive, negative and/or inadequate data.Data presented 
is the mean and standard error of the mean (SEM) of data repeats, analysed with GraphPad Prism® 
Log(agonist) vs. response (three parameters). 
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A number of in vitro studies have shown that EDC binding affinity is species specific 
(Lang et al., 2012; Wilson et al., 2007). Aiming to explore the current in vitro tools for 
interspecies endocrine MoA, transient transfection of novel NR for transactivation 
assays, was evaluated. Common roach (Rutilus rutilus) ERα and ARβ reporter assays 
were piloted herein, as mechanistic studies relevant to model ecotoxicity species 
indigenous to the UK.  
 The roach (R. rutillus) Estrogen Receptor α (ERα) construct was 
successfully transfected and expressed in HEK293 cells. 
 Response of transiently transfected HEK293 cells in response to E2, DES, 4-
Benzylphenol and BPA, was successfully measured in dual luciferase 
reporter assays.  
Figure 5.21 presents HeLa9903 hERα STTA assay and roachERα transactivation assay 
results; highlighting variability in the in vitro potency of tested EDC’s. In roachERα 
transactivation assays E2 (EC50 44.4pM) was more potent than DES (EC50 53.5pM), 
which differed from human ER (E2 EC50 63.7pM vs DES EC50 1.46pM). The 
anthropogenic chemicals Bisphenol A and 4-Benzylphenol induced Roach ERα 
transactivation, providing a biological mechanism for in vivo apical endpoints observed 
in fish. The EC50 and LogEC50 of roachERα transactivation in response to BPA exposure 
were 0.58μM and -6.24 M, respectively. The hERα in HeLa9903 cell transactivation 
assays demonstrated higher BPA sensitivity; equivalent exposure presented EC50 
74.4pM and LogEC50 -10.13 M (Table 5.13) 4-BP exposure in HEK293 cells transiently 
transfected with roachERα, agonised reporter gene production, presenting EC50 and 
LogEC50 values of 1.33μM and -5.88 M, respectively. In HeLa9903 cells, the EC50 and 
LogEC50 were 13.43μM and -4.87, respectively; suggesting the common roach is more 
susceptible to 4-BP agonism of ERα transcativation.  
 Clear differences in the agonistic responses consequent to 48 hour test 
substances exposure, in HEK293 roachERα TA and HeLa9903 ST hERα TA, 
were demontrated.  
The R. rutillus Androgen Receptor β (ARβ) was successfully transfected into the 
HepG2 cell line, as demonstrated by the firefly luciferase activity induced by 100 pM 
17α-Methyltestosterone (17-MT) (Figure 5.20). However, none of the other androgens 
induced AR transactivation at the tested concentrations (100nM-0.1pM), limiting 
comparisons with HeLa4-11 ST AR TA results. 17-MT has been used in aquaculture to 
induce sex reversal, skewing the sex ratio towards males (Pandian et al. 1995). 
Demonstrated to be more potent than testosterone in fish, the observed activity of 17-
MT in this assay is not surprising (Pandian et al., 1995).  
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Figure 5.22 Agonistic AR Transactivation Concentration-Response in HeLa4-11 Cells 
Consequent to 24 Hour Chemical Exposure 
Lines of best fit of mean (±SEM) data were drawn using GraphPad Prism® Log(agonist) vs. Response 
(three parameters). Graphs show the adjusted and normalised relative light units (RLU) emitted 
consequent to Testosterone, E2, DES, PRG, MBPA, 19-ND, MeP, TCN or OMC exposure. Results were 
normalised by subtracting vehicle control (DMSO) RLU and adjusted by dividing by the RLU of 1nM 
testosterone (maximal agonistic response). The dotted line (y=0.2) highlights 20% positive control (1nM 
testosterone ~ maximal response) luciferate induction, as a threshold for categorising positive, negative 
and/or inadequate data.  
 
 
Figure 5.23 Antagonistic AR Transactivation Concentration Responses in HeLa4-11 Cells 
Consequent to 24 Hour Chemical Exposure 
Drawn with GraphPad Prism® Log(inhibitor) vs. Response (three parameters), the graph show the 
adjusted and normalised relative light units (RLU) emitted by lysed HeLa4-11 cells during luciferase 
assays, consequent to co-exposure of testosterone (1fM) with 1:10 log dilutions (100μM to 1pM) of either 
Flutamide, E2, EE2, Diethylstilbestrol, Progesterone, 4-Benzylphenol, Bisphenol A, M-BPA, 
Dibutylphthalate or Butylbenzylphthalate. Results were normalised by subtracting vehicle control 
(DMSO) RLU and adjusted by dividing by 1fM testosterone RLU (maximal agonistic response). 
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Conversely, 17-MT is US FDA approved for use as an orally active weak synthetic 
androgen during menopause; presenting relatively weak affinity to the human androgen 
receptor (Barrett-Connor et al., 1999). Furthermore, androgen receptor-independent 
effects observed in rats, has led to confusion regarding the pharmacological mode of 
action of 17-MT’s (Mor et al., 2001).  
The lack of AR transactivation, observed for Testosterone, 11-Ketotestosterone (11-KT) 
and Dihydrotestosterone, may be as a result of inadequate roachARβ transfection, assay 
insensitivity (higher dose requirements (> 100nM)), or the the mammalian HepG2 cell 
line may not be a suitable in vitro model, to predict R. rutilus AR transactivation. 
Interestingly, pilot reporter gene studies of roachARα transiently transfected into HEK293 
cells, identified agonism of AR transactivation, at all tested concentrations of 
Testosterone (6.1Appendix G).  
Developed to detect androgenic activity, HeLa4-11 cells are stably transfected with a 
hAR expression construct and a firefly luciferase reporter gene under the control of the 
MMTV promoter. 
 HeLa4-11 cells stably transfected AR transactivation assays successfully 
evaluated the in vitro androgenicity of potential EDCs.  
In agreement with concepts detailed in OECD TG455, cells were suspended in 10% 
DCC-FBS-EMEM and plated at 1 x 10
4
 cells/100μL per 96-well and allowed to attach 
for 3 hours, prior to the addition of 100 μL of 10% DCC-FBS-EMEM and 0.2μL of test 
substances in 100% DMSO. Figure 5.22 summarises the in vitro concentration-response 
results of AR transactivation, in HeLa4-11 cells plated in 96-wells, consequent to 24 
hour exposure. Negative responses are detailed in Table 5.13.  
However, agonism of AR transactivation in HeLa4-11 cells presented a number of 
irregularities. In 24-well plates, Testosterone exposures presented LogEC50 and EC50 of 
-9.90 M and 0.126nM, respectively (R
2
=0.9599, n=58), presenting comparable 
sensitivity to the MDA-kb2 cell line (Orton et al., 2014) and S. cerevisiae yeast 
androgen bioassay (Michelini et al., 2005). However, all concentrations of Testosterone 
(1x10
-6
 M to 1x10
-24
 M) induced maximal AR transactivation in 96-well plates (4/4 day 
repeats). Avogadro’s constant (NA) 6.022x10
23
 approximates the number of constituent 
molecules in a mole (Mohr et al., 2008), thus, in light of the dilutions, the assay appears 
to induce maximal AR transactivation in response to trace concentrations of 
Testosterone. The mean 96-well plate (n=32) Z’prime value was 0.5, emphasising the 
statistical significance of responses generated in HeLa4-11 AR transactivation assays. 
Nevertheless, the marked differences observed between plate formats are disconcerting.  
 The sensitivity of AR responses reported herein leads the author to suggest 
modification of AR transcriptional machinery in the HeLa4-11 cell line, via 
cofactor expression, AR polymorphisms, modifications in the LBD of cross-
talk between signalling pathways.  
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Table 5.13 Summary of Stably Transfected Transactivation Assay Results for ER 
Agonism (HeLa9903) and AR Agonism and AR Antagonism (HeLa4-11) 
Table shows the results generated herein, in addition to OECD/ICCVAM ER STTA values. The 
HeLa9903 assay sensitively identified ER agonists; reporting agonism at lower concentrations of BPA, 
BBP, 4’4-DDE, Testosterone. In the absence of standardised in vitro assays for AR mechanisms, AR 
agonism and antagonism has been demonstrated. Results highlighted green presented atypical dose-
response relationships – inactive at high concentrations, but inducing luciferase production at low doses 
(i.e. reverse curve).   
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The sensitivity of in vitro AR transactivation has been shown to vary with cell 
concentration (Térouanne et al., 2000). Cofactors regulate the transactivation of NR, 
Gelsolin, ARA55 and ARA70 have been demonstrated to enhance AR transactivation, 
in response to residual androgen concentration (Nishimura et al., 2003; Fujimoto et al., 
1999; Yeh et al., 1999a). Furthermore, Yeh et al. (1999b) suggested that cross-talk 
between AR and HER-2/neu pathways stimulated by growth factors, may activate AR. 
It is suggested that HeLa4-11 cells express elevated cofactor concentrations and/or elicit 
inter-cellular signalling, which amplify the response to trace testosterone 
concentrations, when plated in higher concentrations. However, increased sensitivity 
may also be consequent to modification in the AR itself. 4,4’-DDE has been 
demonstrated to inhibit R1881 AR signalling in vitro, while the antagonistic properties 
of 4,4-DDE in utero, have been associated with cryptorchidism incidence (Montes et 
al., 2010). Conversely, 4,4’-DDE (1x10-6 M to 1x10-18 M) induced maximal agonistic 
response in 96-well HeLa4-11 assays. However, Björk et al. (2011) identified alterated 
4,4’-DDE AR agonism and antagonism of transactivation in vitro, relative to androgen 
receptor CAG lengths, which have also been implicated in the aetiology of Testicular 
Germ Cell Cancer (Västermark et al., 2011; see Section 2.2). It may thereore be 
suggested that HeLa4-11 cells express a more sensitive AR polymorphism.  
 Biphasic responses, reflecting low-dose stimulation and high-dose 
inhibition, were identified for DES (EC50 3.27pM), PRG (EC50 3.03pM) and 
MBPA (EC50 2.97pM).  
Further complicating the in vitro HeLa4-11 AR transactivation assay results, biphasic 
responses were identified. A contentious theory in endocrine disruption science, in light 
of the atypical sensitivity of the in vitro assay, believed to be resultant of modifications 
in AR transacriptional machinery, the low-dose stimulation observed herein, should be 
taken with caution. Modulation of in vitro AR transactivation may not resemble the 
scenario in vivo, or the response of other in vitro cell lines. Nevertheless, the data 
presented herein strongly suggest that BPA, 4-BP, 4-NP, DBP, DEHP and BBP do not 
agonise the androgen receptor, in HeLa4-11 cells. Slight luciferase induction was 
observed at 10μM EE2; however, this coincided with cytotoxicity, and is more likely 
associated to cellular breakdown (see Figure 5.1). 
Results of the HeLa4-11 AR antagonism assays identified in this study, which modified 
the in vitro HeLa4-11 AR transactivation assays, to detect AR signalling antagonists, 
demonstrated both agonistic and antagonistic modes of action, depending on the 
concentration and presence of endogenous hormone. The endogenous and synthetic 
hormones inhibited 1fM Testosterone induced AR transactivation, with greater potency 
than Flutamide (Figure 5.14); LogIC50 and IC50 of EE2 were, -8.389 M and 4.08nM, 
respectively Highlighting, the potential for feedback mechanisms, receptor cross-talk 
and diversity in cellular response. Tox21 qHTS assays identified E2 AR antagonism at 
0.06μM (Huang et al., 2014; see Table 5.1). The HeLa4-11 AR transactivation assay for 
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antagonistic responses detailed herein, demonstrated higher sensitivity for E2 MoA; 
IC50 4.08nM E2 + 1fM Testosterone.  
Table 5.12 provides a summary of STTA results for ER agonism (HeLa9903), AR 
agonism and AR antagonism (HeLa4-11). Corroborating Yoshihara et al.’s (2004) 
hypothesis, 4-Methyl-2,4-bis(4-hydroxyphenyl)pent-1-ene (MBPA) induced 
transactivation at either equivalent or lower concentrations, relative to the BPA parent 
compound. In support of the literature, the dual-activity of endogenous hormones, 
eliciting both agonism and antagonism of NR transactivation, presents potentially 
significant challenges to EDC hazard characterisation. It may be suggested that while 
binding and transactivation of NR play vital roles in estrogenicity and androgenicity, the 
neglect of the supporting regulatory mechanisms has left vast uncertainties regarding 
the reliability and applicability of in vitro results. 
The in vitro results aimed to provide mechanistic and potency information for EDC 
hazard characterisation. The stably transfected HeLa9903 and HeLa4-11 cell lines 
successfully identified estrogenicity and androgenicity, respectively. However, the 
results simultaneously haze the reliability of in vitro responses. In particular, the 
predicted modulation of HeLa4-11 transactivation highlights an array of biological 
responses, variability of which which may render predictions of agonism or antagonism 
futile. Thus, the standardised tools generated standardised responses, but without an 
understanding of the relevance of these mechanisms to the in vivo situation, potency 
predictions are limited.  
5.4.1 In vitro Summary and Milestones  
 The HeLa9903 Stably Transfected ER Transactivation assay in this study 
demonstrated OECD TG455 proficiency in predicting E2 responses;  
 Increasing chemical exposure time to 40 hours significantly increased 
HeLa9903 cell ERα transactivation sensitivity; 
 HeLa4-11 cells stably transfected AR transactivation assays successfully 
evaluated the in vitro androgenicity of potential EDCs; 
 The sensitivity of AR responses reported herein suggests modification of 
HeLa4-11 AR transcriptional machinery; 
 Modulated transactivation has been reported in the literature consequent to 
cofactor expression, AR polymorphisms, modifications in ligand binding 
domain and cross-talk between signalling pathways; 
 The predominant metabolite of BPA, 4-Methyl-2,4-bis(4-
hydroxyphenyl)pent-1-ene, demonstrated equivalent or greater potency that 
the parent compound, in all HeLa ERα and AR transactivation assays;  
 Biphasic responses, reflecting low-dose stimulation and high-dose inhibition, 
were identified for Diethylstilbestrol, Progesterone and 4-Methyl-2,4-bis(4-
hydroxyphenyl)pent-1-ene (MBPA); and 
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 Chemicals presenting dual agonism/antagonism of NR transactivation 
present significant challenges to EDC hazard characterisation. 
5.4.2 Further Work to Aid Development of in vitro Methods for 
EDC Hazard Characterisation 
Genetic polymorphisms, NR cross-talk, co-factors and hormone-response-elements, 
play a significant role in the classic genomic pathway (Section 3.1). These biological 
foundations have been demonstrated to vary between individuals, tissues and cells 
(Västermark et al., 2011; Yeh et al., 1999a, 1999b; Nishimura et al., 2003; Fijimoto et 
al., 1999; Björk et al., 2011), and provide a mechanism for variable transactivation, 
reported in the literature, and observed herein. Further investigation into cellular 
machinery and signalling pathways, may aid evaluation into the relevance of in vitro 
NR transactivation, from a chemical safety perspective, i.e. evaluate the probability of a 
possibility.  
The in vitro HeLa9903, BG1Luc4E2 and HeLa4-11 cells are starved of hormones prior 
to STTA; to increase the sensitivity of transcriptional response and reduce background 
estrogenicity/androgenicity. Subsequently, the cells may be considered ‘primed’ to 
detect positive responses, which may be improbable in vivo. However, amplification 
and/or inhibition of in vitro NR transactivation, in response to mixtures of endogenous 
hormones remains neglected. The dual-activity of endogenous hormones and 
xenobiotics, in eliciting agonism and antagonism of NR, presents significant challenges 
to future work. Evaluating mixtures of the chemicals tested herein could provide 
invaluable information regarding NR mechanisms and ligand promiscuity. E2, DES, 
PRG and M-BPA demonstrated ER agonism in HeLa9903 cells, in addition to agonism 
and antagonism of AR transactivation in HeLa4-11 cells; thus, the mechanistic response 
appears to vary with concentration, mixture and cell line model.  
The increased sensitivity of the HeLa4-11 cell STTA suggests modulated coregulator 
expression, amplifying the response to trace testosterone concentrations. Alternatively, 
AR polymorphisms, such as those reported by Björk et al. (2011), may increase the 
sensitivity of AR. Functional loss of the Thr877 residue, identified the hAR in silico and 
associated to prostate cancer aetiology, may also confer increased ligand promiscuity in 
vitro (Sack et al., 2001; Taplin et al., 1995). However, the specific modifications of the 
HeLa4-11 cell remain spectulative, due to patent restrictions (US7537904B1 Ooe & 
Matsunaga, 2009
54
). A detailed exploration into the mechanism of HeLa4-11 AR 
transactivation is required, to understand the results generated herein. In particular, 
further in vitro testing of the biphasic responses, observed in HeLa4-11 cells exposed to 
DES, PRG and M-BPA, at lower concentrations and in different plate formats, may 
                                                 
54
 Cell for measuring the ability to control the activity of a ligand-responsive transcription control factor 
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provide more conclusive evidence, to either support or deny the low-dose simulation 
and high-dose inhibition demonstrated herein.  
Consequent to the elevated potency of BPA’s predominant metabolite, 4-Methyl-2,4-
bis(4-hydroxyphenyl)pent-1-ene, investigation of metabolites generated in liver S9 
fractions for other test substances, may provide useful information regarding the ‘true’ 
hazard of a chemical and inform risk assessment. The adoption of gene array 
technology, to map the fold-induction of gene expression, consequent to chemical 
exposure, may provide the mechanistic information required to understand the cellular 
responses observed herein.  
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6 GENERAL DISCUSSION AND 
CONCLUSIONS 
From the birds to the bees, a plethora of developmental, reproductive and behavioural 
perturbations have been reported in wildlife exposed to anthropogenic chemicals. The 
reporting of endocrine disruption throughout phylogenetic classes, in addition to the 
homology of biological machinery, has mounted concern regarding the role of EDC 
exposure in the aetiology of human disease. In the EU, health costs associated with 
EDC exposure has been estimated at €31 billion per annum (HEAL, 2014). However, 
reflecting a mechanism rather than a hazard in itself, there are complexities in defining 
endocrine disruption.  
Nuclear receptor binding interactions are the current focus of in vitro and in silico tools 
used to predict EDC mechanisms. Computational chemistry has been suggested as a 
surrogate to binding assays, by replicate the dynamics, energetics and structure of 
ligand-receptor interactions in silico (Taft et al., 2007). An established limitation of in 
vivo toxicology is the inability to elucidate MoA from traditional apical endpoints, 
which may be the result of an array of biological interactions. Thus, there is theoretical 
plausibility to the hypothesis tested herein, that in silico and in vitro mechanistic tools 
are more adept to elucidate endocrine MoA. Aiming to evaluate current in silico and in 
vitro tools for EDC screening and hazard characterisation, the literature identified the 
omnipresence of chemical exposure, in addition to an array of affiliated adverse health 
outcomes. However, more importantly the literature defined the current understanding 
of endocrinology and endocrine disruption, which found and support the inconsistencies 
of in silico and in vitro results.  
Curated on the basis of regulatory concern, exposure, structural variability and assumed 
functionality, the chemical database (n=378) was successfully docked to nuclear 
receptor pseudo-molecular targets (protomols). Docking targets were identified using 
the solvation method. The solvation method accurately predicted the amino acid 
residues and molecular probes responsible for hERα and hAR binding (Brzozowski et 
al., 1997; Shiau et al., 1998; Sack et al., 2001). SYBYL Surflex-Dock ER, AR, PR & 
PPARγ virtual screening demonstrated a sensitivity of 94.5%, relative to in vitro 
bioassay, and surpassing the predictability of the OECD Toolbox ER profiler, DfW and 
binary classification models.  
The study demonstrated important in silico developments in the computational 
prediction of EDC hazards, since the initial application of SYBYL macromolecular 
modelling to EDCs by Wu et al. (2010). However, further investigation of interspecies 
ligand binding in vitro (Lange et al., 2012; Wilson et al., 2007; Wells & Van Der 
Kraak, 2000), is required to validate the sensitivity of molecular model predictions of 
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interspecies variation. The novel Common Roach reporter assay, developed to 
characterise mechanisms of ecological endocrine activity, has been identified as an 
appropriate method to elucidate species differences in NR. The roach, Rutilus rutilus 
ERα and ARβ constructs were successfully transiently transfected into HEK293 cells 
and measured, in response to E2, DES, 4-Benzylphenol and BPA, in a dual luciferase 
transactivation assays. The assay identified interspecies differences in transactivation 
consequent to ligand binding, in agreement with the differences reported in other 
sentinel fish species (Lange et al., 2012). 
With the aim of evaluating currently available in vitro tools for endocrine MoA, the 
literature was reviewed and potential-EDCs were successfully assessed in stably 
transfected ERα and AR transactivation assays (HeLa9903 and HeLa4-11 STTA, 
respectively) in vitro assays. The scope, validation and variety of in vitro assays 
reflected the state of the science, which limited the breadth of MoA and species 
investigated in STTA. However, the aforementioned Common Roach reporter assay 
successfully explored transient transfection technologies for reporter gene assays, to 
elucidate novel receptor endocrine activity. 
Consequent to increased exposure time, the HeLa9903 ER transactivation assay 
demonstrated the 17β-Estradiol STTA proficiency defined by the US EDSP OPPTS 890 
1300 and OECD TG455; LogEC50 -10.2 (Hill slope 1.07). Optimised to the E2 control, 
the results generated herein, suggest that the 16 hour increase in exposure increased the 
sensitivity of HeLa9903 cells to the estrogenicity of EE2, DES and BPA. The 
predominant metabolite of BPA, 4-Methyl-2,4-bis(p-hydroxyphenyl)pent-1-ene 
(MBPA), demonstrated comparable estrogen transactivation to the parent compound. 
However, MBPA was shown to agonise androgen receptor transactivation in HeLa4-11 
cells, while comparable concentrations BPA did not, supporting the theory that BPA 
metabolites may have more toxic potential (Yoshihara et al., 2004). 
Developed to detect androgenic activity, HeLa4-11 cells are stably transfected with a 
hAR expression construct and a firefly luciferase reporter gene under the control of the 
MMTV promoter. HeLa4-11 cell transactivation assays successfully evaluated the in 
vitro androgenicity of potential EDCs. However, the sensitivity of the AR responses 
reported herein suggests modification of AR transcriptional machinery, potentially via 
cofactor expression, AR polymorphisms, modifications in the LBD or cross-talk 
between signalling pathways.  
Mechanisms of potential low dose toxicity (hormesis), sexual dimorphism, 
transgenerational effects and variable endpoints, dependent on the time and duration of 
exposure, have been reported in vivo. Non-monotonic or ‘biphasic’ dose-responses 
remain a contentious issue in endocrine disruptor science. Biphasic responses, reflecting 
low-dose stimulation and high-dose inhibition, were identified for Diethylstilbestrol, 
Progesterone and 4-Methyl-2,4-bis(4-hydroxyphenyl)pent-1-ene (MBPA). To the 
authors’ knowledge, these MoA have not been previously reported; however, in light of 
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the suspected modifications to AR transactivation, these results should be taken 
cautiously. Collectively, the human epidemiology, in vivo toxicological findings 
(Section 2), biological mechanisms (Section 3) and the in vitro transactivation assay 
results (Section 5), highlight the potential errors in predicting potency from 
transactivation, which may vary with cellular metabolomics, which vary at cell, tissue, 
organ and organism levels.  
Phylogenetic analysis mapped the differences in the amino acid sequences of ER and 
AR. These differences were mirrored in the in silico binding, which highlighted 
theoretical functional differences in human, chimpanzee, rat and mouse AR. The in 
vitro transactivational response of hER and roachER, identified in transiently-
transfected HEK293 cells, demonstrates functional differences in nuclear receptors from 
different taxonomic classes. In support of the research conducted at the NIBB (Lange et 
al., 2012; Katsu et al., 2007), the susceptibility to chemical endocrine disruption may be 
in part defined by functional differences in the receptor, identifying a currently 
neglected field of interspecies variation. 
Understanding endocrine mechanisms, and their potential disruption by exogenous 
chemicals, is vital to assess the impacts on environment and health. The significant 
costs of inadequate regulation, both in terms of monetary cost and, mortality and 
morbidity of wildlife and human populations, highlights the political priority of EDCs. 
The literature highlights additional NR signalling complexity, while the in vitro results 
demonstrate dual agonism and antagonism of endogenous hormones and MBPA. Thus, 
the study results agree with Hotchkiss et al.’s (2008) research, which demonstrated 
antagonism of endogenous hormone response by partial agonists; assumed to be 
consequent to competitive binding. Functional cross-talk between NR further 
complicates the EDC biological mechanism. There are approximately 300 nuclear 
receptor coregulators (Lonard et al., 2007), concentrations of which vary between cells, 
tissues, organs and individuals. Without understanding the variability of supporting 
systems, understanding the biological consequences in the variability and activation of 
NR, may not be possible. However, in vitro studies suggest that coactivator recruitment 
is a rate-limiting step in NR-mediated gene transcription, thus, the susceptibility to EDC 
mediated toxicity, consequent to molecular initiation by nuclear receptor binding, is 
likely to be highly variable.  
Table 6.1 summarises the concordance between in silico ER and AR binding with in 
vitro AR transactivation assays. Both the in silico and in vitro results presented herein, 
highlight the need for further investigation of cofactor regulation and modulation of 
nuclear receptor responses. Without this information, predicting the MoA of is severely 
confounded. In many ways the in silico screens and in vitro assays surpass traditional 
apical endpoints, demonstrating excellent sensitivity in detecting either binding or 
transactivation. However, at the current state in time, the relevance of these 
observations to the whole organism is uncertain. 
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Table 6.1 Concordance of in silico human ERα and AR binding scores (SYBYL®) and in 
vitro transactivation assays 
In silico binding scores are in –log(Kd), while in vitro 50% effective concentration (EC50) are presented 
in moles, concordance between the results for ER and AR are highlighted by a green tick, whilst question 
marks reflect the need for more data.  
 
Bisphenol A is a political priority as a consequence of an estimated annual production 
of 4.4 million tonnes in 2012, with approximately 100 tons of BPA being released into 
the atmosphere (Vandenberg et al., 2010). Multiple sources contribute to human BPA 
exposure, however dietary exposure is considered the most significant pathway; the US 
NTP detailed adult oral BPA exposure to range from 0.008 to 1.5 µg kg
-1
 bw/day 
(Vandenberg et al., 2007). However, ensuring the public of the safety of BPA has 
generated over 5000 publications, rendering it a good example of scientific and 
regulatory uncertainty. The in silico screening and in vitro ER (HeLa9903 and roachER 
HEK293) and AR (HeLa4-11) assays reported herein, demonstrate the endocrine 
activity of Bisphenol A, which supports a wealth of in vivo toxicity studies. A plethora 
of studies have investigated the apical endpoints associated with BPA exposure, 
including increased mammary carcinogenesis, hyperactivity, reduced fertility and 
alteration of sexually dimorphic juvenile social interactions (Bergman et al., 2012). 
Many of the observed apical endpoints may be attributed to the potential estrogenicity 
and androgenicity identified herein. However, there is a vast gap in the knowledge, 
regarding the pathway from the in silico/in vitro molecular initiating events to the in 
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vivo adverse outcomes. Elucidating the differences between endocrine activity and 
endocrine disruption, are vital to our accurately understanding the risk of EDC 
exposure. Currently it may be suggested, that pathways between the molecular initiating 
events predicted in silico and in vitro, and the apical endpoints observed in vivo, at the 
individual and population levels, are clouded by an array of uncertain assumptions. 
 In conclusion, SYBYL molecular modelling and Surflex-Dock virtual 
screening sensitively predicted the binding of ERα/β, AR, PR and PPARγ 
potential EDCs, and could be a useful regulatory tool to support EAS 
hazard identification.  
 
 The in vitro transactivation assays in HeLa9903, HeLa4-11 and transiently-
transfected HEK293 cells, sensitively predicted nuclear activity.  
However, in light of the mechanistic complexity of NR signalling identified in the 
literature, and the transactivation responses of HeLa4-11 cells identified herein, it is 
suggested that the potency of NR transactivation, is not necessarily predicted by in vitro 
tools, which may present modifications to amplify or dampen expression. This 
inconsistency appears to be specific to particular ligand-receptor interactions, and as a 
consequence not predictable.    
6.1 Future Research and Requirements 
 Develop a harmonised biotechnology software hub with evaluated, defined in 
silico, in vitro and in vivo evidence, which elucidates positive/negative binding 
classification, from pooled in vitro data; 
 Elucidation of diverse sentinel species NR X-ray crystallography structures and 
validation of in silico methods to elucidate interspecies variations in ligand 
binding; 
 Comparison of SYBYL Surflex-Dock in silico screening and in vitro assays in a 
larger, more mechanistically diverse chemical databases;  
 Modulated transactivation has been identified as a potentially significant 
confounder. Elucidating the natural variation of cofactor expression, NR 
polymorphisms, modifications in ligand binding domain and cross-talk between 
signalling pathways, may play a significant role in understanding the in vivo 
context of in silico ligand binding and in vitro transactivation;  
 Evaluate the role of coregulatory molecules to in silico screening, via 
development of a multi-stage SYBYL Surflex-Dock tool, and identify the in 
vitro implications of cofactor concentrations, potentially via artificial simulation 
of cell profiles;  
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 Consequent to the elevated potency of BPA’s predominant metabolite, 4-
Methyl-2,4-bis(4-hydroxyphenyl)pent-1-ene, investigation of metabolites 
generated in liver S9 fractions, may provide useful information regarding the 
‘true’ hazards of chemical exposure. Incorporating predictions of metabolism to 
in silico (T.I.M.E.S. software) and in vitro (Liver S9 fractions) assays may 
inform hazard characterisation and risk assessment.  
 
Evaluation of in silico and in vitro screening methods for EDC hazard characterisation 
 
 
 Page 181  
  
 
 
 
 
 
 
 
 
 
 
 
 
“Give me fruitful error anytime, full of seeds, bursting with its 
own corrections. You can keep your sterile truth for yourself”  
Vilfredo Pareto 
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APPENDICES 
Appendix A List of Prioritised Endocrine Disrupting Chemicals 
A chemical database (n=378) was curated from prioritisation lists; 166 chemicals from 
the EC candidate list and 241 from the DWI report, of which 37 were EC duplicates, in 
addition to 9 hormones. To enable crude sensitivity assessments of the in silico 
methods, published bioassay data for each of the 378 chemicals was retrieved from 
PubChem (Table 4.1). Table_A 1 details the mechanistic information of the chemical 
database; summarising the published high-throughput agonism and antagonism in vitro 
testing results. Collating information from ChemSpider, PubChem and ZINC12, 
Table_A 1 also summarises the classification, usage and assumed primary endocrine 
mode-of-action. 
Table_A 1 Prioritised Potential EDC list used in in silico analysis of binding affinity  
Table details chemical name, the class/categorisation, usage and exposure pathways and the binding 
information available from PubChem (http://pubchem.ncbi.nlm.nih.gov/#).  
Chemical 
Name 
Usage and Exposure Pathways Toxicity  
ED 
MoA 
1-Naphthol 
Metabolite of carbaryl and naphthalene 
insecticdes. Precursor for the pharmaceutical 
Nadolol. Used in production of azo-dyes. 
Biomarker for PAH exposure (Sreekanth et 
al, 2013). 
1N is associated with decreased testosterone 
levels in adult men (Meeker et al., 2006)   
2-Naphthol/  
Naphthalen-2-ol, used in production of dyes, 
pigments, antioxidants (for ubber, fats oils), 
insecticide, pharmacueticals and as a 
lubricant. Biomarker for PAH exposure 
(Sreekanth et al., 2013).  
Active in ERα signalling pathway agonist 
qHTS assay, potency 43.65-61.65 μM 
(AID743077). Inactive in qHTS assay to detect 
AR signalling pathway antagonists 
(AID743054) and ERα antagonists 
(AID743091).  
ER+ 
2,2'Biphenol 
Biphenols are used as preservatives. Forms 
inter- and intra- molecular hydrogen bonds, 
used as a reagent in chemistry, biology and 
medicine (Sahnoun et al., 2006).  
Cytotoxicity study in Hep-G2 cells identified 
IC50 of 200 μM (AID247905).   
2,2'-Dihydroxy-4,4'-
dimethoxy 
benzophenon 
Phenolic additive for light stabilisation for 
polymers.  
Estrogenicity detected in a yeast hERα assay 
2.5 x 10-5 relative to E2 (Miller et al., 2001). In 
qHTS studies: active inhibitor of BRCA1 
expression in qHTS study (AID624202); active 
PPARγ signalling pathway antagonist 
(AID743199); active ERα signalling pathway 
agonist, 57.52 μM (AID743077); and, active 
AhR activator, 14.60 μM (AID743122).  
ER+    
PPARγ+    
AhR+ 
2,3,4-
Trichlorobiphenyl  
(PCB 33) 
PCBs were used as dielectic, coolant fluids 
(in electric motors) and insulating fluids, 
usually sold as a mixture of congeners.  
  
2,4-D 
Pesticide used to destroy unwanted 
vegetation, particularly weed, grasses and 
woody plants.  
Irritant effects on the eye and gastrointestinal 
system; NOEL 500ppm; ADI: 0.01- 0.03 
mg/kg.  
 
2,4-
Dichlorophenoxybut
yric acid (2,4-DB)/  
4-(2,4-
Dichlorophenoxy) 
butyric acid 
General-use pesticide. Selective systemic 
phenoxy herbicide used to control broadleaf 
weeds in alfalfa, peanuts, soybeans and other 
crops; the active metaboliet inhibtis growth at 
the tips of stems and roots.  
Chronic to in dogs at 25 mg kg-1/day, chronic 
toxicity in rats at 30 mg kg-1/day (EPA, 1988).   
AR+ 
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2,4-Dinitrophenol 
2,4-DNP is used in the manufacture of dyes 
and diaminophenol. A toxic dye, chemically 
related to trinitrophenol (picric acid), used in 
biochemical studies of oxidative processes 
where it uncouples oxidative 
phosphorylation. It is also used as a 
metabolic stimulant.  
Active qHTS assay identifying AR signalling 
pathway antagonists, potency 54.7-61.1 μM 
(AID743042/AID743042).  
AR+ 
2,5-
Dihydroxybenzoic 
acid (2,5-DHBA) 
Patented for cancer, ocular disease, actinic 
keratosis, arthritis and tissue reactive disease 
medical applications. Use as chemical toner.  
  
2-Benzylphenol 
 
Inhibited 5-lipoxygenase (IC50: 63 μM) in rat 
basophilic leukemia (RBL-1) cell line 
(AID6790). Inconclusive results for 
interactions with prostaglandin G/H synthase 
(AID160712).    
 
2-Chlorobiphenyl 
(PCB 1) 
Aroclor1232 (PCB mixture) has not been 
produced commercially in the US since 1977, 
but is environmental persistent and leaches 
out of landfills. Still detected in transforms 
and capacitators (HSDB).  
Inhibition of human cytochrome P450 at 36 
μM (AID241172), inhibition of human 
CYP2A6 at 35.97 μM (AID420671) and 
inhibition of mouse CYP2A5 at 13 μM 
(AID420670).  
 
2-Phenylphenol 
Production and use in rubber chemicals, food 
packaging, an intermediate for dyes and food 
presevrative. Also used as pesticide and 
household disinfectant.  
Active DSSTox Carcinogenic rat bioassay 
results (AID1208) and salmonella 
mutagenicity (AID1194). Acute toxicant in 
DSSTox EPA Fathead Minnow test 
(AID1188). Interactions with aldehyde 
dehydrogenases and mitochondrial membranes 
(AID1030/AID720637).  
 
3,4,5,6-Tetrabromo-
o-cresol 
A preservative in cosmetics, active ingredient 
in deodorants and disinfectants, and a 
fungicide in textile materials.  
Active in NCI Yeast Anticancer Drug Screen 
for rad50, mlh1 rad18, bub3, sgs1 mgt1, mec2-
1 and cln2 rad14 strains 
(AID155/175/167/161/165).  
 
3-Chlorobiphenyl 
(PCB 2)  
Widely used in agriculture and industry for 
several decades, as with other PCBs 
commercially restricted.  
  
3-Methyl 
cholanthrene 
Carcinogen widely used in experimental 
studies of cancer, produced by burning 
organic compounds at high temperatures. 
Derivative of benz[a]anthracene. 3-
Methylcholanthrene builds up in the prostate 
due to cholesterol breakdown, and is 
implicated in prostate cancer (Malins et al., 
2004).  
In qHTS syudy, activated the AhR signalling 
pathway, 0.402 μM (AID:743122). Antagonist 
of AR signalling pathway in MDA cell line, 
0.173 μM (AID:743054), ERα signalling 
pathway antagonism at 0.358 μM 
(AID:743091) and agonism at 6.178 μM 
(AID:743075). Agonist of thyroid hormone 
receptor beta signalling at 44.67 μM 
(AID:588545).  
AR+    
ER+    
AhR+      
TR+ 
3-t-Butyl-4-hydroxy 
anisole 
The primary use of BHA is an antioxidant 
and preservative in food (E number E320), 
food packaging, animal feed, cosmetics, 
rubber and petroleum products. BHA is also 
used in pharmaceuticals, such as isotretinoin, 
lovastatin and simvastatin, and pesticides 
(HSDB, http://toxnet.nlm.nih.gov/cgi-
bin/sis/search/f?./temp/~lBGY6Z:1).  
Acitve in mitochondrial membrane disrupter 
assays (AID:720637), rat bioassay (AID:1208) 
and mouse bioassay (AID:1199) 
carcinogenicity studies. Activator of the 
Pregnane X receptor signalling pathway, 50.12 
μM (AID:720659).        
PXR+ 
4,4'-(1,3-
Dimethylbutylidene)
diphenol 
Colour former, developer and reagent for 
high-performance polymer research. 
Structurally related to Diethylstilbestrol, BPA 
and Dienestrol.  
Active in qHTS assay for AR signalling 
pathway antagonists, potency randing from 
10.58 μM (AID:743063), to 61.2 μM 
(AID:743042). Active in qHTS assay for ERα 
signalling pathway agonists, 97.7 μM 
(AID:743075) and antagonists, 0.062 μM - 
0.31 μM (AID:743069). Active PPARgamma 
antagonist (AID:743199).    
AR+  
ER+     
PPARγ 
4,4'-Biphenol 
Phenolic derivative of biphenyl, structurally 
related to 3,3'-dichlorobenzidine and 
Paraquat. 
Active in qHTS AR signalling pathway 
antagonist assay, 11.028 μM (AID:743035). 
ERα signalling pathway agonist, 36.25 μM 
(AID:743077) and 27.7 μM (AID:743075). 
Active PPARgamma antagonist (AID:743199).  
AR+     
ER+   
PPARγ+ 
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4,4-Dihydroxy 
benzophenon 
Main use as a UV-light stabiliser found in 
cosmetics, plastics, films, adhesives and 
coatings, optical fibre and printed circuit 
boards. It is the precursor to certain 
polycarbonate polymers (Parker et al., 2002). 
Structurally similar to Pterosupin, a drug 
isolated from the Pterocarpus marsupium 
bark and heartwood, believed to lower blood 
sugar activity (Mukherjee et al., 2006).  
Binds to sterol 14α-demethylase (CYP51). 
DHBP represents a benzophenone scaffold 
binding in the CYP51 active site via a type 1 
mechanism, which means that the chemical 
may interfere with sterol biosynthesis (Eddine 
et al., 2008).  
 
4,4'-Ethylidene 
bisphenol/  
Bisphenol E 
Colour former, developer and reagent for 
high-performance polymer research. 
Structurally related to Diethylstilbestrol, BPA 
and Dienestrol.  
  
4-Benzylphenol 
Used as a germicide, antiseptic and 
preservative.  
Active in qHTS ERα signalling pathway 
agonist assay, 50.88 μM (AID:743077) and 
57.06 μM (AID:743075). 
ER+ 
4-Chloro-3-
methylphenol 
Also known as chlorocresol, used as a 
disinfectant and preservative.  
Active in DSSTox (KIERBL) EPA Estrogen 
Receptor Ki Binding Study (Laws et al. 2006). 
Active in qHTS assay for TR signalling 
pathway agonists, 27.3 μM (AID:743066).   
ER+   
TR+ 
4-Chloroaniline 
4-Chloroaniline's used as an intermediate for 
the synthesis of dyes, pharmaceuticals and 
agricultural chemicals. It is a precursor to the 
widely used antimicrobial and bacteriocide 
chlorhexidine and is used in the manufacture 
of pyraclostrobin, anilofos, monolinuron and 
chlorphthalim pesticides. Degradation 
product of phenylurea herbicide.  
Active in qHTS assay for PPARgamma 
antagonists (AID:743199), ERα signalling 
pathway antagonists, 9.14 μM (AID:743078) 
and 9.94 μM (AID:743069), active TR 
signalling pathway antagonist, 27.78 μM 
(AID:743065).  
PPARγ+  
ER+   
TR+ 
4-Chlorobiphenyl 
(PCB 3) 
Widely used in agriculture and industry for 
several decades, as with other PCBs 
commercially restricted.  
Inhibition of mouse CYP2A5, IC50 13.002 μM 
(AID:420670). Inhibitory of mouse 
cytochrome P450 2A5, IC50 18 μM 
(AID:241174). Inhibitory concentration against 
recombinant human cytochrome P450 1A2, 
IC50 49 μM (AID:241334).  
 
4-Chloroxylenol/ 
4-Chloro-3,5-
diethylphenol 
Chloroxylenol's used as an antibacterial, 
germicide, antiseptic and in mildew 
prevention, commonly used in adhesives, 
emulsions, paints and wash tanks. It is also 
commonly used in antibacterial soaps and 
household antiseptics, such as Dettol liquid 
and cream 
 Not believed to be significantly toxic to 
humans and other mammals 
(http://www.epa.gov/oppsrrd1/REDs/factsheet
s/3045fact.pdf).  
 
4-Hydroxy-4'-
chlorobiphenyl/ 
4-Chloro-4’-
hydroxybiphenyl 
Also known as 4-Chloro-4'-biphenylol. 
Biphenyl are used as the building blocks of 
liquid crystals and functional materials. 
Metabolite of 4-Chloro and 4,4'-Dichloro 
Biphenyl in rats (Safe et al., 1974).  
Active DSSTox (NCTRER) National Center 
for Toxicological Research Estrogen Receptor 
Binding Database (AID:1204) (Fang et al., 
2001).  
ER+ 
4-
Hydroxypropiophen
one 
Intermediate in the formation of liquid 
crystals. Patented for use in pharmaceuticals 
and pesticides. Drug name, Paroxypropione, 
under pituitary gonadotropic hormone 
inhibitor (anti-gonadotropin) therapeutic 
class.  
Activator of calcium-activated chloride 
channels (AID:623877).   
4'-Isoburyl 
acetophenone 
Structurally related to Ibuprofen; a 
degradation product of Ibuprofen in tablets.     
4-iso-Pentylphenol 
On EC priority list of substances. Data 
lacking.    
4-Nitrophenol 
4-NP is used in the manufacture of methyl 
and ethyl parathion, acetominophen, 
dyestuffs and leather treatment agents. In 
addition, it is the degradation product and 
impurity of parathion, the insecticide.  
Active in qHTS assay to identify AR signalling 
pathway agonists, potency 0.001μM 
(AID:743053). 
AR+ 
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4-Nitrotoluene 
4-Nitrotoluene's used in the manufacture of 
azo and sulfur dye intermediates and 
explosives.  
Evidence of toxicity and carcinogenicity in 
mice (NTP, 2002). Active in DSSTox 
carcinogenicity potency database (AID:1189) 
and rat bioassay (AID:1208). Ihhibitor of 
acetylcholinesterase, IC50 0.1 μM 
(AID:32248).  
 
4-Nonylphenol/  
4-[(2R)-2,6-
Dimethylheptyl] 
phenol 
Alkylphenol used in the preparation of 
lubricating oil additives, resins, plasticisers, 
surface active agents, stabilisers, petroleum 
demulsifiers, fungicides, rubber antioxidants 
and as a starting material for the production 
of phenolic resins.  
Active in qHTS ERα signalling pathway 
agonist, 12.20 μM and 6.93 μM (AID:743079). 
DRUGMATRIX: Active ERα radioligand 
binding. IC50 0.377 μM (AID:625258). 
Inhibitory concentration against recombinant 
rat AR expressed in E. coli using R1881 and 
Testosterone, IC50 11.48 μM (AID:255211). 
Cytotoxic in MultiTox-Fluor Cytotoxicity 
Assay - LYMP1-003-Dead cells, 39.81 μM 
(AID:961). Active in qHTS assay for inhibitors 
of aldehyde dehydrogenase 1 (ALDH1A1) 
(AID:1030).  
ER+    
AR+ 
4-Phenylphenol 
4-phenylphenol is used in the manufacture of 
dyes and resins, rubber chemicals, fungicide 
and nonionogenic emulsifiers. Also formed 
through the photodegradation of 4-
chlorobiphenol.  
Active in qHTS assay for ER signalling 
pathway agonists, 0.44 μM - 21.58 μM 
(AID:743075), and 8.52 μM in the BG1 cell 
line (AID:743079). DSSTox (NCTRER) 
Estrogen Receptor Binding database 
(AID:1204). Active in qHTS AR signalling 
pathway antagonist assay, 27.31 μM 
(AID:743042).  
ER+   
AR+ 
4-sec-Pentylphenol/ 
Pentylcyclohexanol 
Also known as 4-Pentylcyclohexanol.  
EC50 was 1.68 μM in human ER MCF-7 cell 
assay and 0.91 μM in rat ER CV-1 cell assay 
(Sun et al., 2007).   
ER+ 
4-t-Butylphenol 
Also known as 
 4-(2-Methyl-2-propanyl)phenol.  
Active in DSSTox (NCTRER) Estrogen 
Receptor Binding Database (AID:1204). 
Estrogenic activity in human MCF-7 cells 
assessed as cell proliferation after 7 days by 
WST-8 assay (AID:721698).  
ER+ 
4-t-Octylphenol 
Alkylphenol. The Surface-Active Agents 
modify interfacial tension of water, usually 
substances that have one lipophilic and one 
hydrophilic group in the molecule; includes 
soaps, detergents, emulsifiers, dispersing and 
wetting agents and several groups of 
antiseptics.  
Active AR signalling pathway antagonist in 
qHTS assay, 15.09 μM (AID:743035). 
Displaced 5αDihydrotestosterone from human 
sex hormone binding globulin, 2.14  μM Kd 
(AID:318680). Active ER signalling pathway 
agonist, 0.86 μM and 1.19 μM  (AID:743079). 
Antagonist of ER signalling at 33.49 μM 
(AID:743080) and 33.49 μM in BG1 cell line 
(AID:743091). On DSSTox (NCTRER) 
Estrogen Receptor Binding Database 
(AID:1204). 
ER+   
AR+ 
4-Vinylguaiacol (4-
VG) 
Aromatic substance used as a flavouring 
agent, responsible for the natural aroma of 
buckwheat (Janes et al., 2008).  
  
4-Vinylphenol (4-
VP) 
4-Vinylphenol is a phenolic compound 
produced by the spoilage yeast 
Brettanomyces, and is found in wine and 
beer.  
  
5-Aminosalicylic 
acid  
 
5-Amino-2-hydroxybenzoic acid, also known 
as Mesalamine, structurally related to 
salicylates, Mesalamine is used as an anti-
inflammatory agent in the treatment of 
inflammatory bowel disease, Crohn's disease 
and ulcerative colitis (Sandborn et al., 2007). 
Mesalamine is also used in the manufacture 
of light-sensitive paper and, azo and sulfur 
dyes.  
Inhibitor of Prostaglandin G/H synthase 1 
(Chen et al., 2002) and inhibitor of 
Prostaglandin G/H synthase 2 (Cipolla et al., 
20002). PPARγ signalling agonist 
(Desreumaux et al., 2006). Inhibitor of Nuclear 
Factor Kappa-B Kinase subunit beta (NF-
Kappa-B) (Bantel et al., 2000). Inhibitor of 
Arachidonate 5-lipoxygenase (Nielsen et al., 
1987).  
PPARγ+ 
6-Bromo-2-naphthol 
Aromatic polycyclic hydrocarbons, 
Naphthalenes.  
Active in NCI Yeast Anticancer Drug Screen 
for rad50, mlh1 rad18, bub3, sgs1 mgt1, mec2-
1 and cln2 rad14 strains 
(AID157/175/161/165/167).  
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9-cis-Retinoic acid 
9-cis-retinoic acid is a form of vitamin A, 
used as a regulator of gene expression used as 
a antineoplastic agent.  
Dissociation constant for retinoid X receptor 
alpha (RXR), 0.0015 μM (AID:254256). qHTS 
ERα signalling pathway antagonist in the BG1 
cell line, 0.179 μM (AID:743091). Thyroid 
Receptor signalling pathway agonist, 1.535 μM 
(AID:743066). PPARγ signalling agonist, 3.21 
μM (AID:743140).  
RXR+ 
ER+    
TR+ 
PPARγ 
Acebutolol 
A cardioselective beta-1 adrenergic 
antagonist with little effect on the bronchial 
receptors. The drug has stabilising and 
quinidine-like effects on cardiac rhythm, as 
well as weak inherent sympathomimetic 
action.  
Beta-1 adrenergic receptor partial agonist 
(Chen et al., 2002), Beta-2 adrenergic receptor 
partial agonist (Fraysse et al., 2005). 
Cytochrome P450 2D6 inhibitor (Preissner et 
al., 2010).  
 
Acephate 
Acephate is an organophosphate foliar 
insecticide, used for control of aphids in 
vegetables and in horticulture.  
Acephate is considered to be a fetotoxin (can 
poisin the fetus) (Briggs, 1992).   
Acetaminophen 
(Paracetemol) 
Acetaminophen is used as an analgesic and in 
the manufacture of azo dyes and 
photographic chemicals. Antipyretic 
derivative of acetanilide with weak anti-
inflammatory properties and is used as a 
common analgesic, but may cause liver, 
blood cell and kidney damage.  
  
Acetochlor 
Chloroacetanilide herbicide developed by 
Monsanto Company and Zeneca, which 
works by inhibition of geranylgeranyl 
pyrophosphate (GGPP) cyclisation enzymes 
and elongase inhibition (Arregui et al., 2010).  
Active in qHTS assay to identifiy small 
molecule antagonists of the AR signalling 
pathway, 21.9 μM (AID:743035) and 54.48 
μM (AID:743042), results consistently 
replicated. qHTS ERα signalling pathway 
antagonist, 24.54 μM (AID:743069) and 
agonism, 0.71 μM (AID:588514).  
AR+    
ER+ 
Acipimox 
Hypolipidemic agent, used to lower levels of 
certain lipids in the blood and to treat 
hyperlipidemias. Acipimox inhibits the 
production of triglycerides by the liver and 
secretion of VLDL, indirectly leading to a 
reduction in LDL and increase in HDL.  
Active at GRP109a in CHO cells, indicated by 
inhibition of forkolin-induced cAMP 
generation, IC50 5.3 μM (AID:281255). IC50 39 
μM required for inhibition of free fatty acid 
liberation in Canine myocardial lipase assay 
(AID:143599). Inactive in ER and AR qHTS 
assays.  
 
Alachlor 
Alachlor is a chloroacetanilide herbicide used 
to control the growth of broad-leafed weeds 
and grasses in crops, by inhibiting elongase 
and geranylferanyl pyrophosphate (GGPP) 
crystalisation enzymes. Mixes well with other 
herbicides, and is found in mixed 
formulations with atrazine, glyphosate, 
trifluralin and imazaquin.  
Activity in qHTS ERα agonist signalling 
pathway assay, 0.159 μM (AID:588514), 
agonist of the antioxidant response element, 
4.19 μM (AID:743219). qHTS AR signalling 
pathway antagonist: 26.66 μM (AID:743035), 
26.6 μM (AID:743063) and 38.9 μM 
(AID:743035); in the MDA cell line, potencies 
were slightly lower, 61.13 μM (AID:743042). 
qHTS TR signalling pathway antagonist, 54.5 
μM (AID:743065).  
ER+    
AR+   
TR+ 
Aldicarb 
Carbamate insecticide effective against 
thrips, aphids, spider mites, and lygus, 
fleahoppers, by inhibiting cholinesterase, 
which prevents the breakdown of 
acetylcholine in the synapse. Aldicarb is the 
active substance in the pesticide Temik. 
Active in qHTS agonsts of AhR signalling 
pathway, 39.8 μM (AID:651777) and PPARγ 
signalling pathway, 39.81 μM (AID:588537). 
Agonist of the Antioxidant Response Element 
(ARE), 27.31 μM (AID:651741).  
AhR+     
PPARγ+ 
Amitriptyline  
Tricyclic antidepressant with anticholinergic 
and sedative properties. It appears to prevent 
the re-uptake of norepinephrine and serotonin 
at nerve terminals, thus potentiating the 
action of these neurotransmitters. 
Amitriptyline also appears to antagonise 
cholinergic and alpha-1 adrenergic responses 
to bioactive amines.  
0.00005 μM IC50 for inhibitory activity against 
Alpha-1 adrenergic receptor (AID:36031).   
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Amitraz 
Non-systemic acaricide and insecticide with 
alpha-adrenergic agonist activity, octopamine 
receptor interaction and inhibition of 
monoamine oxiase and prostaglandin 
synthesis, leading to insect death.  
qHTS PPARδ signalling pathway antagonist, 
24.53 μM (AID:743213). Activator of the Aryl 
Hydrocarbon Receptor signalling, 41.82 μM 
(AID:743122). Antagonist of PPARγ 
signalling, 43.83 μM (AID:743218). 
Antagonist of AR signalling pathway, 43.83 
μM (AID:743033). Thyroid Receptor 
signalling antagonist, 48.51 μM (AID:743064). 
Glucocorticoid Receptor signalling antagonist, 
49.19 μM (AID:720693).  
PPARδ
+ 
AhR+ 
PPARγ+ 
AR+ 
TR+ 
GR+ 
Amitrol/  
3-amino-1,2,4-
triazole 
A non-selective post-emergence triazole, 
translocated herbicide, used to control annual 
grasses and broad-leaves and aquatic weeds. 
3-AT is a competitive inhibitor of 
imidazoleglycerol-phosphate dehydratase, the 
product of the HIS3 gene. Suspected as a 
carcinogen, irreversible inhibitor of catalase 
and thus impairs activity of peroxisomes.  
Active in qHTS assay to identify ERα 
signalling pathway agonists, 61.1μM 
(AID:743079).  
ER+ 
Amoxicillin 
Broad spectrum semi-synthetic antibiotic, 
used to treat gram positive and gram negative 
bacterial infections.   
  
Amphetamine 
L-amphetamine is a powerful central nervous 
system stimulant and sympathomimetic 
which blocks the uptake of adrenergics and 
dopamine, stimulates monoamine release and 
inhibits monoamine oxidase.  
  
Ampicillin 
Broad-spectrum semi-synthetic penicillin 
derivative.  
  
Androstanedione 
Also know as Androstane-3,17-dione. 
Endogenous 19-carbon steroid hormone 
produced in the adrenal glands and the 
gonads as an intermediate in androgen 
(testosterone) and estrogen (estrone and 
estradiol) biosynthesis.  
Androstenedione acts as a partial agonist of the 
androgen receptor, however, in the presence of 
stronger agonists (i.e. tesosterone or DHT), it 
can antagonise (Chen et al., 2004).  
AR+ 
Androsterone 
The metabolite of testosterone of 
androstenedione with a 3-alpha-hydroxyl 
group and without the double bond. The 3-
beta hydroxyl isomer is epiandrosterone. Can 
be converted to diydrotestosterone (DHT) 
from 17-hydroxyprogesterone, bypassing 
conventional intermediates, such as 
androstenedione and testosterone 
Potency approximately 1/7 of testosterone, but 
can displace DHT from human sex hormone 
binding globulin, 0.71 μM (AID:318680).  IC50 
40.74 μM antagonistic activity in recombinant 
rat AR expressed in E. coli using R1881 
(AID:255211).  
AR+ 
Anisole 
Aromatic compound with the smell of anise 
seed; many of its derivatives are found in 
natural and artifical fragrances.  
Inhibition of human CA4 using 4NPA as 
substrate for 3 minutes by Lineweaver burk 
plot analysis (AID:667535).  
 
Anthracene 
Anthracene is a component of coal tar, as a 
natural component of incomplete fossil fuel 
combustion. Also, anthracene is used in the 
product of red dye alizarin.     
Active qHTS activator of the Aryl 
Hydrocarbon Receptor (AhR) signalling 
pathway, 27.31 μM (AID:743085).  
AhR+ 
Aspirin 
Prototypical analgesic used in the treatment 
of mild to moderate pain, with anti-
inflammatory and antipyretic properties. Acts 
as an inhibitor of cyclooxygenase which 
results in the inhibition of the biosynthesis of 
prostaglandins. Aspirin also inhibits platelet 
aggregation and is used in the prevention of 
arterial and venous thrombosis.  
COX-1 inhibition.  
 
Atenolol 
A cardioselective beta-1 adrenergic blocker, 
possessing properties and potency similar to 
propranolol, but without a negative inotropic 
effect, used primarily in the treatment of 
cardiovascular disease.  
In vitro inhibitory activity against beta-1 
adrenergic receptor, measured by inhibition of 
positive chronotropic effect of isoproterenolin, 
0.024 μM (AID:39943).  
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Atorvastatin  
Atorvastatin is a statin used for lowering 
blood cholesterol, marketed by Pfizer under 
the trade name Lipitor. Atorvastatin is a 
competitive inhibitor of 
hydroxymethylglutaryl-coenzyme A (HMG-
CoA) reductase, the rate determining enzyme 
in cholesterol biosynthesis via the mevalonate 
pathway.   
qHTS assay to identify small molecule 
antagonists of AR signalling pathway, 10.64 
μM (AID:743063). TR signalling pathway 
antagonist in qHTS assay in rat, 57.11 μM 
(AID:743065).  
AR+     
TR+ 
Atrazine 
Selective triazine herbicide used to control 
grass and broadleaf weeds in crops such as 
sorghum, maize, sugarcane, lupins and pine.  
Activator of the Aryl Hydrocarbon Receptor 
(AhR) signalling pathway, 68.5 μM 
(AID:743085). 
AhR+ 
Azithromycin/ 
Sumamed 
A semi-synthetic macrolide antibiotic 
structurally related to erythromycin. It has 
been used in the treatment of mycobacterium 
avium intracellulare infections, 
toxoplasmosis and cryptosporidiosis.  
qHTS assay to identify antagonists of TR 
signalling pathway (ratTRbeta), 36.13 μM 
(AID:743065) and cell viabilitiy screen 29.85 
μM (AID:743064). 
TR+ 
Bendroflume 
thiazide 
Bendroflumethiazide is a thiazide diuretic 
used to treat hypertension; works by 
inhibiting sodium reabsorption at the 
beginning of the distal convoluted tube. 
Similar to hydrochlorothiazide, it has been 
used in the treatment of familial 
hyperkalemia, hypertension, edema and 
urinary tract disorders.  
  
Benomyl 
Benomyl is a systemic benzimidazole 
fungicide that is selectively toxic to 
microorganisms and invertebrates, commonly 
used on stone fruit. Benomyl interacts with 
tubulin, affecting polymerisation of 
microtubules.  
Activator of the human Aryl Hydrocarbon 
Receptor (AhR) signalling pathway, 6.08 μM 
(AID:743085). qHTS rat TR signalling 
pathway antagonist, 7.66 μM (AID:743065), 
8.31 μM (AID:743067). Rat pregnane X 
receptor (PXR) signalling pathway antagonist, 
11.2 μM (AID:651751). Human ERα 
signalling pathway agonist, 27.31 μM 
(AID:743079). Human AR signalling 
antagonist, 38.71 μM (AID:743033) and 61.34 
μM (AID:743035).  
AhR+  
TR+   
PXR+    
ER+    
AR+ 
Bentazone 
Bentazone is a selective thiadiazine herbicide 
that only damages plants unable to 
metabolise the chemical, and is considered 
safe for use on alfalfa, beans, corn, peanuts, 
peas, pepper, rice and soybeans.  
  
Benz(a) anthracene/  
Tetraphene 
Polycyclic aromatic hydrocarbon that occurs 
in coal tar. Primarily the product of 
incomplete combustion, including vegetation 
and food products.  
qHTS activator of human Aryl Hydrocarbon 
Receptor (AhR) signalling pathways, 4.86 μM 
(AID:743122). Agonist of the ERα signalling 
pathway in the BG1 cell line, 19.33 μM 
(AID:743079). Activator of rat pregane X 
receptor (PXR) signalling pathway, 28.18 μM 
(AID:651751). Agonist of AR signalling 
pathway in MDA cell line, 68.59 μM 
(AID:743040).  
AhR+    
ER+    
PXR+    
AR+ 
Benzo[a]pyrene/  
7,12-Dimethyl 
benz[a]anthracene 
An environmental pollutant, as a component 
of coal tar, incomplete combustion and 
tobacco smoke, benzo(a)pyrene is a potent 
mutagen and carcinogen. 
qHTS activator of human AR signalling 
pathway in the MDA cell line, 0.22 μM 
(AID:743054) and ERα signalling in the BG1 
cell line, 0.85 μM (AID:743091). Activator of 
the AhR signalling pathway, 1.24 μM 
(AID:743085). Agonist of PPARdelta 
signalling pathway, 2.41 μM (AID:743227) 
and PPARγ, 4.28 μM (AID:743140). Agonist 
of the glucocorticoid receptor (GR) signalling 
pathway, 2.81 μM (AID:720719).  
AR+    
ER+    
AhR+    
PPARδ 
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Benzophenone 
Benzophenone is an organic compound, 
derivatives of which (oxybenzone and 
dioxybenzone) are used in sunscreen. In 
addition, benzophenone can be used as a 
photo initiator in UV-curing applications 
such as inks, imaging and clear coatings in 
the printing industry, as it prevents UV 
damage of scents and colours in products.  
qHTS agonist of the human AR in the MDA 
cell line, 26.6 μM (AID:743040). ERα agonist 
in BG1 cell line, 27.31 μM (AID:743079).  
AR+    
ER+ 
Benzotriazole 
Benzotriazole's is used as a corrosion 
inhibitor, photographic restrainer, UV 
absorber and chemical intermediate.  
Agonist of the vitamin D receptor (VDR) 
signalling pathway, 38.9 μM (AID:743224). 
Active in qHTS asssay for PPARdelta 
signalling pathway antagonists, 38.9 μM 
(AID:743213).  
PPARδ
+ 
(-) Benzoylecgonine 
Benzoylecgonine is the major metabolite of 
cocaine, formed by the hydrolysis of cocaine 
in the liver, catalysed by carboxylesterases, it 
is excreted in the urine of cocaine users after 
processing in the liver.  
Relative binding affinity against human 
antibody 2E2, compared to [H3]cocaine, Ki 
0.043 μM (AID:127360).  
 
Benzylparaben/ 
Benzyl-4-
hydroxybenzoate 
Parabens are widely used as preservatives in 
cosmetics and pharmaceuticals.  
qHTS ERα signalling pathway agonist in the 
BG1 cell line, 10.59 μM (AID:743079). 
PPARγ signalling pathway antagonist, 43.6 
μM (AID:743191). Antagonist of the TR 
signalling pathway in qHTS assay, 74.1 μM 
(AID:743067). DSSTox (KIERBL) EPA ER 
Ki Binding study database (AID:1576).  
ER+    
PPARγ+    
TR+ 
Betaxolol 
A cardioselective beta-1 adrenergic 
antagonist with no partial agonist activity, 
used in the treatment of hypertension and 
glaucoma.  
Interacts with cytochrome P450 1A2 (Preissner 
et al., 2010).   
Bezafibrate (BZF) 
An antilipemic agent that lowers cholesterol 
and triglycerisdes by decreasing low density 
lipoproteins and increasing high density 
lipoproteins.  
Agonist of PPARγ in HepG2 cells 
transactivation assay, EC50 1.05 μM 
(AID:696365) and CV1 cells, EC50 3 μM 
(AID:320687). Agonist activity of human 
PPARδ in transcriptional activation assay, 
EC50 20 μM (AID:156469).   
PPARδ
+   
PPARγ+ 
Bifenthrin 
Pyrethroid insecticide used against the red 
imported fire ant, by influencing the 
invertebrate nervous system.  
Significant differences in estrogenic potential 
were observed between the two enantiomers in 
the in vitro human breast carcinoma MCF-7 
cell proliferation assay (i.e. E-Scrren), the 
relative proliferative effect rations of 1S-cis-
BF and 1R-cis-BF were 74.2% and 20.9%, 
respectively. The data suggest that 
enantioselectivity should be considered in 
acute and chronic endocrine studies (Wang et 
al., 2007).  
ER+ 
Bisoprolol  
A cardioselective beta-1 adrenergic blocker, 
bisoprolol is used in the management of 
hypertension and angina pectoris.  
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Bisphenol A 
As a biphenol, it has two hydroxyphenyl 
functionalities. BPA is used as a plasticiser 
and in epoxy resins, commonly found in 
consumer goods. World production capacity 
of BPA was 1 millions tons in the 80's and 
more than 2.2 million tons in 2009 (Fiege et 
al., 2000).  
qHTS assay in the BG1 cell line for ER 
signalling agonists, 0.22 μM (AID:743079). 
Lipoxygenase 15-LO enzyme inhibition, IC50 
1.30 μM (AID:625146). Serotonin (5-
hydroxytryptamine) 5-HT6 radioligand 
binding, IC50 5.42 μM (AID:625221).  
Antagonist of human PPARγ signalling 
pathway (AID:743199). Antagonist of ER 
signalling pathway, 8.71 μM (AID:743069). 
Activator of human PXR signalling pathway, 
19.95 μM (AID:720659). Agonist of PPARδ 
signalling pathway, 22.27 μM (AID:743211). 
Antagonist in qHTS stufy of glucocorticoid 
receptor signalling pathway, 24.26 μM 
(AID:720692). Activator of the Aryl 
Hydrocarbon Receptor (AhR), 30.64 μM 
(AID:743219). qHTS AR antagonist, 39.96 
μM (AID:743063). Antagonist of the TR 
signalling pathway, 61.13 μM (AID:743065).  
ER+    
PPARγ+   
AR+    
AhR+   
PPARδ
+    
PXR+ 
Bisphenol B/  
2,2-Bis(4-
hydroxyphenyl) 
butane 
As a biphenol, it has two hydroxyphenyl 
functionalities. Bisphenols are used as 
plasticisers and in epoxy resins and 
commonly found in consumer goods.  
qHTS Agonist of human ERα signalling 
pathway, 0.14 μM (AID:743077) and 
antagonism at 0.31 μM (AID:743069). 
DSSTox (NCTRER) Estrogen Receptor 
Binding Database (AID:1204). Antagonist of 
PPARδ signalling pathway, 19.49 μM 
(AID:743215). PPARγ antagonist, 30.87 μM 
(AID:743191). Human AR antagonist, 21.85 
μM (AID:743035). PXR activator, 35.48 μM 
(AID:720659). Antagonist of glucocorticoid 
receptor (GR) signalling pathway, 43.64 μM 
(AID:720692).  TR antagonists in the MDA 
cell line, 63.46 μM (AID:743065).  
ER+    
PPARδ
+   
PPARγ+    
PXR+     
TR+  
AR+ 
Bisphenol F/  
4,4’-
Dihydroxydiphenyl 
methane 
Bis(4-hydroxyphenyl)methane, the bisphenol 
has two hydroxyphenyl funcitonalities.  
Active in qHTS ER agonist signalling 
pathway, 2.45 μM (AID:743079), 15.61 μM 
(AID:743075). DSSTox (NCTRER) estrogen 
receptor binding database.  
ER+ 
Bitertanol Triazole, azole heterocyclic compound.  
Active in qHTS assay for human pregnane X 
receptor (PXR) signalling pathway activators, 
10 μM (AID:720659) and agonist or 
antioxidant response element (ARE) signalling 
pathway, 68.59 μM (AID:651741).  
PXR+ 
Bromacil 
First registered for use as a pesticide in 1961, 
it works by interfering with photosynthesis. 
As a substituted uracil, bromacil is used as a 
broad spectrum herbicide for bush control 
and non-cropland areas, in addition to citrus 
fruit and pineapples.  
qHTS activator of the Aryl Hydrocarbon 
Receptor (AhR) signalling pathway, 21.67 μM 
(AID:743085) and 21.67 μM (AID:743122).  
AhR+ 
Bromoform 
Bromoform is a trihalomethane, brominated 
organic solvent. Natural production of 
bromoform by phytoplankton and seaweed is 
believed to be a predominant environmental 
source.  
Carcinogenic 
 
Bromoxynil/  
3,5-dibromo-4-
hydroxybenzonitrile 
Nitrile herbicide used to control post-
emergent annual broadlead weeds, and in 
particular cereal, corn, soghum, onions, flax 
and on non-cropland.  
qHTS human AR signalling pathway agonist, 
0.769 μM (AID:743040). Retinoid X Receptor 
(RXR) agonist, 15.84 μM (AID:588544). AhR 
activator, 21.67 μM (AID:743122). PPARα 
signalling pathway agonist, 25.12 μM 
(AID:651778). Human PPARγ antagonist, 
54.89 μM (AID:743191). ERα signalling 
pathway antagonist, 52.46 μM (AID:743080). 
Thyroid Receptor antagonist in qHTS assay, 
52.46 μM (AID:43065/AID:743067).  
AR+    
RXR+     
AhR+     
PPARα
+   
PPARγ+    
ER+ 
Butylated 
hydroxytoluene 
(BHT)/  
2,6-Di-tert-9-
methylphenol 
A lipophillic di-tert-butylphenol with 
antioxidant properties, primarily used as a 
food additive (E321), but also as an 
antioxidant additive in cosmetics, 
pharmaceuticals, rubber, electrical 
transformer oil and embalming fluid.  
Retinoid X Receptor qHTS agonist, 17.78 μM 
(AID:588544). Antagonist of the rat Thyroid 
receptor (TR) signalling pathway, 30.64 μM 
(AID:743065). qHTS human ER signalling 
pathway antagonist in the BG1 cell line, 34.45 
μM (AID:743080).  
PXR+     
TR+    
ER+ 
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Butylbenzyl 
phthalate (BBP)/ 
Benzylbutyl 
phthalate 
The phthalate BBP is an ester of phthalic 
acid, benzyl alcohol and n-butanol, 
commonly used as a plasticiser for PVC and 
cellulose resins.  
Agonists of ER signalling, 6.31 μM 
(AID:588514) and 10.87 μM in the BG1 luc 
cell line (AID:743079). Aryl Hydrocarbon 
Receptor (AhR) signalling pathway, 7.70 μM 
(AID:743085). Agonist of the PPARδ 
signalling pathway, 19.49 μM (AID:743211). 
qHTS antagonist of the human AR signalling 
pathway, 21.70 μM (AID:743035).  
ER+    
AhR+    
PPARδ
+   AR+ 
Butylparaben/  
Butyl-4-hydroxy 
benzoate 
Butylparaben is used as a preservative in 
topical antibiotics or corticosteroid 
preparations, and as a food preservative.  
qHTS ER signalling pathway agonst in BG1 
cell line, 5.52 μM (AID:743079). Inhibitor of 
cytochrome P450 2C19, 6.31 μM (AID:899). 
Antagonist of ER signalling pathway, 44.20 
μM (AID:743069). Antagonist of the AR 
signalilng pathway, 45.35 μM (AID:743063).  
ER+   
AR+ 
Caffeine 
A naturally occuring methylxanthine which 
stimulates the central nervous system, 
increasing alertness and agitation. Caffeine 
relaxes smooth muscle, and stimulates 
cardiac muscles and is used as a 
pharmacological agent. Caffeine inhibits the 
cyclic nucleotide phosphodiesterases, 
antagonises the adenosine receptors and 
modulates intracellular calcium handling.  
Antagonistic activity against human adenosine 
A2B receptor, Ki 10.4 μM (AID:494495). 
qHTS assay aromatase inhibitors, 55.15 μM 
(AID:743084) and antagonist of AR signalling 
pathway in MDA cell line, 49.15 μM 
(AID:743042).  
AR+ 
Captopril 
Potent and specific inhibitor of peptidyl-
dipeptidase A, blocking the conversion of 
angiotensin I to angiotensin II, a 
vasoconstrictor and important regulator of 
arterial blood pressure. Captopril is used in 
the treatment of hypertension and congestive 
heart failure. Captopril suppresses the renin-
angiotensin system and inhibits pressure 
responses to exogenous angiotensin.  
Inhibitory concentration against angiotensin I 
converting enzyme, 0.023 μM (AID:254756).   
Carazolol 
Carazolol is an anagonist and partial inverse 
agonist of the beta-adrenergic receptor (beta-
blocker).  
Dissociation constant against beta-adrenergic 
receptor, Kd 0.0001 μM (AID:41147).   
Carbamate/  
Carbamic acid 
Carbamates are organic compounds derived 
from carbamic acid, which are functional 
groups that are inter-related structurally and 
often interconverted chemically.  
  
Carbamazapine 
Carbamazepine (CBZ) is an anticonvulsant 
and mood stabilising drug used in the 
treatment of epilepsy, bipolar disorder and 
trigeminal neuralgia.  
Active in qHTS assay to identify agonists of 
the AR signalling pathway, 4.42 μM 
(AID:743053) and 11.88 μM in the MDA cell 
line (AID:743040)  
AR+ 
Carbaryl 
A carbamate insecticide and potent 
anticholinesterase agent which reversibly 
inhibits cholinesterase. Carbaryl is branded 
under the name Sevin by the Bayer company, 
but is referred to as Carbaril when used for 
veterinary applications.  
Active in qHTS assay to identify agonists of 
the AR signalling pathway in the MDA cell 
line, 29.85 μM (AID:743040). Inhibitor of 
HADH2 (Hydroxyacyl-coenzyme A 
dehydrogenase, Type II), 39.81 μM (AID:886). 
Activator of the Aryl Hydrocarbon Receptor 
(AhR), 27.31 μM (AID:743085).  
AR+    
AhR+ 
Carbendazim 
Widely used broad spectrum benzimidazole 
fungicide; casting worm control agent in turf. 
Metabolite of the fungicide benomyl, listed 
collectively on EU pesticides database 
(http://ec.europa.eu/sanco_pesticides/public/?
event=substance.resultat&s=1).  
qHTS antagonist of the Vitamin D Receptor 
(VDR) signalling pathway (AID:743242). 
Agonist of the p53 signalling pathway, 14.22 
μM (AID:720552). Activator of the Aryl 
Hydrocarbon Receptor (AhR), 10.87 μM 
(AID:743085).  
AhR+ 
Evaluation of in silico and in vitro screening methods for EDC hazard characterisation 
 
 
 Page 227  
  
Carbofuran 
Carbofuran is a carbamate pesticide used as a 
systematic insecticide, acaricide and 
nematocide by inhibiting cholinesterase. 
Carbofuran is used to control insects on field 
crops such as potatoes, corn and soybeans.  
Active in qHTS ERα agonist singalling 
pathway in the BG1 cell line, 24.33 μM 
(AID:743079).  
ER+ 
Carisoprodol 
A centrally acting skeletal muscle relaxant, 
used as an adjuct in the symptomatic 
treatment of musculoskeletal conditions 
associated with painful muscle spasm 
Inhibitor of HP1-beta Chromodomain 
Interactions with Methylated histone tails, 
0.006 μM (AID:488953).  
 
Cashmeran 
Cashmeran is a synthetic compound used in 
perfume for its unique musky, powdery 
odour. Also known as 6,7-dihydro-1,1,2,3,3-
pentamethyl-4-(5H)indanone.  
  
Cefuroxime 
Broad-spectrum second generation 
cephalosporin antibiotic, resistant to beta-
lactamse, discovered by GlaxoSmithKline 
(Zinacef).  
  
Celestolide 
Also known as acetyl tert-butyl 
dimethylindan, which is a substance, extract 
or preparation for diffusing or imparting an 
agreeable or attractive smell (perfume). As a 
synthetic musk, the aromachemical emulates 
the scent of natural musk.  
Active in qHTS assay to identiy aromatase 
inhibitors, 27.31 μM (AID:743083), antagonist 
of TR signalling pathway, 43.28 μM 
(AID:743064) and PPARδ, 43.64 μM 
(AID:743211).  
TR+    
PPARδ
+ 
Celiprolol 
A cardioselective beta-1 adrenergic 
antagonist that has symopathomimetic 
activity, used in the management of angina 
pectoris and hypertension.  
  
Chlofentezine 
An arcaricide belonging to the tetrazine 
chemical group which acts as an ovicide, 
used to control mites on apples, pears, stone 
fruit, nuts, ornamentals and almonds.  
qHTS agonist of ERα signalling pathway in 
BG1 cell line, 1.53 μM (AID:743079) and Aryl 
Hydrocarbon Receptor (AhR), 20.68 μM 
(AID:743122). Activator of the human 
pregnane X receptor (PXR) signalling 
pathway, 11.22 μM (AID:720659).  
ER+     
AhR+    
PXR+ 
Chloramphenicol 
Chloramphenicol is a broad-spectrum 
bacteriostatic antimicrobial isolated from 
Streptomyces venequelae, which act by 
interfering with bacterial protein synthesis.  
Inhibitor of human tyrosyl-DNA 
phosphodiesterase 1 (TDP1), 6.51 μM 
(AID:686978). qHTS inhibitor of aldehyde 
dehydrogenase 1 (ALDH1A1), 14.13 μM 
(AID:1030).  
 
Chlorazepate 
Benzodiazepine derivative with anxiolytic, 
anticonvulsant, sedative, hypnotic and 
skeletal muscle relaxant properties. Used in 
the treatment of anxiety. Modulator of the 
GABA receptors.  
  
Chlordimeform 
An acaricide used against many 
organophosphate and carbamate resistant 
pests, which acts as an uncoupling agent and 
monoamine oxidase inhibitor. Target species 
include ticks and Lepidoptera insects.   
Cytotoxicity study in chicken DT40 cell line, 
61.13 μM (AID:743012).   
Chlorfenvinphos 
An organophosphorus cholinesterase 
inhibitor, trade name was 
Dermaton®/Birlane® and was used to control 
flies.  
qHTS rat Pregnane X Receptor (PXR) 
signalling pathway activator, 12.59 μM 
(AID:651751), and activator of the Aryl 
Hydrocarbon Receptor (AhR) signalling 
pathway, 50.12 μM (AID:651777).  
PXR+    
AhR+ 
Chloridazon/ 
5-Amino-4-chloro-2-
phenylpyridazin-3-
(2H)-one 
Also known as Pyrazon. Chloridazon is a 
selective pyridazine-derived herbicide, which 
inhibits photosynthesis and the Hill reaction, 
used in beet cultivation.  
Active in uHTS fluorescent assay for 
identification of inhibitors of hexokinase 
domain containing I (HKDC1) (AID:493160).  
 
Chloroform/ 
Trichloromethyl 
Chloroform is a commonly used laboratory 
trihalomethane solvent, used in the 
manufacture of PTFE, previously used as an 
anesthetic.  
Active in qHTS assay to identiy AR signaling 
pathway antagonists, 48.6 μM (AID:743033), 
and inhibitor of RGS12 GoLoco motif Activity 
(red fluorophore) (AID:880).  
AR+ 
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Chlorotetracycline 
A tetracycline with a 7-chloro substitution, in 
veterinary medicine chlortetracycline  is 
commonly used to treat conjunctivitis in cats.  
  
Chlorpyrifos 
Organophosphate insecticide, which acts on 
the nervous system of insects by inhibiting 
acetylcholinesterase.  
binding of Cytochrome P450 3A4, 5.01 μM 
(AID:884). Activator of the Aryl Hydrocarbon 
Receptor (AhR) signaling pathway, 9.69 μM 
(AID:743122). Antagonist of the PPARγ 
signalling pathway, 24.61 μM (AID:743194). 
Thyroid receptor antagonist, 27.36 μM 
(AID:743064) and androgen receptor (AR) 
antagonist, 49.09 μM (AID:743033).  
AhR+    
PPARγ+    
TR+    
AR+ 
Chrysene 
Also known as Benzo[a]phenanthrene. 
Polycyclic aromatic hydrocarbon, consisting 
of four fused benzene rings, that occurs in 
coal tar. Primarily the product of incomplete 
combustion.   
qHTS rat Pregnane X Receptor (PXR) 
signalling pathway activator, 1.995 μM 
(AID:651741), and activator of the Aryl 
Hydrocarbon Receptor (AhR) signalling 
pathway, 4.42 μM (AID:743122) and 11.22 
μM (AID:651777).  
PXR+   
AhR+ 
Cimetidine 
A histamine  H2-receptor antagonist that 
inhibits stomach acid produciton, used in the 
treatment of heartburn and peptic ulcers.  
  
Ciprofloxacin 
A broad-spectrum antimicrobial 
carboxyfluoroquinoline used in the treatment 
of respiratory, urinary tract, gastrointestinal 
and abdominal infections.  
Inhibition of human CYP2C19 (Cytochrome 
P450 2C19) (AID:678712).   
Clarithromycin 
A semi-synthetic macrolide antibiotic 
structurally related to erythromycin. It 
inhibits protein synthesis in bacteria by 
reversibly binding to the 50S ribosomal 
subunits. This inhibits the translocation of 
aminoacyl transfer-RNA and prevents 
peptide chain elongation.  
Inhibition of human CYP2C9 (Cytochrome 
P450 2C9) (AID:668268).   
Clenbuterol 
A substituted phenylaminoethanol that has 
beta-2 adrenomimetic properties at very low 
doses, used as a bronchodilator in asthma.  
Adrenergic beta2 agonist, 0.013 μM 
(AID:395059).   
Clofibrate 
A fibric acid derivative used in the treatment 
of hyperlipoproteinemia type III and severe 
Hypertriglyceridemia. It increases lipoprotein 
lipase activity, promoting conversion of 
VLDL to LDL.  
ERα signalling pathway agonist in qHTS 
assay, 26.6 μM (AID:743079). PPARα agonist 
(AID:742844). Inhibition of human CYP2C19 
(AID:678712).  
ER+    
PPARα
+ 
Clotrimazole 
An imidazole derivative with broad-spectrum 
antimycotic activity. Clotrimazole inhibits 
biosynthesis of the fungal cell membrane 
component, ergostol, increasing membrane 
permeability and disruption of enzyme 
systems bound to the membrane.  
Antagonist of PPARγ signalling pathway, 
11.88 μM (AID:743191) and antagonist of ER 
signaling pathway, 6.44 μM (AID:743069). 
Inhibitor of human Cytochrome P450 17A1 
activity, 0.082 μM (AID:53377), among 
others.  
PPARγ+   
ER+ 
Cocaine 
An alkaloid ester extracted from the leaves of 
plants including coca, functioning as a local 
anaesthetic and vasoconstrictor. Potent 
central nervous sytems effects, involving 
multiple mechanisms on catecholaminergic 
neurons.  
Inhibitor of Sodium-dependent serotonin 
transporter and sodium-dependent 
noradrenaline transporter.  
 
Codeine 
Also known as 3-methylmorphine, codeine is 
a naturally occurring methylated morphine, 
used for its analgesic, antitussive, 
antidiarrheal, antihypertensive, anxioltic, 
antidepressant, sedative and hypnotic 
properties.  
Inhibition of sterorspecific [H3]-naltrexone 
(10e-9 M) binding towards opiate receptor, 
0.01 μM (AID:145933). qHTS agonist of the 
AR signaling pathway, 61.44 μM 
(AID:743040).  
AR+ 
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Cortisol 
The main glucocorticoid secreted by the 
adrenal cortex, also used in the treatment of 
inflammation, allergy, collagen diseases, 
asthma, adrenocortical deficiency, shock, and 
some neoplastic conditions.  
qHTS assay for agonists of the Human AR 
signalling pathway, 0.0103 μM (AID:743053) 
and glucocorticoid receptor (GR) signalling 
pathway, 0.039 μM (AID:720719).  Agonist of 
the ERα signalling pathway in the BG1 cell 
line, 3.75 μM (AID:743079).  
AR+    
GR+ 
Cortisone 
A naturally occuring glucocorticoid, which 
though inactive in itself, is converted to 
hydrocortisone in the liver. Used as an anti-
inflammatory agent and in adrenal 
insufficiency.  
Agonist of AR signaling pathway in qHTS 
assay, 0.014 μM (AID:743036), and 
glucocorticoid receptor (GR) signaling 
pathway, 6.92 μM (AID:720692).  
AR+   
GR+ 
Coumestrol 
A phytochemical, coumestrol is a daidzein 
derivative, occuring naturally in forage crops. 
Detected in clover, legumes, soybeans, 
brussel sprouts and spinach.  
Human ERα binding affinity, IC50 0.002 μM 
(AID:70514) and ERα agonist in qhTS assay, 
0.057 μM (AID:743079). Inhibitor of human 
Glutaminase (GLS), 7.94 μM (AID:624170). 
Aryl Hydrocarbon Receptor (AhR) signaling 
pathway, 46.5 μM (AID:743122).  
ER+   
AhR+ 
Cyanazine 
Cyanazine is the active triazine substance in 
an effective herbicide, registered as a Plant 
Protection Product.   
qHTS activator of the Aryl Hydrocarbon 
Receptor (AhR) signalling pathway, 61.01 μM 
(AID:743085).  
AhR+ 
Cyclophosphamide 
Precursor of an alkylating nitrogen mustard 
antineoplastic and immunosuppressive agent 
that is activated in the liver, previously used 
in the treatment of lymphoma and leukemia.  
Inhibition of Cytochrome P450 enzymes 
(AID:678712).   
Cyhalothrin 
A pyrethroid insecticide that mimics the 
structure and insecticidal properties of 
pyrethrum.  
  
Cypermethrin 
A synthetic pyrethroid used as an insecticide 
in large-scale commercial agriculture and 
consumer goods.  
Inhibitor of Aldehyde Dehydrogenase 1 
(ALDH1A1), 25.12 μM (AID:1030).  qHTS 
activator of Human PXR, 35.48 μM 
(AID:720659).  
PXR+ 
Cyproconazole Broad-spectrum fungicide.  
qHTS aromatase inhibitor, 24.19 μM 
(AID:743083). Activator of rat Pregnane X 
Receptor (rPXR) signalling pathway, 31.62 
μM (AID:651751).  
PXR+ 
Daidzein 
Isoflavone present in a number of plants and 
herbs.  
qHTS antagonist of human ERα signalling 
pathway, 0.0015 μM (AID:743075). Binding 
affinity against human ERβ, IC50 0.303 μM 
(AID:70514) and diaplacement of estradiol 
from human recombinant ERβ , IC50 1.2 μM 
(AID:361464). Activator of the Aryl 
Hydrocarbon Receptor (AhR) signaling 
pathway, 4.86 μM (AID:743085). 
Glucocorticoid Receptor antagonism, 4.89 μM 
(AID:720692). Activator of PXR signaling 
pathway, 44.67 μM (AID:720659).  
ER+    
AhR+   
GR+   
PXR+ 
DDT 
Dichlorodiphenyltrichloroethane (DDT) is an 
organochloride insecticide, resistant to 
destruction by light and oxidation. These 
unusual properties have led to residues in 
water, soil and foodstuffs, despite its ban.  
Agonist of the human ERα signalling pathway 
in qHTS assay, 4.36 μM (AID:743075), and in 
the BG1 cell line, 6.16 μM (AID:743079). 
Agonist of the vitamin D receptor (VDR), 13.8 
μM (AID:743224). Antagonist of the 
Glucocorticoid Receptor (GR) signalling 
pathway, 16.93 μM (AID:720692). Antagonist 
of the PPARγ pathway, 17.37 μM 
(AID:743194) and PPARδ at 49.32 μM 
(AID:743211). Thyroid Receptor (TR) 
antagonism in qHTS assay at 18.83 μM 
(AID:743064). Human PXR activator at 39.8 
μM (AID:720659). Antagonist of the human 
AR signalling pathway at 43.64 μM 
(AID:743035).  
ER+    
GR+   
PPARγ+  
TR+  
PXR+  
AR+ 
Dehydroabietic Acid 
Diterpene component, that is a component of 
resin acid, used in soap manufacture.    
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Dehydrotestosterone 
Also known as Boldenone, 
dehydrotestosterone is an anabolic steroid 
developed for veterinary use, mostly for 
horses - stimulating anabolism and inhibiting 
catabolism, stimulating muscle mass, strength 
and power.   
Androgen Receptor agonist (Merlanti et al., 
2007).  
AR+ 
Deltamethrin 
Pyrethroid ester insecticide, preventing 
spread of diseases carried by tick-infested 
prairie dogs, rodents and burrowing animals. 
Also eliminates spiders, fleas, ticks, carpenter 
ants, carpenter bees, cockroaches and bed-
bugs.  
human Pregnane X Receptor (PXR) signalling 
pathway activator, 11.22 μM (AID:720659) 
and TR signalling pathway antagonist, 71.27 
μM (AID:743067).  
PXR+    
TR+ 
Demeclocycline  
Tetracycline antibiotic derived from 
Streptomyces aureofaciens. Demeclocycline 
excreted slower than tetracycline, increasing 
the half life of the drug.   
  
Demeton-s-methyl 
Demeton-s-methyl is a flammable 
organothiophosphate acaricide and an 
aliphatic organothiophosphate insecticide.  
Active in qHTS assay for agonists of the 
antioxidant response element (ARE) signalling 
pathway, 54.48 μM (AID:651741).  
 
Desethylatrazine 
(DEA)/ 
6-Chloro-2N-
(propan-2-yl)-1,3,5-
triazine-2,4-diamine 
Desethylatrazine is the degradation product 
of atrazine, a widely used herbicide.    
DET/ 
N,N-Diethyl-2-(1H-
Indol-3-yl) 
ethanamine 
DET, also known as diethyltryptamine, is a 
psychedelic drug, active orally (50-100 mg) 
without the MAO inhibitors, lasting 2-4 
hours, believed to work via serotonin receptor 
agonism. DET is a substituted tryptamine, 
structurally similar to DMT and 
dipropyltryptamine (DPT).    
  
Dexamethasone An anti-inflammatory 9-fluoro-glucocorticoid 
Activity at human Glucocorticoid receptor in 
CV1 cells, ED50 0.0001 μM (AID:330359), GR 
agonistic activity IC50 0.00051 μM 
(AID:626146). Androgen Receptor signalling 
pathway agonist in MDA cell line, 0.0078 μM 
(AID:743040). qHTS rat pregnane X receptor 
signalling pathway activator, 6.31 μM 
(AID:651751). DRUGMATRIX: Progesterone 
radioligand binding, IC50 23.29 μM 
(AID:625172) and Androgen AR radioligand 
binding , IC50 24.56 μM (AID:625228).  
GR+     
AR+     
PXR+    
PR+ 
Di-(2-
ethylhexyl)phthalate 
(DEHP)/  
Bis(2-ethylhexyl) 
phthalate 
An ester of phthalic acid, DEHP is an 
odourless liquid plasticiser for resins and 
elastomers. DEHP is the most common class 
of phthalate plasticisers, accounting for 54% 
of the market share 
(http://www.ceresana.com/en/market-
studies/additives/plasticizers/)  
Activator of the rat pregnane X receptor 
signalling pathway, 11.22 μM (AID:651751). 
Human Aryl Hydrocarbon Receptor (AhR) 
signalling pathway activator, 24.34 μM 
(AID:743085).  
AhR+    
PXR+ 
Diatrizoic acid 
A commonly used X-ray contrast medium 
used for gastrointestinal studies, angiography 
and urography.  
  
Diazepan 
A benzodiazepine with anticonvulsant, 
anxiolytic, sedative, muscle relaxant and 
amnesic properties, actions of which are 
mediated by enhancement of gamma-
aminobutyric acid activity.  
Active in qHTS Human ERα signalling 
pathway antagonist in the BG1 cell line, 23.71 
μM (AID:743080) and antagonist of the AR 
signalling pathway, 15.72 μM (AID:743035). 
Antagonist of the Glucocorticoid receptor (GR) 
signalling pathway, 13.45 μM (AID:720692). 
Thyroid Receptor signalling pathway 
antagonist, 69.63 μM (AID:743067).  
ER+    
AR+     
GR+     
TR+ 
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Diazinon 
A cholinesterase inhibitor that is used as an 
organothiophosphorus insecticide, used to 
control cockroaches, silverfish, ants and 
fleas.  
Activator of the Aryl Hydrocarbon Receptor 
(AhR) signalling pathway, 6.86 μM 
(AID:743085). Antagonist of the Thyroid 
Receptor signalling pathway, 17.23 μM 
(AID:743064) and aromatase inhibitor, 17.23 
μM (AID:743083). Antagonist of the 
Glucocorticoid receptor signalling pathway, 
43.64 μM (AID:720693). PPARδ signalling 
pathway agonist, 54.94 μM (AID:743211).  
AhR+     
TR+      
GR+     
PPARδ
+ 
Dibenzo(a,h)anthrac
ene/ 
Dibenz[a,h] 
anthracene 
Also known as 1,2,5,6-dibenzanthracene.  
Activator of the Aryl Hydrocarbon Receptor 
(AhR) signalling pathway, 0.085 μM 
(AID:743085). Agonist of ER signalling 
pathway, 7.69 μM (AID:743077) and thyroid 
hormone receptor beta agonist, 39.81 μM 
(AID:588545).  
AhR+    
ER+    
TR+ 
Dibromochloro 
methane/  
Chlorodibromo 
methane 
Dibromochloromethane is a trihalomethane 
compound formerly used as a flame retardant 
and laboratory reagent. 
Dibromochloromethane is also formulated 
during drinking water chlorination processes 
and by ocean algae in small quantities.  
qHTS antagonist of the androgen receptor 
(AR) signalling pathway in the MDA cell line, 
60.08 μM (AID:743042).   
AR+ 
Dichlorobromometh
ane 
Bromodichloromethane is a trihalomethane 
previousoly used as a flame retardant, solvent 
for fats and mineral separation. Also occurs 
in municipally-treated drinking water as a by 
product of chlorination.  
qHTS agonist of the human AR signalling 
pathway, 21.95 μM (AID:743036).  
AR+ 
Dicyclohexylphthala
te (DCPH) 
Dicyclohexylphthalate is used as a plasticiser 
for nitrocellulose, ethyl cellulose, chlorinated 
rubber, polyvinyl acetate, polyvinyl chloride 
and other polymers.  
Antagonist of the Thyroid Receptor (TR) 
signalling pathway, 22.86 μM (AID:743064). 
qHTS agonist of the PPARδ signalling 
pathway, 46.01 μM (AID:743211). Aromatase 
inhibitor, 72.3 μM (AID:743084).   
TR+    
PPARδ
+ 
Dichlorvos 
An organophosphorus insecticide that inhibits 
acetylcholinesterase.  
qHTS agonist of the AR signalling pathway, 
4.95 μM (AID:743036) and an antagonist of 
ERα signalling pathway, 10.68 μM 
(AID:743069). Human Pregnane X receptor 
(PXR) signalling pathway activator, 39.81 μM 
(AID:720659). Antagonist of PPARγ 
signalling pathway (AID:743199).  
AR+    
ER+    
PXR+    
PPARγ+ 
Diclofenac 
A non-steroidal anti-inflammatory agent 
(NSAID) with antipyretic and analgesic 
actions. Diclofenac is used to treat pain, 
inflammatory disorders and dysmenorrhea.  
In vitro inhibitory activity against human 
whole blood Prostaglandin G/H synthase 2, 
IC50 0.05 μM (AID:162494).  
 
Dicofol 
Dicofol is an organochlorine insecticide, 
structurally related to DDT, used to control 
the red spider mite.  
Antagonist of the PPARγ signalling pathway, 
15.48 μM (AID:743194). Antagonist of the 
Androgen Receptor (AR) signalling pathway, 
48.97 μM (AID:743033). Aromatase inhibitor, 
61.13 μM (AID:743084).  
PPARγ+    
AR+ 
Dieldrin 
An organochlorine insecticide, used to 
control locusts, tropical disease vectors and 
non-food seed and plant treatment.  
DRUGMATRIX: Androgen AR radioligand 
binding (Mibolerone), IC50 6.89 μM 
(AID:625228). Aromatase inhibitor, 17.22 μM 
(AID:743083). Antagonist of the thyroid 
receptor signalling pathway, 30.64 μM 
(AID:743064). Activator of human PXR 
signalling pathway, 39.81 μM (AID:720659).  
AR+    
TR+    
PXR+ 
Diethylphthalate 
DEP is a phthalate ester used as a plasticiser, 
detergent base and to bind cosmetics and 
fragrances.  
Activator of the Aryl Hydrocarbon Receptor 
(AhR) signalling pathway, 62.19 μM 
(AID:743085).  
AhR+ 
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Diethylstilbestrol 
(DES) 
A synthetic nonsteroidal estrogen used in the 
treatment of menopausal and postmenopausal 
disorders. DES was given to cattle as a 
growth supplement and misguidingly given to 
pregnant women to reduce the risk of birth 
complications.  
In vitro agonist of ERα transcriptional 
activation in MCF-7 cells at 10 pM (EC50 7e-
0.6) (AID:102438). Activation of Estrogen 
Response element in HeLa cells stably 
transfected with human ERα, EC50 2e-0.5 μM 
(AID:70505). Displacement of 0.5nM E2 from 
human ER , Ki 0.00049 μM (AID:70002). 
DRUGMATRIX Progesterone radioligand 
binding, IC50 4.68 μM (AID:625172) and 
Glucocorticoid Radioligand binding, IC50 10.6 
μM (AID:625263). qHTS TR signaling 
pathway antagonist, 13.69 μM (AID:743065). 
Inhibitor of recombinant rat AR in E. coli 
using R1881, IC50 14.125 μM (AID:255211), 
human AR antagonism confirmed in qHTS 
assay in MDA cell line, 27.72 μM 
(AID:743054).  
ER+     
PR+    
TR+    
AR+ 
Diethyltoluamide 
(DEET)/ 
N,N-Diethyl-3-
methhylbenzamide 
DEET is used as a topical insect repellent, 
providing protection against mosquitos, ticks 
and fleas.  
qHTS assay ERα signalling pathway agonist, 
5.31 μM (AID:743079). Aryl Hydrocarbon 
Receptor (AhR) signalling pathway activator, 
60.51 μM (AID:743085).  
ER+    
AhR+ 
Difenoconazole 
Difenoconazole is a broad spectrum fungicide 
used to control Aschomycetes, basidomycetes 
and deuteromycetes families, acting as a seed 
treatment, foliar spray and systemic 
fungicide.  
Antagonist of ERα signalling pathway in the 
BG1 cell line, 11.29 μM (AID:743091). 
Thyroid receptor signalling pathway, 12.19 μM 
(AID:743065). qHTS androgen receptor 
antagonist in the MDA cell line, 13.69 μM 
(AID:743042). Aromatase inhibitor, 30.64 μM 
(AID:743083). Small molecule antagonist of 
the retinoid X receptor signalling, 39.81 μM 
(AID:588546). Antagonist of the 
glucocorticoid receptor signalling pathway, 
43.64 μM (AID:720692). PPARδ signalling 
pathway agonist/antagonist 48.97 μM 
(AID:743211/743194).  
ER+     
TR+      
AR+      
RXR+     
GR+    
PPARδ
+ 
Diflubenzuron 
An insect growth regulator which interferes 
with the formation of the insectcuticle, 
effective in the control of mosquitoes and 
flies.  
Human Aryl Hydrocarbon Receptor (AhR) 
signalling pathway activator, 0.086 μM 
(AID:743085). qHTS ERα signalling pathway 
agonist in the BG1 cell line, 4.33 μM 
(AID:743079). Retinoid X Receptor signalling 
agonist, 15.85 μM (AID:588544).  
AhR+    
ER+     
RXR+ 
Digoxigenin 
Digoxigenin is a steroid found in the flowers 
and leaves of the Digitalis species, which as a 
hapten, has many molecular biology 
applications. Digoxigenin is used as an all-
purpose immunotag. The aglycon of digoxin.  
Antagonist of Thyroid Stimulating Hormone 
Receptor (AID:504810).   
Dihydrotestosterone/  
Stanolone 
Also known as Androstanolone and 
Stanolone, dihydrotestosterone is a potent 
androgenic metabolite of testosterone 
produced by the action of the enzyme 3-Oxo-
5α-steroid 4-deyhydrogenase.  
AR agonist in mouse C2C12 cells, EC50 5e-05 
μM (AID:569780), activity in human Saos2 
cells, IC50 5e-05 (AID:319592). Displacement 
of DHT from human sex hormone binding 
globulin, Kd 0.000182 μM (AID:318680) and 
binding to human AR in CV1 cells, Ki 0.0002 
μM (AID:290231). qHTS TR signalling 
pathway antagonist, 0.0014 μM (AID:743065).  
Agonist of ERα signaling pathway in BG1 cell 
line, 0.42 μM (AID:743079).  Displacement of 
progesterone from rabbit PR, IC50 0.44 μM 
(AID:578353). DRUGMATRIX: Progesterone 
radioligand binding, IC50 1.25 μM 
(AID:625172). Angatonist of the 
Glucocorticoid  Receptor (GR) signaling 
pathway, 1.396 μM (AID:743077). Agonist of 
Retinoid X Receptor alpha signalling, 7.94 μM 
(AID:588544).   Antagonist of the thyroid 
receptor (TR) signalling pathway, 26.6 μM 
(AID:743067).  
AR+     
ER+      
GR+       
PR+      
RXR+    
TR+ 
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Diisobutylphthalate 
(DIBP) 
Prepared by the esterification of isobutanol 
and phthalic anhydride, DIBP, is a heat and 
light stable plasticiser. The concentration of 
mono-isobutyl phthalate (MIBP), a 
metabolite of DIBP steadily increased 
between 1999-2008 in American's urine 
(http://www.cdc.gov/exposurereport/).  
qHTS ERα agonist in the BG1 cell line, 0.0027 
μM (AID:743079). Active in aromatase 
inhibitor qHTS assay, 61.13 μM 
(AID:743083).  
ER+ 
Diisodecylphthalate  
Diisodecyl phthalate is used as an all purpose 
plasticiser for polyvinyl chloride.  
qHTS antagonist of the Androgen receptor 
(AR) signalling pathway, 9.77 μM 
(AID:743063).   
AR+ 
Diisononylphthalate 
Diisononylphthalate (DINP) is a plasticiser 
used in food contact materials, typically 
consisting of various isononyl esters of 
phthalic acid.  
  
Dilantin/ 
Phenytoin 
Also known as Phenytoin, Dilantin is an 
anticonvulsant, used in a wide variety of 
seizures, which also acts as an anti-
arrhythmic and muscle relaxant.  
qHTS human pregnane X receptor signalling 
pathway activator, 35.48 μM (AID:720659).  
PXR+ 
Diltiazem 
Diltiazem is a benxothiazepine, 
nondihydropyridine calcium channel blocker, 
used in the treatment of hypertension, angina 
pectoris and some types of arrhythmia.  
Antagonist of thyroid receptor (TR) signalling 
pathway, 23.71 μM (AID:743064).  
TR+ 
Dimethoate 
An organothiophosphorus cholinesterase 
inhibitor that is used as a systemic and 
contact insecticide.  
qHTS Aryl Hydrocarbon Receptor (AhR) 
signalling pathway (AID:743122).  
AhR+ 
Dimethylformamide 
(DMFA)/ 
N,N-
Diethylformamide 
Dimethylformamide is an organic solvent 
with a low evaporation rate, which is used in 
the productio of acrylic fibres and plastics.  
qHTS retinoid X receptor signalling agonist, 
14.13 μM (AID:588544).  
RXR+ 
Di-n-butylphthalate 
(DBP) 
A plasticiser used in most plastics, which is 
also used in adhesives and printing inks.  
qHTS ERα signalling pathway agonist in the 
BG1 cell line, 30.64 μM (AID:743079).  
ER+ 
Diphenyl/ 
Biphenyl 
Organic compound used as the starting 
material for the production of polychlorinated 
biphenyls (PCBs), but also used as an 
intermediate for the production of 
emulsifiers, optical brighteners, crop 
protection products and plastics.  
qHTS agonist of the retinoid X receptor (RXR) 
signalling pathway, 35.48 μM (AID:588544).  
RXR+ 
Diuron 
Also known as DCMU or 3-(3,4-
dichlorophenyl)-1,1-dimethylurea, Diuron is 
a herbicide introduced by Bayer that inhibits 
photosynthesis.  
qHTS Aryl Hydrocarbon Receptor (AhR) 
signalling pathway, 22.82 μM (AID:743122).  
AhR+ 
Domperidone 
A specific dopamine receptor blocker, 
increasing the speed of gastrointestinal 
peristalsis and causes prolactin release.  
Antagonise of the thyroid receptor signalling 
pathway, 26.60 μM (AID:743064).  
TR+ 
Doxazosin 
A quinazoline selective alpha-1-adrenergic 
blocker, used to treat high blood pressure and 
urinary retention associated with benign 
prostatic hyperplasia. Rlated to prazosin.  
  
Enalapril 
Angiotensin-converting enzyme inhibitor 
used to treat hypertension.    
Endosulfan 
A polychlorinated compound used as an 
insecticide, by repetitive nerve discharges 
increasing the temperature. Endosulfan is a 
neurotoxicant.  
qHTS ERα signalling agonist, 1.41 μM 
(AID:588514), confirmed in the BG1 cell line, 
1.935 μM (AID:743079). IC50 23.44 μM 
against recombinant rat AR in E. coli 
(AID:255211). PPARγ signalling pathway 
antagonist, 24.53 μM (AID:743194) and 
PPARδ agonist, 24.53 μM (AID:743211). 
Aromatase inhibitor, 27.33 μM (AID:743080). 
Thyroid Receptor antagonist, 30.61 μM 
(AID:743064). Glucocorticoid Receptor 
signalling pathway antagonist, 48.94 μM 
(AID:720693).  
ER+     
AR+    
TR+    
PPARγ+    
PPARδ
+   GR+ 
Evaluation of in silico and in vitro screening methods for EDC hazard characterisation 
 
 
 Page 234  
  
Epiandrosterone 
A metabolite of testosterone and 
androstenedione with a 3-alpha hydroxyl 
group without the double bond. The 3-beta 
hydroxyl isomer of epiandrosterone.  
Binds to Androgen Receptor (Stobaugh et al., 
1990).  
AR+ 
Epichlorohydrin (-
R) 
Epichlorohydrin is organochlorine epoxide 
used in the production of glycerol, plastics, 
epoxy glues and resins, and elastomers.  
  
Epichlorohydrin (-S) 
A chlorinated epoxy compound used as an 
industrial solvent, strong skin irritant and 
carcinogen.  
  
Epoxiconazole 
Epoxiconazole is an azole fungicide, 
developed to protect cereals, wheat, barley, 
rye and triticale, soybeans, banana, rice, 
coffee, turnips and beats.  
Aryl Hydrocarbon Receptor signalling 
pathway activator, 23.34 μM (AID:743085). 
Thyroid Receptor (TR) antagonist, 30.64 μM 
(AID:743065). Antagonist of the Androgen 
Receptor (AR) signalling pathway, 48.96 μM 
(AID:743035) and 66.01 μM in the MDA cell 
line (AID:743054). Estrogen Receptor (ERα) 
signalling pathway antagonist, 66.59 μM in the 
BG1 cell line (AID:743080). Aromatase 
inhibitor (AID:743139).  
AhR+     
TR+     
AR+    
ER+ 
Erythromycin 
A bacteriostatic antibiotic macrolide 
produced by Streptomyces erythreus, which 
inhibits protein synthesis by binding to 50S 
ribosomal subunits, which inhibits peptidyl 
transferase activity and interferes with 
translocation of amino acids during 
translation and protein assembly.  
Active in qHTS estrogen receptor alpha (ERα) 
signalling pathway agonist assay in the BG1 
cell line, 9.44 μM (AID:743079). However, 
was inactive in 17 of 18 studies.  
ER+ 
Esfenvalerate/ 
Fenvalerate 
Also known as the S-enantiomer of 
Fenvalerate, esfenvalerate is a synthetic 
pyrethroid insecticide.  
qHTS rat pregnane X receptor (rPXR) 
signalling pathway activator, 14.13 μM 
(AID:651751) and human PXR activator at 
31.62 μM (AID:720659).  
PXR+ 
Ethofenoprox/ 
Etofenprox 
Ethofenoprox is a pyrethroid insectice, used 
in veterinary medicines.    
Ethylparaben/  
Ethyl-4-hydroxy 
benzoate 
Ethylparaben (ethyl-p-hydroxybenzoate) is an 
antifungal preservative, used as a food 
additive (E number E214). Sodium ethyl 
para-hydroxybenzoate, the sodium salt of 
ethylparaben, has the same uses and is given 
the E number E215. Also used to preserve 
pharmaceuticals and cosmetic products.  
qHTS human estrogen receptor alpha (ERα) 
signalling pathway agonist in the BG1 cell 
line, 23.71 μM (AID:743079). DSSTox 
(NCTRER) National Center for Toxicological 
Research Estrogen Receptor Binding Database 
(AID:1204).  
ER+ 
Etofenamate 
Used in the treatment of joint and muscular 
pain, Etofenamate is a non-steroidal anti-
inflammatory drug.  
  
Etofibrate 
Etofibrate is a amphipathic carboxylic acid, 
used to treat metabolic disorders, such as 
hypercholesterolemia, and is a hypolipidemic 
agent.  
  
Etridiazole/ 
Imidazole 
Also known as Terrazole, Etridiazole is a 
fungicide used to control Pythium and 
Phytophthora root rot and stem rot, 
commonly used on turf and nursing 
ornamentals. It is also used in barley, bean, 
corn, cotton, peanut, pea, sorghum, soybean, 
safflower and wheat production.  
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Exifone An antiplatelet drug 
qHTS activator of the Human Aryl 
Hydrocarbon Receptor (AhR) signalling 
pathway, 20.48 μM (AID:743122). Androgen 
Receptor signalling pathway antagonist, 24.54 
μM (AID:743035). Aromatase inhibitor, 34.27 
μM (AID:743084). qHTS Thyroid Receptor 
(TR) signalling pathway, 43.15 μM 
(AID:743056). ERα signalling antagonist in 
the BG1 cell line, 61.13 μM (AID:743081).  
AhR+     
AR+    
TR+     
ER+ 
Famotidine 
Famotidine is a competitive histamine H2-
receptor antagonist, inhibiting gastric 
secretion and used in the treatment of ulcers.   
  
Fenarimol 
Fenarimol inhibits fungal biosynthesis, and is 
used to protect against rusts, blackspot and 
mildew.  
qHTS ERα signalling agonist in BG1 cell line, 
9.69 μM (AID:743079). Androgen Receptor 
signalling antagonist, 24.54 μM (AID:743035). 
Thyroid Receptor signalling pathway 
antagonist, 36.34 μM (AID:743014). 
Glucocorticoid Receptor signalling pathway 
antagonist, 48.96 μM (AID:720692).  
ER+ 
AR+ 
TR+ 
GR+ 
Fenitrothion 
Dimethyl o-(3-methyl-4-nitrophenol) 
phosphorothioate or Fenitrothion is an 
organophosphate insecticide and acaricide 
used in greenhouses.  
qHTS Human AR signalling pathway 
antagonist, 7.76 μM (AID:743063). Activator 
of the Aryl Hydrocarbon Receptor signalling 
pathway, 21.69 μM (AID:743085). Aromatase 
inhibitor (AID:743129).  
AR+     
AhR+ 
Fenofibrate 
Antilipemic fibrate drug used to reduce 
cholesterol and triglycerides in the blood.   
PPARα signalling pathway agonist, EC50 30 
μM (AID:91237). Binding affinity at PPARγ, 
EC50 41 μM (AID:317698). Androgen 
Receptor signalling antagonist in the MDA cell 
line, 48.56 μM (AID:743042). ERα signalling, 
61.13 μM (AID:743091). Thyroid Receptor 
signalling antagonist, 61.13 μM (AID:743065).  
PPARα
+ 
PPARγ+ 
AR+ 
ER+ 
TR+ 
Fenoprofen (FNP) 
Fenoprofen is pharmacologically similar to 
Aspirin, functioning as an anti-inflammatory 
analgesic, typically used to relieve the 
symptoms of rheumatoid arthritis, 
osteoarthritis and pain. Inhibits 
cyclooxygenase.  
  
Fenoterol 
Fenoterol is a sympathomimetic beta-2-
adrenergic agonist, used in the treatment of 
asthma as a bronchodilator and tocolytic.  
  
Fenothrin 
Fenothrin (Phenothrin) is a synthetic 
pyrethroid insecticide, used to control lice, 
fleas and ticks.  
  
Fenoxycarb 
Fenoxycarb is a carbamate insecticide, which 
mimics juvenile hormones, preventing insects 
from reaching maturity.  
qHTS PPARγ signalling pathway antagonist, 
38.90 μM (AID:743191). Estrogen Receptor 
(ERα) signalling pathway antagonist, 38.90 
μM (AID:743069) and 43.64 μM 
(AID:743078). Pregnane X Receptor (PXR) 
signalling activator, 50.12 μM (AID:720659). 
Antagonist of AR signalling in the MDA cell 
line, 54.47 μM (AID:743042).  
PPARγ+    
ER+     
PXR+    
AR+ 
Fentiazac 
Non steroidal anti-inflammatory analgesic 
used in muscular and joint pain.  
Agonist of human PPARγ signalling pathway, 
1.51 μM (AID:743140). Aryl Hydrocarbon 
Receptor (AhR) signalling pathway activator, 
29.85 μM (AID:743122).  
PPARγ+   
AhR+ 
Fenvalerate 
Insecticide used to control insects in food, 
feed and cotton products, and flies and ticks 
in barns and stables.  
Agonist of Estrogen Receptor (ERα) signalling 
pathway in the BG1 cell line, 13.69 μM 
(AID:743079). Thyroid Receptor signalling 
antagonist, 17.47 μM (AID:743067). 
Antagonist of the AR signalling pathway, 
50.89 μM (AID:743063).  
ER+     
TR+    
AR+ 
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Ferulic acid 
A phenolic compound in asafoetida,  from 
fennel (Ferula communis), Ferulic acid has 
antibacterial and antioxidant properties. 
Pharmacological actions include, anti-
inflammatory, anticoagulant, 
antihypertensive and cholagogues and 
choleretic actions. Found widely in soil 
humus.  
  
Fipronil 
Broad-spectrum insecticide that disrupts the 
central nervous system via GABA receptors.  
Antagonist of the AR signalling pathway in the 
MDA cell line, 1.14 μM (AID:743054). ERα 
signalling pathway antagonist in the BG1 cell 
line, 7.50 μM (AID:743080). Pregnane X 
Receptor signalling pathway activator, 12.59 
μM (AID:720659). Aromatase inhibitor, 19.45 
μM (AID:743083). Thyroid Receptor 
signalling antagonist, 26.60 μM (AID:743065). 
PPARδ signalling pathway antagonist, 43.90 
μM (AID:743213) and PPARγ at 49.26 μM 
(AID:743194).  
AR+     
ER+    
PXR+    
TR+     
PPARδ
+   
PPARγ+ 
Flumethasone 
Flumethasone is an anti-inflammatory 
glucocorticoid in veterinary practices, 
structurally related to dexamethasone.  
qHTS Glucocorticoid Receptor (GR) signalling 
pathway agonist, 0.0016 μM (AID:720719). 
Androgen receptor signalling pathway agonist 
in the MDA cell line, 0.0025 μM 
(AID:743040).  
GR+   
AR+ 
Fluorene 
Product of incomplete combustions. Fluorene 
is extractable from coal tar, but can also be 
synthesied from the dehydrogenation of 
diphenylmethane.  
qHTS Thyroid Receptor (TR) signalling 
pathway antagonist, 66.01 μM (AID:743067).  
TR+ 
Fluoxetine 
Commonly known as Prozac, fluoxetine is a 
selective serotonin reuptake inhibitor (SSRI), 
used as an antidepressant, which is prescribed 
in the treatment of depression, obsessive-
compulsive disorder, bulimia nervosa, panic 
disorder and premenstrual dysphoric disorder.  
qHTS Peroxisome proliferator-activated 
receptor delta (PPARδ) signalling antagonist, 
9.52 μM (AID:743213). Antagonist of the 
thyroid receptor (TR) signalling pathway, 
11.88 μM (AID:743065). Aryl Hydrocarbon 
Receptor (AhR) signalling activator, 23.7 μM 
(AID:743086). Antagonist of the AR signalling 
pathway in the MDA cell line, 27.82 μM 
(AID:743041).  
PPARδ
+   TR+     
AhR+     
AR+ 
Flurbiprofen 
An anti-inflammatory analgesic and 
antipyretic, Flurbiprofen inhibits carbonic 
anhydrase and is used in peridontal disease.  
qHTS agonist of the Estrogen Receptor (ERα) 
signalling pathway in the BG1 cell line, 4.52 
μM (AID:743079). Agonist of the PPARγ 
signalling pathway (AID:743140).  
ER+     
PPARγ+ 
Fluticasone 
Fluticasone is a synthetic glucocorticoid 
agonist, used as an anti-allergic, anti-
inflammatory, bronchodilator and 
dermatologic agent.  
Androstane GR+ 
Flutriafol 
Flutriafol is a pesticide used to control fungal 
disease on wheat, barley and canola.  
Aromatase inhibitor (AID:743139).  
 
Fluvalinate 
As a pyrethroid inseccticide, Fluvalinate is 
used to control varroa mites in honey bea 
colonies.  
  
Formononetin 
Formononetin is phytochemical present in 
leguminous plants and Fabaceae (beans and 
soy).  
qHTS agonist of the ERα signalling in the BG1 
cell line, 1.54 μM (AID:743079). Activator of 
the Aryl Hydrocarbon Receptor (AhR), 5.05 
μM (AID:743122).  
ER+     
AhR+ 
Furosemide 
Furosemide is a benzoic-sulfonamide-furan 
diuretic used in the treatment of congestive 
heart failure and edema.  
Estrogen Receptor (ERα) signalling pathway 
agonist, 14.96 μM (AID:743079). Androgen 
Receptor (AR) signalling antagonist, 26.83 μM 
(AID:743063).  
ER+     
AR+ 
Gabapentin 
Also known as Neurontin, Gabapentin is used 
in the treatment of epilepsy and neuropathic 
pain.  
  
Galaxilide 
Also known as Galoxolide, Galaxolide is a 
polycyclic aromatic synthetic musk used in 
soaps, cosmetics and detergents.   
Agonist of ERα signalling pathway in qHTS 
assay, 11.22 μM (AID:588514).  
ER+ 
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Gemfibrozil (GFB) 
Gemfibrozil is a lipid-regulating agent that 
decreases serum triglycerides; incrases HDL 
subfraction HDL2 and HDL3, in addition to 
apolipoproteins A-I and A-II.  
Aryl Hydrocarbon Receptor (AhR) signalling 
pathway activator, 48.90 μM (AID:743085).  
AhR+ 
Genistein 
An isoflavonoid compound that inhibits 
protein-tyrosine kinase and topoisomerase-II, 
and has been identified as an antineoplastic 
and antitumor agent.  
Displacement of [H3]E2 from human ERβ in 
293T cells, IC50 0.0013 μM (AID:257300). 
Inhibition of human ERα LBD, IC50 0.0097 
μM (AID:292714). Cytotoxicity against human 
MCF-7 cells after 48 hours by MTT assay, IC50 
1 μM (AID:517124). Aryl Hydrocarbon 
Receptor signalling pathway activator, 3.35 
μM (AID:743085). Thyroid Receptor 
antagonist, 11.88 μM (AID:743065). PPARγ 
signalling pathway antagonist, 17.37 μM 
(AID:743191). Human Pregnane X receptor 
(PXR) signalling, 19.95 μM (AID:720659). 
Androgen Receptor (AR) signalling pathway 
antagonist, 24.13 μM (AID:743063). Retinoid 
X Receptor signalling antagonist, 35.48 μM 
(AID:588546). Antagonist of the 
glucocorticoid receptor (GR) signalling 
pathway, 54.02 μM (AID:720693).  
ER+    
AhR+    
TR+    
PPARγ+    
PXR+    
RXR+    
AR+   
GR+ 
Glufosinate 
Glufosinate interferes with the biosynthetic 
pathway of glutamine, and is used in non-
selective herbicides and pre-harvest crop 
desiccation.  
  
Glycitein 
As an O-methylated isoflavone, glycitein is a 
phytestrogen present in soy products.  
Activity in human ER expressed in transfenic 
Arabidopsis plant at 5 μM by pER8-GFP 
reporter assay (AID:402363).  
ER+ 
Glyphosate 
Systemic broad-spectrum herbicide, used on 
broadleaf weeds and grasses.    
Hexachlorobenzene 
(HCB) 
An agricultural fungicide and seed treatment.  
  
Hydrochlorothiazide 
A thiazide diuretic used in the treatment of 
edema, hypertension, diabetes insipidus and 
hypoparathyroidism.  
Peroxisome proliferator-activated receptor 
delta (PPARδ) signalling agonist, 38.32 μM 
(AID:743213).  
PPARδ
+ 
Hydrocinnamic acid/ 
3-Phenylpropanoic 
acid 
Hydrocinnamic acid is used as a preservative, 
prolonging the life of frozen foods, spices, 
fragrances and medicides.  
  
Hydroxyhydro 
quinone/ 
1,2,3-Benzenetriol 
Also known as hydroxyquinol is a 
benzenetriol biodegradation product of 
Bradyrhizobium japonicum.  
  
Ibuprofen 
Ibuprofen is an anti-inflammatory analgesic 
used in the management of rheumatism and 
arthritis.  
Inhibition activity against recombinant human 
Prostaglandin G/H synthatse 2, IC50 0.1 μM 
(AID:162632). Active in qHTS assay for ERα 
signalling pathway agonists, 47.6 μM 
(AID:743079).  
ER+ 
Ifosfamide 
Immunosuppressive alkylating agent, trade 
name Mitoxana® is a chemotherapeutic agent 
used to treat sarcoma, testicular cancer and 
some lymphomas.  
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Imazalil/ 
Enilconazole 
Also known as Enilconazole, Imazalil is 
fungicide widely used in the post-harvest 
treatment of bananas and citrus fruits.  
Human aromatase inhibitor, 0.387 μM 
(AID:743139). Aryl hydrocarbon receptor 
(AhR) signalling pathway activator, 8.66 μM 
(AID:743122). Pregnane X receptor signalling 
pathway activator, 15.85 μM (AID:651751).  
Glucocorticoid receptor signalling pathway 
antagonist, 21.94 μM (AID:720693). PPARδ 
signalling pathway antagonist, 24.54 μM 
(AID:743215). Thyroid Receptor signalling 
pathway antagonist, 30.64 μM (AID:743065). 
Estrogen Receptor antagonist in the BG1 cell 
line, 48.56 μM (AID:743091).  Androgen 
receptor antagonist, 49.12 μM (AID:743033). 
Aromatase inhibitor (AID:743139).  
AhR+     
PXR+    
PPARδ
+    TR+    
ER+    
AR+ 
Indapamide 
Benzamide-sulfonamide-indole diuretic that 
inhibts sodium chloride symporters. 
Indapamide is used in the treatment of 
hypertension.  
  
Indenol(1,2,3-
cd)pyrene 
Polycyclic aromatic hydrocarbon that occurs 
in coal tar. Primarily the product of 
incomplete combustion, including vegetation 
and food products.  
  
Indomethacin (IDM) 
Used to reduce fever, pain, stiffness and 
swelling, indomethacin inhibits 
cyclooxygenases enzymes necessary for the 
formation of autacoids, such as 
prostaglandins. Indomethacin is a non-
steroidal anti-inflammatory agent which also 
inhibts the motility of polymorphonuclear 
leukocytes.  
PPARγ signalling pathway agonist, 1.96 μM 
(AID:743094).  
PPARγ+ 
Iohexol 
low-chemotoxic non-ionic water soluble 
contrast agent used in myelography, 
arthrography, nephroangiography, 
anteriography and radiographic procedures.  
  
Iopamidol 
Non-ionic water soluble contrast agent used 
in myelography, arthrography, 
nephroangiography, anteriography and 
radiographic procedures.  
Active in qHTS Androgen Receptor (AR) 
signalling pathway agonist assay, in the MDA 
cell line, 10.12 μM (AID:743040). 
Glucocorticoid Receptor signalling pathway 
agonist, 7.23 μM (AID:720719).  
AR+     
GR+ 
Iopromide 
Marketed under Ultravist, Iopromide is a 
non-ionic water soluble contrast agent.    
Iothalamic acid Contrast medium.  
  
Ioxynil/ 
4-Hydroxy-3,5-
diiodobenzonitrile 
Also known as Bentrol, nitrile substituted 
active ingredient in Plant Protection Product, 
used in combination with a number of 
herbicides.  
Agonist of PPARα signalling pathway, 15.85 
μM  (AID:651778). qHTS antagonist of the 
Thyroid Receptor signalling pathway, 21.69 
μM  (AID:743065). ER signalling pathway 
antagonist, 27.54 μM  (AID:743078). 
Androgen Receptor signalling pathway 
antagonist, 43.64 μM  (AID:743033). 
Aromatase inhibitor (AID:743139).  
PPARα
+   TR+     
ER+     
AR+ 
Iprodione 
Marketed by Bayer CropScience, Iprodione is 
used to control Botrytis bunch rot, brown rot, 
Sclerotinia and other fungal diseases in 
plants.  
Activator of the Aryl Hydrocarbon Receptor 
(AhR) signalling pathway, 4.86 μM  
(AID:743085). PPARγ antagonist, 44.67 μM  
(AID:588537).  
AhR+    
PPARγ+ 
Irgarol 
Trade name Cybutryne, Biocide algaecide 
triazine that inhibits photosynthesis and is 
used in marine antifouling agent 
Activator of the Aryl Hydrocarbon Receptor 
(AhR) signalling pathway, 0.49 μM  
(AID:743122). Androgen Receptor (AR) 
signalling pathway antagonist, 48.97 μM  
(AID:743033). PPARδ agonist, 48.97 μM  
(AID:743211).  
AhR+     
AR+    
PPARδ
+ 
Isoproturon 
Isoproturon is a herbicide that disrupts 
photosynthesis and is applied to soil to 
control weeds.  
Activator of the Aryl Hydrocarbon Receptor 
(AhR) signalling pathway, 61.07 μM  
(AID:743122).  
AhR+ 
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Kaempferol 
Kaempferol and its glucoside  is a natural 
flavonoid found in tea, broccoli, witch-hazel, 
grapefruit, kale, beans, endive, leek and a 
number of other plant sources.  
Inhibition of Aryl Hydrocarbon Receptor 
(AhR), IC50 0.028 μM (AID:311070). qHTS 
agonist of the estrogen receptor (ERα) 
signalling pathway, 7.94 μM (AID:588514), 
and 9.65 μM in the BG1-cell line 
(AID:743079). Antagonism of the Androgen 
Receptor in MDA-kb2 cells, assessed as 
inhibition of DHT-induced luciferase activity, 
IC50 9.7 μM (AID:429199). Antagonist of 
PPARγ signalling pathway, 29.47 μM 
(AID:743191). qHTS activator of the human 
PXR signalling pathway, 44.67 μM 
(AID:720659). Antagonist of the thyroid 
receptor (TR) signalling pathway, 60.88 μM 
(AID:743065). Inhibition of PPARγ-meidated 
adipocyte differentiation in mouse 3T3L1 cells 
(AID:517389). Antagonist of the 
Glucocorticoid receptor signalling pathway 
(AID:720725).  
AhR+    
ER+     
AR+    
PPARγ+    
PXR+      
TR+       
GR+ 
Ketoconazol 
Broad-spectrum antifungal agent, typically 
used in immunosupressed patients, at high 
doses for long periods of time.  
  
Ketoprofen (KTP) 
Non-steroidal anti-inflammatory drug, with 
analgesic and antipyretic properties similar to 
ibuprofen, used in the treatment of 
rheumatoid arthritis and osteoarthritis.  
  
Ketorolac 
Non-steroidal anti-inflammatory (NSAID) 
pyrrolizine carboxylic acid derivative, related 
to indomethacin, used as an analgesic.  
  
Lansoprazole 
A 2,2,2-trifluoroethoxypyridyl derivative of 
timoprazole used in the treatment of stomach 
ulcers, inhibits an ATPase found in gastric 
parietal cells.  
Activator of the Aryl Hydrocarbon Receptor 
(AhR) signalling pathway, 4.22 μM 
(AID:743085). Antagonist of the PPARγ 
signalling pathway (AID:743199).  
AhR+    
PPARγ+ 
Levonorgestrel 
A synthetic progestational hormone with 
actions similar to those of progesterone, it is 
used for contraception, control of menstrual 
disorders and treatmetn of endometriosis.  
Progesterone Receptor agonist (AID:742449). 
qHTS agonist of the AR signalling pathway, 
0.001 μM (AID:743053). Displacement of 
[3H]5α-Dihydrotestosterone from human Sex 
Hormone Binding Globulin, Kd 0.00123 μM 
(AID:318680). Agonism of AR in MDA cell 
line, 0.0047 μM (AID:743040). Antagonism of 
AR signalling pathway, 0.017 μM 
(AID:743035). Agonism of ERα Signalling 
pathway in BG1 cell line, 0.039 μM 
(AID:743079). qHTS Glucocorticoid Receptor 
signalling pathway antagonist (AID:720725).  
AR+     
PR+     
ER+    
PR+ 
Lincomycin 
A Streptomyces lincolnesis antibiotic used in 
the treatment of staphylococcal, streptococcal 
and bacteroides fragilis infections.  
  
Lindane 
Organochlorine insecticide, also known as 
hexachlorocyclohexane and Gammaxene, 
used as a pediculicide and scabicide. Lindane 
is approved for use as a second-line topical 
treatment therapy for Pediculosis capitis 
(head lice) by the FDA.  
qHTS agonist of the Estrogen Receptor (ERα) 
signalling pathway, 0.195 μM (AID:743075), 
and in the BG1 cell line, 3.86 μM 
(AID:743079). Thyroid Receptor (TR) 
signalling pathway antagonist, 33.49 μM 
(AID:743067). Glucocorticoid  Receptor (GR) 
signalling pathway agonist, 39.68 μM 
(AID:720691). qHTS activator of the human 
PXR signalling pathway, 44.67 μM 
(AID:720659). PPARδ signalling pathway 
agonist, 52.87 μM (AID:743227). Activator of 
the Aryl Hydrocarbon Receptor (AhR), 61.69 
μM (AID:743085).  
ER+     
TR+     
GR+     
PXR+   
PPARδ
+    
AhR+ 
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Linuron 
Also known as Afalon, Lorox and Linurex, 
Linuron is a pre- and post-emergence 
herbicide.  
qHTS activator of the AhR signalling pathway, 
8.64 μM (AID:743085). Antagonist of the AR 
signalling pathway, 34.82 μM (AID:743063). 
Thyroid Receptor (TR) signalling pathway, 
61.13 μM (AID:743067).  
AhR+    
AR+     
TR+ 
Loratadine 
Second-generation histamine H1 receptor 
antagonist used in the treatment of allergic 
rhinitis and urticaria.  
Thyroid Receptor signalling pathway 
antagonist, 9.69 μM (AID:743065). Agonist of 
the PPARδ signalling pathway, 10.59 μM 
(AID:743211). Antagonist of the PPARγ 
signalling pathway, 13.33 μM (AID:743191). 
Antagonist of the AR signalling pathway, 
17.37 μM (AID:743035). Glucocorticoid 
Receptor (GR) signalling pathway antagonist, 
23.92 μM (AID:720692). ERα signalling 
pathway antagonist, 22.58 μM (AID:743078).  
TR+    
PPARδ
+   
PPARγ+    
AR+    
GR+    
ER+ 
Malathion 
Alphatic organophorphate (organophosphate 
parasympathomimetic) broad-spectrum 
insecticide, used commercially and 
domestically, that binds to cholinesterase.  
Activator fo the Aryl Hydrocarbon Receptor 
(AhR) signalling pathway, 32.97 μM 
(AID:743122).  
AhR+ 
Maneb/  
Amobam 
Complexed manganese derivative of 
ethylenebisdithiocarbamate used as an 
agricultural fungicide. Maneb has been 
shown to affect glucocorticoid metabolism by 
interfering with the conversion of cortisol to 
cortisone, via the 11β-hydroxysteroid 
dehydrogenase type-2 enzyme.  
  
MCPA/ 
4-Chloro-2-
methylphenoxy) 
acetic acid 
2-Methyl-4-chlorophenoxyacetic acid 
(MCPA) is a powerful selective phenoxy 
herbicide (weed killer).  
  
Meclocycline/  
Samil 
Meclocycline (INN), also known as 
Meclociclina and Meclocyclinum, INN is a 
tetracycline antibiotic, used topically to treat 
skin infections. INN is not taken orally as it 
may cause systemic liver and kidney damage.  
  
Meclofenamic acid/  
Meclofenamate 
Branded as Meclomen, Meclofenamic acid is 
NSAID agent with antipyretic and 
antigranulation activity, while inhibiting 
prostaglandin biosynthesis, typically used for 
joint, muscular pain, arthritis and 
dysmenorrhea.  
  
Mecoprop/  
2-(4-Chloro-2-
methylphenoxy)prop
anoic acid 
Also known as 
methylchlorophenoxypropionic acid or 
MCPP, Mecoprop is a broad-spectrum 
herbicide, primarily used to control broadleaf 
weeds.  
  
Mefenamic acid 
Non-steroidal anti-inflammatory 
cyclooxygenase inhibitor analgesic with 
antipyretic properties, used in the treatment 
of menstrual pain.  
qHTS antagonist of the Thyroid Receptor (TR) 
signalling pathway, 21.13 μM (AID:743065) 
and antagonist of the Glucocorticoid Receptor 
(GR) signalling pathway, 48.97 μM 
(AID:720692). Antagonist of the PPARγ 
signalling pathway (AID:743199).  
TR+    
GR+   
PPARγ+ 
Mestranol 
As a 3-methyl ether prodrug of 
ethinylestradiol, Mestraol  has to be 
demethylated in the liver to be biologically 
active, and is a component of some oral 
contraceptives.  
qHTS agonist of ERα signalling pathway in 
BG1 cell line, 0.0008 μM (AID:743079), 
Drugmatrix ER IC50 0.018 μM (AID:625258). 
Androgen Receptor (AR) signalling pathway 
antagonist, 3.34 μM (AID:743063) and 
Drugmatrix AR IC50 10.68 μM (AID:625228). 
Glucocorticoid Receptor (GR) signalling 
pathway antagonist (AID:720725).  
ER+    
AR+    
GR+ 
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Methoxychlor 
Synthetic organochlorine insecticide used to 
protect crops, ornamentals, livestock and 
pets.  
qHTS human ERα signalling pathway agonst 
in BG1 cell line, 6.08  μM (AID:743079).  
Antagonist of the PPARγ signalling pathway, 
13.60 μM (AID:743194). Androgen Receptor 
(AR) signalling pathway antagonist, 17.48 μM 
(AID:743063). Thyroid Receptor (TR) 
signalling pathway, 21.56 μM (AID:743064). 
Glucocorticoid Receptor (GR) signalling 
pathway, 24.39 μM (AID:720692). Pregnane X 
Receptor activation, 28.18 μM (AID:651751).  
ER+     
PPARγ+   
AR+   
TR+    
GR+     
PXR+ 
Methylester/ 
Methyl-2-amino-4,5-
dimethylthiophene-
3-carboxylate 
Also known as methyl 2-amino-4,5-
dimethylthiophene-3-carboxylate, classified 
as a PPP regulated product and chemical 
reagent.  
  
Methylparaben 
Methylparaben, or Methyl 4-
hydroxybenzoate, is the methyl ester of p-
hydroxybenzoic acid, naturally found in 
fruits, which is commonly artificially added 
to cosmetics, personal care products and food 
items (E number E218).  
qHTS activator of the Aryl Hydrocarbon 
Receptor signalling pathway, 69.29 μM 
(AID:743085). Listed in the DSSTox 
(NCTRER) National Center for Toxicological 
Research Estrogen Receptor Binding Database 
(AID:1204).  
AhR+    
ER+ 
Metolachlor 
A derivative of aniline, metolachlor is an 
organic herbicide.  
Androgen Receptor signalling pathway 
antagonist, 44.40 μM (AID:743063) and in the 
MDA cell line, 51.34 μM (AID:743054). 
PPARγ signalling pathway antagonist 
(AID:743199).  
AR+    
PPARγ+ 
Metoprolol 
Selective adrenergic β1 receptor blocker used 
in the treatment of cardiovascular diseases, 
such as angina pectoris, hypertension and 
cardiac arrhythmias.  
  
Metribuzin 
Also known as 4-amino-6-tert-butyl-3-
(methylthio)-as-triazin-5 (4H)-one, 
Metribuzin is a pre- and post- emergence 
herbicide, that inhibits photosynthesis and is 
commonly used on soy beans, potatoes, 
tomatoes and sugar cane.  
qHTS agonist of the retinoid X receptor (RXR) 
signalling pathway, 39.81 μM (AID:588544).  
RXR+ 
Metronidazole 
Nitroimidazole antibiotic used against the 
anaerobic bacteria and protozoa, associated 
with amebiasis, vaginitis, trichomonas 
infections, giardiasis and treponemal 
infections. Highlighted as a potential 
radiation-sensitising agent.  
qHTS PPARγ signalling pathway antagonist, 
48.97 μM (AID:743194).  
PPARγ+ 
Mevinphos 
Organophosphate cholinesterase inhibitor 
insecticide.    
Mirex 
Banned organochlorine insecticide, 
previously used to control fire ants.    
Molinate 
Also known as Ethyl N, N'-
Hexamethylenethiolocarbamate, Molinate is a 
pre- and post- emergent systemic 
thiocarbamate herbicide, used to cotnrol 
Echinochloa sp. And Diplachne fusca. WHO 
assigned a drinking water quality guideline of 
6 μg/L.  
  
Mono-2-
ethylhexylphthalate 
(MEHP)/ 
2-(((2-
ethyl)hexyl)oxy)carb
onyl benzoic acid 
Plasticiser and hydrolysed product of DEHP.  
qHTS PPARγ signalling pathway agonist, 3.34 
μM (AID:743140) and PPARα at 28.18 μM 
(AID:651778). Human PXR signalling 
pathway activator, 14.13 μM (AID:720659).  
PPARγ+    
PPARα
+   
PXR+ 
Mono-n-
butylphthalate  
Plasticiser 
Developmental toxicity in F1 Wistar rats has 
been reported at  500 mg kg-1/day maternal 
exposure on days 7-15 (Ema et al., 1995).  
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Musk ketone 
Also known as white musks, are synthetic 
aromachemicals used in perfumery.  
qHTS Retinoid X receptor signalling agonist, 
28.18 μM (AID:588544). Estrogen Receptor 
alpha (ERα) sgnalling pathway antagonist in 
the BG1 cell line, 30.64 μM (AID:743080). 
PXR signalling pathway activator, 44.67 μM 
(AID:720659).  
RXR+    
ER+    
PXR+ 
Mycobutanil 
Also known as Systhane, myclobutanil is a 
triazole systemic fungicide, that inhibits 
ergosterol biosynthesis.  
qHTS aromatase inhibitor, 24.19 μM 
(AID:743083). Activator of rat Pregnane X 
Receptor (rPXR) signalling pathway, 31.62 
μM (AID:651751). Antagonist of the ERα 
signalling pathway, 43.10 μM (AID:743091).  
PXR+  
ER+ 
2-Acetylamino 
fluorene/ 
N-(9N)-Fluoren-2-yl 
acetamide 
Also known as n-2-fluorenylacetamide, 
2AAF is an aromatic hepatic carcinogen.  
Estrogen Receptor (ERα) signalling pathway 
agonist, 11.04 μM (AID:743079). Activator of 
the Aryl Hydrocarbon Receptor (AhR) 
signalling pathway, 34.90 μM (AID:743122). 
Glucocorticoid Receptor (GR) signalling 
pathway (AID:720725).  
ER+     
AhR+    
GR+ 
Nadolol 
Non-selective beta-adrenergic antagonist 
used in the treatment of cardiovascular 
disease for arrhythmias, angina pectoris and 
hypertension. The preparation is a mixture of 
stereoisomers.  
  
Naproxen 
An anti-inflammatory, antipyretic, used in the 
treatment of rheumatoid arthritis, 
muscoskeletal disorders, dysmenorrhea and 
acute gout.  
In vitro inhibition of prostaglandin G/H 
synthase in rat neutrophils (AID:160881).  
Naphthalene 
Simplest polycyclic aromatic hydrocarbon 
used in the manufacture of phthalic anhydride 
and plastics. Product of wood, fossil fuel and 
crude oil incomplete combustion.  
  
Naringenin 
Flavonone found in grapefruit, oranges and 
tomatoes, with antioxidant properties.  
qHTS Cytochrome P450 interactions 
(AID:884).   
n-Butylbenzene N-butylbenzene is used in organic synthesis.  
  
Nimesulide 
COX-2 selective non-steroidal anti-
inflammatory drug (NSAID) used in the 
treatment of osteoarthritis and 
dysmenorrhoea.  
qHTS antagonist of ERα signalling pathway in 
BG1 cell line, 61.13 μM (AID:743081) and 
PPARγ signalling pathway (AID:743199).  
ER+ 
PPARγ+ 
Nitroso piperidine 
N-Nitrosopiperidine is a disinfection 
byproduct of water treatment.  
DSS Carcinogenic Potency Database Rat 
Bioassay Results (AID1208).   
N-Nitroso 
dimethylamine 
NMDA is a industrial-by-product of several 
industrial processes, present in foodstuffs at 
trace concentrations.  
  
Norethindrone 
A synthetic progestational hormone with 
action similar to progesterone, functioning as 
an inhibitor of ovulation in the contraceptive 
pill. Norethindrone has also been used to treat 
amenorrhea, functional uterine bleeding and 
endometriosis.  
Dissociation constant for progesterone 
receptor, Kd 0.0004 μM (AID:162459) and for 
the rat uterine estrogen receptor alpha, Kd 
0.00063 μM (AID:69387). Modulation of hPR-
B in co-transfected CV-1 cells, EC50 0.0022 
μM (AID:161792). Agonist of the Androgen 
receptor signaling pathway, 0.0022 μM 
(AID:743053). IC50 against recombinant rat 
AR in E. coli using R1881, 0.12 μM 
(AID:255211). DRUGMATRIX: 
Glucocorticoid radioligand binding, 0.397 μM 
(AID:625263). Thyroid Receptor signaling 
pathway antagonist, 6.86 μM (AID:743065).  
PR+     
ER+     
AR+    
GR+     
TR+ 
Norfloxacin 
Synthetic fluoroquinolone broad-spectrum 
antibacterial agent, which inhibits bacterial 
DNA gyrase.  
  
Nortriptyline 
Antidepressive metabolic breakdown product 
of Amitriptyline, used in the treatment of 
depression and dysthymia.  
qHTS cytochrome P450 binding (AID:891).  
 
o,p-DDD 
Known as Mitotane, DDD is a derivative of 
dichlorodiphenyldichloroethane (DDT) 
which inhibits the cells of the adrenal cortex 
and is used in the treatment of adrenal 
tumours.  
qHTS small molecule agonist of ERα 
signalling pathway in BG1 cell line, 2.37 μM 
(AID:743079). Antagonists of TR signalling 
pathway, 13.33μM (AID:743064). 
Glucocorticoid Receptor (GR) signalling 
pathway antagonist, 18.99 μM (AID:720692). 
ER+ 
TR+ 
GR+ 
AR+ 
PPARδ
+ 
PPARγ+ 
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Activator of PXR signalling pathway, 31.62 
μM (AID:720659). AR signalling pathway 
antagonist, 38.9 μM (AID:743033). PPARδ 
signalling pathway agonist, PPARγ antagonist 
(AID743194).  
o,p-DDE/ 
2,2-Bis(4-
chlorophenyl)-1,1-
dichloroethylene 
 
2,2-(2-chlorophenyl-4’-chlorophenyl)-1,1-
dichloroethene. 
Inhibitory concentration against recombinant 
AR expressed in E. coli against R1881, IC50 
20.42 μM (IAD:255211). DSSTox (NCTRER) 
Estrogen Receptor Binding Database 
(AID:1204). 
AR+ 
ER+ 
o,p-DDT 
Dichlorodiphenyltrichlroethane is a 
organochlorine widely used as an insecticide, 
prior to its ban in 1972.  
qHTS ERα signalling pathway agonist, 0.696 
μM (AID:743075) and PPARδ agonist, 14.37 
μM (AID:743211) and antagonism of PPARγ, 
16.13 μM (AID:743194). TR signalling 
pathway antagonist, 17.95 μM (AID:743065).  
ER+ 
PPARδ
+ 
PPARγ+ 
TR+ 
Octyl-4-
Methoxycinnamate 
(OMC)/ 
4-Hydroxy-3,5-
diidobenzonitrile 
 
Octylmethoxycinnamate (OMC)/ Ethylhexyl 
methoxycinnamate is a UV-B filter used in 
sunscreens and lip balms.  
Schlumpf et al. (2001) detected in vitro 
estrogenicity.  
ER+ 
17α-Ethinylestradiol 
(EE2) 
Semi-synthetic alkylated estradiol with high 
oral bioavailability, used in contraceptive 
pills.  
qHTS ERα signalling pathway agonist, 
0.00077 μM (AID:743077), binding affinity to 
ERα IC50 0.008 μM (AID:478658) and ERβ 
IC50 0.0081 μM (AID:265000). Displacement 
of 5α-dihydrotestosterone from human sex 
hormone binding globulin, 0.155 μM Kd 
(AID318680). AR signalling pathway, 0.687 
μM (AID:743035). Progesterone radioligand 
binding, 1.067 μM (AID:625172). 
Glucocorticoid radioligand binding, 1.71 μM 
(AID:625228).  Thyroid receptor signalling 
pathway, 9.689 μM (AID:743065). PXR 
signalling pathway, 12.59 μM (AID:720659). 
PPARδ antagonist (AID:743226).  
ER+ 
AR+ 
PR+ 
GR+ 
TR+ 
PXR+ 
PPARδ
+ 
17β-Estradiol (E2) 
An aromatised C18 steroid with hydroxyl 
group at the 3-beta and 17-beta position, and 
is the most potent endogenous mammalian 
estrogenic steroid. E2 is the most 
predominant circulating hormone during 
reproductive years.  
Agonist of human ERα signaling pathway, 
0.00052 μM (AID:743077). Antagonist of the 
Androgen receptor (AR), 0.06 μM 
(AID:743063) and agonist at 2.23 μM 
(AID:743036). Antagonsit of Glucocorticoid 
Receptor signalling, 7.795 μM (AID:588533). 
Thyroid receptor signaling pathway antagonist, 
23.71 μM (AID:743065). Antagonist of 
PPARγ signaling pathway, 39.8 μM 
(AID:588537).  
ER+   
PPAR+    
AR+   
TR+    
GR+ 
17β-Eestriol (E3) 
Hydroxylated metabolite of E2, produced in 
large quantities during pregnancy.  
qHTS ERα signalling pathway agonist in the 
BG1 cell line, 0.0007 μM (AID:743079), ERα 
radioligand binding IC50 0.00169 μM 
(AID:625258). Displacement of 5α-
dihydrotestosterone from human sex hormone 
binding globulin, Kd 0.234 μM (AID:318680). 
qHTS AR signalling pathway antagonist, 13.8 
μM (AID:743063). GR signalling pathway 
antagonist, 38.89 μM (AID:720692). Thyroid 
Receptor signalling pathway antagonist, 61.13 
μM (AID:743067).  
ER+ 
AR+ 
GR+ 
TR+ 
Estrone (E1) 
Mammalian estrogen converted from 
androstenedione or testosterone via estradiol, 
produced primarily by the ovaries and 
adipose tissue.  
Growth response in MCF-7 cells, 7.72e-05 μM 
(AID:103554). EC50 in STTA ERα, 0.0007 μM 
(AID:70186) and 0.0008 μM in the BG1 cell 
line (AID:743079). Displacement of 5α-
dihydrotestosterone from human sex hormone 
binding globulin, Kd 0.0066 μM 
(AID:318680). qHTS assay antagonist of AR 
signalling pathway, 0.054 μM (AID:743033). 
Thyroid Receptor signalling pathway, 0.1508 
μM (AID:743064).  GR signalling pathway 
antagonist, 3.89 μM (AID:720692). 
Progesterone radioligand binding, IC50 16.098 
μM (AID:625172). PXR signalling pathway 
activator, 39.8 μM (AID:720659).  
ER+ 
AR+ 
TR+ 
GR+ 
PR+ 
PXR+ 
Ofloxacin 
Synthetic fluoroquinolone antibacterial agent, 
which inhibits DNA gyrase.    
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2-Hydroxyhippuric 
acid  
Also known as Salicyluric acid (salicylurate), 
glycine conjugate of salicylic acid, excreted 
in the urine.  
  
Olanzapine 
Antipsychotic drug used in the treatment of 
schizophrenia and bipolar disorder.  
Thyroid Receptor signalling pathway 
antagonist, 13.33 μM (AID:743064).  
TR+ 
Omethoate 
Also known as dimethoxon, Omethoate is a 
systemic organophosphorous insecticide and 
acaricide used to control insects and mites.  
  
Oxazepam 
Benzodiazepine used in the treatment of 
anxiety, insomnia and symptoms of alcohol 
withdrawal.  
qHTS ERα agonist signalling pathway in BG1 
cell line, 0.668 μM (AID:743079). AR 
signalling pathway agonist in the MDA cell 
line, 6.16 μM (AID:743040) and antagonist at 
27.53 μM (AID:743054). GR signalling 
pathway antagonist, 39.24 μM (AID:720692). 
TR signalling pathway antagonist, 54.92 μM 
(AID:743065).  PPARγ signalling pathway 
antagonist (AID:743199).  
ER+ 
AR+ 
GR+ 
TR+ 
PPARγ+ 
Oxydemeton-methyl 
Also known as methyl demeton, 
Oxydemeton-methyl is an 
organothiophosphate acaricide/insecticide.  
  
Oxytetracycline Broad spectrum tetracycline antibiotic.  
qHTS Aryl Hydrocarbon Receptor (AhR) 
signalling pathway activator, 61.13 μM 
(AID:743085).  
AhR+ 
Palmitic acid 
A common saturated fatty acid found in olive 
oil, palm oil and body lipids.  
qHTS ERα signalling pathway agonist in the 
BG1 cell line, 0.668 μM (AID:743079).  
ER+ 
Papaverine 
Alkaloid found in opium, which acts as a 
smooth muscle relaxant. Papaverine is used 
in the treatment of visceral spasm, vasospasm 
and erectile dysfunction.  
  
Paraquat 
Poisonous dipyridilium compound used as a 
herbicide.    
Parathion 
Cholinesterase inhibitor used as an acaricide 
and insecticide.  
Aryl Hydrocarbon Receptor (AhR) signalling 
pathway activator, 10.58 μM (AID:743085). 
PXR signalling pathway activator, 11.22 μM 
(AID:720659).  
AhR+ 
PXR+ 
Paroxetine 
Serotonin uptake inhibitor effective in the 
treatment of depression.  
qHTS AR signalling pathway antagonist, 8.485 
μM (AID:743033). PPARδ signalling pathway 
antagonist, 8.485 μM (AID:743213). Thyroid 
Receptor signalling pathway, 11.88 μM 
(AID:743064).  
AR+ 
PPARδ
+ 
TR+ 
p-Coumaric acid/ 
4-Hydroxycinnamic 
acid  
p-coumaric acid is a major component of 
lignin, detected in peanuts, navy beans, 
tomatoes, carrots and garlic.  
  
Penconazole Heterocyclic azole fungicide 
qHTS Glucocorticoid Receptor signalling 
pathway antagonist, 3.089 μM (AID:720692). 
Antagonist of AR signalling pathway, 43.64 
μM (AID:743035). ERα signalling pathway 
antagonist, 52.87 μM (AID:743078). Thyroid 
Receptor signalling pathway antagonist, 61.13 
μM (AID:743065).  
GR+ 
AR+ 
ER+ 
TR+ 
Pendimethalin 
Dinitroaniline premergence and 
postemergence herbicide, which inhibits 
broadleaf weed cell division and elongation.  
qHTS ERα signalling pathway agonist in the 
BG1 cell line, 7.688 μM (AID:743079).  
ER+ 
Pentachlorobenzene/ 
1,2,3,4,5-Pentachloro 
benzene 
Chlorinated aromatic hydrocarbon byproduct, 
with no large scale direct industrial 
applications.  
  
Pentachloro phenol 
Insecticide, herbicide and preservative that is 
a widespread environmental contaminant; 
exposure via contaminated air, groundwater, 
drinking water, food and dermal contact with 
soils or products treated with the chemical.  
qHTS Aryl Hydrocarbon Receptor signalling 
pathway activator, 3.36 μM (AID:743085). 
PPARγ signalling pathway antagonist, 3.398 
μM (AID:743191). TR signalling pathway 
antagonist, 8.79 μM (AID:743065). ERα 
signalling pathway antagonist, 10.74 μM 
(AID:743078).   
AhR+ 
PPARγ+ 
TR+ 
ER+ 
Perchloroethylene/ 
Tetrachloroethylene 
Also known as tetrachloroethylene. 
  
Perfluorodecanoic 
acid (PFDA) 
Synthetic perfluorinated carboxylic acid, used 
as a surfactant and polymerisation agent.  
qHTS ERα signalling pathway antagonist, 
15.485 μM (AID:743069) and agonist of 
antioxidant response element signalling 
pathway, 24.34 μM (AID:743202).  
ER+ 
Permethrin 
Pyrethroid insecticide used against lice and 
scabies.  
Activator of the Aryl Hydrocarbon Receptor 
(AhR) signalling pathway, 13.65 μM 
AhR+ 
PXR+ 
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(AID:743085) and rat PXR signalling pathway, 
19.95 μM (AID:651751).  
Phenanthrene 
Polycyclic aromatic hydrocarbon found in 
cigarette smoke and coal tar. Phenanthrene is 
also the molecular backbone of the 
pharmaceutical morphinan, among other 
psychoactive chemicals.  
  
Phenol phthaleine 
Acid-base indicator, which is colourless in 
acids, but pinky red in alkaline solution, with 
cathartic properties on ingestion.  
Agonist of ERα signalling pathway, 3.37 μM 
(AID:743075) and TR signalling pathway 
antagonist, 13.33 μM (AID:743065).  Aryl 
Hydrocarbon Receptor (AhR) Signalling 
pathway activator, 20.72 μM (AID:743122). 
AR signalling pathway antagonist, 26.83 μM 
(AID:743063).  PXR signalling pathway 
activator, 31.62 μM (AID:720659). GR 
signalling pathway, 35.48 μM (AID:588533). 
PPARγ signalling antagonist, 39.81 μM 
(AID:588537) and PPARδ, 54.59 μM 
(AID:743213).  
ER+ 
TR+ 
AhR+ 
AR+ 
PXR+ 
GR+ 
PPARγ+ 
PPARδ
+ 
Phenothrin 
Synthetic pyrethroid used in the treatment of 
headlice.  
  
Phloretin 
Dihydrochalcone phenol found in apple tree 
leaves and the Manchurian apricot. Phloretin 
inhibits the active transport of glucose into 
cells by SGLT1 and SGLT2, leading to 
reduced glucose absorption in the small 
intestine and the inhibition of renal glucose 
reabsorption.  
qHTS ERα signalling agonist, 4.96 μM 
(AID:743079). AR signalling antagonist, 48.20 
μM (AID:743063), and activator of the Aryl 
Hydrocarbon Receptor, 49.65 μM 
(AID:743085). Thyroid Receptor signalling 
antagonist, 55.70 μM (AID:743065). 
Antagonist of PPARγ signalling pathway 
(AID:743199).  
ER+ 
AR+ 
AhR+ 
TR+ 
PPARγ+ 
Picloram/ 
4-Amino-2,5,6-
trichloropyridine-2-
carboxylic acid 
Picolinic acid derivative used as a systemic 
herbicide for woody and broad-leaf plant 
control.  
qHTS Aryl Hydrocarbon Receptor signalling 
pathway activator, 32.72 μM (AID:743122).  
AhR+ 
Pindolol 
Lipophilic beta-adrenergic antagonist, with 
non-cardioselective and sympathomimetic 
actions.  
qHTS activator of the Aryl Hydrocarbon 
Receptor signalling pathway, 29.85 μM 
(AID:743085).  
AhR+ 
Piperonyl butoxide 
Piperonly butoxide is an insecticide synergist, 
particularly for pyrethroids such as rotenone.  
qHTS activator of the AhR signalling pathway, 
20.31 μM (AID:743122). Thyroid Receptor 
signalling pathway, 21.95 μM (AID:743064). 
Androgen Receptor signalling pathway 
antagonist in the MDA cell line, 31.01 μM 
(AID:743042). PXR signalling activator, 44.67 
μM (AID:720659).  
AhR+ 
TR+ 
AR+ 
PXR+ 
Piroxicam 
Cyclooxygenase inhibiting, non-steroidal 
anti-inflammatory agent used in the treatment 
of rheumatoid arthritis, osteoarthritis and 
muscoskeletal disorders, dysmenorrhea and 
postoperative pain.  
Aryl Hydrocarbon Receptor signalling  
pathway, 32.13 μM (AID:743122).  
AhR+ 
Pravastatin 
Competitive inhibitor of HMG CoA 
reductase extracted from cultures of Nocardia 
autotrophica.  
  
Prednisone 
Synthetic anti-inflammatory glucocorticoid 
derived from cortisone used as an 
immunosuppressant drug to treat 
inglammatory diseases.  
qHTS Androgen Receptor signalling 
antagonist, 0.035 μM (AID:743063). 
Antagonist of GR signalling, 2.46 μM 
(AID:720692). qHTS ERα signalling agonist in 
the BG1 cell line, 54.48 μM (AID:743079).  
AR+ 
GR+ 
ER+ 
Prednisolone 
Glucocorticoid with corticosteroid properties 
used to treat inflammatory and auto-immune 
conditions. Prednisolone is the active 
metabolite of prednisone.  
Displacement of FITC-dexamethasone from 
GR in fluorescence polarisation asssy, ki 
0.0015 μM (AID:351941). qHTS androgen 
receptor signalling pathway agonist in the 
MDA cell line, 0.037 μM (AID:743040).  
GR+ 
AR+ 
Primidone 
Antiepileptic agent structurally related to 
barbituates.  
qHTS AR signalling agonist, 17.78 μM 
(AID:588515). 
AR+ 
Prochloraz Industrial fungicide 
qHTS AhR signalling pathway activator, 0.545 
μM (AID:743085). Activator of rat PXR 
signalling pathway, 15.85 μM (AID:651751). 
Androgen Receptor signalling antagonist, 
19.91 μM (AID:743035). Thyroid Receptor 
signalling antagonist, 27.89 μM (AID:743065). 
PPARδ signalling, 44.57  μM (AID:743211). 
ERα signalling antagonist, 61.13 μM 
AhR+ 
PXR+ 
AR+ 
TR+ 
PPARδ
+ 
ER+ 
GR+ 
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(AID:743080). Antagonist of GR signalling 
pathway (AID:720725).  
Prodiamine 
Dinitroaniline herbicide registered for 
selective, pre-emergent control of broadleaf 
and grass weeds. Also known as Marathon.  
qHTS Thyroid Receptor antagonist, 13.64 μM 
(AID:743064).  Rat PXR signalling pathway 
activator, 15.85 μM (AID:651751). PPARδ 
signalling pathway agonist, 19.45 μM 
(AID:743194). Estrogen Receptor-α signalling, 
31.62 μM (AID:588513). qHTS antagonist of 
the AR signalling pathway, 38.8 μM 
(AID:743033). Aryl Hydrocarbon Receptor 
signalling activator, 60.94 μM (AID:743086). 
Glucocorticoid Receptor signalling pathway, 
48.85 μM (AID:720693).  
TR+ 
PXR+ 
PPARδ
+ 
ER+ 
AR+ 
AhR+ 
GR+ 
 
Progesterone 
Progestational steroid secreted primarily by 
the corpus luteum and placenta, 
progestesterone is required for implantation, 
pregnancy maintenance and the development 
of mammary tissue. Converted from 
pregnenolone, is an intermediate in steroid 
hormone and corticosteroid biosynthesis.  
Activation of progesterone receptor in human 
T47D cells by PRE-tagged luciferase, 0.001 
μM (AID:469431). Agonistic activity of PR, 
0.0005 μM (AID:339656). qHTS AR agonist 
signalling, 0.0251 μM (AID:588515). 
Displacement of dexamethasone from GR, Ki 
0.0305 μM (AID:74227).  Antagonist ER 
activity in CV-1 cells, IC50 10 μM 
(AID:162110). Antagonist of the TR, 16.15 
μM (AID:743067). PPARγ signalling 
antagonist, 43.396 μM (AID:743194) and 
PPARδ, 48.69 μM (AID:743211).  
PR+ 
AR+ 
ER+ 
AR+ 
GR+ 
TR+ 
PPARγ+ 
PPARδ
+ 
Prometryn 
Triazine selective pre- and post-emergence 
herbicide.  
Pregnane X Receptor signalling pathway 
activator, 14.13 μM (AID:720659).  
PXR+ 
Pronamide/ 
N-(3,4-
dichlorophenyl) 
propanamide 
Herbicide to control grasses and weeds, also 
called propyzamide and 3,5-dichloro-N-(1,1-
dimethylpropynyl)benzamide 
qHTS PXR signalling activator, 11.22 μM 
(AID:720659). Antagonist of the AR signalling 
pathway, 44.05 μM (AID:743063).  
PXR+ 
AR+ 
Propanil Chlorinated anilide herbicide.  
Antagonist of AR signalling pathway, 20.67 
μM (AID:743063). Antagonist of TR 
signalling pathway, 49.55 μM (AID:743054). 
ERα signalling antagonist in the BG1 cell line, 
54.48 μM (AID:743080). Aryl Hydrocarbon 
Receptor signalling pathway, 54.48 μM 
(AID:743085).  
AR+ 
TR+ 
ER+ 
AhR+ 
Propranolol 
Sympatholytic non-selective beta-blocker 
used in the treatment of myocardial 
infarction, arrhythmia, angina pectoris, 
hypertension, hyperthyroidism, migraine, 
pheochromocytoma and anxiety.  
qHTS PPARδ signalling agonist, 24.54 μM 
(AID:743211). ERα signalling pathway agonist 
in the BG1 cell line, 30.64 μM (AID:743079). 
Thyroid receptor signalling, 30.64 μM 
(AID:743064). PPARγ signalling antagonist, 
55.499 μM (AID:743191).  
PPARδ
+ 
PPARγ+ 
TR+ 
ER+ 
Propazine Poorly soluble in water, herbicide.  
qHTS pregnane X receptor signalling pathway 
activator, 35.48 μM (AID:720659) and AhR 
signalling activator, 68.59 μM (AID:743085).  
PXR+ 
AhR+ 
Propiconazole 
Triazole fungicide known as DMI, or 
demethylation inhibiting fungicide due to its 
MoA.  
qHTS pregnane X receptor signalling activator, 
22.38 μM (AID:720659). Activate AhR 
signalling, 24.33 μM (AID:743085). ERα 
signalling antagonist in the BG1 cell line, 27.8 
μM (AID:743080). Thyroid Receptor 
signalling, 30.63 μM (AID:743064). AR 
signalling pathway, 43.64 μM (AID:743035).  
PXR+ 
AhR+ 
TR+ 
ER+ 
AR+ 
Propoxur 
A carbamate non-systemic insecticide, which 
inactivates acetylcholinesterase.    
Propylparaben/ 
Propyl-4-
hydroxybenzoate 
Naturally occurring n-Propyl ester of p-
hydroxybenzoic acid, synthesised for use in 
cosmetics, pharmaceuticals and food. E 
number E216.  
qHTS ERα signalling agonist, 3.55 μM 
(AID:588514) and AR signalling antagonist, 
25.11 μM (AID:588516). PPARγ signalling 
antagonist, 35.48 μM (AID:588537).  
ER+ 
AR+ 
PPARγ+ 
Pyrene 
Polycyclic aromatic hydrocarbon formed 
during incomplete combustion of organics.    
Quercetin 
Flavonol found in fruits, vegetables, leaves 
and grains with antioxidant properties.  
qHTS ERα signalling agonist, 10.96 μM 
(AID:743077). Aryl Hydrocarbon Receptor 
signalling activator, 12.19 μM (AID:743085). 
TR signalling antagonist, 30.88  μM 
(AID:743064). Androgen Receptor signalling 
antagonist in the MDA cell line, 38.88 μM 
(AID:743054). Glucocorticoid Receptor 
signalling antagonist, 48.96 μM (AID:720692).  
ER+ 
AhR+ 
TR+ 
AR+ 
GR+ 
Quinalphos Organthiophosphate pesticide qHTS Aryl Hydrocarbon Receptor signalling 
AhR+ 
ER+ 
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activator, 1.22 μM (AID:743085). ERα 
signalling agonist, 15.35 μM (AID:743079). 
Androgen Receptor signalling antagonist, 
48.97 μM (AID:743063).  
AR+ 
Ramipril 
Angiotensin-converting enzyme (ACE) 
inhibitor, converted to ramiprilat in the liver, 
to treat high blood pressure and congestive 
heard failure. 
  
Ranitidine 
Histamine H2-receptor antagonist that 
inhibits stomach acid production, used in the 
treatment of gastrointestinal ulcers.  
  
Resbenzophenone/ 
2,4-Dihydroxy 
benzophenone 
Also known as 2,4-dihydroxybenzophenone, 
benzophenone-1, and Benzoresocrinol, 
Benzophenones are used in paints, plastics, 
packaging, inks and coatings to prevent UV 
colour and scent damage.  
qHTS Estrogen Receptor –α signalling agonist 
in the BG1 cell line, 9.876 μM (AID:743079). 
Androgen Receptor (AR) signalling antagonist, 
25.02 μM (AID:743033). Thryoid Receptor 
signalling agonist, 30.64 μM (AID:743066). 
PPARδ signalling antagonist, 35.34 μM 
(AID:743213).  
ER+ 
AR+ 
TR+ 
PPARδ
+ 
Resmethrin 
Pyrethroid insecticide used to control adult 
mosquito populations.  
qHTS activator of PXR signalling, 44.67 μM 
(AID:720659).  Androgen Receptor signalling 
antagonist, 49.05 μM (AID:743035). 
Glucocorticoid Receptor (GR) signalling 
antagonist, 55.035 μM (AID:720692). PPARγ 
signalling pathway antagonist (AID:743199).  
PXR+ 
AR+ 
GR+ 
PPARγ+ 
Resorcinol 
Dihydroxybenzene with antifungal, 
antibacterial properties, used in the treatment 
of ringworm, eczema, psoriasis, seborrheic, 
dermatitis, acne rosaceae.  
  
Retene 
Also known as methyl isopropyl 
phenanthrene or 1-methyl-7-isopropyl 
phenanthrene, retene is a polycyclic aromatic 
hydrocarbon present in coal tar.  
  
Retinol 
Vitamin A is a retinol derivative which plays 
a role in metabolic functioning.  
ERα signalling pathway agonist in the BG1 
cell line, 0.944 μM (AID:743079). Pregnane X 
Receptor (PXR) signalling activator, 2.82 μM 
(AID:720659). qHTS GR signalling 
antagonist, 55.63 μM (AID:720692). Androgen 
Receptor signalling antagonist, 61.88 μM 
(AID:743042). TR signalling antagonist, 61.88 
μM (AID:743065). Antagonist of the PPARγ 
signalling pathway (AID:743199).  
ER+ 
PXR+ 
GR+ 
AR+ 
TR+ 
PPARγ+ 
Roxithromycin 
Semi-synthetic macrolide antibiotic used in 
the treatment of respiratory, urinary and 
genital tract infections.  
  
Salbutamol/ 
Albuterol 
Also known as Albuterol, salbutamol is a 
short-acting beta-2 adrenergic agonist used in 
the treatment of asthma.  
  
Salicylic acid 
Active metabolite of Aspirin. Obtained from 
willow and wintergreen bark, salicylic acid is 
a monohydroxybenzoic acid plant hormone, 
which is also used as an anti-acne treatment.  
  
Sertraline 
Selective serotonin inhibitor used in the 
treatment of depression.    
Simazine 
Triazine herbicide used to contral broad-leaf 
weeds and grasses.    
Simvastatin 
Hypolipidemic drug used to control 
hypercholesterolemia, derivative of 
lovastatin, may interfere with steroid 
hormone production.  
Androgen Receptor signalling pathway 
antagonist, 5.71 μM (AID:743063) and agonist 
10.12 μM (AID:743040).  Glucocorticoid 
Receptor signalling, 7.23 μM (AID:720719). 
ERα signalling agonist in the BG1 cell line, 
11.36 μM (AID:743079). PPARδ signalling 
pathway antagonist, 16.93 μM (AID:743213) 
and agonist at 29.85 μM (AID:743211). 
Thyroid Receptor signalling antagonist, 38.57 
μM (AID:743064).  
GR+ 
AR+ 
ER+ 
PPARδ
+ 
TR+ 
Sotalol 
Beta-adrenergic receptor antagonist used in 
the treatment of arrhythmias.  
Androgen Receptor signalling agonist in the 
MDA cell line, 33.49 μM (AID:743040).  
AR+ 
Stearic acid 
Saturated fatty acid with IUPAC name 
octadecanoic acid, present in many animal 
and vegetable oils.   
ERα signalling agonist in the BG1 cell line, 
0.611 μM (AID:743079).  
ER+ 
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Styrene 
Colourless, aromatic compound used to make 
rubbes, polymers and copolymers and 
polystyrene plastics.  
  
Sulfadimethoxine 
A sulphanilamide used as an anti-infective 
agent.    
Sulfamethoxazole 
Sulfonamide bacteriostatic antibiotic, which 
acts by interfering with folic acid synthesis in 
susceptible bacteria.  
  
Sulfapyridine 
Antibacterial used to treat skin diseases, with 
potential toxicity due to crystalisation in the 
bladder or urethra.  
  
Sulfasalazine  
Drug used in the management of 
inflammatory bowel disease.  
Aryl Hydrocarbon Receptor (AhR) signalling 
pathway activator, 27.39 μM (AID:743086). 
ERα signalling antagonist in the BG1 cell line, 
34.48 μM (AID:743081).  
AhR+ 
ER+ 
Tamoxifen 
Selective Estrogen Receptor Modulator, with 
tissue specific activities. Tamoxifen acts as 
an anti-estrogen in the mammary tissue, but 
an estrogen (stimulating agent) in cholesterol 
metabolism, bone density and cell 
proliferation in the endometrium.  
Effective dose for estradiol against 
proflieration of MCF-7 cells, EC50 0.00011 μM 
(AID:102435).  Antagonistic activity of ERβ 
LBD expressed in yeast, IC50 1.66 μM 
(AID:482348). Antagonist of TR signalling, 
8.63 μM (AID:743064). qHTS AR signalling 
antagonist, 13.89 μM (AID:743033). PPARγ 
signalling antagonist, 21.87 μM (AID:743194). 
Antagonist of GR signalling, 24.54 μM 
(AID:720693). PPARδ signalling antagonist, 
24.70 μM (AID:743194).  
ER+ 
TR+ 
AR+ 
PPARγ+ 
PPARδ
+ 
Tebuconazole 
Triazole fungicide used to treat plant 
pathogenic fungi.  
Activator of the rat PXR signalling pathway, 
25.12 μM (AID:651751). ERα signalling 
antagonist in the BG1 cell line, 29.277 μM 
(AID:743091). Glucocorticoid Receptor 
signalling antagonist, 43.64 μM (AID:720692). 
Androgen Receptor signalling antagonise, 
48.97 μM (AID:743035). Thyroid Receptor 
signalling pathway antagonist, 54.48 μM 
(AID:743063).  
PXR+ 
ER+ 
GR+ 
AR+ 
TR+ 
Terbutalin 
Also known as terbutaline, Terbutalin is a 
selective beta-2 adrenergic agonist used a 
bronchodilator and tocolytic.  
  
Terbutryn Pesticide to destroy unwanted vegetation.  
AhR signalling pathway activator, 3.85 μM 
(AID:743085).  Androgen receptor signalling 
antagonist, 21.87 μM (AID:743035). PPARδ 
antagonist signalling, 38.86 μM (AID:743213). 
Antagonist thyroid Receptor signalling, 67.78 
μM (AID:743067).  
AhR+ 
AR+ 
PPARδ
+ 
TR+ 
Terbutylazine 
Selective chlorotriazine herbicide, 
structurally related to atrazine and simazine.  
qHTS ERα agonistic signalling in the BG1 cell 
line, 2.43 μM (AID:743079). Human GR 
signalling antagonist (AID:720725).  
ER+ 
GR+ 
Tetrachlorvinphos 
Organophosphate cholinesterast inhibitor 
used as an insecticide.  
qHTS PPARγ signalling antagonist, 4.89 μM 
(AID:743191). ERα signalling antagonist, 
16.72 μM (AID:743078). AR signalling 
pathway antagonist, 21.87 μM (AID:743035). 
GR signalling pathway antagonist, 24.54 μM 
(AID:720692). qHTS human PXR signalling, 
25.12 μM (AID:720659). Thyroid Receptor 
signalling antagonist, 27.3 μM (AID:743065).  
PPARγ+ 
ER+ 
AR+ 
GR+ 
TR+ 
PXR+ 
Tetracyclin 
Also known as Tetracycline. A naphthacene 
antibiotic that inhibits amino acyl TRNA 
binding during protein synthesis.  
HTS Estrogen Receptor-α coactivator binding 
inhibitor (AID629).  
ER+ 
Tetra 
hydronaphthol-2/  
1,2,3,4-Tetrahydro 
napthalen-2-ol 
Also known as Tetralol.  
  
Thiram 
Dithiocarbamate ectoparasiticide used to 
prevent fungal disease in seeds and crops. 
Also used in rubber processing industry.  
Thyroid Receptor signalling antagonist, 0.0154 
μM (AID:743065). PPARδ signalling pathway 
agonist, 0.0309 μM (AID:743213). 
Glucocorticoid Receptor signalling agonist, 
0.0608 μM (AID:720691). Androgen Receptor 
signalling antagonist in the MDA cell line, 
0.0611 μM (AID:743042). PPARγ signalling 
antagonist, 0.0765 μM (AID:743194). AhR 
signalling pathway activator, 0.1536 μM 
TR+ 
PPARδ
+ 
GR+ 
AhR+ 
PPARγ+ 
AhR+ 
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(AID:743086).  
Thyroxine 
Tyrosine-based hormone from the thyroid 
gland. Thyroxine is released from 
thyroglobulin by proteolysis and secreted into 
the blood. Thyroxine is peripherally 
deiodinated to form triiodothyronine which 
exerts a braod spectrum stimulatory effect on 
metabolism.  
qHTS TR signalling pathway agonist, 0.0084 
μM (AID:743066). Activator of the AhR 
signalling pathway, 15.45 μM (AID:743122). 
PPARγ signalling antagonist, 39.81 μM 
(AID:588537). Antagonist of the GR signalling 
pathway (AID:720725).  
TR+ 
AhR+ 
PPARγ+ 
GR+ 
Timolol 
Non-selective beta-adrenergic receptor 
antagonist used in the treatment of glaucoma, 
heart attacks and hypertension.  
  
Tolfenamic acid 
Non-steroidal anti-inflammatory drug used to 
treat migraines.  
Thyroid Receptor signalling pathway 
antagonist, 8.41 μM (AID:743064). PPARδ 
signalling agonist (AID:743227) and PPARγ 
signalling (AID:743199). Glucocorticoid 
Receptor signalling antagonist (AID:720725).  
TR+ 
PPARδ
+ 
PPARγ+ 
GR+ 
Tonalide/ 
1-(3,5,5,6,8,8-
hexamethyl-5,6,7,8-
tetrahydronaphthale
ne-2-yl) ethanone 
Also known as acetyl methyl tetramethyl 
tetralin and Tonalid. Tonalide is a synthetic 
musk, which emulates the aroma of natural 
musk.  
qHTS TR signalling antagonist, 21.69 μM 
(AID:743064).  
TR+ 
Toxaphene 
Toxaphene is a mixture of at least 177 C10 
polychloro derivatives, used as an insecticide, 
but a believed carcinogen.  
qHTS ERα signalling agonist in the BG1 cell 
line, 3.81 μM (AID:743079). Antagonist of 
Thyroid Receptor signalling, 5.96 μM 
(AID:743064). Glucocorticoid Receptor 
signalling antagonist, 13.45 μM (AID:720693). 
Androgen Receptor signalling antagonist, 
17.18 μM (AID:743035). PPARγ signalling 
antagonist, 21.62 μM (AID:743194). PPARδ 
signalling agonist, 34.27 μM (AID:743211).  
 
ER+ 
TR+ 
GR+ 
AR+ 
PPARγ+ 
PPARδ
+ 
Tramadol 
A narcotic analgesic used for severe pain, 
acting vai opioid receptors, it may be 
habituating.  
  
Tris(2-
butoxyethyl)phospha
te 
Flame retardant.  
  
Triadimefon 
Triadimefon is used to control fungal disease 
in fruit and non-food sites.  
Activator of the AhR signalling pathway, 
35.68 μM (AID:743122). ERα signalling 
agonist, 39.81 μM (AID:588514). Pregnane X 
Receptor signalling activator, 44.67 μM 
(AID:720659).  
AhR+ 
ER+ 
PXR+ 
Triadimenol 
Triadimenol is used as a seed treatment on 
barley, corn, cotton, oats, rye, sorghum and 
wheat.  
Pregnane X Receptor signalling activator, 6.31 
μM (AID:720659). Aryl Hydrocarbon 
Receptor signalling activator, 21.69 μM 
(AID:743122). Antagonist of AR signalling in 
the MDA cell line, 61.13 μM (AID:743042).  
PXR+ 
AhR+ 
AR+ 
Triamcinolone 
Glucocorticoid taken orally, via injection of 
inhalation or as a topical ointment, for the 
treatment of eczema, psoriasis, arthritis, 
allergies, ulceratives colitis and lupus among 
other ailments.  
qHTS Androgen Receptor signalling agonist in 
the MDA cell line, 0.0273 μM (AID:743040). 
Glucocorticoid Receptor signalling agonist, 
0.032 μM (AID:720719). qHTS ERα 
signalling agonist in the BG1 cell line, 4.73 
μM (AID:743079).  
AR+ 
GR+ 
ER+ 
Triamcinolone 
acetonide 
Anti-inflammatory glucocorticoid used in the 
treatment of skin disorders.  
Glucocorticoid Receptor signalling agonist, 
0.00187 μM (AID:720719). qHTS AR 
signalling pathway agonist in the MDA cell 
line, 0.0022 μM (AID:743040). Estrogen 
Receptor α signalling pathway agonist, 2.371 
μM (AID:743079). Activator of the AhR 
signalling pathway, 69.01 μM (AID:743085).  
GR+ 
AR+ 
ER+ 
AhR+ 
Tributylphosphate Solvent and plasticiser for cellulose esters.  
qHTS Estrogen Receptor-α signalling pathway 
agonist in the BG1 cell line, 15.35 μM 
(AID:743079).  
ER+ 
Trichlorfon 
Irreversible organophosphate 
acetylcolinesterase inhibitor, used to control 
flies and roaches, and in the treatment of 
schistosmiasis.  
  
Trichlorobenzene 
Used in industry as a solvent and organic 
intermediate.    
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Triclosan 
Diphenyl ether derivative used in cosmetics 
and toilet soaps as an antiseptic – 
bacteriostatic and fungistatic action.  
PPARδ signalling pathway antagonist, 4.47 
μM (AID:743213) and PPARγ antagonist, 6.30 
μM (AID:743194). Thyroid Receptor 
signalling antagonist, 8.83 μM (AID:743065). 
ERα signalling pathway antagonist, 11.22 μM 
(AID:743074). Antagonist of the AR signalling 
pathway, 12.59 μM (AID:743033). Activator 
of the AhR signalling pathway, 19.78 μM 
(AID:743086).  Glucocorticoid Receptor 
signalling antagonist, 22.39 μM (AID:720693).  
PPARγ+ 
PPARδ
+ 
TR+ 
ER+ 
AR+ 
AhR+ 
GR+ 
Trifluralin 
Microtubule-disrupting pre-emergence 
herbicide, used to control annual grass and 
broadleaf weed species.  
  
Trimethoprim 
Pyrimidine inhibitor of dihydrofolate 
reductase, trimethoprim is an antibacterial 
related to pyrimethamine.  
  
Triiodothyronine 
(T3)/ 
Liothyronine 
T3 is a thyroid hormone secreted from the 
thyroid gland.  
Displacement of [125I]T3 from human TRα 
receptor, Kd 5.8e-05 μM (AID:323174). 
Inhibitory activity against [125I]T3 binding to 
human TRβ receptor, Kd 8e-05 μM 
(AID:213185). qHTS assay to identify TR 
signalling pathway agonists, 0.0021 μM 
(AID:743066). Aryl Hydrocarbon Receptor 
(AhR) signalling activator, 3.349 μM 
(AID:743122). ERα signalling pathway, 9.51 
μM (AID:743075). Glucocorticoid Receptor 
signalling antagonist (AID:720725).  
TR+ 
AhR+ 
ER+ 
GR+ 
Valsartan 
Angiotensin-receptor blocker used to treat 
cardiac conditions, such as hypertension, 
isolated systolic hypertension, left ventricular 
hypertrophy and diabetic nephropathy.   
  
Vinclozolin 
Dicarboximide fungicide used to control 
blights, rots and moulds in vineyards and on 
fruits and vegetables (raspberries, kiwi, 
lettuce, snap beans and onions).  
qHTS Androgen Receptor signalling 
antagonist, 9.69 μM (AID:743054) and 
inhibitor of aromatase, 54.15 μM 
(AID:743083). PPARδ signalling pathway 
antagonist, 54.63 μM (AID:743213).  
AR+ 
PPARδ
+ 
Vinyl acetate 
Organic precursor (monomer) to polyvinyl 
acetate, worldwide production millions of 
tonnes per annum.  
  
Warfarin 
Anticoagulant used in the prevention of 
thrombosis and thromboembolism, by 
inhibiting the synthesis of vitamin K-
dependent coagulation factors.  
qHTS PPARγ signalling pathway agonist, 9.08 
μM (AID:743140).  
PPARγ+ 
β-Sitosterol 
Phytosterol (plant sterol), structurally related 
to cholesterol, found ubiquitously in the plant 
kingdom.  
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Appendix B Supplementary Phylogeny Results 
Assuming protein sequence is indicative of protein function, phylogeny highlights the 
potential variability in function consequent to evolutionary divergence. Figure_Apx 1 
shows the phylogeny of primate androgen receptors, highlighting inter- and intra- 
species variance within clades.  
 
Figure_Apx 1 Phylogeny of Primate Androgen Receptors 
Androgen receptor sequence homology reflects the taxonomic order, species and family, highlighting the infraorders 
human, simian and prosimian. The bootstrapped consensus phenogram, on a scale of 0.01, representing 1% sequence 
difference, presents a Ʃbranch length of 0.439, suggesting limited phylogenetic divergence within primates. However, 
the sequences of a number of human androgen receptor splice variants emphasise potential intraspecies variability. In 
order of appearance, the UniProtKB protein identifier and organism name (Latin) are: G4VV16 Human (Homo 
Sapiens) Androgen Receptor (AR) Isoform 8; C0JKD7 Human AR Splice Variant (SV) 6; C0JKD6 Human AR SV 
5; C0JKD3 Human AR SV 3; C0JKD5 Human AR SV 4b; C0JKD4 Human AR SV 4; D3YPP9 Human AR Isoform 
1 (ISO 1) Transcript Variant (TV) 1; D2Y6K2 Human AR ISO 1 TV1; D3YPQ1Human AR ISO 1 TV1; D3YPQ0 
Human AR ISO 1 TV1; D3YPQ2 Human AR ISO 1 TV1; D3YPQ3 Human AR ISO 1 TV1; P10275 Human 
Androgen Receptor (Nuclear receptor subfamily 3 group C member 4); D2KF13 Human AR Variant (5-7); D5M8Q2 
Human Mutant AR ISO 1 TV1; O97775 Common Chimpanzee (Pan Troglodytes) AR; A4LAN9 Black-capped 
Squirrel Monkey (Saimiri boliviensis) AR; E3SWD5 Common Marmoset (Callithrix Jacchus) AR; O97952 Crab-
eating Macaque (Macaca fascicularis) AR; Q6QT55 Rhesus Macaque (Macaca mulatta) AR; O97960 Hamadryas 
baboon (Papio hamadryas) AR; Q25AU6 Horsfield’s Tarsier (Tarsius bancanus) AR; O97776 Collared Brown 
Lemur (Eulemur fulvus collaris) AR; Q25AV2 Great Bamboo Lemur (Hapalemur simus) AR; Q25AV4 Ring-tailed 
Lemur (Lemur catta) AR; Q25AV0 Fat-tailed Dwarf Lemur (Cheirogaleus medius) AR; Q25AU8 Crowned Sifake 
(Propithecus deckenii coronatus) AR. 
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Appendix C SYBYL in silico Molecular Modelling of NR 
Advances in computer-aided drug design has led to a variety of in silico molecular 
dynamics-based docking programs to predict ligand-receptor interactions and docking. 
For the purpose of this study, Tripos ® SYBYL software for macromolecular 
modelling, simulation and virtual screening was used. Supplementary information to 
Section 4 ‘Endocrine Activity in Silico; is presented herein. Figure_Apx 2 details Bloat 
parameters, Figure_Apx 3 shows coregulatory protein preparation and Figure_Apx 4 
shows the Surflex-Dock results browser for coregulatory binding.  
 SYBYL Software Parameters  
 
 
Figure_Apx 2 SYBYL Surflex-Dock Protomol Bloat Parameter 
Consisting of molecular probes, such as CH4, C=O and N-H, protomol’s provide an object-orientated 
framework for molecular dynamics and virtual screening. SYBYL’s Surflex-Dock can generate 
protomols through the ligand, specific residues or using the solvation method, default values are set at 0.5 
Threshold and 0 Bloat. Bloat inflates the protomol to include nearby crevices (scale 0 to 1 (A)). 
Superimposed onto ligand binding domain stick models, the left side protomol was created with bloat of 
0, while the right shows the same protomol, generated with bloat of 1. Increasing the bloat reduces the 
specificity of the binding pocket.   
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 Molecular Modelling of Coregulators  
 
Figure_Apx 3 SYBYL Surflex-Dock LXXXLL Cofactor (NCO1) Protein Preparation 
SYBYL Surflex-Dock software browser screen-print during protein preparation of LXXXLL containing 
coregulatory molecule.   
 
 
Figure_Apx 4 SYBYL Surflex-Dock Cofactor Binding Experiment Results Browser 
Coregulatory molecules have been demonstrated to play a vital role in ligand-dependent nuclear receptor 
transactivation. SYBYL Surflex-Dock software generated protomols of specific residues, on ligand-
bound receptor complexes, to screen coregulatory molecules with LXXXLL motifs. The Surflex-Dock 
binding methods, which generate a hypothetical binding region, did not effectively identify the 
coregulatory-NR affinity, generating a positive score (i.e. energetically unfavourable). The docking 
results browser shows the score (-107122 –log(Kd)) of NCO1 coactivator binding to a protomol generated 
from residues Ile358, Val376, Leu379, Glu380 and Met543 (Shiau et al., 1998). Surflex-Dock, while 
appropriate for binding cavities (‘pockets’), does not appear to be appropriate for surface interactions.  
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 SYBYL SiteID Solvation Method Ligand Binding Pockets 
 
 
Figure_Apx 5 Human and Rat Estrogen Receptor-β (ERβ) Ligand Binding Pockets 
Identified with Solvation Method in SYBYL SiteID 
The Human ERβ (1L2J), rendered with α-helices and β-sheet secondary structure features, was bound to 
tetrahydrochrysene-2,8-diol, an antagonist, and presents a ‘clamped’ conformation. Residues identified 
within 8Å of the solvents include Lys401, Leu339, Glu305, Thr299, Leu298, Glu276 and Met295. The 
rat ERβ (1HJ1) was bound to the ICI164,384 antiestrogen. Residues identifies within 8Å of the solvent 
spheres include Ile331, Tyr352, Phe311, Arg301, Gly297, Met295, Val293, Met291, Leu254 and Leu253. 
SYBYL identified the reside regions associated with binding for both human and rat ERβ.   
 
 
Figure_Apx 6 Chimpanzee (1T7T) and Mouse (2PQY) Androgen Receptor Ligand 
Binding Pockets Identified with Solvation Method in SYBYL SiteID 
Image of SYBYL SiteID MOLCAD outputs for Androgen Receptors (AR); Chimpanzee (Pan 
troglodytes) AR structure was complexed with 5α-dihydrotestosterone, Mouse (Mus musculus) AR was 
complexed with 5α-dihydrotesterone and an allosteric regulator 4-(4-hydroxy-3-ido-phenoxy)-3,5-
diiodophenyl)-acetic acid. Residues within 8Å of the solvent spheres in chimpAR include: Pro682, Gln711, 
Val715, Leu744 and Met745. In mouseAR, the LBP visually appeared to be a completely different shape. 
However identifying: Leu701, Leu704, Asn705, Gly708, Val715, Met742, Met745, Val746, Ala748, 
Arg752, Phe764 and Leu873, both mouseAR and chimpAR identified the LBP region (residues 675-900).  
 
Evaluation of in silico and in vitro screening methods for EDC hazard characterisation 
 
 
 Page 256  
  
 
Figure_Apx 7 The Rat Androgen Receptor Ligand Binding Pocket Identified in SYBYL 
SiteID using Solvation Method 
Figure shows a ribbon representation of the rat (R. norvegicus) Androgen Receptor (AR), with the 
MOLCAD surface and SiteID solvent spheres superimposed, is also enlarged to the right. The X-ray 
crystallography structure used to model the protein was complexed to an n-aryl-oxazolidin 2-imine 
inhibitor LGB (2-chloro-4-{[(1R,3Z,7S,7aS)-7-hydroxy-1-(trifluoromethyl)tetrahydro-1H-pyrrolo[1,2-
c][1,3]oxazol-3-ylidene]amino}-3-methylbenzonitrile), explaining the αH12 clamped conformation. 
Residues within 8Å of solvent spheres in ratAR LBP: Gln711, Val715, Leu744, Ala748 and Arg752. The 
LGB ligand, has been demonstrated to bind and block AR with an EC50 of 0.2 nM (Nirschl et al., 2009).   
 
Figure_Apx 8 Human Progesterone Receptor (hPR) 1SQN Dimer and Monomer Ligand 
Binding Pockets Identified with Solvation Method in SYBYL SiteID 
The Human PR (1SQN) dimer rendered with α-helices and β-sheet secondary structure features 
complexed with Norethindrone. B (rendered) and C (MOLCAD shading) show residues identified within 
5Å of the solvents: Leu718, Asn719, Leu721, Gly722, Gln725, Trp755, Met759, Arg766, Met801, 
Leu887, Cys891 (steroid binding residues 700-900). The white spheres in B, suggest another, smaller, 
hydrophobic pocket; possible allosteric ligand binding or coregulatory binding.  
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Figure_Apx 9 Human Peroxisome Proliferator Activated Receptor-γ (1PRG) Ligand 
Binding Pocket Identified with Solvation Method in SYBYL SiteID 
The Human PPARγ (1PRG), rendered with α-helices and β-sheet secondary structure features and 
MOLCAD shading around the SiteID LBP presented, was bound to rosiglitazone during X-ray 
crystallography. Residues modelled (207-476) in contact with solvent spheres: Tyr222, Phe226, Leu228, 
His266, Gly284, Phe287, Glu291, Ala292, Glu295, Met329, Val339, Ile341 and Met364, correctly 
identifying the entry opening and binding site region (Nolte et al., 1998).  
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Appendix D Amino Acid Properties 
Amino acids, also termed residues in the context of proteins, consist of an amine (-
NH2) and carboxylic acid (-COOH) functional group, in addition to a central side-chain 
specific to each amino acid. Figure_Apx 10 shows the common classifications of the 21 
amino acids reported in Eukaryotes.  
 
Figure_Apx 10 The Twenty-one Amino Acid's Found in Eukaryotes 
CC BY-SA 3.0: Dan Cojocari, University Health Network, University of Toronto 
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Appendix E SYBYL Surflex Dock Potential EDC Receptor Binding 
Score Data 
Surflex-Dock enables flexible molecular docking, incorporating small-molecule force 
fields which evaluate Cartesian coordinates, constrained by ligand energetics (Jain, 
2007), supporting dynamic ring flexibility and optimisation of docked ligand poses. The 
Surflex-Dock results generated for in silico modelled ER, AR. PR and PPARγ are 
presented in Table_Apx 2. The score for each ligand of the chemical database (n=378) 
represents the highest calculated -log(Kd) value achieved from 10 poses, irrespective of 
crash score. 
Table_Apx 2 Virtual Screening of Potential-EDC’s against in silico Nuclear Receptor 
models (ERα/β, AR, PR and PPARγ) in SYBYL Surflex-Dock 
All protomols were generated with a 0.5 Threshold and 0 Bloat. Results show S = score in –log(Kd) and 
C = crash (degree of inappropriate binding, scores nearing 0 preferable). For each compound (column 1), 
MoA reported in the literature are summarised in column 3. Colour coding is reference to concordance of 
in silico predictions with the literature: True positives are in green, assumed positives (on the basis of 
mechanistic studies in other vertebrates) are shaded light green. False negatives are redy-orange, 
presumed false negatives (on the basis of mechanistic studies in other vertebrates) are shaded pink. 
Unfavourable binders are shaded light-orange/tan. The results presented were replicated on three separate 
occasions, however, due to increased chemical database minimisation, the results were the same on each 
day (Standard Deviation = 0).  
Chemical Name 
Chemical 
Category 
Mode 
of 
Action 
3DT3 
hERα 
1X7J 
hERβ 
1HJ1 
ratERβ 
3V49 hAR 
1T7T 
chAR 
21HQ 
ratAR 
2QPY 
mAR 
1SQN hPR 
1PRG 
hPPARγ 
S C S C S C S C S C S C S C S C S C 
TRICLOSAN 
Antibacterial/ 
Cosmetic 
PPARγ 
PPARδ 
TR 
 ER AR, 
AhR, GR 
3.45 -1.39 3.07 -0.81 3.16 -0.84 3.6 -0.18 2.41 -1.79 3.3 -0.58 2.35 -1.37 2.64 -0.32 3.74 -1.46 
(-)TETRA 
CYCLINE 
Antibiotic ER 2.07 -8.47 -10.6 -21.1 -2.11 -8.85 0.14 -10.4 -1.61 -11.3 -10.1 -21.3 -2.44 -11.5 -0.32 -9.31 4.84 -2.05 
CEFUROXIME 
SODIUM 
Antibiotic - 6.22 -1.18 3.45 -4.78 3.99 -2.36 4.63 -4.16 0.24 -8.32 -1.19 -10.8 1.37 -5.96 4.21 -5.04 5.95 -4.25 
CHLOR 
AMPHENICOL 
Antibiotic - 3.27 -0.72 2.86 -2.69 4.68 -1.14 4.26 -1.83 2.52 -2.6 1.46 -3.53 3.79 -2.12 3.43 -1.87 5.2 -1.34 
CHLORO 
TETRACYCLINE 
Antibiotic - -0.21 -7.11 -5.55 -15.3 -0.87 -6.94 2.17 -6.55 -2.06 -10.7 -7.11 -17.2 1.97 -6.84 3.51 -7.42 3.65 -1.6 
CIPROFLOXACIN Antibiotic - 5.45 -4.34 5.12 -3.31 4.76 -4.01 7.42 -3.62 3.55 -4.33 4.79 -4.9 5.58 -2.7 4.67 -3.44 4.72 -1.55 
CLARITHRO 
MYCIN 
Antibiotic - -40.6 -57.5 -107 -126 -50.8 -66 -92.7 -110 -135 -153 -136 -157 -94.1 -113 -106 -126 1.25 -6.55 
DEMECLO 
CYCLINE 
Antibiotic - -0.27 -5.01 -1.41 -10.7 0.91 -4.46 -0.52 -7.65 -2.64 -11.1 -13.2 -21.8 0.62 -8.76 -0.91 -10.8 4.12 -1.37 
ERYTHROMYCIN Antibiotic ER -29.3 -41.7 -106 -126 -12.3 -23 -91.5 -110 -101 -120 -125 -144 -77.8 -95.5 -75.8 -96.4 6.57 -3.15 
KETOCONAZOLE Antibiotic - 6.04 -2.85 -4.42 -15.2 5.96 -1.15 -6.94 -19.1 -14.3 -26.8 -16.3 -27.5 -4.15 -15.6 -10.4 -22.4 8.95 -3.35 
LINCOMYCIN Antibiotic - 5.68 -5.65 -2.23 -13 6.09 -3.22 6.32 -7.37 -2.14 -12.9 -3.82 -16 3.18 -8.77 4.64 -7.86 9.65 -4.87 
OXYTETRA 
CYCLINE 
Antibiotic AhR 0.33 -8.57 -6.44 -16.2 -1.21 -8.47 2.91 -7.37 -0.83 -12.1 -7.05 -17.9 -0.48 -8.98 2.56 -8.28 4.3 -4.9 
SAMIL Antibiotic - 3.12 -7.08 0.14 -11.8 3.1 -4.02 -0.17 -9.08 -3.02 -13.5 -4.19 -17.1 1.64 -8.59 2.87 -7.6 4.84 -3.85 
SULFADI 
METHOXINE 
Antibiotic - 8.07 -2.04 3.75 -3.29 3.1 -3.36 5.34 -1.21 1.92 -4.98 3.74 -3.88 3.84 -2.15 5.01 -1.58 5.22 -1.13 
SULFA 
METHOXAZOLE 
Antibiotic - 4.29 -2.51 3.95 -1.48 4.85 -0.6 4.23 -1.14 3.33 -0.93 3.62 -1.48 4.58 -1.06 3.66 -1.48 3.49 -0.8 
SULFAPYRIDINE Antibiotic - 6.29 -1.04 5.64 -0.53 4.87 -1.42 6.12 -1.46 4.44 -0.73 4.72 -1.25 3.07 -1.35 4.06 -1.21 4.3 -0.8 
TRIMETHOPRIM Antibiotic - 7.53 -2.06 5.33 -2.24 5.24 -1.55 6.95 -1.24 4.89 -2.59 4.06 -4.1 4.94 -1.89 5.08 -1.47 6.35 -1.3 
2-HYDROXY 
BENZOIC ACID 
Antibiotic/ 
Fungicide/ 
Cosmetic 
- 2.84 -0.24 3.18 -0.44 2.79 -0.39 3.46 -0.47 3.06 -0.88 2.26 -0.14 2.62 -0.18 3.75 -0.34 3.82 -1.45 
ROXITHRO 
MYCIN 
Antibiotic/ 
Pharmaceutical 
- -49.4 -60.1 -128 -148 -43.6 -54.9 -127 -145 -153 -172 -164 -186 -118 -138 -117 -137 -0.07 -8.49 
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Chemical Name 
Chemical 
Category 
Mode 
of 
Action 
3DT3 
hERα 
1X7J 
hERβ 
1HJ1 
ratERβ 
3V49 hAR 
1T7T 
chAR 
21HQ 
ratAR 
2QPY 
mAR 
1SQN hPR 
1PRG 
hPPARγ 
S C S C S C S C S C S C S C S C S C 
(R)-EPICHLORO 
HYDRIN 
Chemical Reagent - 1.48 -0.08 1.61 -0.13 1.57 -0.27 2.31 -0.25 2.44 -0.24 2.18 -0.3 2.36 -0.34 2.45 -0.53 2.68 -0.13 
1,2,3,4 5-
PENTACHLORO 
BENZENE 
Chemical Reagent - 1.47 -0.28 0.72 -0.46 1.09 -0.09 1.63 -0.25 0.99 -0.62 2.21 -0.44 0.86 -0.46 1.05 -0.16 1.52 -0.67 
1,2,3 4-TETRA 
HYDRONAPHTH
ALEN-2-OL 
Chemical Reagent - 3.8 -0.6 4.36 -0.8 4.22 -0.9 4.58 -1.35 4.18 -0.73 3.95 -1.73 3.71 -0.6 4.13 -0.36 3.99 -0.88 
1-NAPHTHOL Chemical Reagent - 3.88 -0.2 3.62 -0.8 3.84 -0.49 3.81 -0.14 3.63 -0.99 4.38 -0.67 3.15 -0.83 3.61 -0.64 3.9 -0.49 
1H-BENZO 
TRIAZOLE 
Chemical Reagent PPARδ 3.64 -0.29 2.58 -0.13 3.34 -0.34 2.78 -0.25 3.16 -0.44 2.56 -0.11 3.24 -0.99 3.89 -0.25 4.12 -0.07 
2,2'-DIHYDROXY-
4 4-DIMETHOXY 
BENZOPHENONE 
Chemical Reagent 
PPAR, 
ER, AhR 
5.24 -1.31 3.9 -2.57 4.74 -1.88 5.73 -0.71 4.12 -1.58 5.14 -1.65 4.52 -1.66 4.86 -0.45 4.8 -1.73 
2 4-DINITRO 
PHENOL 
Chemical Reagent AR 3.52 -0.42 2.24 -0.57 4.09 -0.41 2.67 -0.39 1.45 -0.6 3.34 -0.62 2.67 -0.35 1.99 -0.4 4.53 -0.09 
2-BENZYL 
PHENOL 
Chemical Reagent - 3.46 -0.38 4.61 -2.19 4.71 -1.57 3.44 -0.35 4.56 -0.33 4.83 -0.87 3.78 -0.52 4.5 -0.75 4.27 -0.77 
4-NITRO 
TOLUENE 
Chemical Reagent - 3.35 -0.71 3.75 -0.53 2.74 -0.48 3.29 -0.78 1.86 -0.83 2.89 -0.28 3.08 -0.45 2.5 -0.43 4.12 -1.15 
4-PENTYL 
CYCLOHEXANOL 
Chemical Reagent ER 6.02 -1.86 6.58 -0.81 7.37 -1.03 4.83 -0.9 4.97 -0.56 6.02 -0.74 5.06 -1.56 5.73 -1.36 6.69 -1.4 
4-PHENYL 
PHENOL 
Chemical Reagent ER, AR 4.03 -0.76 3.5 -0.79 3.47 -0.59 2.92 -0.49 4.2 -0.39 4.49 -1.26 3.19 -0.29 3.17 -0.48 3.22 -0.29 
4-TERT-BUTYL 
PHENOL 
Chemical Reagent ER 3.54 -0.53 3.92 -0.68 3.75 -0.58 5.86 -2.17 4.03 -0.83 3.37 -0.8 3.89 -0.55 4.1 -0.48 3.64 -0.58 
4-TERT-OCTYL 
PHENOL 
Chemical Reagent ER, AR 6.14 -0.64 5.89 -0.86 5.84 -1.29 5.54 -2.21 5.72 -2.01 5.64 -2.2 5.13 -0.63 5.57 -0.58 5.07 -0.86 
4-NONYL 
PHENOL 
Chemical Reagent ER, AR 6.36 -0.81 6.55 -0.67 6.79 -0.97 7.45 -1.18 6.46 -0.81 6.41 -2.84 7.13 -0.78 7.33 -0.79 6.04 -2.98 
ANISOLE Chemical Reagent - 3.54 -0.5 3.25 -0.22 3.18 -0.39 4.02 -0.26 3.17 -0.24 3 -0.21 3.41 -0.58 2.98 -0.37 3.71 -2.27 
BENZOPHENONE Chemical Reagent AR, ER 3.75 -0.53 4 -1 3.3 -1.4 3.33 -0.95 3.47 -0.34 4.05 -0.44 3.13 -0.34 3.7 -0.48 3.78 -0.87 
BIPHENYL Chemical Reagent RXR 3.71 -0.33 3.89 -0.86 3.11 -0.41 4.56 -0.36 2.91 -0.31 3.7 -1.13 2.55 -0.26 2.99 -0.35 2.5 -0.53 
BROMOFORM Chemical Reagent - 2.88 -0.13 2.79 -0.07 2.7 -0.09 2.72 -0.11 2.51 -0.14 2.7 -0.61 2.77 -0.17 2.83 -0.13 2.73 -0.05 
CARBAMIC ACID Chemical Reagent - 1.72 -0.06 1.69 -0.06 1.95 -0.07 2.05 -0.13 2.14 -0.17 0.98 -0.13 1.59 -0.03 2.96 -0.33 3.36 -0.36 
DEHYDRO 
ABIETIC ACID 
Chemical Reagent - 4.64 -3.94 4.02 -4.3 0.26 -8.12 1.08 -6.05 -1.42 -8.78 -0.83 -10.5 3.1 -4.77 5.14 -2.56 4.24 -1.98 
N N-DIMETHYL 
FORMAMIDE 
Chemical Reagent RXR 3.2 -0.91 2.31 -0.29 2.21 -0.23 2.01 -0.28 4.11 -1.2 5.15 -1.55 3.67 -0.56 2.62 -0.12 3.24 -0.37 
N-(9H-FLUOREN-
2-YL) 
ACETAMIDE 
Chemical Reagent 
ER, AhR, 
GR 
3.99 -0.4 4.29 -1.38 3.61 -0.61 4.08 -0.89 4.8 -0.74 5.54 -0.51 3.27 -0.4 3.59 -0.56 3.78 -0.43 
NAPHTHALEN-2-
OL 
Chemical Reagent ER 3.75 -1.11 3.7 -0.76 3.75 -0.87 4.21 -0.42 3.2 -0.59 2.9 -0.86 3.39 -0.45 3.59 -0.74 4.17 -1.29 
PHENOL 
PHTHALEIN 
Chemical Reagent 
ER, TR, 
AhR, 
AR, 
PXR, 
GR, 
PPARγ, 
PPARδ 
4.96 -2.37 5.01 -3.65 4.18 -3.07 0 -6.92 -2.6 -9.64 -3 -10.1 -0.01 -4.89 -0.09 -6.58 3.13 -1.7 
(S)-EPICHLORO 
HYDRIN 
Chemical Reagent - 1.73 -0.08 1.67 -0.19 2.31 -0.27 2.07 -0.36 2.23 -0.13 2.06 -0.32 1.72 -0.68 2.7 -0.18 2.83 -0.09 
CHLOROFORM Chemical Reagent AR 2.52 -0.16 2.34 -0.06 2.64 -0.16 2.35 -0.3 2.55 -0.13 2.83 -0.24 2.39 -0.11 2.8 -0.1 2.5 -0.15 
4-NITROPHENOL Chemical Reagent AR 3.44 -0.31 3.07 -0.17 2.68 -0.21 2.29 -0.33 2.89 -1.12 2.14 -0.53 2.63 -1.24 3.72 -0.46 4.6 -0.16 
2 5-DIHYDROXY 
BENZOIC ACID 
Chemical 
Reagent/ 
Pharmaceutical 
- 3.43 -0.24 3 -0.6 2.43 -0.79 2.97 -0.54 3.14 -0.82 2.76 -0.28 2.66 -0.54 3.33 -0.74 3.8 -0.18 
2 5-DIHYDROXY 
BENZOIC ACID 
Chemical 
Reagent/ 
Pharmaceutical 
- 3.44 -0.2 3.06 -0.51 2.35 -0.79 3.04 -0.75 2.45 -0.89 2.92 -0.67 2.93 -0.42 3.59 -0.94 3.74 -0.18 
METHYL-2-
AMINO-4 5-
DIMETHYLTHIOP
HENE-3-
CARBOXYLATE 
Chemical 
Reagent/ PPP  
- 3.84 -0.23 3.51 -0.92 4.18 -0.35 4 -0.36 3.02 -0.82 4.61 -0.33 4.81 -0.94 3.09 -0.77 3.7 -1.13 
2 2'-BIPHENOL 
Chemical 
Reagent/ 
Preservative 
- 4 -0.78 4.41 -1.23 3.16 -0.9 2.74 -0.61 4.49 -0.59 3.63 -0.87 3.53 -0.3 3.73 -1.62 3.61 -1.22 
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Chemical Name 
Chemical 
Category 
Mode 
of 
Action 
3DT3 
hERα 
1X7J 
hERβ 
1HJ1 
ratERβ 
3V49 hAR 
1T7T 
chAR 
21HQ 
ratAR 
2QPY 
mAR 
1SQN hPR 
1PRG 
hPPARγ 
S C S C S C S C S C S C S C S C S C 
3-METHYL 
CHOLANTHRENE 
Combustion 
Product 
AR, ER, 
AhR, TR 
4.21 -1.88 5.65 -2.27 5.35 -1.68 4.89 -1.98 3.73 -3.52 3.12 -4.97 4.76 -2.28 5.12 -1.31 4.54 -0.27 
7 12-DIMETHYL 
BENZ[A] 
ANTHRACENE 
Combustion 
Product 
AR, ER, 
AhR, 
PPARδ 
5.03 -1.05 5.88 -0.77 5.58 -0.77 5.56 -2.74 4.31 -2.22 2.41 -6.11 2.81 -1.75 4.82 -0.82 4.82 -1.09 
DIBENZ[A H] 
ANTHRACENE 
Combustion 
Product 
AhR, ER, 
TR 
3.62 -1.05 2.88 -5.06 4.47 -1.17 6.08 -1.78 3.11 -3.97 2.8 -4.77 2.9 -3.92 2.55 -3.7 3.85 -0.62 
FLUORENE 
Combustion 
Product 
TR 3.9 -0.25 3.44 -0.52 3.44 -0.18 3.97 -0.47 3.07 -1.11 4.11 -0.37 3.18 -0.34 3.34 -0.47 4.13 -0.46 
INDENO(1,2 3-
CD)PYRENE 
Combustion 
Product 
- 5.14 -2.63 4.54 -0.91 5.12 -0.81 2.78 -2.97 2.56 -3.83 -0.5 -7.08 4.66 -2.07 4.8 -1.36 3.64 -2.85 
PHENANTHRENE 
Combustion 
Product 
- 3.81 -0.33 3.95 -0.43 3.89 -0.42 4.25 -0.39 3.68 -0.3 4.22 -1.42 2.89 -0.42 3.96 -0.22 3.03 -0.38 
PYRENE 
Combustion 
Product 
- 4.79 -0.4 4.33 -0.51 3.84 -0.5 4.36 -0.9 3.41 -1.03 2.69 -2.78 3.4 -1.79 4.19 -0.4 2.78 -2.31 
RETENE 
Combustion 
Product 
- 3.61 -0.91 4.6 -1.95 4.77 -1.58 6.51 -0.91 5.21 -1.17 4.41 -3.02 4.99 -0.98 5.15 -0.45 5.36 -1.56 
TETRAPHENE 
Combustion 
Product 
AhR, ER, 
PXR, AR 
4.87 -0.75 4.09 -0.83 4.3 -0.59 4.85 -1.46 4.66 -0.13 3.94 -2.13 4.74 -0.78 5.05 -0.32 4.12 -1.38 
ANTHRACENE 
Combustion 
Product/ Reagent 
AhR 4.12 -0.2 4.15 -0.77 3.73 -0.48 4.39 -0.5 2.96 -0.35 3.74 -0.51 2.92 -0.76 3.11 -0.33 3.49 -0.23 
NAPHTHALENE 
Combustion 
Product/ Reagent 
- 2.77 -0.32 3.29 -0.25 3.45 -1.17 4.17 -0.17 2.87 -0.36 4.38 -0.57 3.11 -0.76 3.86 -0.5 3.31 -0.23 
CHRYSENE 
Combustion 
Production 
PXR, 
AhR 
4.54 -0.58 3.62 -1.25 4.11 -0.55 5.77 -0.59 4.23 -0.59 4.03 -2.07 3.79 -0.96 4.43 -1.44 3.92 -0.55 
CASHMERAN Cosmetic - 4.2 -0.58 4.35 -1.54 4.34 -0.96 3.19 -3.11 3.37 -1.33 3.02 -5 3.96 -1.36 3.7 -1.64 4.51 -0.99 
CELESTOLIDE Cosmetic 
TR, 
PPARδ 
4.95 -2.62 2.22 -4.13 3.61 -2.86 0.36 -6.74 -1.94 -8.31 -0.15 -8.02 2.32 -4 1.43 -5.39 4.16 -1.58 
GALAXOLIDE Cosmetic ER 3.36 -3.31 4.47 -3.28 4.76 -2.34 2.05 -5 4.59 -2.62 -0.73 -8.96 5.27 -1.75 4.13 -2.66 4.01 -1.51 
PROPYL-4-
HYDROXY 
BENZOATE 
Cosmetic/ Food 
Additive 
ER, AR, 
PPARγ 
4.24 -1.5 5.02 -0.41 4.65 -0.28 3.67 -0.49 3.7 -0.64 4.22 -0.98 3.56 -0.38 4.12 -0.36 3.35 -0.86 
2 4-DIHYDROXY 
BENZOPHENONE 
Cosmetic/ 
Industrial 
Chemical 
ER, AR, 
TR, 
PPARδ 
4.34 -0.48 4.02 -1.68 4.71 -0.64 4.37 -0.79 4.69 -0.48 4.03 -0.47 3.95 -0.36 4.18 -0.38 4.26 -1.53 
MUSK KETONE Cosmetic/ Musk 
RXR, 
ER, PXR 
4.35 -2.92 3.89 -3.33 3.94 -2.01 -0.83 -6.49 3.12 -2.03 1.04 -6.31 0.64 -3.83 3.42 -2.24 3 -2.09 
4-METHOXY 
CINNAMIC ACID  
Cosmetic/ UV 
Filter 
ER 6.09 -1.44 4.26 -4.74 5.51 -3.12 6.55 -3.94 2.04 -6.87 5.05 -6.66 6.87 -2.45 6.64 -2.81 6.3 -1.68 
DICHLORO 
BROMO 
METHANE 
Flame Retardant/ 
Reagent 
AR 2.36 -0.3 2.53 -0.07 2.47 -0.33 2.57 -0.3 2.79 -0.1 2.96 -0.21 2.51 -0.06 2.84 -0.21 2.82 -0.14 
TRIS(2-
BUTOXYETHYL)
PHOSPHATE 
Flame Retardant/ 
Reagent 
- 10.4 -3.58 1.19 -11.6 6.79 -3.02 6.47 -6.04 3.76 -9.83 1.44 -14.6 3.32 -7.41 6.58 -6.32 9.21 -2.43 
2-METHOXY-4-
VINYLPHENOL 
Food Additive/ 
Component 
- 3.48 -1.41 3.83 -0.62 4.03 -0.6 3.55 -0.36 3.95 -0.79 3.79 -1.27 3.79 -1.04 4.05 -0.34 4.93 -1.61 
4-VINYLPHENOL 
Food Additive/ 
Component 
- 3.5 -0.48 3.15 -0.19 3.9 -0.45 3.07 -0.48 2.56 -0.8 3.28 -0.64 3.48 -0.32 3.2 -0.16 5.41 -0.13 
CAFFEINE 
Food Additive/ 
Component/ 
Pharmaceutical 
AR 3 -0.91 3.35 -0.28 3.99 -0.65 4.05 -1.3 3.3 -0.94 3.95 -1.09 2.05 -0.25 3.3 -0.44 3.41 -0.25 
2 6-DI-TERT-
BUTYL-4-
METHYLPHENOL 
Food Additive/ 
Industrial 
Chemical 
PXR, 
TR, ER 
4.61 -1.92 2.85 -2.87 4.81 -1.66 2.49 -4.63 5.14 -1.92 1.56 -6.45 6.35 -1.18 6.25 -1.82 4.54 -1.65 
BUTYLATED 
HYDROXY 
ANISOLE 
Food Additive/ 
Pesticide/ 
Antioxidant 
PXR 3.41 -0.76 4.41 -1.28 5.51 -0.74 4.33 -1.8 4.28 -0.53 4.22 -2.4 4.54 -0.71 3.87 -1.52 3.88 -0.67 
3-PHENYL 
PROPANOIC 
ACID 
Food Additive/ 
Preservative 
- 3.8 -1.06 4 -0.91 3.62 -0.26 4.55 -0.62 3.93 -0.54 4.36 -0.69 4.57 -1.44 4.27 -0.66 4.77 -0.45 
MANEB Fungicide - 2.6 -0.77 2.26 -1.36 2.87 -1.24 2.47 -1.07 2.02 -0.37 2.46 -1.04 2.55 -0.25 2.6 -1.41 2.45 -0.51 
BENOMYL Fungicide 
AR, TR, 
PXR, 
ER, AR 
3.2 -1.73 3.76 -2.14 4.54 -1.91 2.87 -2.66 4.59 -2.6 3.41 -4.43 3.91 -1.35 2.38 -3.14 3.41 -2.17 
CARBENDAZIM Fungicide AhR 3 -0.42 1.87 -0.12 2.97 -1.13 3.16 -0.87 2.19 -0.43 3.23 -0.47 3.64 -1.95 2.29 -1.13 3 -0.67 
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Chemical Name 
Chemical 
Category 
Mode 
of 
Action 
3DT3 
hERα 
1X7J 
hERβ 
1HJ1 
ratERβ 
3V49 hAR 
1T7T 
chAR 
21HQ 
ratAR 
2QPY 
mAR 
1SQN hPR 
1PRG 
hPPARγ 
S C S C S C S C S C S C S C S C S C 
DIFENOCON 
AZOLE 
Fungicide 
ER, TR, 
AR, 
RXR, 
GR, 
PPARδ 
5.65 -1.64 -0.49 -9.43 6.19 -1.55 4.85 -4.23 -1.05 -9.34 0.31 -10.5 3.65 -5.23 3.12 -4.75 5.96 -1.93 
ENILCONAZOLE Fungicide 
AhR, 
PXR, 
PPARδ, 
TR, ER, 
AR 
5.98 -1.62 6.08 -1.25 5.59 -1.46 5.35 -1.63 5.11 -2.03 5.46 -1.33 4.14 
  
5.06 -1.59 5.63 -1.79 
EPOXICON 
AZOLE 
Fungicide 
AhR, TR, 
AR, ER 
5.29 -1.24 2.93 -3.94 3.76 -2.91 3.95 -3.97 3.71 -2.57 1.45 -6.26 4.09 -1.03 4.91 -1.44 5.09 -0.82 
FENARIMOL Fungicide 
ER, AR, 
TR, GR 
5.35 -1.41 0.87 -4.46 3.86 -0.93 2.95 -2.59 -0.29 -5.78 -1.57 -6.43 -0.57 -5.15 0.6 -4.15 3.35 -1.57 
MYCLOBUTANIL Fungicide PXR, ER 6.1 -0.96 4.35 -1.72 5.26 -2.01 5.35 -2.15 4.97 -1.61 5.85 -2.31 4.46 -1.74 4.19 -2.9 5.2 -1.21 
PENCONAZOLE Fungicide 
GR, AR, 
ER, TR 
4.96 -1.61 4.33 -1.65 5.23 -1.98 4.93 -1.28 4.24 -1.39 2.91 -2.62 4.88 -2.06 5.63 -1.87 4.86 -2.51 
PROCHLORAZ Fungicide 
AhR, 
PXR, 
AR, TR, 
PPARδ, 
ER, GR 
4.69 -1.92 2.89 -5.02 3.86 -2.7 3.9 -2.96 1.84 -4.2 0.39 -6.15 4.14 -2.78 3.72 -3.5 6.15 -1.18 
PROPICONAZOLE Fungicide 
PXR, 
AhR, TR, 
ER, AR 
5.93 -2.31 3.63 -4.02 5.22 -3.07 5.35 -2.31 4.49 -2.32 3.36 -4.48 3.78 -2.48 4.47 -2.74 4.34 -3.55 
TEBUCONAZOLE Fungicide 
PXR, 
ER, GR, 
AR, TR 
4.73 -1.42 5.22 -2.81 4.36 -2.91 3.63 -4.3 4.85 -1.68 3.25 -4.34 4.6 -2.42 4.78 -2.4 6.23 -2.2 
THIRAM Fungicide 
TR, GR, 
PPARγ, 
PPARδ, 
AhR, AR 
2.96 -1.17 3.32 -1.61 3.78 -1.31 1.5 -4.21 2.94 -1.03 3.53 -1.95 2.96 -0.5 3.72 -1.89 2.9 -1.8 
VINCLOZOLIN Fungicide 
AR, 
PPARδ 
2.66 -1.76 1.8 -2.35 2.66 -1.69 4.13 -0.7 2.58 -1.21 4.18 -1.74 2.49 -1.37 2.35 -0.96 5.13 -0.64 
RESORCINOL 
Fungicide/ 
Pharmaceutical 
- 4.4 -0.36 2.84 -0.29 3.23 -0.38 2.92 -0.37 3.02 -0.41 3.63 -0.28 2.82 -0.43 3.16 -0.3 2.65 -0.76 
4-BENZYL 
PHENOL 
Germicide/ 
Antiseptic/ 
Preservative 
ER 4.28 -0.51 4.88 -0.58 4.17 -0.45 3.39 -1.24 3.65 -0.62 4.39 -0.81 3.78 -1.01 3.8 -0.8 4.38 -0.86 
4-CHLORO-3 5-
DIMETHYL 
PHENOL 
Germicide/ 
Antiseptic/ 
Preservative 
- 4.1 -0.24 4.32 -0.66 4.18 -0.66 4.55 -0.17 4.32 -0.52 3.89 -0.24 4.52 -0.36 5.32 -0.37 4.44 -1.8 
2 3-D Herbicide - 3.63 -0.78 3.19 -0.71 3.59 -0.54 3.93 -1.57 3.7 -0.44 2.64 -0.73 4.05 -1.47 3.71 -0.44 5.66 -0.79 
3 5-DIBROMO-4-
HYDROXY 
BENZONITRILE 
Herbicide 
AR, 
RXR, 
AhR, 
PPARα, 
PPARγ, 
ER 
1.95 -0.32 1.21 -0.58 1.46 -0.11 3.29 -0.49 1.43 -0.39 1.77 -1.03 1.3 -0.42 0.84 -1.01 3.05 -0.74 
PRONAMIDE Herbicide PXR, AR 2.04 -1.69 1.86 -2.62 1.89 -2.36 2.97 -0.54 3.44 -0.79 2.81 -1.7 3.24 -0.66 1.96 -1.05 2.66 -0.52 
3-AMINO-1,2 4-
TRIAZOLE 
Herbicide ER 3.49 -0.25 2.98 -0.2 3.09 -0.31 2.83 -0.14 2.04 -0.3 2.25 -0.17 2.35 -0.19 2.69 -0.83 2.72 -0.06 
4-(2 4-DICHLORO 
PHENOXY) 
BUTANOICACID 
Herbicide AR 3.74 -0.43 3.87 -0.9 3.81 -0.47 4.68 -2.23 4.72 -0.96 4.47 -0.46 5.11 -0.99 4.42 -0.81 5.21 -0.72 
4-AMINO-2,5 6-
TRICHLORO 
PYRIDINE-2-
CARBOXYLIC 
ACID  
Herbicide AhR 2.26 -0.44 2.59 -0.22 2.3 -0.93 3.04 -0.21 1.86 -0.27 3.02 -0.91 2.55 -1.06 2.2 -0.24 3.5 -0.84 
ACETOCHLOR Herbicide AR, ER 5.4 -1.03 3.45 -3.36 4.27 -2.54 3.22 -3.5 2.66 -3.3 3.02 -5.03 3.51 -2.66 5.09 -1.4 4.65 -2.24 
ALACHLOR Herbicide 
ER, AR, 
TR 
4.5 -1.02 3.33 -3.9 4.02 -1.76 0.7 -4.58 2.96 -3.86 1.92 -5.28 3.51 -1.05 4.06 -1.92 3.86 -3.41 
ATRAZINE Herbicide AhR 3.76 -0.83 3.57 -1.04 3.84 -0.66 4.26 -1.18 3.51 -1.09 3.53 -2.25 3.69 -1.3 4.69 -0.77 3.91 -1.14 
BENTAZON Herbicide - 3.38 -0.55 2.98 -2.11 3.88 -0.83 2.6 -2.62 3.91 -0.89 3.24 -1.07 4.04 -0.51 2.05 -3.38 3.49 -1.02 
BROMACIL Herbicide AhR 3.17 -0.7 2.85 -1.03 4.2 -0.77 3.87 -0.63 3.58 -0.41 3.39 -0.72 3.23 -0.5 3.64 -1.3 4.11 -0.67 
DIURON Herbicide AhR 1.71 -0.88 2.05 -0.76 2.21 -2.09 3.7 -0.48 2.41 -0.29 3.95 -0.26 2.62 -0.87 2.82 -0.4 2.63 -0.59 
GLUFOSINATE 
AMMONIUM 
Herbicide - 3.99 -1.02 3.89 -0.78 4 -1.19 4.09 -0.86 3.37 -0.57 3.66 -1.9 3.72 -1.29 4.01 -0.98 6.13 -1.46 
GLYPHOSATE Herbicide - 2.55 -0.4 3.73 -0.92 2.75 -1.21 3.62 -0.88 3.56 -0.39 3.1 -0.81 3.02 -1.09 3.54 -0.42 3.84 -0.57 
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Chemical Name 
Chemical 
Category 
Mode 
of 
Action 
3DT3 
hERα 
1X7J 
hERβ 
1HJ1 
ratERβ 
3V49 hAR 
1T7T 
chAR 
21HQ 
ratAR 
2QPY 
mAR 
1SQN hPR 
1PRG 
hPPARγ 
S C S C S C S C S C S C S C S C S C 
N-(3 4-DI 
CHLOROPHENYL
) PROPANAMIDE 
Herbicide PXR, AR 3.81 -1.06 1.9 -0.33 3.21 -0.93 3.13 -0.6 2.32 -0.45 3.47 -0.46 2.09 -0.58 3.04 -1.55 3.15 -0.83 
PARAQUAT Herbicide - 3.4 -1.32 4.53 -0.83 4.8 -0.72 4.95 -0.24 4.61 -0.48 5.31 -0.3 3.05 -0.6 3.89 -0.81 3.55 -0.44 
PENDIMETHALIN Herbicide ER 6.07 -1.65 3.22 -4.41 5.46 -2.01 3.8 -2.31 1.44 -3.34 3.86 -3.69 4.99 -1.75 3.65 -1.95 6.2 -3.5 
PROMETRYN Herbicide PXR 3.94 -1.94 4.64 -1.7 3.91 -0.46 3.19 -4.05 3.99 -1.79 2.13 -5.63 3.56 -2.39 4.12 -1.99 4.26 -1.4 
PROPAZINE Herbicide 
PXR, 
AhR 
2.82 -1.22 3.73 -1.28 4.98 -0.69 4.6 -1.86 3.33 -1.58 3.5 -3.12 3.69 -1.65 4.62 -1.01 3.27 -2.28 
SIMAZINE Herbicide - 2.92 -1.17 2.79 -0.96 3.35 -2.01 4.3 -1 2.52 -1.01 4.46 -1.09 2.99 -0.68 3.22 -0.63 3.26 -0.57 
TERBUTRYN Herbicide 
AhR, 
AR, 
PPARδ, 
TR 
3.63 -2 4.75 -1.73 4.96 -0.76 4.26 -1.49 4.97 -1.7 3.98 -3.28 4.05 -2.37 4.83 -0.68 3.44 -1.05 
TERBUTYLAZINE Herbicide ER, GR 6.66 -2.89 7.02 -2.51 5.76 -2.25 6.49 -2.76 6.7 -1.85 5.47 -4.94 6.53 -1.94 6.5 -1.58 7.52 -1.79 
TRIFLURALIN Herbicide - 6.34 -1.39 -0.58 -7.82 5.43 -1.57 0.73 -5.7 3.02 -3.47 1.64 -4.84 3.37 -2.63 4.71 -1.63 7.06 -3.29 
1,2 3-TRICHLORO 
BENZENE 
Industrial 
Chemical 
- 1 -0.12 1.64 -0.22 1.86 -1.05 2.83 -0.17 1.36 -0.79 2.48 -0.13 1.77 -0.31 1.72 -0.18 1.51 -1.16 
BISPHENOL B 
Industrial 
Chemical 
ER, AR, 
TR, 
PXR, 
PPARγ, 
PPARδ 
5.17 -1.26 4.06 -2.33 4.36 -2.58 4.05 -1.76 3.04 -2.35 2.89 -5.82 4.54 -2.07 6.16 -0.98 5.47 -1.24 
2,3 4-TRICHLORO 
BIPHENYL 
Industrial 
Chemical 
- 3.28 -0.97 3.46 -1.08 2.88 -0.84 3.39 -0.4 3.02 -0.98 4.18 -0.38 2.3 -0.94 3.4 -0.4 2.91 -0.43 
2-(((2-
ETHYLHEXYL)O
XY)CARBONYL)
BENZOIC ACID 
Industrial 
Chemical 
PPARγ, 
PPARα, 
RXR 
7.6 -2.32 6.11 -3.12 7.71 -1.77 6.09 -2.19 7.56 -1.66 4.89 -3.45 5.69 -1.24 5.97 -1.79 6.13 -1.6 
2-CHLORO 
BIPHENYL 
Industrial 
Chemical 
- 3.57 -0.98 3.34 -0.55 3.26 -1.36 3.39 -0.86 3.15 -1.14 3.26 -0.38 2.73 -0.38 3.1 -0.36 3.07 -0.81 
3-CHLORO 
BIPHENYL 
Industrial 
Chemical 
- 3.6 -0.78 3.96 -0.45 3.34 -0.27 3 -0.7 2.93 -0.92 3.84 -0.37 2.53 -0.48 2.82 -0.77 3.23 -0.48 
4 4'-BIPHENOL 
Industrial 
Chemical 
AR, ER, 
PPARγ 
3.27 -0.96 4.8 -0.7 5.46 -0.76 4.41 -0.87 5.46 -0.7 4.9 -1.53 4.72 -0.57 3.96 -0.55 3.62 -1.87 
BISPHENOL F 
Industrial 
Chemical 
ER 4.28 -1.01 4.08 -1.46 4.87 -0.65 3.63 -1.14 4.04 -0.81 4.92 -1.42 4.07 -0.73 4.91 -0.4 4.32 -0.83 
4-CHLORO-4'-
HYDROXY 
BIPHENYL 
Industrial 
Chemical 
ER 4.7 -0.68 4.14 -0.49 4.32 -0.55 3.71 -0.32 3.61 -0.24 4.02 -0.46 3.7 -0.47 3.36 -0.51 3.69 -0.6 
4-CHLORO 
BIPHENYL 
Industrial 
Chemical 
- 3.09 -0.22 2.57 -0.29 3.07 -0.3 2.24 -0.63 2.89 -0.45 3.52 -0.62 1.55 -1.4 2.85 -0.66 2.8 -0.85 
4-ISOPENTYL 
PHENOL 
Industrial 
Chemical 
- 4.14 -0.63 4.57 -1.12 4.77 -0.57 4.51 -1.12 4.47 -0.23 5.18 -1.38 4.71 -0.51 4.14 -0.83 5.31 -0.47 
6-BROMO-2-
NAPHTHOL 
Industrial 
Chemical 
- 3.52 -0.65 3.1 -0.84 3.52 -0.34 3.14 -0.1 3.71 -0.49 3.5 -1.15 3.33 -0.53 2.6 -0.34 2.87 -0.17 
BENZYLBUTYL 
PHTHALATE 
Industrial 
Chemical 
ER, AhR, 
PPARδ, 
AR 
7 -0.7 6.84 -2.18 5.56 -1.45 3.6 -3.92 6.96 -1.84 3.64 -6.04 5.25 -1.54 5.03 -1.38 7.11 -2.27 
BIS(2-
ETHYLHEXYL) 
PHTHALATE 
Industrial 
Chemical 
AhR, 
PXR 
8.76 -2.99 0.02 -13.4 6.35 -4.99 0.34 -11.7 -1.5 -14.8 -10.6 -23.6 -2.84 -12.7 4.47 -8.01 8.29 -0.76 
BISPHENOL A 
Industrial 
Chemical 
ER, 
PPARγ, 
AR, 
AhR, 
PPARδ, 
PXR 
4.88 -0.62 5.76 -0.63 5.21 -0.82 4.97 -0.87 3.11 -1.66 3.65 -3.17 3.46 -1.66 4.39 -0.98 4.8 -0.91 
BISPHENOL E 
Industrial 
Chemical 
- 3.93 -1.32 4.48 -0.53 5.3 -0.66 4.41 -1.48 3.19 -2.53 4.08 -2.96 3.01 -1.61 4.76 -2.09 4.87 -1.03 
BUTYLBENZENE 
Industrial 
Chemical 
- 3.62 -0.67 4.13 -0.53 3.4 -0.48 3.57 -0.98 3.34 -0.68 4.08 -0.53 3.59 -1.27 4.05 -1.4 3.57 -0.22 
CHLORO 
DIBROMO 
METHANE 
Industrial 
Chemical 
AR 2.52 -0.07 2.6 -0.03 2.56 -0.47 2.77 -0.27 3.05 -0.11 2.59 -0.4 2.51 -0.18 2.9 -0.19 2.99 -0.13 
DIBUTYL 
PHTHALATE 
Industrial 
Chemical 
ER 7.15 -2.02 4.35 -4.21 6.55 -1.74 5.49 -3.72 5.9 -1.74 5.96 -3.9 5.68 -1.58 7.3 -1.55 6.22 -0.9 
DICYCLOHEXYL
PHTHALATE 
Industrial 
Chemical 
TR, 
PPARδ 
6.61 -2.03 4.12 -6.2 5.93 -1.78 -0.75 -9.04 -0.21 -9.56 -6.68 -16.8 0.6 -6.88 2.13 -6.87 6.82 -1.46 
DIETHYL 
PHTHALATE 
Industrial 
Chemical 
AhR 4.13 -1.98 4.59 -0.69 5.24 -0.98 3.95 -1.37 3.7 -0.85 3.98 -1.99 4 -0.81 3.99 -1.27 4.41 -0.66 
DIISOBUTYL 
PHTHALATE 
Industrial 
Chemical 
ER 5.81 -1.42 5.02 -2.86 6.62 -1.32 3.95 -5.64 4.36 -2.72 3.99 -5.1 4.76 -2.06 6.01 -2.67 6.43 -1.11 
Evaluation of in silico and in vitro screening methods for EDC hazard characterisation 
 
 
 Page 266  
  
Chemical Name 
Chemical 
Category 
Mode 
of 
Action 
3DT3 
hERα 
1X7J 
hERβ 
1HJ1 
ratERβ 
3V49 hAR 
1T7T 
chAR 
21HQ 
ratAR 
2QPY 
mAR 
1SQN hPR 
1PRG 
hPPARγ 
S C S C S C S C S C S C S C S C S C 
DIISODECYL 
PHTHALATE 
Industrial 
Chemical 
AR 8.13 -3.4 -0.59 -15.2 5.84 -5.97 -6.38 -21.4 -18.1 -31.6 -19.1 -35.2 -1.49 -13.8 -0.74 -16 8.42 -4.93 
DIISONONYL 
PHTHALATE 
Industrial 
Chemical 
- 11 -3.48 -5.6 -19.8 7.17 -4.08 5.47 -8.98 -6.84 -17.9 -16 -29.3 0.29 -13.7 2.52 -11.4 9.62 -1.09 
MONOBUTYL 
PHTHALATE 
Industrial 
Chemical 
- 6.24 -0.73 5.6 -1.25 5.19 -1.55 4.96 -0.93 6.19 -0.77 5.55 -0.66 4.15 -0.59 6.72 -1.17 5.77 -0.38 
N-NITROSO 
DIMETHYL 
AMINE 
Industrial 
Chemical 
- 2.05 -0.12 2.49 -0.15 2.17 -0.24 2.58 -0.42 2.55 -0.37 2.75 -0.31 3.06 -0.21 2.63 -0.34 3.18 -0.22 
N-NITROSO 
PIPERIDINE 
Industrial 
Chemical 
- 3.04 -0.77 3.43 -0.63 3.16 -0.26 3.57 -0.74 3.24 -0.3 2.4 -0.55 3.6 -0.51 3.66 -0.74 4.6 -0.74 
PERFLUORO 
DECANOIC ACID 
Industrial 
Chemical 
ER 4.17 -1.27 3.9 -1.75 5.34 -1.17 3.89 -1.75 5.5 -1.83 4.34 -3.41 5.58 -1.34 5.11 -1.19 6.05 -1.95 
STYRENE 
Industrial 
Chemical 
- 3.2 -0.63 3.18 -0.22 2.41 -0.4 3.36 -0.43 3.18 -0.65 3.46 -0.12 3.32 -0.67 2.97 -0.17 3.18 -0.57 
TETRACHLORO 
ETHYLENE 
Industrial 
Chemical 
- 0.5 -0.17 0.47 -0.18 0.63 -0.22 0.75 -0.03 0.36 -0.18 0.83 -0.04 0.25 -0.07 0.35 -0.05 0.67 -0.17 
TRIBUTYL 
PHOSPHATE 
Industrial 
Chemical 
ER 6.69 -1.67 6.93 -1.79 5.91 -2.07 6.13 -2.28 7.28 -1.74 6.81 -2.85 7.11 -1.51 6.72 -1.32 6.17 -0.97 
VINYLACETATE 
Industrial 
Chemical 
- 2.86 -0.3 2.95 -0.85 3.02 -0.24 3.04 -1.19 2.48 -0.14 3.13 -0.24 3.27 -0.46 3.07 -0.41 4.47 -0.38 
DDE Insecticide AR, ER 2.4 -2.12 1.31 -2.88 2.57 -0.5 2 -2.09 -1.36 -4.34 1.2 -2.19 0.81 -2.08 2.61 -0.88 3.96 -0.9 
ACEPHATE Insecticide - 4.33 -0.6 1.97 -0.67 3.24 -0.53 3.24 -0.56 2.11 -1 3.53 -1.31 2.57 -1.24 3.56 -0.55 3.42 -1.66 
BIFENTHRIN Insecticide ER 4.48 -5.19 0.02 -10.3 1.91 -2.86 -4.37 -15.3 -1.57 -12 -11.6 -20.9 1.07 -8.16 5.49 -4.99 6.33 -2.34 
CHLOR 
FENVINFOS 
Insecticide 
PXR, 
AhR 
6.11 -1.28 3.89 -2.56 5.54 -1.16 4.57 -2.01 3.36 -2.99 1.55 -5.36 3.21 -2.16 4.43 -1.43 3.97 -1.02 
DDD Insecticide 
ER, TR, 
GR, 
PPARδ, 
PPARδ, 
AR 
3.7 -0.89 2.41 -2.15 2.69 -1.39 3.19 -1.38 0.1 -3.32 0.98 -2.81 1.75 -1.7 3.02 -0.94 3.76 -1.35 
DDT Insecticide 
ER, GR, 
PPARγ, 
TR, 
PXR, AR 
2.78 -0.87 1.55 -2.72 1.66 -2.27 1.27 -2.95 -0.5 -3.64 -2.3 -6.76 -0.21 -3.41 2.46 -1.4 3.41 -1.29 
DELTAMETHRIN Insecticide PXR, TR 5.74 -1.61 -4.21 -12.8 3.32 -4.96 0.33 -9.22 -7.43 -15.2 -5.33 -15.6 -4.39 -12.6 0.18 -8.31 5.53 -1.92 
DEMETON-S-
METHYL 
Insecticide - 4.46 -1.05 4.2 -1.35 5.06 -0.86 4.01 -1.28 4.09 -0.61 4.7 -1.79 3.68 -2 4.75 -1.66 4.67 -1.35 
DIAZINON Insecticide 
AhR, TR, 
GR, 
PPARδ 
6.12 -1.6 5.17 -3.72 6.54 -1.94 6.24 -1.81 4.16 -3.28 4.46 -4.41 6.14 -1.28 6.56 -2.1 5.54 -3.72 
DICHLORVOS Insecticide 
AR, ER, 
PXR, 
PPARγ 
2.65 -0.57 2.06 -0.65 3 -0.64 2.78 -1.49 1.99 -0.8 2.86 -0.76 2.29 -1.1 4.07 -0.71 3.85 -1.13 
DICOFOL Insecticide 
PPARγ, 
AR 
1.25 -4.17 0.51 -3.68 2.23 -2.74 0.28 -3.58 -0.58 -4.63 -1.48 -5.86 -0.31 -2.89 2.05 -1.76 2.25 -1.32 
DIELDRIN Insecticide 
AR, TR, 
PXR 
0.57 -3.63 0.11 -3.96 -2.02 -5.1 -7.51 -10.6 -1.95 -4.74 -8.43 -13.4 -1.19 -4.88 0.68 -2.64 0.3 -4.62 
DIMETHOATE Insecticide AhR 4.68 -0.67 3.06 -0.79 5.13 -1.08 3.47 -1.91 3.11 -0.79 2.34 -2.34 2.95 -1.34 3.32 -2.35 4.74 -0.87 
ETOFENPROX Insecticide - 6.94 -1.61 2.06 -8.11 5.34 -1.65 0.75 -8.75 1.69 -9.3 -10.4 -21.4 0.85 -8.14 3.93 -6.9 8.23 -1.53 
FENITROTHION Insecticide AR, AhR 4.62 -1.38 5.04 -1.36 5.67 -0.78 4.37 -1.42 3.86 -1.25 5.51 -1.4 4.36 -0.88 3.54 -1.74 4.47 -1.71 
FENOXYCARB Insecticide 
PPARγ, 
AR, ER, 
PXR 
6.34 -1.45 4.71 -2.79 5.78 -2.06 7.92 -1.67 5.73 -1.8 6.86 -3.18 7.41 -1.73 6.33 -3.41 5.17 -1.17 
FENVALERATE Insecticide 
PXR, 
ER, TR, 
AR 
4.83 -3.48 -4.09 -15.6 5.17 -3.58 3.78 -7.39 -6.75 -17 -17 -25.6 -0.83 -10.2 -2.61 -13.7 6.79 -2.59 
FIPRONIL Insecticide 
AR, ER, 
PXR, 
TR, 
PPARδ, 
PPARγ 
0.29 -3.78 2.95 -3.76 0.78 -3.28 3.13 -3.8 0.82 -4.25 1.38 -4.56 2.43 -2.11 1.92 -2.67 2.12 -2.37 
FLUVALINATE Insecticide - 5.25 -3.45 -3.52 -16.7 7.92 -4.35 -7.57 -19.8 -3.59 -15.9 -18.6 -30.4 -4.11 -15.2 0.44 -11.8 6.51 -2.25 
LINDANE Insecticide 
ER, TR, 
GR, 
PXR, 
PPARδ, 
AhR 
1.79 -0.66 2.02 -0.7 1.42 -0.83 1.19 -2.14 1.03 -2.15 0.95 -2.44 1.03 -0.74 1.35 -0.49 1.99 -0.4 
MALATHION Insecticide AhR 5.48 -1.48 4.73 -2.46 4.81 -4.24 5.89 -2.17 5.31 -2.86 3.89 -4.57 3.81 -2.05 5.59 -1.8 5.28 -2.98 
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Chemical Name 
Chemical 
Category 
Mode 
of 
Action 
3DT3 
hERα 
1X7J 
hERβ 
1HJ1 
ratERβ 
3V49 hAR 
1T7T 
chAR 
21HQ 
ratAR 
2QPY 
mAR 
1SQN hPR 
1PRG 
hPPARγ 
S C S C S C S C S C S C S C S C S C 
MEVINPHOS Insecticide - 4.44 -0.73 4.14 -0.96 4.63 -0.88 5.13 -1.05 4.3 -0.82 4.52 -1.53 4.55 -0.98 5.21 -0.95 6.69 -1.15 
MIREX Insecticide - -6.25 -8.58 -7.7 -9.73 -4.53 -7.45 -13.3 -17.8 -9.33 -12.1 -18.3 -20.9 -7.83 -10.6 -4.27 -6.35 -1.18 -0.45 
OMETHOATE Insecticide - 4.01 -0.77 4.56 -0.76 4.14 -0.67 4.44 -1 3.25 -1.02 3.87 -0.86 3.92 -1.67 4.92 -1.27 4.03 -0.7 
OXYDEMETON-
METHYL 
Insecticide - 4.79 -0.98 4.35 -1.18 4.88 -0.72 4.49 -1.31 3.82 -1.7 4.84 -1.28 3.79 -1.63 3.91 -0.99 5.56 -1.32 
PARATHION Insecticide 
AhR, 
PXR 
4.17 -0.59 5.76 -2.17 4.62 -1.61 4.36 -1.3 3.68 -1.82 4.6 -2.37 4.49 -1.64 3.71 -1.26 5.36 -1.19 
PERMETHRIN Insecticide 
AhR, 
PXR 
3.11 -7.21 -0.54 -9.62 4.71 -3.72 -0.32 -10.3 -6.09 -12.6 -4.38 -14.1 0.54 -7.49 4.3 -6.04 5.93 -1.29 
PROPOXUR Insecticide - 4.01 -0.61 5.23 -0.44 4.76 -0.47 2.94 -2.02 4.12 -0.7 3.81 -1.95 4.15 -2.7 3.57 -0.74 4.43 -0.87 
RESMETHRIN Insecticide 
PXR, 
AR, GR, 
PPARγ 
6.5 -4.86 1.42 -10.1 5.97 -3.69 6.01 -5.35 -3.04 -13.8 -3.87 -13.8 1.32 -8.08 3.64 -6.89 7.18 -1.82 
TETRACHLORVI
NPHOS 
Insecticide 
ER, AR, 
GR, TR, 
PPARγ, 
PXR 
4.05 -1.31 3.17 -2.35 3.81 -1.91 3.19 -2.31 3.08 -1.81 2.29 -3.46 2.46 -1.62 3.72 -1.89 3.42 -1.45 
TOXAPHENE Insecticide 
ER, TR, 
GR, AR, 
PPARδ, 
PPARγ 
0.68 -3.37 -2.58 -6.13 -1.75 -5.37 -1.98 -8.26 -1 -5.42 -7.53 -11.9 -2.47 -6.07 0.79 -1.98 0.53 -3.16 
TRICHLORFON Insecticide - 2.74 -1.4 2.67 -0.8 2.62 -0.77 2.27 -1.38 1.57 -1.58 0.85 -2 1.95 -1.19 3.23 -0.41 2.72 -0.75 
PIPERONYL 
BUTOXIDE 
Insecticide  
AhR, TR, 
AR, PXR 
7.43 -2.33 5.34 -5.9 7.36 -2.43 8.85 -2.59 3.26 -5.81 5.22 -7.97 9.13 -2.17 8.05 -2.9 8.36 -1.28 
TONALIDE Musk Ketone TR 2.77 -2.86 5.86 -2.48 3.78 -2.97 0.27 -6.32 2.27 -5.15 -1.57 -12.3 2.96 -3.91 3.97 -4.33 4.45 -2.61 
RETINOL 
Natural 
Compound 
ER, 
PXR, 
GR, AR, 
TR, 
PPARγ 
6.64 -2.49 5.97 -4.94 6.04 -3.79 8.16 -3.63 6.04 -6.4 4.55 -8.4 6.46 -3.12 6.94 -4.25 7.43 -1.63 
STEARIC ACID 
Natural 
Compound 
ER 7.59 -2.19 6.77 -3.41 8.51 -2.37 8.62 -2.65 8.34 -3.61 3.7 -10.2 9.32 -4.08 9.02 -3.68 9.29 -1.54 
ANDRO 
STANEDIONE 
Natural Hormone AR 3.47 -2.63 3.49 -4.6 3.45 -4.01 2.76 -4.61 7.74 -0.95 0.48 -8.71 6.99 -1.11 5.31 -2.22 3.77 -5.81 
ANDRO 
STERONE 
Natural Hormone AR 4.1 -4.36 1.9 -6.1 2.45 -6.16 2.86 -4.89 7.44 -1.64 1.58 -8.71 3.12 -3.46 5.51 -4.39 3.3 -1.18 
DEHYDRO 
TESTOSTERONE  
Natural Hormone AR 5.06 -0.91 1.26 -5.62 5.05 -1.97 3.84 -4.81 7.14 -0.86 -3.2 -11.9 6.14 -1.43 5.85 -1.92 3.54 -2.43 
CORTISONE Natural Hormone AR. GR 4.58 -3.91 0.92 -8.72 3.95 -4.9 -0.7 -10.6 5.27 -4.44 -3.38 -14.4 5.54 -4.68 7.89 -3.33 4.51 -0.84 
EPI 
ANDROSTERONE 
Natural Hormone AR 3.52 -4.68 2.44 -6 4.13 -5.36 4.04 -4.46 7.94 -1.46 2.83 -7.85 6.76 -1.18 4.22 -2.72 4.39 -0.87 
ESTRADIOL Natural Hormone 
ER, AR, 
TR, GR, 
PPARγ 
5.09 -1.21 5.47 -3.85 5.19 -1.82 4.42 -3.39 4.49 -2.84 -0.13 -7.94 4.32 -2.73 5.21 -0.66 4.28 -1.27 
ESTRIOL Natural Hormone 
ER, AR, 
GR, TR 
6.47 -0.99 5.78 -2.15 7.91 -1.18 5.37 -3.01 7.49 -1.08 4.34 -5.28 6.53 -1.78 6.18 -1.35 2.81 -2.11 
ESTRONE Natural Hormone 
ER, AR, 
TR, GR, 
PR, PXR 
6.2 -0.75 5.55 -1.86 8.13 -0.85 4.69 -2.9 4.87 -1.5 3.78 -4.41 5.84 -1.7 6.21 -0.95 5.22 -1.16 
L-THYROXINE Natural Hormone 
TR, AhR, 
PPARγ, 
GR 
-0.62 -7.93 -6.6 -13.6 0.94 -6.39 -3.02 -10.3 -2.53 -8.67 -8.27 -14.8 -4.1 -10.9 -0.48 -9.44 3.59 -3.57 
PROGESTERONE Natural Hormone 
PR, AR, 
ER, GR, 
TR, 
PPARγ, 
PPARδ 
4.1 -3.55 3.59 -6.91 3.55 -4.91 2.05 -6.41 5.99 -3.54 -2.13 -12.3 6.56 -2.96 8.35 -2.37 3.86 -0.85 
STANOLONE Natural Hormone 
AR, ER, 
GR, PR, 
RXR, TR 
4.08 -2.67 3.5 -5.51 4.44 -3.91 3.58 -5.94 9.38 -0.57 -0.1 -9.16 8.18 -0.97 7.15 -2.22 4.52 -1.46 
LIOTHYRONINE 
Natural Hormone/ 
Pharmaceutical 
TR, AhR, 
ER, GR 
1.17 -6.93 -0.01 -6.75 -2.55 -9.07 -0.95 -7.1 -4.81 -11.3 -0.88 -9.61 0.96 -7.04 0.42 -6.08 5.15 -2.38 
BUTYL-4-
HYDROXY 
BENZOATE 
Paraben/ 
Antiseptic 
ER, AR 4.56 -1.13 4.93 -0.56 4.69 -0.88 3.88 -0.63 5.17 -0.6 4.33 -0.73 5.1 -0.47 4.07 -0.13 4.75 -0.91 
ETHYL-4-
HYDROXY 
BENZOATE 
Paraben/ 
Antiseptic 
ER 3.95 -0.73 3.89 -0.27 3.76 -0.9 2.9 -0.84 3.17 -0.92 3.17 -0.82 3.2 -0.19 4.36 -0.58 4.59 -0.19 
METHYL-4-
HYDROXY 
BENZOATE 
Paraben/ 
Antiseptic 
AhR, ER 3.57 -1.42 3.8 -0.72 3.34 -0.44 3.38 -0.55 3.05 -0.31 3.41 -0.48 3.18 -0.3 3.32 -0.62 3.48 -0.85 
BENZYL-4-
HYDROXY 
BENZOATE 
Paraben/ 
Bactericidal/ 
Fungicidal 
ER, 
PPARγ, 
TR 
4.76 -0.87 4.17 -1.04 4.2 -0.53 4.28 -0.43 4.64 -0.34 5.3 -0.66 4.31 -0.53 4.47 -0.61 2.8 -0.43 
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(4-CHLORO-2-
METHYLPHENOX
Y)ACETIC ACID 
Pesticide - 4.35 -0.7 3.79 -0.63 4.11 -0.63 5.66 -1.36 4.1 -0.47 3.5 -0.32 5.2 -1.46 3.77 -0.74 6.97 -0.94 
2-(4-CHLORO-2-
METHYLPHENOX
Y)PROPANOIC) 
ACID 
Pesticide - 3.96 -0.78 3.93 -1.23 4.21 -0.4 5 -1.64 3.99 -1.17 3.17 -0.59 4.29 -0.62 4.87 -0.72 5.98 -0.82 
4-HYDROXY-3 5-
DIIODOBENZONI
TRILE 
Pesticide 
AhR, 
PPARγ 
1.98 -0.52 0.71 -0.31 1.55 -0.13 2.69 -1.16 -0.17 -1.82 1.27 -0.84 0.77 -0.44 0.52 -0.34 3.01 -0.12 
5-AMINO-4-
CHLORO-2-
PHENYLPYRIDA
ZIN-3(2H)-ONE 
Pesticide - 2.79 -0.22 4.04 -1.29 3.82 -0.53 0.84 -3.55 2.91 -0.42 3.98 -0.69 3.09 -0.47 3.06 -0.14 3.85 -0.43 
6-CHLORO-2-N-
(PROPAN-2-YL)-
1,3,5-TRIAZINE-2 
4-DIAMINE 
Pesticide - 3.25 -1.19 3.59 -0.27 3.08 -0.34 4.22 -0.42 2.22 -0.63 3.81 -0.34 2.51 -0.5 2.34 -0.86 3.7 -1 
ALDICARB Pesticide 
AhR, 
PPARγ 
2.52 -1.54 4.39 -0.85 3.9 -0.54 2.58 -1.92 3.23 -0.47 3.01 -1.6 3.59 -0.74 3.16 -0.46 4.47 -1.67 
AMITRAZ Pesticide 
PPARδ, 
PPARγ, 
AhR, 
AR, TR, 
GR 
5.6 -3.12 -1.61 -10.2 6.17 -4.5 3.85 -6.03 0.46 -10.1 0.74 -8.47 3.39 -5.45 4.63 -3.17 5.87 -1.17 
BITERTANOL Pesticide PXR 5.41 -1.69 1.56 -7.25 6.22 -1.5 4.63 -5.67 4.03 -6.13 -1.16 -11.3 2.45 -5.25 6.01 -2.9 6.87 -1.43 
CARBARYL Pesticide AR, AhR 3.84 -0.68 3.42 -0.57 4.78 -0.28 3.39 -2.73 2.59 -0.72 4.84 -0.46 3.08 -1.01 4.72 -0.38 3.75 -0.8 
CARBOFURAN Pesticide ER 3.83 -0.97 4.16 -0.89 4.36 -1.33 4.53 -1.96 3.2 -2.23 3.61 -2.52 3.69 -1.01 4.56 -0.9 4.61 -0.58 
CHLORDIMEFOR
M 
Pesticide - 3.74 -1.26 3.58 -0.46 4.76 -0.91 4.13 -1.08 4.44 -0.82 4.94 -0.14 3.77 -0.51 4.05 -0.63 4.12 -0.88 
CHLORPYRIFOS Pesticide 
AhR, 
PPARγ, 
TR, AR 
5.03 -1.21 4.39 -1.23 3.36 -1.22 3.03 -2.37 3.69 -2.09 2.31 -3.4 3.14 -1.15 3.61 -2.35 4.72 -1.01 
CLOFENTEZINE Pesticide 
ER, AhR, 
PXR 
3.34 -0.98 3.3 -2.3 3.29 -0.98 3.02 -1.79 2.76 -2.21 2.7 -2.6 3.49 -0.92 4.13 -1.36 3.74 -0.84 
CYANAZINE Pesticide AhR 3.79 -0.85 2.75 -2.08 3.24 -1 3.63 -1.38 2.65 -1.17 3.12 -2.64 2.6 -1.33 4.42 -1.27 3.04 -0.98 
CYHALOTHRIN Pesticide - 4.58 -4.98 -5.03 -13.3 3.4 -4.17 -0.19 -9.47 -3.71 -14.3 -13.7 -23.3 -2.83 -12 -1.86 -11.1 4.95 -2.87 
CYPERMETHRIN Pesticide PXR 5.39 -3.56 -4.68 -13.3 4.71 -2.26 -0.66 -11 -4.05 -14.6 -4.81 -16.1 -0.34 -11.1 2.61 -7.79 5.71 -3.42 
CYPROCONAZOL
E 
Pesticide PXR 3.43 -1.35 3.97 -3.97 4.04 -2.19 5.68 -2.31 2.6 -2.86 2.39 -5.49 5.24 -1.69 4.79 -1.2 5.69 -1.11 
DIFLU 
BENZURON 
Pesticide 
AhR, ER, 
RXR 
3 -1.04 0.79 -3.84 3.24 -0.84 3.12 -2.55 1.9 -2.39 0.57 -4.18 2.85 -1.92 3.2 -2.14 4.62 -0.65 
ENDOSULFAN Pesticide 
ER, AR, 
TR, 
PPARγ, 
PPARδ, 
GR 
-0.55 -3.19 -0.81 -4.81 1.48 -2.63 0.05 -3.11 -2.14 -4.85 -7.95 -11.6 -0.83 -3.77 0.07 -3.1 0.53 -3.81 
FLUTRIAFOL Pesticide - 4.26 -1.17 4.42 -0.79 4.8 -0.98 4.03 -1.81 3.75 -1.46 1.35 -5.16 5.28 -2.18 4.63 -0.84 4.65 -1.07 
HEXACHLORO 
BENZENE 
Pesticide - 0.78 -0.36 0.46 -0.36 0.87 -0.17 1.3 -0.9 1.04 -0.54 1.27 -1.69 0.54 -0.7 1.01 -0.51 0.38 -0.22 
IMIDAZOLE Pesticide - 1.89 -0.11 1.91 -0.26 1.86 -0.08 2.07 -0.34 1.51 -0.38 2.18 -0.28 2.48 -0.16 2.47 -0.23 3.29 -0.02 
IPRODIONE Pesticide 
AhR, 
PPARγ 
-0.62 -4.95 -1.5 -6.04 -0.61 -5.48 2.98 -3.34 0.31 -4.7 -1.78 -7.68 1.65 -2.47 0.78 -5.18 3.79 -0.78 
IRGAROL Pesticide 
AhR, 
AR, 
PPARδ 
3.89 -1.46 3.48 -3.13 4.85 -1.54 3.52 -2.74 1.75 -3.38 3.93 -3.55 3.37 -2.66 4.63 -1.4 5.03 -0.9 
ISOPROTURON Pesticide AhR 3.98 -0.83 4.47 -2 3.65 -1.23 4.69 -0.64 4.53 -1.43 4.82 -3.07 4.03 -1.09 3.5 -0.73 2.8 -0.74 
LINURON Pesticide 
AhR, 
AR, TR 
2.57 -1.58 3.27 -0.3 2.83 -0.93 3.4 -0.64 2.92 -0.43 3.78 -0.47 2.13 -0.29 2.76 -0.45 3.3 -1.42 
METHOXY 
CHLOR 
Pesticide 
ER, AR, 
TR, GR, 
PXR, 
PPARγ 
4.17 -1.95 1.87 -6.05 3.11 -1.22 2.8 -5.04 -3.68 -9.43 -1.24 -7.91 2.8 -3.94 3.49 -2.46 4.84 -2.14 
METOLACHLOR Pesticide 
AR, 
PPARγ 
5.93 -1.52 2.19 -5.28 4.29 -1.61 1.51 -6.41 2.5 -4.02 2.07 -6.6 3.48 -2.77 5.27 -3.28 3.29 -3.37 
METRIBUZIN Pesticide RXR 3.39 -0.99 3.43 -1.23 3.25 -0.87 3.66 -2.45 4.59 -0.72 4.69 -0.79 3.9 -0.64 3.77 -1.37 4.01 -1.5 
MOLINATE Pesticide - 4.05 -1.14 4.4 -1.1 4.6 -0.7 4.39 -2.63 3.73 -1.63 4.53 -1.37 3.64 -1.09 4.51 -1.06 3.25 -0.51 
N N-DIETHYL-3-
METHYL 
BENZAMIDE 
Pesticide ER, AhR 4.09 -0.57 4.24 -1.28 4.05 -0.9 3.34 -1.58 2.54 -0.32 2.53 -0.39 3.54 -0.58 3.96 -1.04 4.25 -2 
PHENOTHRIN Pesticide - 6.7 -0.7 -0.34 -11 5.68 -3.56 -0.31 -12.6 0.26 -9.79 -16.1 -25.4 -0.29 -8.51 4.9 -4.1 6.77 -0.95 
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Chemical Name 
Chemical 
Category 
Mode 
of 
Action 
3DT3 
hERα 
1X7J 
hERβ 
1HJ1 
ratERβ 
3V49 hAR 
1T7T 
chAR 
21HQ 
ratAR 
2QPY 
mAR 
1SQN hPR 
1PRG 
hPPARγ 
S C S C S C S C S C S C S C S C S C 
PRODIAMINE Pesticide 
TR, 
PXR, 
PPARδ, 
ER, AR, 
AhR, GR 
5.43 -2.41 0.65 -6.84 5.26 -3.22 1.2 -5.55 3.27 -3.46 0.62 -6.78 2.43 -2.52 5.18 -0.91 5.32 -1.48 
QUINALPHOS Pesticide 
AhR, 
AR, ER 
5.38 -1.41 5.07 -1.83 4.18 -1.73 5.01 -0.92 5 -0.97 4.04 -3.23 4.52 -1.33 5.71 -1.78 4.81 -1.3 
TRIADIMEFON Pesticide 
AhR, ER, 
PXR 
4.55 -1.12 4.14 -0.61 4.76 -0.77 5.22 -2.47 3.81 -1.42 2.97 -4.11 3.87 -1.8 3.94 -1.49 4.67 -0.81 
TRIADIMENOL Pesticide 
PXR, 
AhR, AR 
4.43 -0.9 4.73 -0.9 4.49 -2.07 4.41 -2.63 5.36 -1.52 3.5 -3.12 3.67 -1.86 4.24 -2.44 5.67 -1.35 
PENTACHLORO 
PHENOL 
Pesticide/ 
Disinfectant 
AhR, 
PPARγ, 
TR, ER 
0.83 -2.8 0.97 -0.32 1.91 -0.63 1.8 -0.42 0.98 -1.38 1.49 -1.27 1.14 -0.5 2.02 -0.2 1.78 -0.26 
4-CHLORO 
ANILINE 
Pesticide/ Reagent 
PPARγ, 
ER, TR 
3.23 -0.17 3.09 -0.28 2.78 -0.28 2.57 -0.53 2.17 -0.68 2.55 -0.14 1.81 -0.19 2.45 -0.22 3.02 -0.17 
4-NITROPHENOL Pesticide/ Reagent AR 3.48 -0.19 3.1 -0.18 2.72 -0.38 2.26 -0.33 2.97 -1.12 2.43 -0.38 3.57 -0.31 3.74 -0.43 3.66 -0.95 
(-)BENZOYLEC 
GONINE 
Pharmaceutical - 5.68 -0.67 5.41 -2.14 5.34 -1.4 4.95 -0.97 5.2 -0.66 4.66 -1.53 4.24 -1.21 4.59 -1.22 7.53 -0.84 
2-HYDROXY 
HIPPURIC ACID 
Pharmaceutical - 4.2 -1.06 4.23 -1.76 3.24 -0.49 2.83 -0.7 2.98 -0.72 3.29 -0.89 4.64 -1 3.81 -1 5.07 -0.82 
9-CIS-RETINOIC 
ACID 
Pharmaceutical 
RXR, 
ER, TR, 
PPARγ 
6.65 -2.66 4.74 -4.87 6.5 -3.59 3.14 -5.86 3.99 -6.04 1.31 -9.38 5.35 -3.6 4.9 -6.43 7.3 -3.1 
TRIAM 
CINOLONE 
Pharmaceutical 
AR, ER, 
GR 
2.33 -7.02 -2 -11.7 1.03 -7.63 -4.77 -11.9 2.11 -7.81 -5.12 -16.8 -1.26 -8.53 3.84 -4.67 2.71 -4.09 
ACEBUTOLOL 
HYDRO 
CHLORIDE 
Pharmaceutical - 6.35 -2.55 1.1 -6.91 5.52 -2.91 6.71 -4.63 4.85 -4.94 -1.11 -11.2 5.57 -4.62 6.37 -3.11 7.46 -1.97 
AMITRIPTYLINE 
HYDRO 
CHLORIDE 
Pharmaceutical - 5.92 -2.14 5.21 -5.28 6.16 -2.89 4.37 -3.81 4.89 -3.36 2.67 -7.08 3.89 -3.46 6.76 -2.79 6.37 -0.46 
AMOXICILLIN 
TRIHYDRATE 
Pharmaceutical - 5.57 -3.04 3.62 -6.48 5.44 -4.66 6.2 -4.31 7.68 -5.36 1.78 -8.86 7.95 -2.49 6.96 -3.79 5.88 -0.9 
AMPICILLIN Pharmaceutical - 5.76 -3.2 5.55 -4.35 6.75 -2.8 3.5 -3.66 4.4 -3.81 1.85 -6.42 4.53 -1.98 7.45 -1.51 5.72 -1.44 
ASPIRIN Pharmaceutical - 3.95 -1.3 4.56 -0.81 3.9 -0.84 3.68 -1.35 2.83 -0.56 2.73 -0.29 3.28 -1.18 4.19 -1.06 4.8 -0.32 
BENDROFLU 
METHIAZIDE 
Pharmaceutical - 5.17 -2.8 2.69 -5.53 4.78 -4.05 4.77 -2.96 3.83 -4.52 -0.96 -10.4 5.81 -3.08 3.42 -4.7 6.13 -1.18 
BETAXOLOL Pharmaceutical - 7.27 -3.51 6.59 -4.53 7.26 -1.87 6.69 -3.49 7.34 -3.44 5.43 -5.15 8.17 -2.71 7.03 -4.17 6.55 -1.78 
BEZAFIBRATE Pharmaceutical 
PPARδ, 
PPARγ 
2.01 -5.11 3.5 -6.33 6.05 -2.54 0.84 -5.92 0.67 -5.68 -5.37 -13 3.16 -5.41 1.83 -3.45 6.33 -1.86 
BISOPROLOL 
FUMARATE 
Pharmaceutical - 6.49 -2.56 6.61 -5.26 7.72 -2.6 8.29 -3.8 7.61 -3.82 5.39 -6 7.86 -2.64 8.6 -4.81 9.1 -1.89 
CAPTOPRIL Pharmaceutical - 3.94 -0.75 3.98 -0.55 3.66 -0.68 3.49 -1.2 3.9 -4.87 4.13 -2.35 3.97 -1.29 4.64 -1.97 3.74 -0.79 
CARAZOLOL Pharmaceutical - 6.75 -3.16 4.03 -5.32 5.98 -3.33 6.01 -2.8 4.29 -4.37 3.39 -7.63 5.34 -2.62 7.16 -2.77 6.34 -1.61 
CARB 
AMAZEPINE 
Pharmaceutical AR 4.85 -0.48 3.47 -1.65 5.09 -1.78 5.02 -0.99 4.79 -2.5 2.81 -3.8 5.02 -1.17 5.08 -1.33 5.45 -1.01 
CARISOPRODOL Pharmaceutical - 5.95 -2.58 4.49 -3.77 4.62 -1.86 6.72 -1.85 6.12 -1.77 5.25 -3.54 5.14 -1.52 6.57 -1.02 6.56 -1.78 
CELIPROLOL 
HYDRO 
CHLORIDE 
Pharmaceutical - 4.49 -2.81 -1.83 -14.2 4.99 -3.07 5.14 -6.48 -5.12 -16.9 -5.99 -16.9 1.49 -8.67 -0.34 -10.2 6.06 -1.79 
CHLORAZEPATE Pharmaceutical - 5.52 -0.56 1.83 -4.04 5.18 -1.17 0.46 -4.88 0.45 -4 -1.51 -7.72 0.79 -5.42 0.49 -4.55 4.21 -1.44 
CIMETIDINE Pharmaceutical - 5.77 -2.25 5.64 -2 4.45 -0.96 6.57 -0.73 5.82 -0.85 4.93 -3.16 5.57 -1.92 4.54 -1 4.67 -1.34 
CLENBUTEROL 
HYDRO 
CHLORIDE 
Pharmaceutical - 4.2 -1.82 3.93 -2.91 5.64 -1.01 4.31 -2.66 3.78 -1.44 2.75 -3.08 4.25 -1.36 4.77 -1.3 4.18 -0.71 
CLOFIBRATE Pharmaceutical 
ER, 
PPARα 
4.1 -0.94 3.59 -1.01 3.83 -2.49 5.24 -0.73 4.25 -0.99 4.32 -1.4 3.99 -0.68 4.52 -1.17 4.54 -0.58 
CLOTRIMAZOLE Pharmaceutical 
ER, 
PPARγ 
5.23 -3.84 -6.84 -14 -2.88 -8.78 -6.14 -13.6 -5.25 -12.4 -12.4 -19.6 -4.26 -10.4 -2.89 -9.93 1.56 -5.64 
DEXA 
METHASONE 
Pharmaceutical 
GR, AR, 
PXR, PR 
4 -4.22 -3.91 -13.6 -0.06 -8.44 -2.82 -10.9 5.67 -4.92 -6.1 -16.5 3.54 -5.31 8.24 -3.5 4.25 -2.63 
DIATRIZOIC 
ACID 
Pharmaceutical 
AhR, 
PXR 
0.68 -3.88 -0.81 -5.64 1.26 -3.94 -4.56 -9.89 -5.88 -9.42 -8.85 -12.2 -1.41 -5.24 -2.71 -7.12 1.57 -1.69 
DIAZEPAM Pharmaceutical 
ER, AR, 
GR, TR 
5.88 -1.52 2.15 -5.14 5.24 -0.53 -0.15 -4.39 1.12 -3.84 0 -6.4 1.81 -2.46 2.21 -4.84 4.06 -1.34 
DICLOFENAC 
SODIUM 
Pharmaceutical - 5.27 -1.52 4.41 -2.76 4.33 -1.48 1.95 -3.84 3.24 -2.56 1.61 -3.32 3.41 -2.64 3.59 -1.31 3.14 -2 
DIGOXIGENIN Pharmaceutical - -4.91 -13 -10.4 -20.4 -5.14 -12.6 -8.03 -17.4 -5.26 -16 -16.2 -25.6 0.98 -9.42 -4.34 -11.1 2.77 -1.36 
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Chemical Name 
Chemical 
Category 
Mode 
of 
Action 
3DT3 
hERα 
1X7J 
hERβ 
1HJ1 
ratERβ 
3V49 hAR 
1T7T 
chAR 
21HQ 
ratAR 
2QPY 
mAR 
1SQN hPR 
1PRG 
hPPARγ 
S C S C S C S C S C S C S C S C S C 
DILTIAZEM 
HYDRO 
CHLORIDE 
Pharmaceutical TR 4.22 -5.31 -3.67 -14.5 2.24 -6.25 1.15 -11.1 -5.31 -15.7 -3.78 -16.4 -0.36 -11 1.8 -7.68 6.67 -2.53 
DOMPERIDONE Pharmaceutical TR 7.96 -3.3 2.2 -8.9 5.14 -1.65 2.02 -7.39 0.74 -9.9 -6.94 -16.5 1.89 -7.18 4.6 -6.42 7.81 -3.62 
DOXAZOSIN 
MESYLATE 
Pharmaceutical - 4.31 -3.33 -6.95 -18.1 4.95 -1.29 -6.42 -16.4 -10.6 -20.6 -20.4 -30 0.77 -9.45 -11.5 -22 6.5 -1.99 
ENALAPRIL Pharmaceutical - 7.68 -3.08 3.39 -6.89 7.82 -2.27 7.24 -4.36 5.61 -5.93 -0.17 -14 4.17 -6.69 9.3 -3.34 7.36 -1.37 
ETOFENAMATE Pharmaceutical - 6.73 -1.77 4.55 -4.85 6.15 -2.52 4.98 -5.28 3.09 -3.75 1.4 -8.43 7.01 -2.56 5.41 -2.42 6.83 -1.61 
ETOFIBRATE Pharmaceutical - 5.62 -1.34 4.06 -4.82 6.84 -1.92 4.65 -3.84 5.17 -3.57 -1.24 -9.01 4.2 -2.35 4.82 -2.61 6.51 -1.7 
FAMOTIDINE Pharmaceutical - 6.57 -2.51 4.49 -2.05 5.58 -1.5 4.85 -2.58 3.03 -3.24 2.78 -4.18 5.37 -1.11 5.75 -1.15 6.54 -1.12 
FENOFIBRATE Pharmaceutical 
PPARγ, 
PPARα, 
AR, ER, 
TR 
1.48 -4.13 -0.43 -8.9 5.42 -2.06 5.41 -4.62 1.69 -5.98 -1.88 -10.1 0.65 -8.17 7.11 -3.05 5.96 -1.15 
FENOPROFEN Pharmaceutical - 5.43 -0.56 4.6 -2.19 4.53 -1.31 4.42 -1.9 4.97 -1.44 4.21 -2.27 5.1 -2.33 5.03 -1.14 5.84 -0.91 
FENOTEROL 
HYDROBROMIDE 
Pharmaceutical - 6.36 -2.04 5.01 -4.8 6.45 -1.78 7.11 -2.01 6.58 -2.97 6.17 -4.49 6.8 -2.48 6.7 -1.82 7.26 -1.17 
FENTIAZAC Pharmaceutical 
PPARγ, 
AhR 
3.74 -1.37 -0.94 -6.53 4.1 -1.05 2.91 -3.72 2.71 -2.91 -0.03 -6.32 -1.15 -4.07 0.94 -4.26 5.16 -1.78 
FLUOXETINE 
HYDRO 
CHLORIDE 
Pharmaceutical 
PPARδ, 
TR, AhR, 
AR 
6.25 -1.38 6.87 -1.8 5.26 -2.8 6.94 -1.5 5.27 -2.22 4.78 -3.94 5.7 -2.37 6.06 -1.76 6.89 -1.55 
FLURBIPROFEN Pharmaceutical 
ER, 
PPARγ 
4.81 -0.58 4.55 -1.53 3.9 -1.54 5.59 -1.39 3.98 -0.91 3.92 -1.83 4.31 -0.93 4.7 -0.83 3.97 -1.05 
FLUTICASONE 
PROPIONATE 
Pharmaceutical GR -0.51 -11.3 -21 -30.9 -8.26 -20.9 -11.6 -23.1 -9.57 -20.8 -19.3 -30.2 -8.89 -19 -1.73 -12.6 0.67 -7.8 
FUROSEMIDE Pharmaceutical ER, AR 4.72 -2.36 4.41 -1.36 4.87 -1.93 4.14 -1.38 3.37 -2.79 2.51 -3.99 4.71 -1.61 3.84 -0.9 5.44 -1.77 
GABAPENTIN Pharmaceutical - 4.38 -0.34 4.85 -0.85 4.54 -0.43 4.04 -0.61 6.42 -0.82 3.19 -2.11 5.3 -0.94 5.58 -1.16 5.88 -1.66 
GEMFIBROZIL Pharmaceutical AhR 5.64 -1.41 5.77 -2.04 7.86 -2.26 7.7 -1.34 5.76 -2.27 5.66 -2.73 6.47 -0.99 6.91 -1.45 6.55 -1.56 
HYDROCHLORO
THIAZIDE 
Pharmaceutical PPARδ 2.9 -0.47 3.65 -1.26 3.43 -0.86 2.73 -0.53 2.3 -1.06 3.41 -3.27 1.74 -1.76 2.83 -1.33 5.26 -0.61 
IBUPROFEN Pharmaceutical ER 4.82 -0.18 5.77 -1.31 4.61 -1.14 4.9 -0.49 4.46 -0.51 4.69 -1.33 5 -0.59 5.72 -0.73 5.32 -0.78 
IFOSFAMIDE Pharmaceutical - 4.45 -0.77 3.64 -1.56 4.16 -0.77 4.34 -0.91 4.41 -1.12 4.19 -1.54 3.56 -1.08 4.82 -1.22 5.11 -1.72 
INDAPAMIDE Pharmaceutical - 2.82 -6.39 2.15 -6.54 4.01 -1.64 4.6 -4.41 -0.52 -8.86 1.76 -6.24 0.69 -5.4 2.92 -6.06 5.08 -1.44 
INDOMETHACIN Pharmaceutical PPARγ 4.49 -2.88 1.68 -7.59 5.23 -1.72 2.41 -4.53 1.44 -6.53 0.1 -8.8 3.17 -4.07 2.34 -4.49 4.89 -3.15 
IOHEXOL Pharmaceutical - 1.33 -7.5 -18.2 -28.8 -2.16 -10.6 -10.6 -20.2 -18.1 -25.4 -15.6 -27.3 -12.5 -19.7 -10.1 -19.3 3.45 -5.28 
IOMAPIDOL Pharmaceutical AR, GR -2.81 -12.5 -16.6 -27.7 -7.94 -15.6 -14.5 -25.2 -21 -29.9 -16.1 -24.9 -11.4 -20.3 -14.4 -22.4 3.02 -4.23 
IOPROMIDE Pharmaceutical - -1.04 -11.4 -17.7 -28.4 -0.78 -5.48 -10.8 -23.1 -16 -26.5 -19.4 -28.8 -5.26 -18.6 -11.6 -22.3 3.2 -5.83 
IOTHALAMIC 
ACID 
Pharmaceutical - -1.23 -5.21 -1.49 -6.01 1.1 -4.4 -4.49 -9.91 -3.14 -7.98 -7.88 -13.6 -2.22 -5.21 -3.22 -6.46 1.28 -2.26 
KETOPROFEN Pharmaceutical - 5.31 -1.45 5.45 -1.14 5.3 -0.27 4.93 -2.76 5.22 -1.01 3.9 -2.81 4.87 -2.11 5.77 -0.8 5.42 -1.65 
KETOROLAC 
TROMETHAMINE 
Pharmaceutical - 4.64 -1.16 5.1 -1.03 7.19 -0.91 5 -1.22 5.23 -1.52 5.42 -1.71 5.2 -0.96 6.03 -1.32 6.49 -0.96 
L-
AMPHETAMINE 
Pharmaceutical - 3.77 -0.28 4 -1.76 3.96 -0.62 3.05 -0.47 4.65 -0.96 4.61 -0.53 3.56 -0.55 4.11 -0.57 4.29 -0.54 
LANSOPRAZOLE Pharmaceutical 
AhR, 
PPARγ 
5.64 -1.62 5.22 -2.9 6.84 -1.35 6.13 -1.69 3.43 -4.38 0 -8 4.13 -2.83 5.78 -1.77 5.8 -1.75 
LORATADINE Pharmaceutical 
TR, 
PPARδ, 
PPARγ, 
AR, GR, 
ER 
4.86 -2.61 -2.33 -13.4 0.04 -7.78 -0.02 -9.51 -9.97 -19 -12.1 -22.1 1.14 -8.94 -2.76 -12.2 6.04 -1.52 
MECLO 
FENAMATE 
SODIUM 
Pharmaceutical - 4.98 -1.16 3.06 -2.27 4.54 -1.38 2.43 -2.18 3.54 -1.35 2.5 -3.41 2.33 -1.4 2.9 -0.6 3.49 -1.21 
MEFENAMIC 
ACID 
Pharmaceutical 
TR, GR, 
PPARγ 
5.54 -1.16 5.07 -1.27 3.98 -2.07 4.24 -0.95 4.55 -1.55 4 -2.05 4.75 -1.79 4.82 -2.04 4.27 -2.57 
MESTRANOL Pharmaceutical 
ER, AR, 
GR 
4.31 -3.25 -0.44 -7.66 3.87 -5.69 2.78 -6.26 2.8 -6.11 2 -8.32 4.35 -4.83 2.8 -5.46 2.97 -1.38 
METHYLTRIENO
LONE (R1881) 
Synthetic 
Hormone 
AR 4.72 -1.83 2.73 -5.79 6.66 -1.96 5.28 -4.38 6.63 -1.35 6.12 -4.4 6.79 -1.17 6.9 -1.01 3.99 -0.99 
N N-DIETHYL-2-
(1H-INDOL-3-
YL)ETHAN 
AMINE 
Pharmaceutical - 5.52 -1.24 6.3 -0.84 6.18 -0.76 6.44 -1.59 6.09 -1.52 5.95 -1.86 5.11 -0.71 6.53 -0.78 6.18 -1.12 
NADOLOL Pharmaceutical - 5.92 -4.61 4.96 -4.99 6.56 -1.27 4.66 -5.91 7.09 -2.98 3.46 -7.62 7.15 -2.76 7.51 -2.66 7.39 -2.22 
NAPROXEN Pharmaceutical - 5.16 -0.8 4.54 -0.88 4.2 -0.87 5.19 -1.47 3.65 -0.72 4.71 -1.66 3.62 -1.46 6.03 -1.01 3.8 -0.52 
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Chemical Name 
Chemical 
Category 
Mode 
of 
Action 
3DT3 
hERα 
1X7J 
hERβ 
1HJ1 
ratERβ 
3V49 hAR 
1T7T 
chAR 
21HQ 
ratAR 
2QPY 
mAR 
1SQN hPR 
1PRG 
hPPARγ 
S C S C S C S C S C S C S C S C S C 
NIMESULIDE Pharmaceutical 
ER, 
PPARγ 
4.89 -0.99 4.07 -2.25 4.92 -0.65 3.06 -1.65 1.21 -2.79 1.47 -4.29 3.19 -0.61 3.23 -1.27 5.8 -1.09 
NORFLOXACIN Pharmaceutical - 4.6 -3.76 6.06 -2.9 4.19 -2.2 8.01 -3.48 4.61 -4.48 5.93 -3.83 6.24 -1.99 5.24 -2.05 4.39 -0.87 
NORTRIPTYLINE 
HYDRO 
CHLORIDE 
Pharmaceutical - 5.03 -2.77 5.02 -3.32 5.81 -1.05 4.37 -4.71 4.66 -3.34 3.72 -6.27 4.22 -2.41 5.29 -1.47 6.01 -1.05 
OFLOXACIN Pharmaceutical - 4.21 -5.08 3.78 -6.38 4.63 -1.19 5.99 -4.56 5.87 -3.91 5.04 -5.66 2.96 -5.54 4.25 -3.37 5.61 -2.23 
OLANZAPINE Pharmaceutical TR 4.31 -3.61 1.12 -7.06 4.22 -2 -2.17 -8.24 -2.69 -10.4 -0.27 -7.33 1.69 -4.61 1.15 -5.8 5.44 -0.74 
OXAZEPAM Pharmaceutical 
ER, AR, 
GR, TR, 
PPARγ 
5.91 -1 2.31 -4.01 4.31 -1.47 2.59 -2.29 0.37 -4.75 -0.83 -5.89 1.58 -1.55 2.68 -2.23 4.2 -1.49 
PAPAVERINE 
HYDRO 
CHLORIDE 
Pharmaceutical - 6.4 -2.57 3.07 -6.98 3.97 -5.3 5.83 -4.67 -0.53 -7.89 -0.99 -11.3 6.79 -1.84 4.6 -5.39 7.26 -2.73 
PAROXETINE 
HYDRO 
CHLORIDE 
Pharmaceutical 
AR, 
PPARδ, 
TR 
7.97 -1.88 5 -4.47 7.07 -2.46 6.53 -2.82 4.47 -3.46 4.88 -4.36 6.46 -2.46 6.78 -1.78 7.7 -1.56 
PHENYTOIN 
SODIUM 
Pharmaceutical PXR 4.65 -2.31 1.98 -4.24 4.44 -1.77 4.87 -0.7 1.69 -1.7 1.08 -4.63 2.07 -3.28 2.7 -2.28 5.51 -1.68 
PINDOLOL Pharmaceutical AhR 6.72 -1.49 7.69 -1.45 5.98 -1.86 6.43 -1.73 6.12 -2.22 7.29 -2 7.28 -0.92 6.29 -1.41 6.35 -2.6 
PIROXICAM Pharmaceutical AhR 4.21 -2.79 5.34 -1.56 4.23 -0.88 4.43 -1.43 4.95 -3.85 2.66 -4.78 3.7 -4.11 2.77 -3.05 3.33 -1.6 
PRAVASTATIN 
SODIUM 
Pharmaceutical - 6.02 -3.63 0.44 -13.5 6.46 -7.54 4.58 -8.45 -0.88 -13.3 -8.75 -21 2.5 -10 3.17 -11.2 7.81 -4.45 
PREDNISOLONE Pharmaceutical AR, GR 3.91 -3.29 -3.8 -11.7 1.54 -7.66 -0.17 -8.06 5.68 -4.17 -2.67 -12.6 4.13 -4.73 7.52 -2.82 2.39 -3.04 
PREDNISONE Pharmaceutical 
AR, ER, 
GR 
4.34 -2.8 -0.84 -7.87 1.65 -5.63 -3.38 -10.6 5.27 -3.37 -6.6 -16 4.67 -4.39 5.26 -3.25 3.07 -2.09 
PRIMIDONE Pharmaceutical AR 4.15 -1.06 3.05 -2.1 4.25 -2.18 4.09 -1.12 3.15 -1.41 3.09 -2.63 2.68 -0.6 4.74 -1.25 3.47 -0.95 
PROPRANOLOL 
HYDRO 
CHLORIDE 
Pharmaceutical 
PPARδ, 
PPARγ, 
ER, TR 
6.55 -1.75 6.84 -2.17 5.96 -1.87 6.26 -3.2 6.81 -1.99 7.98 -2.48 6.69 -0.77 7.26 -1.34 5.68 -1.74 
RAMIPRIL Pharmaceutical - 4.64 -6.96 -1.66 -14.1 5.12 -4.54 2.81 -10.8 1.97 -10.8 -4.35 -17.9 4.63 -7.35 7.42 -6.19 6.66 -1.94 
RANITIDINE Pharmaceutical - 5.78 -2.24 6.86 -1.93 6.94 -1.06 6.67 -2.48 6.81 -2.67 3.79 -5.54 7.09 -2.18 7.6 -2.3 7.76 -1.23 
SERTRALINE 
HYDRO 
CHLORIDE 
Pharmaceutical - 5.72 -1.76 2.33 -5.16 5.98 -1 3.85 -4.19 2.32 -4.56 2.28 -6.25 2.83 -3.25 3.67 -2.89 4.63 -0.79 
SIMVASTATIN Pharmaceutical 
GR, AR, 
ER, 
PPARδ, 
TR 
5.99 -8.02 -0.86 -15.4 4.01 -9.12 0.54 -14.4 -3.4 -17.7 -11.4 -25.4 -0.11 -12.6 3.52 -10.5 7.3 -1.8 
SOTALOL 
HYDRO 
CHLORIDE 
Pharmaceutical AR 3.53 -1.41 4.65 -2.5 3.68 -3.04 6.55 -1.41 5.13 -3.3 5.59 -3.19 5.77 -1.36 6 -1.47 5.77 -0.98 
SULFASALAZINE Pharmaceutical AhR, ER -7.48 -12.1 -4.67 -9.65 1.49 -1.11 -0.32 -5.83 -18.8 -24.5 -12.3 -17.8 -3.74 -9.72 -8.83 -16 4.23 -1.24 
SUMAMED Pharmaceutical TR -31.9 -44.5 -118 -139 -17.2 -33.9 -83.1 -105 -94.9 -116 -115 -136 -90.4 -111 -85.3 -104 4.6 -3.6 
TAMOXIFEN 
CITRATE 
Pharmaceutical 
ER, AR, 
TR, 
PPARδ, 
PPARγ 
4.96 -5.75 -0.67 -13.3 2.84 -8.4 -3.69 -15.1 -1.63 -11.8 -12.8 -25 0.18 -10.7 6.28 -6.05 6.83 -3.38 
TERBUTALINE 
HEMISULFATE 
Pharmaceutical - 5.8 -0.96 4.44 -1.2 5.28 -1.6 5.25 -1.33 5.67 -1.49 5.29 -1.79 5.64 -2.74 5.57 -1.87 7.77 -0.88 
TIMOLOL 
MALEATE 
Pharmaceutical - 5.38 -2.83 4.59 -3.83 5.24 -1.56 6.86 -3.36 5.99 -3.33 3.97 -5.97 6.45 -2.59 6.12 -3.34 6.3 -1.31 
TOLFENAMIC 
ACID 
Pharmaceutical 
TR, GR, 
PPARγ, 
PPARδ 
4.96 -1.3 3.7 -1.54 4.03 -2.05 2 -1.6 3.74 -1.01 3.76 -1.58 2.02 -0.85 3.35 -0.81 2.72 -1.6 
TRAMADOL 
HYDRO 
CHLORIDE 
Pharmaceutical - 4.28 -2.16 6.8 -2 5.4 -1.16 4.89 -4.49 3.37 -4.8 2.35 -6.62 4.83 -1.79 4.25 -2.79 5.45 -1.34 
TRIAMCINOLON
E ACETONIDE 
Pharmaceutical 
GR, AR, 
ER, AhR 
1.81 -8.86 -8.04 -19.5 -6.51 -12.8 -4.7 -14.7 -3.32 -14.5 -18.5 -29.3 -5.83 -13.9 3.61 -7.64 3.15 -4.07 
VALSARTAN Pharmaceutical - 3.7 -4.94 -3.29 -15 4.15 -4.85 -0.83 -11.7 0.37 -12.6 -11.4 -23.3 -4.38 -15.3 5.13 -6.85 6.9 -2.87 
WARFARIN Pharmaceutical PPARγ 5.9 -1.45 5.09 -2.16 5.7 -1.28 5.21 -1.74 4.98 -3.23 4 -4.35 5.55 -1.71 4.35 -1.86 4.4 -2.65 
ACIPIMOX Pharmaceutical  - 2.53 -1.36 3.22 -0.89 3.09 -0.46 2.75 -0.13 2.3 -0.95 2.06 -0.3 1.95 -0.94 2.64 -0.39 4 -0.24 
ALBUTEROL Pharmaceutical  - 6.33 -1.79 5.9 -1.49 5.1 -1.83 8.36 -1.51 5.21 -1.67 5.84 -1.97 5.46 -1.25 5.76 -2.14 6.63 -1.06 
ATORVASTATIN 
CALCIUM 
Pharmaceutical  AR, TR -1.76 -16.4 -22.6 -38 3.26 -5.82 -27.6 -43.6 -28 -41.5 -26 -40.1 -22.2 -34.5 -18.9 -30.6 9.01 -2.14 
METOPROLOL 
TARTRATE 
Pharmaceutical  - 6.72 -4.13 6.3 -2.75 6.57 -1.09 6.85 -3.44 6.7 -2.53 8.87 -4.15 8.22 -2.51 7.37 -1.76 6.94 -1.78 
CYCLOPHOSPHA
MIDE 
Pharmaceutical/ 
Chemical Reagent 
- 3.19 -1.53 3.87 -1.21 2.7 -2.28 4.12 -1.97 3.87 -2 3.76 -2.44 2.73 -1.36 3.85 -0.87 3.08 -1.38 
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Chemical Name 
Chemical 
Category 
Mode 
of 
Action 
3DT3 
hERα 
1X7J 
hERβ 
1HJ1 
ratERβ 
3V49 hAR 
1T7T 
chAR 
21HQ 
ratAR 
2QPY 
mAR 
1SQN hPR 
1PRG 
hPPARγ 
S C S C S C S C S C S C S C S C S C 
4'-HYDROXY 
PROPIOPHENONE 
Pharmaceutical/ 
Reagent 
- 3.55 -0.44 3.88 -0.79 5.59 -1.47 3.81 -0.45 3.27 -0.73 3.97 -0.58 3.56 -0.27 4.01 -0.46 4.69 -1.46 
4-ISOBUTYL 
ACETOPHENONE 
Pharmaceutical/ 
Reagent 
- 4.58 -0.78 4.25 -1.58 4.54 -0.65 4.38 -0.98 5.38 -0.84 4.78 -0.32 3.72 -0.85 3.92 -1.15 5.43 -0.88 
5-AMINO-2-
HYDROXY 
BENZOIC ACID 
Pharmaceutical/ 
Reagent 
PPARγ 3.85 -0.53 3.37 -0.38 4.09 -0.63 3.67 -0.11 3.05 -0.61 4 -0.64 3.29 -0.48 3.29 -0.4 3.12 -0.51 
ACET 
AMINOPHEN 
Pharmaceutical/ 
Reagent 
- 3.79 -0.37 3.03 -0.61 3.91 -0.69 2.98 -0.47 3.22 -0.37 3.28 -1.07 3.01 -0.79 3.58 -0.85 3.43 -1.37 
BENZOYLEC 
GONINE 
Pharmaceutical/ 
Recreational Drug 
- 5.11 -1.15 1.79 -4.96 4.7 -1.44 4.09 -2.74 4.88 -2.35 1.66 -5.82 4.79 -1.91 4.84 -2.26 5.57 -3.11 
COCAINE 
Pharmaceutical/ 
Recreational Drug 
- 5.41 -0.82 2.88 -4.53 5.56 -2.06 3.27 -3.68 4.93 -3.52 1.95 -6.84 5.55 -2.85 5.79 -2.51 5 -1.97 
CODEINE 
Pharmaceutical/ 
Recreational Drug 
AR 3.39 -3.1 -2.04 -7.6 2.78 -2.69 5.35 -3.12 2.43 -6.09 -2.97 -10.6 2.31 -4.42 4.62 -3.3 3.9 -0.5 
FLUMETHASONE 
Pharmaceutical/ 
Veterinary M 
GR, AR 3.39 -5 -2.32 -12.3 0.4 -7.75 -4.24 -12.5 5.28 -5.18 -7.97 -18.2 4.06 -6.18 7.94 -3.72 4.4 -2.8 
METRONID 
AZOLE 
Pharmaceutical/ 
Antibiotic 
PPARγ 4.16 -0.84 2.73 -0.2 3.85 -0.38 3.83 -0.67 3.02 -0.52 3.43 -0.94 4.12 -0.41 3.91 -0.83 4.57 -0.35 
ATENOLOL Pharmacuetical - 6.69 -1.49 6.27 -3.06 5.56 -2.27 5.94 -2.26 6.6 -1.98 5.95 -4.96 7.94 -2.08 7.2 -1.21 6.89 -1.33 
1,2 4-BENZENE 
TRIOL 
Phytochemical - 3.47 -0.34 2.67 -0.69 2.87 -0.35 2.86 -0.73 2.91 -0.41 3.54 -0.48 2.64 -0.53 2.83 -0.57 2.74 -0.3 
4-HYDROXY 
CINNAMIC ACID 
Phytochemical - 3.73 -0.42 2.98 -0.47 3.95 -0.57 3.3 -0.54 3.59 -0.7 4.3 -0.4 3.06 -0.93 3.91 -1.03 2.81 -0.29 
BETA-
SITOSTEROL 
Phytochemical - -0.97 -10.2 -17.2 -29.4 -0.65 -8.96 -17.4 -30.7 -17.4 -29.7 -23.4 -36.1 -8.5 -20.6 -11 -22.5 5.64 -5.82 
COUMESTROL Phytochemical ER, AhR 5.83 -0.9 5.5 -0.47 6.54 -0.4 5.67 -0.77 4.65 -0.88 4.77 -1.65 4.17 -0.36 4.03 -1.16 4.28 -1.64 
DAIDZEIN Phytochemical 
ER, AhR, 
GR, PXR 
5.4 -1.69 5.99 -0.85 6.28 -0.8 4.6 -1.16 5.56 -0.68 5.81 -0.84 4.61 -0.63 4.39 -0.84 4.21 -0.55 
FERULIC ACID Phytochemical - 3.94 -0.46 3.41 -0.42 4.27 -0.87 4.23 -0.57 3.2 -0.33 3.51 -0.55 3.27 -0.62 3.37 -0.9 3.75 -1.2 
FORMONONETIN Phytochemical ER, AhR 3.06 -1.83 4.33 -2.52 5.02 -1.67 5.4 -2.03 4.96 -1.47 4.35 -2.72 4.18 -1.28 4.95 -1.82 5.08 -0.86 
GENISTEIN Phytochemical 
ER, AhR, 
TR, 
PPARγ, 
PXR, 
RXR, 
AR, GR 
5.9 -1.93 5.76 -1.32 5.09 -1.64 4.35 -1.64 4.63 -0.78 5.94 -1.2 4.68 -0.39 3.99 -1.2 5.07 -1.61 
GLYCITEIN Phytochemical ER 5.91 -2.39 4.92 -2.5 5.75 -2.67 6.52 -2.71 5.09 -2.4 4.84 -2.15 5.29 -1.3 6.18 -1.8 4.31 -0.69 
KAEMPFEROL Phytochemical 
AhR, ER, 
AR, 
PPARγ, 
PXR, 
TR, GR 
6.96 -0.68 5.82 -0.62 5.32 -0.89 5.22 -1.33 4.69 -1.45 5.15 -1.74 3.99 -0.51 4.19 -0.3 4.56 -0.89 
NARINGENIN Phytochemical - 7.17 -0.84 6.63 -1.62 6.39 -1.68 4.89 -0.73 5.11 -1.01 4.63 -1.46 5.42 -0.86 5.35 -1.75 5.01 -1.83 
PALMITIC ACID Phytochemical ER 6.95 -1.5 8.16 -2.18 8.18 -1.92 8.38 -1.82 8.07 -1.62 6.5 -5.58 9.44 -2.66 7.63 -2.18 8.47 -0.94 
PHLORETIN Phytochemical 
ER, AR, 
AhR, TR, 
PPARγ 
5.34 -1.45 5.42 -2.11 6.4 -1.56 6.45 -1.03 5.96 -0.93 6.65 -1.86 5.7 -1.41 5.42 -1.31 5.28 -0.83 
QUERCETIN Phytochemical 
ER, AhR, 
TR, AR, 
GR 
7.13 -0.78 6.15 -1.19 4.61 -1.6 7.61 -1.27 4.15 -1.46 4.75 -1.81 4.15 -0.76 4.91 -1.71 5.08 -1.12 
2-PHENYL 
PHENOL 
Plasticiser/ 
Preservative/ 
Pesticide 
- 4.59 -0.8 4.22 -1.27 3.84 -0.71 3.12 -0.46 4.32 -0.68 3.72 -1.08 3.07 -0.43 3.34 -0.5 3.57 -1.2 
4,4'-(1 3-
DIMETHYLBUTY
LIDENE) 
DIPHENOL 
Plasticiser/ Toner/ 
Reagent 
AR, ER, 
PPARγ 
4.56 -2.79 4.15 -4.66 4.52 -0.98 6.44 -1.97 3.4 -4.53 -1.07 -8.37 3.76 -2.51 4.87 -2.51 4.95 -1.43 
4-CHLORO-3-
METHYLPHENOL 
Preservative/ 
Disinfectant 
ER, TR 3.49 -0.71 4.01 -0.45 3.48 -0.28 2.83 -0.78 4.25 -0.24 3.1 -0.28 4.35 -0.19 4.86 -0.23 5.34 -0.5 
3,4,5 6-
TETRABROMO-
O-CRESOL 
Preservative/ 
Fungicide 
- 1.05 -0.75 1.78 -0.51 2.41 -1.06 1.43 -1.45 2.7 -0.62 2.58 -2.24 0.58 -0.65 3.66 -0.61 2.07 -0.47 
DIETHYLSTILBE
STROL 
Synthetic 
Hormone/ 
Pharmaceutical 
ER, PR, 
TR, AR 
5.71 -3.87 6.08 -2.13 6.35 -2.46 3.76 -2.73 5.85 -1.56 4.32 -5.54 6.26 -1.14 5.19 -2.7 5.56 -2.43 
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Chemical Name 
Chemical 
Category 
Mode 
of 
Action 
3DT3 
hERα 
1X7J 
hERβ 
1HJ1 
ratERβ 
3V49 hAR 
1T7T 
chAR 
21HQ 
ratAR 
2QPY 
mAR 
1SQN hPR 
1PRG 
hPPARγ 
S C S C S C S C S C S C S C S C S C 
ETHINYL 
ESTRADIOL 
Synthetic 
Hormone/ 
Pharmaceutical 
ER, AR, 
PR, GR, 
TR, 
PXR, 
PPARδ 
6.04 -1.34 2.81 -5.17 6.35 -2.99 4.64 -3.98 5.51 -3.65 2.7 -7.32 6.3 -2.78 7.14 -1.98 2.8 -1.27 
LEVON 
ORGESTREL 
Synthetic 
Hormone/ 
Pharmaceutical 
AR, PR, 
ER, GR 
4.71 -3.91 1.06 -8.04 5.4 -5.11 5.55 -4.34 5.01 -4.54 2.49 -9.42 4.44 -4.11 8.27 -1.85 3.88 -4.92 
NOR 
ETHINDRONE 
Synthetic 
Hormone/ 
Pharmaceutical 
PR, ER, 
AR, GR, 
TR 
3.88 -2.94 1.04 -6.53 3.98 -4.44 5.12 -3.55 6.44 -3.43 2.16 -8.25 4.83 -2.82 6.61 -1.38 2.78 -2.04 
4 4'-DIHYDROXY 
BENZOPHENONE 
UV Stabiliser/ 
Cosmetic 
- 3.97 -0.72 4.44 -1.08 3.84 -0.83 4.08 -1.2 5.54 -0.6 4.2 -1.73 4.01 -0.53 4.5 -0.86 4.33 -0.86 
BIOCHANIN A   
 
4.8 -2.39 3.78 -3.41 4.95 -1.84 3.67 -2.17 4.67 -3.05 3.66 -3.18 5.41 -1.12 5.02 -0.68 4.33 -1.02 
HYDRO 
CORTISONE 
  
 
5.09 -3.65 -3.09 -11.2 2.59 -5.91 -2.91 -10.6 4.93 -4.96 -3.89 -14.3 4.98 -4.99 7.6 -3.63 3.94 -2.16 
METHOMYL     2.9 -0.59 3.3 -0.71 3.8 -0.82 3.9 -0.72 2.13 -0.4 2.83 -0.54 3.53 -0.72 2.76 -1.75 3.98 -1.72 
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Appendix F In vitro Testing Plate Layout 
Assays were ‘upscaled’ in the presence of intraplate variation, to minimise error. Data 
replicates presented in the main body of text were colour coded according to assay 
microtitre plate format; highlighting slight differences in method. 
 96-Well Plate Layout 
The plate layouts of in vitro ER and AR Agonism transactivation assays (HeLa9903 and 
HeLa4-11, respectively) included 1nM Testosterone positive controls (n=12 ‘green’), 
DMSO vehicle controls (n=6 ‘red’) and 3 replicates of 7 concentrations. Test substance 
(TS) concentration varied, however, low concentrations were always plated on the left 
(column 3), while the highest concentrations were in column 9. Figure_Apx 11 shows 
the Costar® black clear bottom 96-well plate layout. Cells were plated in outside wells 
to minimise evapouration effects.  
 
Figure_Apx 11 96-Well Plate Layout for STTA Assays in HeLa4-11 and HeLa9903 TA 
Agonism Assays 
For antagonism STTA assays in the HeLa4-11 cell line, the positive control was 1fM 
Testosterone, which was plated in all wells, excluding the DMSO vehicle controls 
(‘red’). Additionally, three of the positive control wells (Column 10, Rows E, F, & G) 
were also exposed to the moderate antagonist Flutamide, with the aim of controlling for 
assay sensitivity – reduction in transactivation consequent to 10x10-5 M Flutamide 
exposure. Z’ values were calculated using columns 2 and 11.  
 
 
1 2 3 4 5 6 7 8 9 10 11 12
A
1 x 104 
HeLa 
1 x 104 
HeLa 
1 x 104 
HeLa
1 x 104 
HeLa 
1 x 104 
HeLa 
1 x 104 
HeLa 
1 x 104 
HeLa
1 x 104 
HeLa 
1 x 104 
HeLa
1 x 104 
HeLa 
1 x 104 
HeLa 
1 x 104 
HeLa 
B
1 x 104 
HeLa
PC       
(1nM)
TS 1pM TS 10pM TS 100pM TS 1nM TS 10nM TS 100nM TS 1μM
PC       
(1nM)
VC (0.1% 
DMSO)
1 x 104 
HeLa 
C
1 x 104 
HeLa
PC       
(1nM)
PC       
(1nM)
VC (0.1% 
DMSO)
1 x 104 
HeLa 
D
1 x 104 
HeLa 
PC       
(1nM)
PC       
(1nM)
VC (0.1% 
DMSO)
1 x 104 
HeLa 
E
1 x 104 
HeLa 
VC (0.1% 
DMSO)
TS2 1pM TS2 10pM
TS2 
100pM
TS2 1nM TS2 10nM
TS2 
100nM
TS2 1μM
PC       
(1nM)
PC       
(1nM)
1 x 104 
HeLa 
F
1 x 104 
HeLa 
VC (0.1% 
DMSO)
PC       
(1nM)
PC       
(1nM)
1 x 104 
HeLa
G
1 x 104 
HeLa 
VC (0.1% 
DMSO)
PC       
(1nM)
PC       
(1nM)
1 x 104 
HeLa 
H
1 x 104 
HeLa 
1 x 104 
HeLa 
1 x 104 
HeLa 
1 x 104 
HeLa
1 x 104 
HeLa
1 x 104 
HeLa 
1 x 104 
HeLa
1 x 104 
HeLa
1 x 104 
HeLa 
1 x 104 
HeLa 
1 x 104 
HeLa
1 x 104 
HeLa 
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 24-Well Plate Layout 
 
Figure_Apx 12 24-Well Plate Layout for 'Upscaled' HeLa9903 Assays and Transient 
Transfection Assays.  
Figure_Apx 12 shows the 24-well plate format for transactivation assays, for both 
HeLa9903 cell STTA and HEK293 and HepG2 cells transient-transfection 
transactivation assays. However, for the latter, to account for potentially low 
transactivation, a higher concentration of 5x10
4
/well was adopted.   
 
 
 
 
1 2 3 4 5 6
A
DMSO 
1 x 104 
HeLa  
DMSO 
1 x 104 
HeLa  
DMSO 
1 x 104 
HeLa  
0.1nM  
1 x 104 
HeLa  
0.1nM  
1 x 104 
HeLa  
0.1nM  
1 x 104 
HeLa  
B
0.1pM  
1 x 104 
HeLa  
0.1pM  
1 x 104 
HeLa  
0.1pM  
1 x 104 
HeLa  
0.1nM  
1 x 104 
HeLa  
0.1nM  
1 x 104 
HeLa  
0.1nM  
1 x 104 
HeLa  
C
1pM      
1 x 104 
HeLa  
1pM      
1 x 104 
HeLa  
1pM      
1 x 104 
HeLa  
10nM     
1 x 104 
HeLa  
10nM     
1 x 104 
HeLa  
10M     
1 x 104 
HeLa  
D
10pM      
1 x 104 
HeLa  
10pM      
1 x 104 
HeLa  
10pM      
1 x 104 
HeLa  
1μM       
1 x 104 
HeLa  
1μM       
1 x 104 
HeLa  
1μM       
1 x 104 
HeLa  
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Appendix G Alternative in vitro Methods 
Pilot MCF-7 proliferation assays were conducted, modifying the methods detailed by 
Oden et al. (1998). MCF-7-GFP cells stably express Green Fluorescent Protein (GFP), 
enabling crude predictions of cell growth via non-invasive fluorescent readings and/or 
confocal microscopy.  One-week old live MCF-7-GFP cells were suspended in 10% 
DCC-FBS, 2% Glutamide EMEM and plated at 1x104 cells per well, and attached for 
24 hours prior to chemical exposure. Figure_Apx 13 shows the confocal microscopy of 
MCF-7-GFP cells in response to 17β-Estradiol (E2).  
 MCF-7 GFP Proliferation Assay Pilot Study 
 
Figure_Apx 13 Confocal Microscopy of MCF-7 GFP Cell E2 Proliferation Assay  
LSM510 ZEISS Model Confocal Microscope, 488nM (excitation) laser; 505-530nM narrow channel 12; 
maximum transparency mode. The images collected of the MCF-7-GFP cells, appeared to reflect 
estrogenic growth proliferation in response to E2, however, these observations were not observed in 
Presto®Blue cell viability assays run in parallel. Interestingly, many of the cells present altered 
morphology (EMT). 
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Appendix H Supplementary in vitro STTA Results 
This section presents the graphs of the in vitro screening of potential-EDCs (Section 
5.3) in Stably Transfected Transcriptional Activation Assays (ER and AR).  All graphs 
were drawn with GraphPad Prism®.  
 Stably Transfected ERα Transactivation Assays for ER Agonism 
 
 
Figure_Apx 14 Estrogen Receptor-α (ERα) Transactivation in HeLa9903 Cells Exposed to 
Testosterone 
Graphs show the adjusted and normalised relative light units (RLU) emitted consequent to 40-48hr 
exposre to the androgen receptor agonist, Testosterone. Results were normalised by subtracting vehicle 
control (DMSO) RLU and adjusted by dividing by the RLU of 1nM E2 (maximal agonistic response). 
Cell’s were plaed in 24-wells (1000μL) with 1x105 HeLa9903 cells per well; testosterone was solvated in 
100% DMSO and administered as a 1μL volumes. GraphPad Prism® Log(agonist) vs. response (three 
parameters) was used to calculate the line of best fit (right), which is presented as the mean and standard 
error of the mean (SEM). LogEC50 and EC50 with 95% Confidence Intervals (95% CI) were calculated 
from this line of best fit. Testosterone bottom -0.0749 (95% CI -0.2846 to 0.1348) and top 0.612 (95% CI 
0.532 to 0.692), R square = 0.722 (n=29). The dotted line (y=0.2) highlights 20% 1nM E2 normalised 
RLU, as a threshold for categorising positive, negative and/or inadequate data.  
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Figure_Apx 15 Estrogen Receptor-α (ERα) Transactivation in HeLa9903 Cells Exposed to 
Anthropogenic Chemicals (4-BP, 4-NP, DDE, TCN, MeP and OMC) 
Graphs show the adjusted and normalised relative light units (RLU) emitted consequent to 40-48hr 
exposre to either 4-Benzylphenol (4-BP), 4-Nitrophenol (4-NP), Dichlorodiphenyldichloroethylene 
(DDE), Methylparaben (MeP), Triclosan (TCN) or Octylmethoxycinnamate (OMC). Results were 
normalised by subtracting vehicle control (DMSO) RLU and adjusted by dividing by the RLU of 1nM E2 
(maximal agonistic response). Cell concentration was 1x10
4
/well in 96-well (200μL) and 1x105/well in 
24-well (1000μL); test chemicals were solvated in 100% DMSO and administered in 0.2μL and 1μL 
volumes, respectively. Lines of best fit were drawn from the mean and standard error of the mean (SEM). 
96-well and 24-well experiment replicates are shown as a scatter plot behind (dark and light teal, 
respectively). Where applicable (4-BP and DDE) GraphPad Prism® Log(agonist) vs. response (three 
parameters) software was used to calculate the LogEC50 and EC50 with 95% Confidence Intervals (95% 
CI). 4-BP bottom 0.110 (95% CI 0.0295 to 0.187) and top 1.110 (95% CI 0.813 to 1.407), R square = 
0.44 (n=84). DDE bottom -0.1313 (95% CI -0.517 to 0.254) and top 0.4401 (95% CI 0.351 to 0.530), R 
square = 0.27 (n=60). The dotted line (y=0.2) highlights 20% 1nM E2 normalised RLU, as a threshold for 
categorising positive, negative and/or inadequate data. 
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Figure_Apx 16 No Observed Agonism in HeLa4-11 Cells Consequent to 24h Exposure 
Drawn using GraphPad Prism® Log(agonist) vs. Response (three parameters) function, graphs show the 
relative light units (RLU) emitted consequent to exposure to either 17α-Ethinylestradiol (EE2), Bisphenol 
A (BPA), 4-Benzylphenol (4-BP), 4-Nitrophenol (4-NP), Dibutylphthalate (DBP), Diethylhexylphthalate 
(DEHP) or Butylbenzylphthalate (BBP). Results were normalised by subtracting vehicle control (DMSO) 
RLU and adjusted by dividing by the RLU of 1nM testosterone (maximal agonistic response). Error 
shown is equivalent to the standard deviation, highlighting the distribution of the data over the different 
testing days. The dotted line (y=0.2) highlights 20% luciferase induction of the positive control (1nM 
testosterone ~ maximal response), as a threshold for categorising positive, negative and/or inadequate 
data. Quality assurance data (Z-prime) for each 96-well plate are stated in blue. Presented data strongly 
suggest that BPA, 4-BP, 4-NP, DBP, DEHP and BBP are not androgen agonists in the HeLa4-11 cell line 
at the tested concentrations. Slight luciferase induction at 1e-05 M EE2 was reported, however, this 
coincided with cytotoxicity (see Figure 5.1). 
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 Stably Transfected AR Transactivation Antagonism 
   
Figure_Apx 17 Antagonism of Androgen Receptor Transactivation in HeLa4-11 Cells 
Exposed to Consumer Products (DDE, OMC, MeP and TCN) for 24 Hours  
Graphs, drawn with GraphPad Prism® Log(inhibitor) vs. Response (three parameters), show the adjusted 
and normalised relative light units (RLU) emitted during luciferase assays, consequent to coexposure of 
testosterone (1fM) and either Dichlorodiphenyldichloroethylene (DDE), Octylmethoxycinnamate (OMC), 
Methylparaben (MeP) or Triclosan (TCN). Results were normalised by subtracting vehicle control 
(DMSO) RLU and adjusted by dividing by 1fM testosterone RLU (maximal agonistic response).Error 
bars show the standard deviation, indicating the distribution of data over the different testing days. 
Quality assurance data (Z-prime) for each 96-well plate are stated in green. DDE, MeP, OMC and TCN 
were not identified as antagonists of androgen receptor transactivation in any of the assays, all of which 
passed quality checks Z’ >0.65.  
 
